


Annual Report 2004 / 2005

OOA



Address

Oncology Graduate School Amsterdam OOA
VU medisch centrum
Kamer CCA 3.36
De Boelelaan 1117
1081 HV Amsterdam

phone: 020-4444054
e-mail: p.keblusek@vumc.nl
website: www.ooa-graduateschool.nl

Contents

1	Preface	5
2	General introduction	7
3	Education	13
4	PhD projects and PhD students	19
5	International guests	
	5.1 international guests 2004	37
	5.2 international guests 2005	39
6	Scientific results	
	6.1 international papers 2004	41
	6.2 international papers 2005	82
7	Theses	
	7.1 theses 2004	133
	7.2 theses 2005	140
	Addendum	
	Faculty of the OOA	145
	Staff members of the OOA	148

1. Preface

The Oncology Graduate School Amsterdam (Onderzoekschool Oncologie Amsterdam - OOA) is a joint venture of the Netherlands Cancer Institute (NKI), the Free University Amsterdam (VU) and the University of Amsterdam (UvA) on the field of oncology. The three organizations strive for excellence in their research and education in basic and clinical oncology.

The mission of the OOA is to offer education in oncology research in the widest sense, and ensure proper supervision to graduate students in the Amsterdam region.

The research program ranges from the basic molecular biology of the cell to clinical bedside research; from fundamental studies on cellular signal transduction and the control of gene

expression to new clinical trials in immunotherapy and the development of new methods to measure quality of life in cancer patients, so that young investigators are trained to perform research at the highest level.

This report summarizes activities within the OOA in 2004 and 2005. The report will give an overview of scientific highlights, and a detailed listing of the activities (e.g. the course program, the PhD theses, and a list of publications).

The Executive Board of directors,

Prof.dr. G.A. Meijer (VU)
Prof.dr. T. Sixma (NKI)
Prof.dr. J.P. Medema(UvA)

2. General introduction

This report concerns the results of the OOA in the years 2004 and 2005.

After 12 years of inspirational and powerful leadership, the founder and director of the executive board of the oncology Graduate School, Prof.dr. C.J.L.M. Meijer, left the board and was replaced by Prof.dr. G.A. Meijer from November 2005. The OOA is grateful for his innovative ideas and his unlimited energy to offer education in oncology research in the widest sense and bring together the graduate students in the Amsterdam region.

The present report comprises the output of the complete OOA. The evaluation of the educational program is given in chapter 3. The PhD students of all three participating institutes and their projects are included in the overview in chapter 4, resulting now in a total of 350 PhD projects. From all the PhD projects 21% was funded by the participants ('eerste geldstroom'), 18% was financed by public funds ('tweede geldstroom') and 58% by private and industrial funds ('derde en vierde geldstroom').

The OOA has a large international network and a large number of international guests has visited the OOA. As shown in chapter 5 the OOA welcomed 143 international guests in 2004 and 99 in 2005.

Chapter 6 of this annual report is offering the scientific output of the three participants. In total 890 publications in 2004 and 1037 publications in 2005 are listed.

As described in chapter 7, 62 PhD students acquired their PhD degree in 2004 and 45 in 2005.

In November 2005 Prof.dr. J.P. Medema replaced Prof. dr. R.P.J. Oude Elferink as representative for the UvA/AMC

Research

Research within the OOA is clustered in two main programs, both comprising two research themes. The program 'Experimental biology' includes the themes 'Oncogenesis' and 'Biology of tumor cells'. The second main program is directed on 'Experimental clinical research' and covers the themes 'Diagnosis of tumors' and 'Prevention and therapy of tumors'. In chapter 4 of this report an overview is given of all current PhD projects, arranged according to these themes.

Theme 1A: Oncogenesis

This theme is aimed to obtain better insight in the oncogenesis of various tumor types, including the major "killer" cancer types (colon, lung, breast). For this purpose, besides isolated or in situ tumor

cells, different tumor model systems are used such as knock out mice, in vitro culture systems, and tumor cell lines.

Further identification of the responsible genes for hereditary components in the main tumor types are pursued and their function will be unravelled using new molecular techniques and model systems. In this respect the conditional knock out approaches including models for frequent tumor types (lung and breast tumors) are very promising. This will help to better understand the correlations between distinct genetic lesions and phenotypic characteristics of tumors

Emphasis is also put on the role of exogenic factors in the genesis of tumors. Both the role and working mechanisms of certain carcinogens and the pathogenic role of viruses (Human papilloma viruses (HPV) and Epstein -Barr virus (EBV) in the genesis of certain carcinomas (cervix, anogenital, oral cavity, tonsil, head and neck carcinoma's,) and lymphomas is under study.

Theme 1B: Tumor cell biology

Tumors are usually the result of a loss of control of cell growth. Many genes are potentially involved in this process. They may be activated or upregulated, which are the proto-oncogenes. Alternatively, they are found inactivated and act as tumor suppressers. Various screens are being performed to identify such genes. These include screens with retroviral libraries or through viral insertion. Many genes have been identified through these technologies. A large portion of these genes code for kinases or phosphatases that are probably involved in controlling various signal transduction pathways. The cell biology of signal transduction is prominent part within Theme 1b. Studies concentrate on signalling through growth factor receptors, through mitogenic phospholipids, but also through the estrogen receptor. The down stream effectors are also studied. These can be immediately downstream of such receptors, like the effects on the MAPkinase pathway, but also more downstream effectors resulting in activation of Polo-kinases, caspases or transcription factors. These processes control cell division, death and growth.

To become activated, or to terminate activation of a growth factor receptor, receptors have to be internalised and degraded. How this pathway is controlled is studied at the cell biological and electron-microscopical level. Novel techniques are developed to follow these processes at the single cell level, employing fluorescence and various microscopical techniques including FRAP, FLIP and FRET.

To execute cell division, a number of processes are crucial, like cytoskeletal changes and motor protein activation. These are controlled by various factors like the small GTPases and are studied by various groups within this Theme. In order to migrate (to form metastasis), cells have to alter their adhesion to the cell substratum and move in a particular

direction. These processes are controlled by adhesion molecules and chemokines, also studied here.

Various targets are identified for either inhibition by small molecular compounds or immunotherapy. Immunotherapy by genetically modified T cells, by activation of the immune response and by antibodies, are all developed and tested for applicability.

Theme 2A: Diagnosis of tumors

Early detection of a primary tumor, metastases or minimal residual disease has a direct influence on the prognosis and the therapy of an individual cancer patient. Early detection of tumor cells in lymph nodes and bone marrow are important for sentinel lymph node procedures in breast carcinomas and in bone marrow staging. Immunohistochemistry with newly developed antibodies is used to make an earlier diagnosis of tumor cells in lymph nodes and bone marrow. Newly developed monoclonal antibodies are used to identify new histologic prognostic parameters and are correlated with corresponding functional assays resulting in better prognostication. These parameters include cell cycle parameters, growth factor receptors, apoptosis pathway proteins, angiogenesis factors, oncoproteins, signal transduction proteins and transcription factors and parameters of the reacting immune system. New drugs or biological agents interfering with the discovered proteins are under study. Examples are trail, glivec, anti-herceptin and anti-angiogenesis drugs.

Microarray facilities support research with the aim to better characterise the various tumor types. Use of these microarrays will result in more accurate diagnosis with individual prognostication and therapy dedicated to the individual patient and the first results in breast carcinomas and lymphomas are confirming this view.

In the PET center clinical studies have shown that with different tracers for different tumor types spectacular results can be obtained (lymphomas, head and neck tumors etc.).

Theme 2B: Prevention and treatment of tumors

The research theme concerning treatment of cancer is intense in all three participating institutes. It can be divided in the following research areas: chemotherapy, immunotherapy, radiotherapy and gene therapy, or a combination of these modalities. Thus, high dose chemotherapy in combination with autologous or allogenic stem cell transplantation is an important subject. Within the area of chemotherapy emphasis lies on pharmacokinetics and pharmacodynamics, either or not in relation to (multi)drug resistance. Resistance is a crucial determinant of chemotherapy; the value of classical resistance parameters is assessed in clinical studies, while new resistance targets are studied in *in vitro* systems and experimental animal models. Recognition of individual variations in drug sensitivity and resistance should lead to a more individualized treatment of cancer.

Once improved treatment modalities are designed, the coordination of multi-center trials is crucial.

Indeed, development and testing of new anticancer agents remains a major task of the EORTC, which coordinates trials throughout Europe. Similarly, the EORTC plays a role in patient trials on chemoprevention. Insight into the mechanism by which factors produced by tumor cells influence angiogenesis will lead to improved treatment of cancer, either or not in combination with chemotherapeutic treatment.

Immunotherapy is a treatment modality that is still rapidly developing. New approaches of immunotherapy are developed on basis of fundamental research, tested in animal models and being implemented in clinical trials. Different approaches involve boosting of the endogenous immune response, but also active immunisation by vaccination with dendritic tumor cells and passive immunisation with tumor specific lymphocytes that have been expanded *in vitro*. Research into radiotherapy aims at optimising treatment protocols as well as the clinical implementation of new modalities such as boron neutron capture therapy for brain tumors and photodynamic therapy for gastrointestinal tumors.

In Gene therapy the most important aims are a. specific and efficient targeting of viral vectors to tumor cells, using the proper surface determinants; b. development of improved viral vectors in which efficient cytotoxic genes are driven by tumor-specific promoters. The cytotoxic genes may either code for enzymes that convert prodrugs, or encode genes that induce apoptosis in the target cells. One of the approaches is the use of conditionally replicating viruses (CRADS) that have considerably higher efficiency in cell killing due to replication within the target cell.

Finally, trials are performed to improve protocols for surgery of tumors with special attention to the combination of chemotherapy and surgery.

A more detailed description of the current research and the results can be found in the annual reports of the individual institutes.

Education

An important activity of the OOA is the training of PhD students. For that purpose the OOA has developed a high quality course program. In 2004 as well as in 2005 the OOA organized besides the graduate courses also the Annual Graduate Student Retreat. All courses were evaluated according to standard procedures. In this way the OOA carefully watches on the quality of the courses. Based on these evaluations the training program is improved continuously.

A summary of the courses is described in chapter 3 of this Annual Report.

Scientific Awards

2004

T. Sixma was appointed Professor of Structure and Function of Proteins at the Erasmus University in Rotterdam (NKI).

M. Verheij was appointed professor in Translational Radiotherapy, and **Hein Te Riele** professor in Genetic Instability and Carcinogenesis, both at the Free University of Amsterdam (NKI).

M. van Herk was appointed professor of Image Analysis in Oncology at the University of Amsterdam (NKI).

Both **T. Sixma** and **M. van Lohuizen** were elected member of EMBO (NKI).

R. Bernards received the Josephine Nefkens Prize for his contributions to cancer research (NKI).

N. Aaronson was awarded the Bernard H Fox Memorial Award by the International Psycho-Oncology Society in recognition of lifetime achievement in psychosocial oncology research, in general, and in particular for his contribution to the development and application of health-related quality of life measures in clinical oncology research and practice (NKI).

M. van Herk received the Breur Award at the biannual ESTRO meeting for his work on image guidance for precision radiotherapy. The research of his team created for us the unique opportunity to exploit the cone beam CT linear accelerator in routine clinical practice, as the first institute in the world (NKI).

Two of our AVL fellows, **B. van Steensel** and **R. Agami** received the prestigious European Young Investigator award (NKI).

The AvL-prize 2004 for young, promising NKI-scientists was awarded to **J. Hendriks** for her work on the role of CD27/CD70 in regulation of the immune response (NKI).

The selected abstract for oral presentation and travel award EMDS-meeting (October 14-16, 2004) was won by **G. van der Bij** (Surgery): Role of macrophages in the prevention of liver metastasis (VUmc).

On November 11, 2004 in Berlin, **C.A. Uyl-de Groot et al.** (Nuclear Medicine) received the EANM Springer award for best clinical paper 2003 (Vumc).

T.D. de Gruijl (Medical Oncology) received the Prostate Cancer Foundation Research Award (\$ 100,000) (VUmc).

S. Dinant (Surgery) won the Altana prize for presentation during *NVGE voorjaarsvergadering*, Veldhoven, 20 maart 2004 (AMC).

M. Bessems (Surgery) won the prize for presentation during *congres Ned Transplantatie*

Vereniging, Tessel, 19 maart 2004 (AMC).

T.N. van Heek (Surgery) had the best publication *Ned. Vereniging voor Heelkunde / Annals of Surgery* (AMC).

S.Q. van Veen (Surgery) won a prize for presentation during SEOHS, Amsterdam, 19 november 2004 (AMC).

E.A.J. Reits (Cellbiology and histology) obtained the NWO VENI fellowship for his studies entitled: "Peptide and protein aggregation in vivo". ZonMW, The Hague, NL (AMC).

R. de Waart (Liver Center), a Ph.D. student (AGIKO) has won the prize for the best contribution to the discussion on the CLDO Ph.D.-student retreat, December 8-9, 2004, Lunteren (AMC)

M. Alders (Clinical Genetics) won the Posterprijs Jubileumcongres van de Dutch Society of Cardiology (AMC).

S. Repping (Clinical Genetics) won the AMC Young Investigator Publication Award 2003 (AMC).

S. Ferdinandusse (Laboratory Genetic Metabolic Diseases) won the SSIEM Award (Poster) (AMC).

Th.M. de Reijke (Urology) became Honorary member of the Polish Urological Association (AMC).

M. Oelke (Urology) had the *Best poster of the day*: "Immunohistochemical presence of cyclic Adenosin Monophosphate and cyclic Guanosin Monophosphate Phosphodiesterase isoenzymes in the human vagina". EAU 2004, Vienna, 25 maart 2004 / *Poster award* "Diagnostik einer Blasenauflassobstruktion durch sonographische Messung der Detrusordicke" (Diagnosis of bladder outlet obstruction with sonographic measurement of detrusor wall thickness). 28. Dreiländertreffen DGUM-SGUM-ÖGUM. Hannover, 7 oktober 2004 / *Best Abstract on Basic Science Female* „Cyclic AMP and cyclic GMP phosphodiesterase isoenzymes in the human vagina- relation to NOS isoforms and VIP-positive nerves“ 11th World Congress of the International Society for Sexual and Impotence Research, ISSIR Buenos Aires, Argentinien, 17 oktober 2004 (AMC).

2005

G.A.M.S. van Dongen was nominated for the Marie Curie Award 2005, European Association of Nuclear Medicine (VUmc)

Y. Goekoop-Ruiterman received the 12th EULAR Abbott Abstract Awards: Primaire preventie van reumatoïde artritis ZONMW, on behalf of the BeSt group Wenen 2005 (VUmc)

M. Levitus received the Chris Meijer award at the V-ICI Annual Plenary Meeting, March 7, 2005 (VUmc)

J. de Wilde won the 1st poster prize Nederlandse Vereniging Voor Pathologie: "Altered gene

expression profiles in HPV16 immortalized keratinocytes following telomerase repression by chromosome 6", Jillian de Wilde, Peter J.F. Snijders, Chris J.L.M. Meijer, Mark A. v.d. Wiel, Bauke Ylstra, Renske D.M. Steenbergen, April 2005, Ede (VUmc)

S.M. Wilting received an award for oral presentation Nederlandse Vereniging Voor Pathologie "Frequent gene copy number increases at chromosome 20q in both squamous cell carcinomas and adenocarcinomas of the cervix", Wilting SM, Snijders PJF, Meijer GA, Ylstra B, Snijders AM, van de Wiel MA, Meijer CJLM, Steenbergen RDM, April 2005, Ede (VUmc)

S.M. Wilting won the 1st poster prize 2nd annual CMSB symposium "Frequent gene copy number increases at chromosome 20q in both squamous cell carcinomas and adenocarcinomas of the cervix", Wilting SM, Snijders PJF, Meijer GA, Ylstra B, Snijders AM, van de Wiel MA, Meijer CJLM, Steenbergen RDM, September 2, 2005, Amsterdam (VUmc)

M. van Miltenburg won the Arthron Reumatologie Aanmoedingsprijs 2005: Sulfasalazine-induced sensitization of glucocorticoid activity, April 5, 2005, Amsterdam (publication: Ned. Tijdschrift voor Reumatologie 2 (2005), 79-81) (VUmc)

I. van der Waal became Honorary Member of the American Academy of Oral Medicine, April 15, 2005, Phoenix, AZ, USA (VUmc)

I. van der Waal became Honorary Member of the Nederlands Tijdschrift voor Tandheelkunde, November 5, 2006, Heerenveen (VUmc)

M.C.G. Bleeker won the award for oral presentation 22nd International Papillomavirus Conference and Clinical workshop "Higher penile viral loads of HPV are found in men with flat penile lesions and those with an HPV type-specific concordant female partner", Bleeker MCG, Berkhof J, Voorhorst F, Hesselink A, Starink T, Stoof T, van den Brule A, Snijders P, Meijer C, April 30 - May 6, 2005 (VUmc)

M.C.G. Bleeker won the Scientific prize Albert Schweitzer hospital, May 2005 (VUmc)

R. Oerlemans received the best oral presentation award 13th International Symposium on Chemistry and Biology of Pteridines and Folates, June 24, 2005, Egmond aan Zee (VUmc)

M.C.G. Bleeker received a PhD degree 'cum laude' "Human papillomavirus infection in sexual partners", July 8, 2005, VU Amsterdam (VUmc)

M. Toebak received a Travel grant for ESDR, September, 2005 (VUmc)

M. Levitus, A.L. Medhurst, M.A. Rooimans, P. Bier, G. Pals, J.P. de Winter and H. Joenje received the Discovery awards from the FA Research Fund, Inc., Eugene, Oregon, for the discovery of *FANCB*, September 30, 2005, Geneva (VUmc)

A.L. Medhurst, P. Bier, J. Steltenpool, H. Joenje and J.P. de Winter received the Discovery awards for the discovery of *FANCM*, September 30, 2005, Geneva (VUmc)

M. Levitus, Y. de Vries, Q. Waisfisz, J. Steltenpool, M.A. Rooimans, G. Pals, F. Arwert, J.P. de Winter and H. Joenje received the Discovery awards for the discovery of *FANCF*, September 30, 2005, Geneva (VUmc)

L. van Veelen received the ESTRO-VARIAN Research Award 2005, October 29, 2005, Paris (VUmc)

S. Senan won the Lungcancer Patientprize 2005, November 3, 2005, Amsterdam (VUmc)

H. Vékony won the 2^e price Robert Frank Award, International Association of Dental Research, November 16, 2005 (VUmc)

T. Rustemeyer won the 'Nederlandse Allergologie Prijs 2005' by the 'Nederlandse Vereniging voor Allergologie', November 18, 2005, Amersfoort (VUmc)

T. Buffart won the Poster prize VUmc 'Wetenschapdag', December 15, 2005 (VUmc)

R. Bernards received the Spinozaprijs of 1.5 miljoen euro for research (NKI)

R. Bernards received the Pezcoller Award (NKI)

R. Bernards received the Ernst W. Bertner Award for Cancer Research of the M.D. Anderson Cancer Center (NKI)

S. Horenblas received the Folke Edsmyr Award of the Karolinska Institutet (NKI)

H. Bartelink received the Antoine Béclère medaille of the International Society of Radiology (NKI)

N. Aaronson received the President's Award of the International Society for Quality of Life Research (NKI)

F. Hilgers became Honorary Corresponding Member of the Deutsche Gesellschaft für Plastische und Wiederherstellungschirurgie (NKI)

A. Bins won the AVL-price 2005 (NKI)

T. Schumacher is appointed full professor in Immune Technology at the University of Leiden (NKI)

S. Hustinx won the Hippocrates prize (AMC)

R. de Waart won the Prize for the best discussant on the CLDO AIO-retreat, December 8-9, 2005, Luntenen (AMC)

A. van der Velde received the Fellowship Dutch Atherosclerosis Society, the Young Investigator Award of the Scandinavian Society for Atherosclerosis Research (SSAR) and the Young Investigator Award of the European Lipoprotein Club (AMC)

J. Florie, S. Jensch, R.A.J. Nievelstein, M. Poulus, M.A. Thomassen, J. Stoker **had the best scientific abstract of the 10th Annual Scientific Meeting of the Radiological Society of The Netherlands (Accuracy of MR colonography using limited bowel preparation in consecutive surveillance patients. Abstract Do 4.6, Memorad 10 (3), 2005)(AMC)**

Dept. of Surgery, Pediatric Surgery won the Schoenmakersprijs 2005 for the best Dutch surgical thesis (AMC)

C. Bezzina became an established investigator 2005 of the Netherlands Heart Foundation (AMC)

N. Oeij won the GEMO prijs 2005 for the beste presentation on the GEMO day (AMC)

C. van Woerden won the ESN/Amelandprijs by the Resort Hotel d'Ameland Kaap, 25 november 2005 (AMC)

H.P. Kok won the 1st prize physics: Kim Young Investigators Award; Improvement of locoregional hyperthermia treatment of oesophageal cancer using treatment planning: ESHO 2005 Book of Abstracts. 22nd Annual Meeting of the European Society for Hyperthermic Oncology p. 12 Graz Austria 08-11 juni, 2005 (AMC)

T. de Reijke became Honorary Member of the Asociatia Romana de Urologie (AMC)

M.Wink, H.Wijkstra, P.Laguna, B.Lagerveld, J.de la Rosette had the "Best poster presentation in session 2: kidney tumours: diagnosis and staging" voor de poster " A new and improved look at renal masses; contrast enhanced ultrasound using contrast pulse sequence imaging" door op de 20th EAU congress in Istanbul 16-19 march 2005 (AMC)

Board and organization of the Oncology Graduate School Amsterdam

Board

Prof.dr. A. Berns, chairman
Prof.dr. S. Rodenhuis
Prof.dr. H.M. Pinedo
Prof.dr. P. Postmus
Prof.dr. C.H.N. Veenhof
Prof.dr. P.A. Voûte

Directors

Prof.dr. C.J.L.M. Meijer, chairman (till nov. 2005)
Prof dr. G.A. Meijer, chairman (from nov. 2005)
Prof.dr. T Sixma
Prof.dr. R.P.J. Oude Elferink (till nov. 2005)
Prof.dr. J.P. Medema (from nov. 2005)

Participants

Vrije Universiteit Amsterdam, administrative center
Contactperson / secretariat: dr. P. Keblusek
de Boelelaan 1117
1081 HV Amsterdam
phone : 020-4444054
fax : 020-4442964
e-mail : p.keblusek@vumc.nl

Universiteit van Amsterdam / Academisch Medisch Centrum
Contactperson / secretariat: dr. Y. Donselaar
Meibergdreef 15
1105 AZ Amsterdam
phone : 020-5668502
fax : 020-5669165
e-mail : y.e.donselaar@amc.uva.nl

Nederlands Kanker Instituut
Contactperson / secretariat: M. van der Velde
Plesmanlaan 121
1066 CX Amsterdam
phone : 020-5122015
fax : 020-5122029
e-mail : m.vd.velde@nki.nl

3. Education

Within the framework of the mission of the OOA , i.e. offering education in the oncology research, the OOA organizes each year several advanced courses in the field of oncology. The program is formulated by the directory board and is based on evaluations of courses given in the past, actual developments in oncological research and on wishes expressed by the PhD students. More and more clinically oriented courses are developed according to the advise of the site visit committee that evaluated the OOA in 2002.

The OOA offers various types of courses. During the last years the format of the courses varies from highly specialized "meet-the-professor-sessions" where the students can discuss their own work with an invited professor in the field, up to a few days to two weeks courses with several national and international specialized invited speakers. There are courses , where besides theoretical also practical work is included, like in the successful annual "Anatomy of the Mouse" course as well as the highly appreciated longitudinal literature courses , where over a longer period weekly several papers are extensively discussed by the participants and the discussion leaders. The goal of the longitudinal courses is two-fold: to learn students critically read papers and to teach students how to write reviews. Since these are valuable investments, we concluded that especially students in their first year have to attend this type of courses.

In 2004 and 2005 13 courses were organized. Both years the successful graduate student retreat was organized. In the following part of this chapter we will report in detail on the given courses and the retreat.

Cell Cycle Checkpoints and Cancer

Organization: Dr. R Agami and dr. R Medema
Time: 21 January – 6 February 2004
Location: NKI

This course was organized with the goal to provide the participating graduate students with a timely overview of the different aspects of control over genomic stability, and the impact of genomic instability on tumorigenesis. The mechanisms that ensure genomic stability (i.e. DNA damage checkpoints, spindle assembly checkpoint) were reviewed extensively. The course consisted of a general introduction on the topic of the course, a 2 hour lecture given by both organizers. The remainder of the course comprised lectures given by 6 different experts in the field. Each of these lectures was preceded by a literature discussion in which key publications on the focus of that particular lecture were presented by the participants of the course and discussed among all participants. Several articles to be

discussed were provided by the speakers and additional papers were selected by the participants. Following the lecture a discussion between the participating graduate students and the speaker was organized to allow the students to raise additional issues they encountered in reading the literature or during the seminar. Overall, the students rated the quality of the course from good to very good. Almost all presentations by the outside speakers were rated very good. Two presentations were very basic and were rated less. The level of literature discussion on average was good. A subset of students rated this as too high, whereas a few others rated it too low. After the extensive literature discussion, the participants no longer need an extensive introduction, and speakers can easily present more advanced material.

A total of 34 PhD students participated in the course. Among the (inter)national speakers were Prof.dr.M Ohren and Prof.dr. E. Nigg.

Anatomy of the mouse

Organization: W.H. Lamers and Prof.dr. C.J.F. van Noorden
Time: 22-25 March 2004
Location: AMC

Most biomedical PhD students perform animal experiments at some stage of their research career, but most students have never had practical instructions with respect to anatomy, histology and pathological anatomy of experimental animals. For this reason, experimental animals are usually not subjected to a thorough and systematic inspection to assess whether, besides the local (expected) effects in the organ(s) under study, other organs are affected as well. This annual successful and fully booked course aims to provide practical insight(s) in the anatomy and histology of the mouse, presently the most frequently used animal. In addition, the course focuses on recognition of pathological changes in the mouse.

This course lasted four days. During the course each student dissected either a male or a female mouse, to learn the topographic anatomy of this species. The microscopic part of the course focuses on the study and understanding of the architecture of normal and pathologically changed mouse tissues. During the practical part, recognition of cell and tissue types, and changes in architecture of tissues as a result of pathological processes, are studied microscopically. In addition to standard staining techniques, functional staining techniques are demonstrated.

25 PhD students (of which 24 from the OOA) and 2 Master students participated in the course. The overall evaluation rate was good with 7.7

Genetics and cell biology of the immune system

Organization: Dr. T. Schumacher and Dr. H. Jacobs
Time: 3 March – 21 April 2004
Location: NKI

In this course recent articles were discussed that relate to the development of T cell immunity and B cell immunity. Focus of the course was primarily on the genetic and cell biological mechanisms that control the development of adaptive immunity. The goal of this course were two-fold:

I) to discuss recent advances in our understanding of the adaptive immune response and
II) to help students analyze the strengths and pitfalls of scientific papers through an in-depth discussion.

Meet the professor – Current concepts in regulation of T cell immune responses

Organization: Dr. F. Raaphorst
Time: 13 May 2004
Location: VUmc

In the morning a small minisymposium was organized where all interested people were welcome.

This was followed in the afternoon by a "Meet the professor" session with short presentations of the participating graduate students (3) and discussions with the invited speakers.

Four speakers were invited.

Prof.dr.J.M. Bos (Department of Microbiology & Immunology, Emory University School of Medicine, Atlanta, USA) who talked about Transcriptional Regulation of MHC-II

Dr. N van der Stoep (Dept. Immunohematol. & Blood Transfusion, LUMC, Leiden) with a presentation about the Regulation and function of MHC class II molecules in melanoma.

Prof.dr. C. Terhorst (Division of Immunology, Harvard Medical School, Boston, USA) with a presentation about The SLAM and SAP gene families and Prof.dr.E.Oltz about Epigenetic regulation of V(D)J recombination

Talks were balanced and clear. Speakers were enthusiastic and the discussions were lively. A very informative meeting that provided sufficient background to understand recent developments in the field. What was really nice was that the entire meeting was very informal. This was particularly noticeable during the discussions and the afternoon program, and ensured that most audience members took part in the discussions.

Summer School on Gastro-intestinal Oncology

Organization: Prof. S.J.H. van Deventer, Prof.dr. C.C.E. Koning, Prof J.J.B. van Lanschot, Prof G.J.A. Offerhaus, Prof.dr. D.J. Richel, Prof H Spits.
Time: 11-24 July 2004
Location: AMC

In the past decade, extensive progress in the field of molecular biology has not only generated insights into the molecular mechanisms underlying progression to malignancy, but also tools for early detection, prognosis determination and the identification of possible targets for therapy. The course was designed to review the basic medical science from a patient-oriented point of view and offered an inviting introduction into translational research.

Among the topics that were discussed were; hereditary predisposition; morphogenes in carcinogenesis; techniques in molecular biology; early diagnosis and screening; prognostic factors; limited versus extended surgery; new targets in cancer therapy; radiosensitization and immunotherapy.

The course content was given through lectures, demonstrations, hands-on trainings, workshops, site visits, critical appraisal of literature and finished with an exam.

This course was intended by both OOA students as well as international students

In the footsteps of Antoni van Leeuwenhoek

Organization: Dr. G.A. Meijer, Prof.dr. P. Peters, Prof.dr. R.J.C. van Noorden
Time: 18-27 August 2004
Location: NKI, AMC, VUmc

This year the course was differently organized and given in combination with a scientific microscopy congress held in Antwerpen, Belgium. First a crash course with basal knowledge microscopy was given followed by a journal club for articles of speakers during the congress. From 22-27 augustus 2004 'The thirteenth European Microscopy Congress' in Antwerpen could be attended.

Although only 2 students followed the whole program, they were quite positive about the combination with and preparation for the congress.

Annual graduate student retreat

Organization: Prof.dr. J.J. Neefjes and M. van der Velde
Time: 13-15 October 2004
Location: Hotel Opduin, De Koog, Texel

The annual retreat for the OOA graduate students is meant to stimulate the (horizontal and vertical) cohesion in the OOA. All OOA graduate students is held in a congress center in a somewhat secluded place, Hotel Opduin at the isle of Texel that offers an excellent atmosphere for our retreat.

A few staff members of the participating institutes are there for back-up, but it is foremost a meeting for the graduate students themselves. The retreat is not only a scientific but also a social happening, that stimulates the networking between the students of the different institutes.

The number of participants is steadily growing with a peak this year. This was mainly caused by new enthusiasm of the AMC with over 20 students. The participation of clinical graduate students can still be improved, in spite of various efforts to convince the supervisors in the hospital to send their students to the retreat. This will be kept in focus for the coming years.

69 evaluation forms (63 %) were returned. Of first time participants 95 % returned the evaluation form.

This year we gave the students the possibility to choose their type of session, which was highly appreciated. The format as it now is, i.e. with chair persons, introduction of the sessions and a poster session is generally satisfactory. With the wide range of different backgrounds of the students a reasonable question that deserves serious attention is the choice whether to present research results or to tell more about the background of the project, the aim of it and eventually the research method.

The discussions after the talks were lively, and the general impression is that sensitive questions were put and adequately answered.

The students appreciated the balance between work and leisure and enjoyed the opportunity to get to know colleagues in an informal setting, but also to learn a lot about the other fields of research in oncology.

110 PhD students attended the retreat of which 68 from the NKI, 22 from the AMC and 20 from the VUMC.

Apoptosis

Organization: Prof.dr. J Borst, Prof. dr. M Verheij Dr. W.J. Blitterswijk
Time: 22 November - 3 December 2004
Location: NKI

In this OOA course on apoptosis (programmed cell death), current concepts on apoptosis initiation, signal transduction and execution were presented. Spread over two weeks, nine speakers of international reputation covered the latest advances in the following topics: apoptosis and development; mechanisms of pro- and anti-apoptotic signaling featuring the role of death receptors and cell organelles (mitochondria; ER); anti-cancer therapy (chemotherapy and radiation) and apoptosis; rational therapy with apoptosis modifiers.

The course started with a general introduction and an introduction about lipid/membrane aspects of

apoptosis. Each day participants presented 2 to 3 papers (Journal Club format, under supervision of two seniors), related to the specific theme of that day and connected to the invited speaker's seminar.

The open seminar was followed by an informal and closed discussion between speaker and participants.

The course was evaluated as very positive (overall 8.3), instructive and inspiring.

23 participants (12 NKI, 6 VU, 5 AMC) attended the course.

The invited speakers were Pascal Meier (Londen), Guy Slavesen (San Diego), Henning Walczak (Heidelberg), Peter Vandenabeele (Gent), Jan Paul Medema (Leiden), Jürg Tschopp (Lausanne), Clemens Schmitt (Berlijn), Boudewijn Burgering (Utrecht) and Wafik El-Deiry (Philadelphia).

Chromatin and Gene Regulation

Organization: Dr. B. van Steensel and Prof.dr. M van Lohuizen
Time: 31 January - 11 February 2005
Location: NKI

The course consisted of 8 afternoon sessions (all supervised by the organisers), each with

- *2x45 min literature discussion.*
- Each student discussed one paper in detail in a ~25 min PowerPoint presentation. For each paper, one other student was asked to write a Referee Report, highlighting the strengths and weaknesses of the paper. This referee report was discussed.
- *A seminar by an internationally renowned guest speaker*
- *45-60 min discussion with the speaker.*
- All students were actively participating in these discussions, with many questions and critical remarks, especially since the literature before was chosen in the field of the guest-speaker's seminar.

In addition, the students had to prepare for the sessions by reading a total of ~10 reviews and 16 research papers.

Speakers and topics were all of internationally high quality

- Giacomo Cavalli - Institute of Human Genetics, Montpellier: Polycomb and Nuclear Compartmentalization in the fruit fly
- Robin Allshire - Wellcome Trust Centre for Cell Biology, Edinburgh: RNA interference and silent chromatin: formation
- Peter Verrijzer - Erasmus University Medical Centre, Rotterdam: Chromatin regulation in development and disease
- Denise Barlow - Center of Molecular Medicine, Vienna: Imprinting and gene silencing - distinct events for imprinted genes?
- Peter Fraser - The Babraham Institute, Cambridge: Higher-order chromatin structure and nuclear organization of transcription

- Tom Misteli - NIH/NCI, Bethesda MD, USA: Dynamics in chromatin structure and function
- Stephen Baylin - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore MD, USA: Altered Chromatin, Gene Silencing and the Progression of Cancer
- Steven Henikoff - Fred Hutchinson Cancer Research Center, Seattle WA, USA: Assembly of variant H3 histones into chromatin.

The seminars were rated very good with an average of 8.0. The overall rate of the course was excellent with an 8.6.

21 PhD students participated in this course.

Viral Oncogenesis

Organization: Prof.dr. J Middeldorp, Prof.dr. C.J.L.M. Meijer, Dr. P.J. Snijders
Time: 30 May - 1 June 2005
Location: VUmc

The program consisted of three days with on day 1 the focus on HPV and human tumour development, day 2 EBV and human tumour development and on day 3 Other pathogens involved in human tumour development

Each day included basic morning lectures and afternoon face-to-face discussions with renowned invited speakers and a round-up session. Topics included basic aspects of virus-driven lymphomagenesis and carcinogenesis, deregulation of cell-cycle, intracellular signalling, growth factor modulation, apoptosis-resistance, immune escape, but also more clinical aspects of immunology, immunotherapy and diagnostic/prognostic applications

The invited speakers included:

HPV:

- Dr. Mariet Feltkamp, LUMC, Leiden
- Dr. Massimo Tomassino, IARC, Lyon, France

EBV:

- Prof. Dorothy Crawford, University of Edinburgh, Scotland, UK
- Prof. Paul Farrell, Imperial College, London, UK
- Prof. Gerald Niedobitek, University of Erlangen-Nurnberg; Erlangen, Germany
- Prof. David Thorley-Lawson, Tuft's University, Boston, USA
- Prof. Lawrence Young, University of Birmingham, Birmingham, UK

KSHV:

- Prof. Thomas Schulz, University of Hannover, Germany

H.Pylori:

- Dr. A.H.M. van Vliet, Erasmus MC, Rotterdam

22 PhD students attended this course that was overall evaluated by an 7.7.

Breastcancer

Organization: Prof.dr. M van der Vijver

Time: 20 June - 1 July 2005

Location: NKI

12 PhD students participated in this course.

The course was organized on diagnosis, treatment and genetic research of breast cancer.

There was a strong emphasis on translational research. Topics that were covered included: Epidemiology of breast cancer, including familial breast cancer; radiological techniques; biopsy; surgery; radiotherapy; systemic treatment and genetic studies of breast cancer, including gene expression based predictive and prognostic classifiers.

In the footsteps of Antoni van Leeuwenhoek

Organization: Dr. G.A. Meijer, Prof.dr. P. Peters, Prof.dr. R.J.C. van Noorden
Time: 27 June - 8 July 2005
Location: VUmc

This year there was a practical course in Microscopy.

The course was evaluated good (8.0). Since only three people participated the course was very closely adapted to the individually needs of the students.

Functional Genomics

Organization: Dr. R Beijersbergen and Prof.dr. R Bernards
Time: 26 - 30 September 2005
Location: NKI

The course consisted of seminars given by people from inside and outside of the OOA and literature discussions of the subjects presented during the seminar or related fields.

List of guest speakers:

Echeverri (Cenix Bioscience, Dresden, Germany)
Richard Janssen (GalAdeno, Leiden)
Perrimon (Harvard Medical school/HHMI, Boston, USA)
Sander van den Heuvel (Department of Developmental Biology, Utrecht - University, Utrecht)

The seminars were rated well by the participants of the course. The students rates the aspects as level of introductions, literature discussions, amount of literature and insight obtained in area on average good. The overall rate of the course was 7.5.

The course was attended by 22 PhD students from the OOA.

Annual graduate student retreat

Organization: Prof.dr. T Sixmaand M. van der Velde
Time: 9-11 November 2005
Location: Hotel Opduin, De Koog, Texel

This year 78 PhD students attended the retreat of which 58 from the NKI, 12 from the AMC and 8

from the VUMC. Unfortunately, the retreat overlapped with other congresses and some courses what lowered the amount of participation. The new and well evaluated format of 2004 was continued.

Radiation Oncology Course

Organization: Dr M.V.M. lafleur
Time: 28 november - 2 december 2005
Location: VUmc

In the course the rationale for the use of radiotherapy in oncological patients was addressed. Topics of the course included: effects of irradiation on DNA, the cellular basis of radiotherapy, radiation injury to tumours and normal tissues, the physical principles of radiotherapy and the use of radiotherapy in the treatment of common malignant diseases.

Also practical work in treatment planning of a virtual patient was part of the course.

New and exciting developments in radiotherapy were discussed.

The course was accessible for multi disciplines. Both fundamental and clinical PhD students attended the course and evaluated the course as good, informative and accessible (overall rate 7.9).

19 PhD students attended this course of which, 6 from the NKI, 5 from the AMC and 8 from the VUmc.

Miscellaneous courses

First year graduate students were stimulated to follow an introduction course on oncology either the NKI course of lectures: "Experimental Oncology" or the "Basiscursus Oncologie: Introductie tot de klinische en fundamentele oncologie" organized by the NVvO (Nederlandse Vereniging van Oncologie).

Besides the specialized oncological courses the graduate students followed several general courses such as courses on biostatistics and epidemiology, on laboratory animal technology and on presentations techniques. These courses were organized by the AMC, VUmc and NKI.

The NDDO (Navigator in Oncology Drug Development) organized several congresses where the students of the OOA were welcome for a reduced price.

7 PhD students participated in the 3rd International symposium on targeted anticancer therapies held from 3-5 March 2005.

4. PhD projects and PhD students

Summary of PhD projects carried out within the OOA. This table shows a summary of all PhD projects carried out within the OOA. For the projects that were ended either in 2004 or 2005 it is shown after the startdate.

Funding:

- 1 Financed by the participants (eerste geldstroom)
- 2 Financed by public funds (tweede geldstroom)
- 3-4 Financed by private funds (derde / vierde geldstroom)

Theme 1A: Oncogenesis

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Clinical Genetics and Antropogenetics (VUmc)				
S. Bakker	The Achillesheel of tumours with the Fanconi anemia phenotype	Joenje/te Riele	2005	1
E. Blom	Structuur en functie van Fanconi anemie genen	Arwert / Joenje	2000	1
F. Léveillé	Cloning and characterization of the Fanconi anemia genes FANCE and/or FANCF	de Winter / Joenje	1999	3
M. Levitus	De rol van Fanconi anemie genen bij transcriptie-regulatie	Waisfisz / Joenje	1999/ 2005	1
Molecular Biology (NKI)				
M. Aarts	High-throughput gene modification by single-stranded DNA oligonucleotides	Te Riele	2004	4
B. Evers	Mammary tumorigenesis in conditional tumor suppressor gene knockout mice	Berns	2003	2
F. Foijer	Specific and redundant functions of the retinoblastoma suppressor gene family in growth control and differentiation	Te Riele	2000	3
P.-A. Genest	Function of a new modified base in DNA, β -D-glucosyl-hydroxymethyluracil (J) and its interaction with proteins	P. Borst	2001	
H. Holstege	The role of BRCA1 and BRCA2 loss-of-function in breast cancer	Berns	2002	3
R. van Leuken	Roles of human Cyclin-dependent kinase subunits HsCks1 and HsCks2 in mitotic progress	Bernards	2003	3
M. Sonneveld	Genetic and environmental modification of ...	Te Riele	2000	3
T. Vormer	The identification of oncogenic events collaborating with loss of function of the retinoblastoma gene family in tumor development and progression	te Riele	2003	3
M. van Vugt	The influence fo extracellular factors on G2-M transition	Medema	2000/ 2005	3
B. van de Weerdt	Checkpoint function in mitosis	Medema	2001	2
E. Wielders	Subtle gene modification to study the role of the mismatch repair complex Msh2/Msh5 in mutation avoid	Te Riele	2004	3
Z.-J. Yu	Function of a new modified base in DNA, β -D-glucosyl-hydroxymethyluracil (J) and its interaction with proteins	P. Borst	2001	
W. van Zon	Control of Mitosis by regulated protein destruction	Wolthuis	2004	1
Molecular Carcinogenesis (NKI)				
L. Carlée	The regulation of the expresion of hTERT, the catalytic subunit of telomerase during immortalization and tumorigenesis	Berns	1999	3
M. Creighton	Dephosphorylations of retinoblastoma family proteins by PP2A	Bernards	2000	3
M. Epping	Molecular basis of anti-cancer activity of HDAC inhibitors	Bernards	2002	4

Name	Title of the project	Supervisor(s)	Start	Funding
A. Fabius	Molecular barcode screens to identify genetic interactions with protein kinases in mammalian cells	Beijersbergen	2004	3
A.C. Faesen	3D repertoire	Sixma	2005	2
P. Knipscheer	Crystal structure determination of the components of an E2/E3 ligase ubiquitination system involved in cell cycle control	Sixma	1999	2
R. Kortlever	Senescence rescue screens	Bernards	2002	1
H.J. Kuiken	HCD/HT using RNAi technology	Bernards	2005	4
J. Mullenders	High throughput functional screens for stable loss-of-function phenotypes	Bernards	2003	3
G. Natrajan	Structural studies of DNA Mismatch repair	Sixma	1999	2
S. Nijman	Genetic screens to identify cancer-relevant genes	Bernards	2001	2
J. Nijwening	Development & application of shRNA in cell based screening technologies	Bernards	2005	4
K. Repanas	Function structure studies of components of the lines retroposition machinery	Perrakis	2001	
A. Reumer	LI & Alu elements: Structural and functional analysis of human non-LTR retrotransposons	Sixma	2005	2
M. Vargas	Structural analysis of the mechanism of ubiquitin conjugation	Sixma	2004	2
Molecular Genetics (NKI)				
A. Alendar	Identificaiton of the PIM regulatory network by micro array analysis and high through put retroviral tagging	Berns	2002	3
R. van Amerongen	Frat-signaling + retroviral insertional mutagenesis (high throughput)	Berns	1999/ 2005	3
E. Boutsma	Functional analysis of BMI-ring finger interacting proteins and application of microarray technology to identify BMI-1 response genes	Bernards	2000	3
U. Braunschweig	Genome-wide analysis of chromatin structure	Van Lohuizen	2005	2
S. Bruggeman	Characterisation of oncogenic potential and mechanism of gene repression of TBX2	v. Lohuizen	2003	3
T. Geiger	Oncogenic function of human DRIL1	Berns	2003	3
T. Kuilman	Novel functional genomic screens to identify pathways that protect mouse & human cells against oncogenic transformation by mutant RAS	Berns	2003	2
M. Lingbeek	Mechanism of transcriptional repression by TBX2 and functional screens to identify S-phase and G2-M phase checkpoint components	Bernards	2000/ 2005	2
A. Loonstra	A new generation of conditional mouse mutants to study onset progression and therapy of a wide range of defined tumors	Berns	1998	3
C. Michaloglou	Senescence-like replicative arrest in melanocytic naevi: a melanoma-suppressive mechanism?	Peeper	2003	1
E.H.M. van Montfort	Development of a mouse model to study the genetic basis of malignant mesothelioma	Berns	2000	3
B. Rowland	The role and mechanism of escape from Ras-induced senescence in oncogenesis	Peeper	2000/ 2005	3
M. Smit	The role of the neurotrophic tyrosine kinase receptor	Berns	2005	3
P. van der Stoop	Genetic screens to identify new components of the senescence/immortalization pathway	Bernards	2000	3
P. Taghavi	Functional analysis of BMI1-ring finger interacting proteins and application of microarray technology to identify BMI1-responsive genes	Van Lohuizen	2000	3
L. Vredeveld	The role and mechanism of escape from Ras induced senescence in oncogenesis	Peeper	2002	3

Gynaecology (VUmc)

B. Hermsen	Risk assessment and preventive measures in women at high risk of developing breast and ovarian cancer	von Mensdorff-Pouilly / Kenemans	2002	4
M.E. Nowee	Oncogenic factors in ovarian and tubal carcinoma	Verheijen	2002	4

Oral and Maxillofacial Surgery and Pathology (VUmc)

J.F. Bremmer	Diagnosis and therapy of genetically altered mucosal lesions in the oral cavity and oropharynx	van der Waal / Brakenhoff	2002	1
--------------	--	---------------------------	------	---

Otolaryngology/Head and Neck Surgery (VUmc)

P.K.E. Börjesson	Tumordetection and -therapy with radiolabeled monoclonal antibodies in patients with head and neck cancer	van Dongen / de Bree	2000	1
A.P. Graveland	Molecular diagnosis of head and neck squamous cell carcinoma (HNSCC)	Brakenhoff	2005	3
S. Smeets	Multi-step head and neck carcinogenesis	Brakenhoff	2003	1
B.M. Visser	A quantitative proteome progression model for squamous cell cancer	Brakenhoff	2004	4
H.J.T. Zeeburg	Innovative therapies of precancerous lesions in the oral cavity and oropharynx	Brakenhoff	2004	1

Pathology (VUmc)

J. van Beek	Characterization of BAP1 as a potential target for immunotherapy of Epstein-Barr virus carrying gastric carcinomas	Meijer / Middeldorp	1999 / 2005	3
R.H.M. van den Berg	Bronchial carcinogenesis: unraveling of the multistep pathways using well-defined clinical material	Snijders/Smit	2003	2
M.M.C.G. Bleeker	Preventie van persisterende HPV gerelateerde PIN en CIN laesies door condoomgebruik	Snijders / Meijer	1999 / 2005	2
L.J.W. Bosch	Methylation for Early Colorectal Cancer Detection - MECCAD	Meijer GA	2005	4
S.S. Bulk	Bepaling van de tijdsduur vanaf infectie met HPV tot het ontstaan van baarmoederhalskanker door normale archiefuitstrijkjes van vrouwen met cervixcarcinoom te testen op HR-HPV	Meijer / Rozendaal	2001/ 2005	2
N.W.J. Bulkman	HPV-BOB	Snijders / Meijer	2001	2
S.A.G.M. Cillessen	Functional analysis of apoptosis signaling pathways in B-cell lymphomas	Oudejans / Meijer	2003	3
M. van Duin	Progression of high risk HPV containing premalignant cervical lesions: role of HPV variants and loss of heterozygosity of putative tumor suppressor gene loci	Snijders / Meijer	1996 / 2004	3
J. van Galen	Polycomb expression in normal human lymphocyte development	Meijer / Oudejans	2002	4
F.E. Henken	Defining the essential molecular pathways involved in cervical carcinogenesis	Snijders	2005	1
A.T. Hesselink	HPV quantification in cervical smears: consequences for screening and management of women with equivocal cervical smears	Snijders / Meijer	2002	1
R.M. Overmeer	TSLC1 silencing, a marker for risk assessment of cervical cancer	Meijer	2005	3
J. de Wilde	Identification of an hTERT repressor on human chromosome 6 involved in human papillomavirus mediated immortalization	Snijders / Steenberg	2002	1
G.D. Zielinsky	HPV in archival smears	Meijer / Snijders	1997 / 2004	4

Anatomy and Embryology (AMC-UvA)

Y. He	Molecular anatomy of liver function: physiology in mice with a conditionally inactive glutamine synthetase gene	Lamers	2000	3
M. Hoogenkamp	Molecular mechanisms underlying the heterogeneous expression of proteins in the liver	Lamers	1999	2
M. de Julio	Molecular anatomy of liver function: identification of a signal-transduction pathway that causes pericentral gene expression in the liver	Lamers	2000/ 2004	
J.L.M. Schoneveld	Structure-function relations in normal and cirrhotic liver	Lamers	1998/ 2004	1
M. Sokolovic	An integrated genomics approach towards gut health	Lamers	2002	2
V. Stanulovic	Spatio-temporal regulation of the expression of glutamine synthetase: mechanism of synergistic interaction between upstream, intron and downstream regions	Lamers	2000	2

Biochemistry (AMC-UvA)

N. Dekker	Alpha-(1,3)-glucan transglycosylases as novel targets for antifungal drug design	Hochstenbach/ Aerts	2000/ 2007	2
A. Kragt	The involvement of the endoplasmic reticulum in peroxisome formation	Tabak	1999/ 2005	2
K.M. Piekarska	The role of peroxisomes in infections caused by the human fungal pathogen, <i>Candida albicans</i>	Distel/ Hochstenbach	2000	1
A.Vos	Biosynthesis of cell-wall alpha-glucan in yeasts	Hochstenbach/ Aerts	2002	1
C.Williams	Function of PTS1 receptor Pex5p in proteinimport in peroxisomes	Distel/Aerts	2002	1

Cell Biology & Histology (AMC-UvA)

J.M.E.D.Gillis	When protein degradation fails	Reits/Van Noorden	2005	2
H.A.G. Krol	Role of peptidases in polyglutamine disorders	Reits/ Van Noorden	2004	1
C.Q. Lisman	Intracellular glycolipid transport and translocation of the cell surface	Van Meer/ Holthuis	2000/ 2004	1
P. Krawczyk	Double strands DNA breaks and their repair	Aten/v. Noorden	2003	3

Center for Experimental Molecular Medicine (AMC-UvA)

J.J. van Baal	Proteomics and expression-arrays for solving molecular mechanisms involved in the metaplastic transformation of inflamed squamous epithelium into Barrett's oesophagus	Peppelenbosch / v Deventer	2002	3
S.A. Bleumink	Morphostasis of the adult gastrointestinal tract	Peppelenbosch / v Deventer	2002	1
C.L. Bos	In vivo action of novel anti-cancer therapeutics	Richel	2001/ 2006	1
H. Braat	Innovative feedingintervention in patients with chronic inflammation	Van Deventer	1999/ 2006	3
S.H. Diks	Tissue factor-dependent signalling	Van Deventer	1999	2
L. Kodach	Early detection of colorectal cancer using proteomic technology	Van Deventer	2003	3
A.M. Rygiel	Follow-up study of a cohort of Barrett's oesophagus patients by brush cytology and fish	Van Deventer	2003	2
F. Milano	Molecular basis for metaplasia and displasia in the esophagus and stomach	Van Deventer	2003	3
J.B. Tuynman	A phase II study on the effects of celecoxib on several pharmacodynamic endpoints, including activity of the Wnt/b-catenin pathway, apoptosis, proliferation, and angiogenesis in sporadic colorectal polyps and colorectal cancer in human	Richel/v Deventer	2002	3

G.Hardenberg	The role of APRIL and its receptors in tumour growth and immune regulation	Medema	2005	3
F.B. Mullauer	Inventory of the anti-cancer efficacy of the plant-derived compound Betulinic acid and the clarification of the mechanisms underlying its induction of tumor-specific apoptosis	Medema	2005	3
Gastroenterology & Hepatology (AMC-UvA)				
T. Deurholt	Development and Clinical Study of a Bioartificial Liver based on Reversibly Immortalised Human Hepatocytes	Oude Elferink	2001	3
A. Groen	The pathophysiological relevance of transporters in the enterohepatic cycle	Groen/Oude Elferink	2002	2
A. Kusters	Molecular regulation of biliary cholesterol secretion	Oude Elferink	1999/ 2005	3
M. Lie-A-Ling	Isolation of a specific promoter for cholangiocarcinoma	Oude Elferink/Bosma	2000/ 2005	2
F. de Lorijn	Anorectal inhibition reflex disorders in infants	Boeckxstaens/ Benninga	2000	3
P. Mardones Hiche	The pathophysiological relevance of transporters in the enterohepatic cycle	Oude Elferink	2003	2
W.A. Marsman	Gene therapy for adenocarcinoma in esophagus	Oude Elferink	2000/ 2005	2
N. van Til	Development of a method for hepatocyt transplantation and repopulation	Oude Elferink	2001	1
Human Genetics (AMC-UvA)				
A.C.J. Ammerlaan	Genetic profiling of gliomas and their recurrences for improvement of diagnosis and prognosis	Hulsebos / Versteeg	2002	3
H.J. Gierman	The human genome: understanding functional nuclear organisation from landmarks in the human transcriptome	Versteeg	2003	1
A. Koppen	Gene silencing by Myc-oncogenes	Versteeg	2001	3
V. van der Limpt	Segmentation defects as a clue to neuroblastoma pathogenesis and differentiation	Versteeg / Westerveld	1998/ 2005	1
I.M. Revet	The role of the MEIS homeobox genes in neuroblastoma pathogenesis	Versteeg	2003	3
Laboratory of Genetic Metabolic Disorders (AMC-UvA)				
D.M. Brink	Transport processes in lipid metabolism	Wanders	2000/ 2005	1
J. Gloerich	Novel fluorescent probes to resolve the role of oxygen radicals in peroxisomal disorders: from single cell to knockout mice and patients	Wanders	2001	2
J. Gootjes	Peroxisomal biogenesis defects: molecular aspects, in vitro therapy and diagnostics	Wanders	1999/ 2004	3
S. Hoogenboom	The role of peroxisomes in mammalian cholesterol metabolism	Waterham/ Wanders	1999/ 2004	2
J. Komen	Refsum's disease: diagnosis, pathology, and treatment	Wanders	2003	3
F.J. Loupatty	Degradation of complicated chained aminoacids in man and genetic deficits	Wanders	2003	1
S.H.L. Mandey	Mevalonate kinase deficiency disorders: how does a defect of isoprenoid biosynthesis contribute to (periodic) fever and inflammation	Wanders	2002	3
R.J. Sanders	X-linked adrenoleukodystrophy and the search for new treatment strategies	Wanders	2002	3
W.F. Visser	Identification and characterisation of proteins involved in metabolite transport across the peroxisomal membrane	Wanders	2000/ 2005	2
N. van Vlies	Carnitine Biosynthesis, transport and pathophysiological role in human	Wanders	2002	3
M. Chegary	Pathogenesis and treatment of mitochondrial fatty acid oxidation	Wanders	2005	3
M.S. Ebberink	Identificatie van het primair onderliggend defect in de groep patiënten met een peroxisomaal defect van onbekende origine	Wanders	2005	3

L.Henneman The link between isoprenoid metabolism and periodic Wanders 2005 3
fever, inflammation and dysregulation of apoptosis

Theme 1B: Tumor cell biology

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Cell Biology (NKI)				
J.I. van den Bout	The role of $\alpha 3\beta 1$ integrin in the development and pathophysiology of the glomerulus	Sonnenberg	2000	3
S. Ellenbroek	Tiam1/Rac signaling and wnt/beta-catenin-induced tumorigenicity	Collard	2004	3
A. Hajdo-Milasinovic	Ras en Rho signaling networks and epithelial-mesenchymal transition	Collard	2001	3
S. Huveneers	Cooperation between the SRC oncogene and integrin $\alpha v\beta 3$ in oncogenic transformations of epithelial cells	Danen	2003	3
M. Ketema	Analysis of the function of a novel nuclear envelope protein, nesprin 3 in anchoring the nucleus to the intermediate filament system	Sonnenberg	2005	2
M. Langeslag	Signalling function of membrane potential	Jalink	2000	1
S. Litjens	The role of the integrin $\alpha 6\beta 4$ in signal transduction controlling cell proliferation	Sonnenberg	1999	1
J. Meijer	Role of the chemokine SDF-1 and its receptor CXCR4 in carcinoma and melanoma metastasis	Roos	2003	3
S. Mertens	Initiation and progression of lymphomas and skin carcinogenesis in Tiam1 mutant mice	Collard	2001	3
J. van Rheenen	Localized phosphoinositide signals	Jalink	2000	2
T. Rygiel	Function based screening for genes involved in invasion of epithelial tumor cells	Collard	2002	3
N. Sachs	Function of integrin-CD151 complexes in tumor cell invasion and metastasis	Sonnenberg	2004	3
I. Zeelenberg	Chemokine receptor homologues: role in dissemination of hemopoietic malignancies	Berns / Roos	1998/ 2004	3
Cellular Biochemistry (NKI)				
C. Berkers	Chemistry-based functional proteomics, new tools for cancer biology	Oova	2004	1
F. Frederiks	The role of histone methylation in the regulation of gene expression	Van Leeuwen	2004	1
J. Hendriks	Role of the CD27/CD70 receptor/ligand pair in control of the immune response	J. Borst	1998/ 2004	2
A. Los	Role of diacylglycerol kinases in cell cycle progression and cytoskeletal organisation	v.Blitterswijk/ Moolenaar	2000	3
L. van Meeteren	LPA receptors: signaling, migration and proliferation	Moolenaar	2001	3
J. Mulder	Rho signaling	Moolenaar	1998/ 2005	3
B. Ponsioen	LPA receptor signaling	Moolenaar	2003	3
G. Valdimarsdottir	TGF β signal transduction in endothelial cells	Ten Dijke	1999/ 2004	3
K. Verzijlbergen	The role of histone methylation in gene silencing and transcriptional memory	v. Leeuwen	2005	2
A. Werner	Role of TNF receptor family members and the Flice protease in apoptosis induction	J. Borst	1998/ 2004	3
L. van Zeijl	Cell-cell connexin signalling: suppression of cell transformation	Moolenaar	2000	3
Immunology (NKI)				
A.H. Bakker	Analysis and manipulation of tumor specific T cell immunity	Schumacher	2002	2
A.D. Bins	Melanoma-specific Tcell immunity in advanced-stage melanoma patients	J. Borst	2001	1
M. Coccoris	Dissecting virus-specific cytotoxic T cell immunity	Kruisbeek	2000	2
C. Gerlach	Cellular barcoding and dissection of T cell differentiation	Schumacher	2005	1

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
M. Heideman	Role of translesion DNA synthesis in Immunity and Cancer Development	J. Borst	2005	2
J. van Heijst	Tracing lineage relationships by cellular barcoding	J. Borst	2004	?
A. Jorritsma	Analysis of vaccine-induced melanoma specific T-cell immunity: a combined human + mouse study	Haanen	2002	3
A.M. Keller	Cellular and molecular basis of effector and memory T cell responses	J. Borst	2002	1
P. Langerak C. Maas	Complementation tagging and lymphocyte development Apoptosis signaling of BH3-only protein Bid, mechanism of action and modes	J. Borst	2003	4
V. Peperzak	The role of CD27/CD70-retulated cell survival in shaping effector and memory T cell responses	J. Borst	2004	2
K. Schepers	Molecular analysis of the cytotoxic T cell response	Kruisbeek	1999	1
S. Schnell	Control of T-cell differentiation	Berns	2003	4
I. Verbrugge	Tumor therapy with ionizing radiation and death ligand Trail efficacy and key mol. Determinants	J. Borst/M. Verheij	2004	3
M. Witte	Induction of T-cell immunity through adoptive transfer of T cell receptors	J. Borst	2003	2
Tumor Biology (NKI)				
R. Bernad	Identification of specific transport pathways through the nuclear pore complex	Fornerod	2001	2
J. Drost	Identification and characterization of human tumor suppressor genes in the p53 pathway	Agami	2005	3
J. van Duijse	Genome wide screens for DNA-damage check point in human cells	Agami	2005	4
A. Duursma	Activated proteolysis in response to DNA damage	Agami	2001	1
D. Engelsma	Synthetic transport signals to predict and regulate nucleocytoplasmic transport	Fornerod	2002	1
A. Griekspoor	The peptide transport TAP inhibitor US6 as a lead to generate novel drug transporter inhibitors	Neefjes	2000	1
T. Groothuis	Characterization of SNARES involved in degranulation of human CTLs	Peters	2000	2
J. Hendriksen	Role of the nuclear pore complex in β -type catenin nuclear signalling	Fornerod	2001	2
T. van den Hoorn	Defining the MHC class II microdomain to understand immune responses	Neefjes	2004	3
I. Jordens	Regulatie MHC klasse II transport	Neefjes	1999/ 2005	2
B. Kalverda	The role of RamBP3 in beta cetenin dependent nuclear signaling and oncogenesis	Fornerod	2004	3
M. Kedde	Studying tumorigenesi using RNAi	Neefjes	2003	3
C. Kuijl	The role of interleukin 10 in immune suppression of tumor responses	Neefjes/Spits	2002	2
M. Marsman	Immunology and parasite-host cell biology of mcrobacterium tuberculosi infections: towards rational vaccine designs	Neefjes	1999	2
R. Nagel	Genome wide search for DNA damage checkpoint functions in humans	Neefjes	2005	4
J. Neijssen	Peptidases and improving the MHC class I response	Neefjes	2002	2/1
N. Rocha	Structure elucidation of cord7 and complexe	Perrakis	2001	1
C. le Sage	Activated proteolysis, a novel rapid resopnse to DNA damage	Agami	2002	2
I. Salomon		Neefjes	2005	4
Y. Souwer	The role of HLA-DO and HLA-DM in effective MHC class II mediated immune activaion	Van Ham/Neefjes	2001	2
V. Theodorou	Cloning of novel mammary tumor progression and metastasis genes	Hilkens	2001	2
A. Zwaagstra W. Zwart	Molecular basis of resistance to anti-estrogens	Hilkens Michalides	2005 2003	1

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Medical Oncology (VUmc)				
B.G. Molenkamp	Immunomodulation of the melanoma sentinel lymph node	de Gruijl	2004	3
D. Oosterhoff	In situ targeting and modulation of dendritic cells for tumor immunotherapy	de Gruijl	2004	2
M.H. Verheije	Development of targeted coronavirus for selective lysis of human cancer cells	Gerritsen	2001	3
Molecular Cellbiology and Immunology (VUmc)				
E.M. van Beek	SIRP-alpha-CD47 interactions in viral and tumor immunity	van den Berg	2003	1
G. van der Bij	Role of macrophages in peritoneal and liver metastasis	van Egmond / Beelen	2003	1
S.J. Oosterling	Prevention of metastases outgrowth after surgery of primary colon carcinoma	van Egmond	2002	1 / 3
Obstetrics and Gynaecology (Vumc)				
M. Moreno	Study of MUC1 as a target for the immunotherapy of patients with breast and ovarian carcinomas	Von Mensdorff-Pouilly / Scheper	2004	1
Pathology (VUmc)				
P.A.J. Krijnen	Epstein-Barr virus LMP1,2 specific immunoreactivity and immunotherapy in Hodgkin's Disease	Middeldorp	2005	3
J. Muris	Apoptose resistentie als oorzakelijk factor in lymfomen met een slechte reactie op chemotherapie	Oudejans / Dukers	2000 / 2004	4
S.J.A.M. Santegoets	Development of the human MUTZ-3NM Dendritic Cell (NMDC) line model towards semi-allogeneic tumor vaccination	de Gruijl / van den Eertwegh / Scheper	2002	3/4
K.B.J. Scholten	NFAT controlled isolation and redirection of virus specific human T cells	Hooijberg	2001	2
R. van de Ven	ABC Transporters in dendritic cell function	Scheffer / de Gruijl	2003	3
Pathology (AMC-UvA)				
E.M.J. Boon	Regulation of cell adhesion and migration with inflammation and tumormetastasis; adhesionmolecule CD44, growthfactors, and receptor tyrosine kinases in the regulation of invasivity, metastases, proliferation and apoptosis of coloncarcinomas	Pals	2000/ 2006	3
D. Gorter	Functional and molecular analysis of HGF/Met signaling in germinal center B cells and B cell neoplasia	Pals	2000	3
E. Tjin	Regulation of cell growth and survival in multiple B cell neoplasia	Pals/ Spaargaren	2000/ 2005	1
R. Groen	Heparan sulfate proteoglycans and HGF activator in HGF/MeT-signaling and lymphomagenesis	Pals/ Spaargaren	2003	2

Theme 2A: Tumordiagnosis

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Gynaecology (Vumc)				
E.M. Davelaar	Serum tumour markers in cervical carcinoma	Verstraeten	2004	2
M. Verbruggen	Clinical and molecular aspects of borderline ovarian tumours	Dorsman	2002	1
Hematology (VUmc)				
J. Zijlstra-Baalbergen	Response monitoring in non-Hodgkin's lymphoma using Positron Emission Tomography	Huijgens / Lammertsma	2003	1
Nuclear Medicine (VUmc)				
W. Direcks	Experimental and clinical studies using positron emission tomography (PET) for monitoring response to chemotherapy in (locally) advanced breast cancer	Molthoff / v.d. Wall	2003	3
J. Emmering	Towards a rational use of PET in breast cancer patients	Teule	2003	1
G.J.M. Herder	The introduction of PET in clinical oncology: evaluation in non-small cell lung cancer	Teule	2003	2
A.J. de Langen	Restaging the mediastinum after induction chemotherapy for stage IIIA-N@ NSCLC: biological determinants of FDG-PET results	Hoekstra	2005	
U. Joshi	Evaluation of scanners for positron emission tomography in oncology	Hoekstra	2004	1
A.A.M. van der Veldt	¹⁸ F-FDG Uptake in carcinoma of the cervix measured by positron emission tomography and biological characteristics	Molthoff	2003	1
Otolaryngology / Head and Neck Surgery (VUmc)				
L.R. Perk	Molecular imaging with PET using long-lived positron emitters	van Dongen	2003	2
A. Senft	Screening for distant metastases and second primary tumors with FDG-PET (the school study)	Leemans	2002	2
B.M. Tjink	Antibody-based therapy with emphasis on head and neck cancer	Van Dongen / de Bree	2004	3
Pathology (VUmc)				
R. van den Berg	The use of molecular biomarkers in early lung cancer	Snijders	2003	2
T. Buffart	Predicting lymph node status in gastric cancer by DNA-based genomic profiling for stratifying surgical therapy	vd Velde / Meijer	2004	3
A. Hardebol	CRC screening by faeces DNA based testing using chromosome 20q genes	G.A. Meijer	2005	4
H. Vekony	Characterization and prognostication of salivary gland tumours	Bloemena	2004	4
S.M. Wilting	Distinction of early, intermediate and late cervical intraepithelial neoplasia grade III (CIN III) lesions by micro-array analysis	Snijders / Steenbergen	2003	3
Paediatrics (VUmc)				
N. Tan	Drug resistance testing, histology and cell biological features in childhood brain tumors and retinoblastoma	Schouten-van Meeteren	2003	4
Radiology (VUmc)				
P. de Graaf	Emission tomography in detecting vital retinoblastoma / Magnetic Resonance Imaging parameters of retinoblastoma in detecting tumor extent	Castelijns	1998	3

Name	Title of the project	Supervisor(s)	Start	Funding
B.M. Klabbers	The value of positron-emission tomography in monitoring the response of head and neck cancer in patients treated with curative radiotherapy	Langendijk / Hoekstra	2000	1
R. Ljumanovic	Prognostic value of MRI-determined lymph node parameters in development of distant metastases in head and neck carcinoma	Castelijns	2003	3
J.H. Weijs	Optimization of US selection criteria of lymph nodes (size, laterality, aspect and behaviour) to perform USgFNAC in follow-up of patients's oral cavity or oropharyngeal carcinoma	Castelijns	2005	
Surgery (VUmc)				
M. Westerterp	The role of FDG PET in eosophageal cancer staging and monitoring the response to neoadjuvant therapy	Molthoff	2005	
Surgical Oncology (VUmc)				
H. Torrença	Sentinel node procedure in breast cancer as a routine in daily practice	Pijpers	2002	3
Pathology (UvA/AMC)				
R. Carvalho	Molecular genetic changes during gastric carcinogenesis	Offerhaus	2002	1
W.W.J. de Leng	Carcinogenesis in het Peutz-Jehgers syndroom	Offerhaus	2002	3

Theme 2B: Prevention and therapy of tumors

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Clinical Oncology (NKI)				
B. Kroon jr.	Dynamic sentinel node biopsy & predictive factors for regional metastases in penile cancer	Horenblas	2003	1
Experimental therapy (NKI)				
N. Appels	The use of novel pharmacodynamic end-points in early clinical trials: focus on farnesyltransferase	Schellens/Beijnen	2001/ 2005	1
P. Breedveld	Implications of activity of BARC for the in vivo pharmacology of substrate drugs	Schellens	2001/ 2005	4
F. Greil	Chromatin Profiling	Van Steensel	2002	1
J. Hannemann	Micro array analysis of breast cancer as a diagnostic tool to guide optimal treatment	Van de Vijver	2002	3
A.E. van Herwaarden	Generation and validation of cytochrome 450 3A k-o and transgenic mice as tools for improved DDR	Schinkel	2001	3
H. Janssen	Hypoxia and perfusion in human tumors: quantification and implications for treatment outcome	Begg/ Hausterman	2000	3
M. Kok	Molecular prediction of therapy outcome in breast cancer	Van 't Veer	2004	4
B. Kreike	Micro-array analysis of breast cancer as a diagnostic tool to guide optimal treatment	V.d. Vijver	2001	1
J. Lagas	Impact of the multidrug transporters p-glycoprot., MRP2 and BCRP on the behaviour of anti-cancer drugs	Schinkel	2004	4
S. Neijenhuis	Determinants of radiosensitivity	Begg	2003	3
R. Oostendorp	Preclinical and clinical pharmacology of oral drugs	Schellens/Beijnen	2004	4
D. Peric-Hupkes	Chromatin Profiling of Human gene silencing complexes	V. Lohuizen	2004	2
E. van der Steeg	The impact of OATP drug carriers on in vivo pharmacology toxicology & physiology	Beijnen	2004	4
M.L. Triesscheijn	mTHPC-mediated photodynamic therapy (PDT): how do drug uptake and distribution influence tumor and normal tissue responses?	Stewart/Baas	2001	3
S. Veltkamp	Clinical Pharmacology of oral gemcitabine and other (oral) anti-cancer agents	Schellens/Beijnen	2003	4
C. Vermeulen	Determinants of radiosensitivity	Begg	2002	3
M. Vlaming	Compound Mrp2 (Abcc2) and other drug transporter knockout mice to study determinants ...	Schinkel	2003	3
M. Vogel	Functional Genomics of Gene Regulation by heterochromatin proteins	Van Steensel	2002	3
A. Vrieling	The IGF system in breast and colorectal carcinogenesis: dietary intervention and mol. studies	Van Leeuwen	2002	3
R. van Waterschoot	Generation and validation of cytochrome P450 3A knockout and transgenic mice as tools for...	Beijnen	2005	2
B. Weigelt	Minimal residual disease detection in breast cancer	Rodenhuis/ Van 't Veer	2001/ 2005	3
E. de Wit	Bioinformatics of transcription regulation	v. Steensel	2003	1
Medical Oncology (NKI)				
J. Bueno de Mesquita	Predictive and prognostic factors in breast cancer	Linn/v.d. Vijver	2003	4
W. Lakhai	Clinical and Translational pharmacology of anti-cancer drugs	Schellens/Beijnen	2002/ 2004	4
Pharmacy and Pharmacology (NKI)				
J.H. Beumer	Metabolisme van cytostatica	Beijnen	2001/ 2004	1
T. Bosch	PK/PD and pharmacogenetics of anticancer drugs	Beijnen	2002	4
E. Brouwers	Bioanalyse van metalen (i.h.b. Platina) in biologische	Beijnen	2003	4

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
C. Ekhart	matrices m.b.v. ICP-MS Genotyping as tool for dose individualization in high-dose chemotherapy	Huitema		
J. Engwegen	Clinical proteomics	Beijnen	2003	4
M.C. Gast	Proteomics in Oncology	Beijnen	2003	4
M.E. de Jonge	Bayesian adaptive dosing in cyclophosphamide-thiotepa-carboplatin (CTC) and mitoxantrone-thiotepa (MT) high dose chemotherapy regimens	Beijnen	2001/ 2004	3
M. Kemper	Transport of taxoids across the blood-brain barrier and CNS-tumor penetration: a preclinical pharmacology study and clinical proof of concept testing in glioma	Beijnen	2000/ 2004	3
M. Klous	Pharmaceutical development of diacetylmorphine formulations	Beijnen	2001	4
I.E. Kuppens	Improvement of oral pharmacology of anticancer drugs	Schellens	2002/ 2004	4
J. Lakhai	Clinical pharmacology of novel anticancer drugs	Beijnen	2000/ 2005	4
S. van der Schoot	Pharmaceutical development of anti cancer agents	Beijnen	2002	1
A. Zandvliet	Population pharmacokinetics & pharmacodynamics of investigational anticancer drugs	Beijnen	2003	4

Psychosocial Research and Epidemiology (NKI)

S. v.d. Belt-Dusebout	Risk of second malignancy and cardiovascular disease after treatment for testicular cancer	Van Leeuwen	2003	3
E.J. de Boer	Subfertility, IVF treatment, and age at menopause	Van Leeuwen	1999/ 2004	3
K. Douma	Long-term psychosocial impact of genetic testing among familial adenomatous polyposis families	Aaronson	2004	3
M. Hooning	Long term risk of second cancers following treatment of Hodgkin's disease, testicular cancer and breast cancer			
B. Kreukels	Effects of chemotherapy on cognitive skills and evoked potentials in women receiving adjuva treatment for breast cancer	Van Leeuwen	2000	3
C. Lammens	LFS-VHI-study -> Psychosocial aspects of genetic testing in families at high risk of multiple tumors	Aaronson	2005	3
A. van Rosmalen	The role of early life-style factors in the etiology of breast cancer	Rookus	2001	4
C. Schilder	Assessment of neuropsych. sequelae of tamoxifen & exemestane in postmenopausal women with breast cancer	Van Dam/ Schagen	2003	4
J. Verloop	Physical activity and breast cancer risk	Van Leeuwen	1997	3

Radiotherapy (NKI)

G. Borst	Optimization of conformal radiation therapy of non-small cell lung cancer by advanced 3-D planning	Lebesque	2003	3
L. McDermott	Dose verification and dose optimization of radiotherapy using portal imaging	Mijnheer/ Van Herk	2001	1
M. Smitsmans	On-line tomographic guidance for RT of the prostate	Bartelink	2003	4
S. Vink	Improvement of tumor response by combined modality treatment: a translational approach	Verheij	2001	3
J. Wolthaus	Optimization of conformal RT of non-small cell lung cancer by advanced 3-D planning	Bartelink	2003	3

Gastroenterology (VUmc)

J.S. Terhaar sive Droste	Colorectal polyps and cancer in Amsterdam	Craanen	2005	3
--------------------------	---	---------	------	---

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Hematology (VUmc)				
C. Hess	The nature of minimal residual disease in acute myeloid leukemia	Schuurhuis / Ossenkoppele	2002	3
I. Houtenbos	Leukemic dendritic cell vaccination in minimal residual disease in acute myeloid leukemia	Ossenkoppele / v d Loosdrecht / Scheper	2001	1
A. van Rhenen	The nature of primitive clonogenic aml cells and the role in emergence of minimal residual disease in AML	Schuurhuis / Ossenkoppele	2002	4
Medical Oncology (VUmc)				
M.A.I. Abou el Hassan	Prevention of doxorubicin-induced cardiotoxicity. New approaches by using flavonoids and genetherapy	Van der Vijgh / Houben	1999/ 2004	4
A. Adema	Interaction of novel deoxynucleoside analogs with targeted agents	Peters	2003	4
A. Adema	Cellular resistance against Troxabitabine in cell lines and patient AML blast cells	Peters	2003	4
A. Adema	The fatty acid derivatives of Ara-C, CP-4055, and gemcitabine, CP-4126, enhance the cytotoxic effect of oxaliplatin and docetaxel	Peters	2003	4
M.N.A. Bijman	Docetaxel: its role in the inhibition of angiogenesis and the mechanism for induction of apoptosis	Boven / Hoekman	2001	3
I. Bijnsdorp	Dual role of thymidine phosphorylase inhibition; enhancement of cytotoxicity and angiogenesis	Peters	2005	3
I. Bijnsdorp	In vitro activity and mechanism of action of multidrugs	Peters	2005	3
L.E. Bröker	Oral taxanes anticancer drugs	Giaccone	2000	4
A. Checinska	The role of caspases in the sensitivity of lung cancer cells to chemotherapy	Kruyt / Rodriguez	2002	3
H. van Cruijssen	Clinical trials with receptor tyrosine kinase inhibitors in patients with advanced cancer	Hoekman	2004	3
M.L. Janmaat	Mechanisms of cytotoxicity of EGFR pathway inhibitors in epithelial cancers	Rodriguez / Kruyt	2000	4
M. Ferrer-Espinosa	Sensitizing tumor cells for cross-linking agents by disruption of the Fanconi anemia pathway	Kruyt	2000/ 2005	2
D. Fontijn	Melanoma: the role of basic Fibroblast Growth Factor (bFGF) and inhibition of bFGF action as a target for treatment	Boven	2000/ 2005	3/4
M.I. Gallegos Ruiz	Mutational and functional analysis of the EGFR pathway in NSCLC patients: correlation with prognosis and response to small molecule EGFR inhibitors	Giaccone	2005	3
C. Lemos	Folate supplementation in chemotherapy: increase of efficacy versus induction of drug resistance	Peters	2005	3
R. Mauritz	Increased thymidylate synthase (TS) but unaltered dihydropyrimidine dehydrogenase (DPD) mRNA levels after administration of 5-fluorouracil (5-FU) to patients with colon cancer	Peters	1998	2
R.A. Middelburg	Drug transport and molecular consequences in vivo	Lankelma / de Haas	2001	3
D. Oosterhoff	Enzyme/prodrug therapy: tumor-specific conversion of CPR-11 to SN-38 by the enzymes carboxylesterase and butyrylcholinesterase	Gerritsen / Haisma	1999/ 2005	3
J. Sigmond	Interaction of gemcitabine with novel molecular targets	Peters	2002	4
C.C. Sombroek	Tumor-induced suppression of DC differentiation and maturation	van Leeuwen	1999/ 2005	3
O.H. Temmink	The effect of thymidine phosphorylase inhibitor (TPI) on trifluorothymidine (TFT) sensitivity and metabolism in (colon) cancer cells	Peters	2001	4
O.H. Temmink	The Hollow Fiber Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells	Peters	2001	4
B. Vischioni	Nuclear/cytoplasmic shuttling of inhibitor of apoptosis proteins (IAP) as a regulatory mechanism for tumor progression	Rodriguez / Giaccone	2001	3

Name	Title of the project	Supervisor(s)	Start	Funding
J. Voortman	Efficacy and mechanism of combination therapy with proteasome inhibitor PS-341 (Velcade(tm)) in NSCLC	Kruyt / Giaccone	2003	4
L. Vroling	Circulating endothelial cells as markers for anti-angiogenic therapy	Broxterman	2005	3
Medical Psychology (VUmc)				
J. van Dijk	Psychosocial functioning and quality of life of retinoblastoma survivors and parents in the Netherlands	Imhof	2004	3
Neurology (VUmc)				
M.J. Vos	Neurotoxiciteit van antikankerbehandeling	Postma	2000	4
Neurosurgery (VUmc)				
S. Idema	Improving oncolytic viral therapy for glioma	Dirven / Lamfers	2003	4
Otolaryngology / Head and Neck Surgery (VUmc)				
P.A. Borggreven	Complications, functional outcome, quality of life and prognosis following surgical treatment of oral and oropharyngeal squamous cell carcinoma reconstructed by microvascular free flap transfer	Leemans	1999/ 2005	1
J. Brouwer	Investigation into cost-effectiveness of diagnostic algorithms of patients with head and neck cancer to prevent unnecessary treatments	Leemans	2000	1
C.D.L. van Gogh	Voice therapy for patients with voice problems after treatment for early glottic cancer / Voice after laryngectomy by means of a sound-producing tracheoesophageal shunt valve	Mahieu	2002	2
A.M. Lo Galbo	Hypothyroidism after treatment for laryngeal cancer	Leemans	2005	1
L. van der Putten	FDG-PET for avoidance of futile direct laryngoscopies under general anesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapy	Leemans	2005	3
L. van der Putten	Positron Emission Tomography (PET) in the diagnosis of head and neck squamous cell carcinoma (HNSCC)	Leemans	2005	3
B.M. Tijink	A multicentre, open-label, single-group study of Foscan-Photodynamic Therapy (PDT) in the palliative treatment of patients with advanced squamous cell carcinoma of the head and neck who have failed prior therapy and are unsuitable for radiotherapy, surgery or systemic chemo	Leemans	2003	3
B.M. Tijink	Electroporation therapy in patients with recurrent head and neck cancer or skin metastases without options for curative treatment	Leemans	2003	3
Pathology (VUmc)				
I. van Houdt	Involvement of resistance to apoptotic cell death in the response to immunotherapy	Kummer / van den Eertwegh	2003	1
J. Molling	Anti-tumor effector functions of skewed natural killer T cells	Scheper / von Blomberg	2002	3
S. Santegoets	Role of phosphatases as new targets in childhood cancer	de Gruijl	2002	3
S. Santegoets	T lymphocyte and dendritic cell (DC) function in patients with metastatic hormone-refractory prostate cancer treated with a GM-CSF-transduced allogeneic prostate cancer vaccine and anti-CTLA-4 antibody	de Gruijl	2002	3

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Pediatrics (VUmc)				
A.I. Buizer	Kinderen met maligniteiten: effecten van chemo- en radiotherapie op aandacht en geheugenprocessen	De Sonnevile / Njiokiktjien / Veerman	1998	4
B.F. Goemans	Cellular resistance to conventional and targeted anticancer agents in relation to molecular biological features in childhood relapsed and refractory acute myeloid leukemia	Kaspers / Zwaan	2002	4
I. Hubeek	Cytarabine resistance in childhood acute myeloid leukemia: mechanisms, modulation and clinical relevance of in vitro resistance parameters	Kaspers / Peters	2001/ 2005	4
M. Luttjeboer	Ex vivo radiosensitivity and modification by anticancer agents in pediatric brain tumors	Kaspers / Sminia	2002	4
S. Mostert	Compliance with chemotherapy in childhood acute lymphoblastic leukemia in a developing country	Veerman	2003	4
J. Vink	Glucocorticoid-induced apoptosis and glucocorticoid resistance in lymphoid malignancies and autoimmune diseases	Kaspers	2001	3/4
D.G. van Vuurden	Innovative therapy for childhood brain tumors	Cloos	2005	1
D.G. van Vuurden	Targeted therapy in pediatric brain tumors	Kaspers	2005	1
Radiology (VUmc)				
K.A. van Nifterik	Malignant glioma genetics and related chemoradiosensitivity as guidance for individualized therapy	Sminia / Hulsebos	2002	3
Radiotherapy (VUmc)				
L.G.M. van Baarsen	Human brain tumour studies: Radiosensitization & Genetics	Verweij	2004	1
Surgical Oncology (VUmc)				
H. Fabry	Strategy and results in early breast cancer	Meijer	2003	1
G. Melis	Quantifications of the generation of arginine in the kidney during liver surgery	Van Leeuwen	2001	2
M.P.C. Siroen	ADMA clearing after liverresection for metastatic cancer	Van Leeuwen/ van der Sijp	2002	2
Gastro-enterology & Hepatology (AMC-UvA)				
M.A. van Geer	Development of infectivity enhanced conditionally replicating adenovirus vectors for gene therapy of pancreatic cancer	Oude Elferink	2002	3
M.P. Kerkhoven	Optimalisation and clinical application of the AMC bioartificial liver	Chamuleau	1999/ 2004	3
Pediatric Oncology (AMC-UvA)				
J.J. Molenaar	Delineating the biological and clinical importance of CyclinD1 in neuroblastoma	Caron	2000	1
A.J.M. de Ruijter	Neuroblastoma: development of novel treatment strategies based on pharmacological gene therapy with newly designed agents	Van Gennip	2001/ 2005 2005	3
E.C. van Dalen	Anthracycline-induced cardiotoxicity in childhood cancer	Caron	2002	3
R.Cuperus	Modulation of Fenecitinide induced apoptosis in Neuroblastoma cells	Caron	2004	3
Radiotherapy (UvA/AMC)				
J. Bergs	Aberrations in premature condensed chromosomes(PCC) as a predictive assay for the response of human cervical carcinomas after radiotherapy combined with hyperthermia	Haveman/ Konings	2002	1

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
H.P. Kok	Development of an new dual modality heating technique form treatment of cancer at the esophagus and other intracavitary locations	Crezee/Konings	2002	3
A.L.J. Uitterhoeve	Results of radiotherapy alone or in combination with chemotherapy in non small cell lung cancer	Gonzalez	1998	1
J. Wiersma	Hyperthermia planning system	Gonzalez / Van Dijk	1998/ 2005	1
Surgery (AMC/UvA)				
R. Bakx	Pouch versus STE-anastomoses bij rectum-carcinoom	Van Lanschot	2001	3
C.J. Buskens	The developmet of gene therapy to prevent carcinogenesis of Barrett's metaplasia of the esophagus	Van Lanschot	2000/ 2004	1
M.C. Janssen	Locale ablatie van levertumoren: het effect van radiofrequente thermoablatie, interstitiele lasercoagulatie en cryoablatie op de acute fase immuunreactie en stollingsactivatie in de rat	Van Gulik	2001	3
I. Schoots	Transportfunctions in the small intestine	Van Gulik	1999/ 2004	3
M. Westerterp	Improving and simplifying diagnostic evaluation of oesophageal cancer with a combination of EUS-FNA and PET	Van Lanschot	2002	3
Urology (AMC-UvA)				
M.M. van Dijk	Prostaatstents in BPH	De la Rosette	2003	

5. International guests

5.1. 2004

Aird, WC, Boston (AMC)
Albers, P, Germany (AMC)
Alkema, M, USA (NKI)
Allanson, J, Canada (AMC)
Amaral Menses, R, Porto, Portugal (VUmc)
Ambt, M, Wurtzburg, Germany (VUmc)
Ashworth, A, UK (NKI)
Assaraf, YG, Haifa, Israel (VUmc)
Aubourg, P, France (AMC)

Barral, Y, Switzerland (NKI)
Basketter, DA, Sharnbrook, UK (VUmc)
Begley, T, USA (NKI)
Biondi, A, Italy (AMC)
Boardman, K, UK (AMC)
Boss, J, Atlanta, USA (VUmc)
Bryant, A, UK (AMC)
Butler, D, UK (AMC)

Camilleri, M, USA (AMC)
Cardiff, R, USA (NKI)
Casteels, M, Belgium (AMC)
Chen, GTY, Boston, USA (VUmc)
Codogno, P, France (AMC)
Constandt, L, Gent, Belgie (VUmc)
Coulie, B, Belgium (AMC)

Danpure, C, UK (AMC)
De Jesus Ferreira, AS, Portugal (AMC)
De Lange, T, USA (NKI)
De Laurenzi, V, UK (NKI)
DeVriendt, K, Belgium (AMC)
Deutsch, E, France (NKI)
Di Lorenzo, C, USA (AMC)
Dogan, N, USA (NKI)
Doz, F, France (AMC)
Duvezin-Caubet, S, Germany (AMC)

Edwards, J, London, UK (VUmc)
Eggert, A, Germany (AMC)
El-Deiry, W, USA (NKI)

Fässler, R, Sweden (NKI)
Fire, A, USA (NKI)
Flavell, R, USA (NKI)
Foulon, V, Belgium (AMC)
Fox, B, Providence, Oregon, USA (VUmc)

Friedl, P, Germany (NKI)

Gibberd, B, UK (AMC)
Ginsberg, D, Israel (NKI)
Glumoff, T, Finland (AMC)
Grabsch, H, Leeds, U.K. (VUmc)
Gruenberg, J, Switzerland (NKI)

Habets, G, USA (NKI)
Hahn, S, USA (NKI)

Hamdy, F, UK (AMC)
Hammond, P, UK (AMC)
Hauptman, M, USA (NKI)
Hawkes, D, UK (NKI)
Heidenreich, A, Germany (AMC)
Hiltunen, K, Finland (AMC)
Holmdahl, R, Lund, Sweden (VUmc)
Horn, M, Norway (AMC)
Horwich, A, UK (AMC)

Jiricny, J, Switzerland (NKI)
Julien, E, France (NKI)

Kersten, S, Germany (AMC)
Kessler, B, USA (NKI)
Kirkali, Z, Turkey (AMC)
Klein, E, USA (AMC)
Kollmeier, B, Oldenburg, Germany (VUmc)
Knapper, S, Spain (AMC)
Koski, K, Finland (AMC)
Kraus, L, USA (NKI)

Lehman, A, Sweden (AMC)
Leroy, B, Belgium (AMC)
Lilford, R, UK (AMC)
Lindhahl, T, UK (NKI)
Linsen, L, Diepenbeek, Belgium (VUmc)
Lloyd, M, UK (AMC)

Maragos, N, Rochester, USA (VUmc)
Marte, B, UK (NKI)
Masucci, M, Sweden (NKI)
McMichael, A, UK (NKI)
Meier, P, UK (NKI)
Meleti, M, Parma, Italy (VUmc)
Michiels, KNA, Leuven, Belgium (VUmc)
Mickisch, GHJ, Germany (AMC)
Molven, A, Norway (AMC)
Monach, P, Boston, USA (VUmc)
Mori, M, Japan (AMC)

Nigg, E, Germany (NKI)

Oltz, EM, Nashville, USA (VUmc)
Omari, T, Australia (AMC)
Opitz, J, USA (AMC)
Oren, M, Israel (NKI)
Orian, A, USA (NKI)

Perou, C, USA (NKI)
Perri, P, Italy (AMC)
Pines, J, UK (NKI)
Ploegh, H, USA (NKI)
Porcelli, S, USA (NKI)
Prestwich, G, USA (NKI)
Pujol, A, Spain (AMC)

Rassweiler, J, Germany (AMC)
Reinecke, C, South Africa (AMC)

Ristimäki, A, Finland (AMC)
Rosenzweig, K, USA (NKI)
Rydholm, A, Sweden (AMC)

Salvesen, G, USA (NKI)
Sauerwein, WA, Essen, Germany (VUmc)
Schmidt, A, Nürnberg, Deutschland (VUmc)
Schmitt, C, Germany (NKI)
Schofield, C, UK (AMC)
Schröck, E, Dresden, Germany (VUmc)
Schuurkes, JA, Belgium (AMC)
Senda, M, Kobe, Japan. (VUmc)
Shiloh, Y, Israel (NKI)
Silva, M, Spain (AMC)
Sisto, S, Palermo, Italy (VUmc)
Skjeldal, O, Norway (AMC)
Sniekers, M, Belgium (AMC)
Solsona Narbón, E, Spain (AMC)
Stephens, D, Cardiff, UK (VUmc)
Sternberg, C, Italy (AMC)
Stevens, M, UK (AMC)
Stoker, N, London, UK (VUmc)

Tack, T, Belgium (AMC)
Tang, N, USA (AMC)
Taymoorian, K, Germany (AMC)
Terhorst, C, Boston, USA (VUmc)
Thiesen, H-J, Rostock, Germany (VUmc)
Tschopp, J, Switzerland (NKI)
Tuveson, D, USA (NKI)

Urba, W, Providence, Oregon, USA (VUmc)

Van Dijk, J, Canada (NKI)
Van Poppel, H, Belgium (AMC)
Vassal, G, France (AMC)
Veltmaat, J, USA (NKI)
Von Ossietzky, C, Oldenburg, Germany (VUmc)

Walczak, H, Germany (NKI)
Ward, M, Southampton, United Kingdom (VUmc)
Wierzbicki, A, UK (AMC)
Wirth, M, Germany (AMC)
Workman, P, UK (NKI)
Wouters, J, Leuven, Belgium (VUmc)

Yernaux, C, Belgium (AMC)

Zlotta, A, Belgium (AMC)

5.2 2005

Adam, R, Germany (VUmc)
Alexandrov, K, Germany (NKI)
Allshire, R, UK (NKI)
Armstrong, J, Ireland (NKI)
Azpiroz, F, Spain (AMC)

Barlow, D, Austria (NKI)
Bastin, J, France (AMC)
Baylin, S, USA (NKI)
Bershadsky, A, Israel (NKI)
Benito, I, Spain (AMC)
Berthoud, H.R., USA (AMC)
Blankenstein, T, Germany (NKI)
Borset, M, Norway (AMC)
Butler, D, United Kingdom (AMC)

Camilleri, M, USA (AMC)
Casteels, M, Belgium (AMC)
Cavalli, G, France (NKI)
Codogno, P, France (AMC)
Conti, E, Germany (NKI)
Coulie, B, Belgium (AMC)
Cramer, P, Germany (NKI)
Crawford, D, Scotland, UK (VUmc)

Dawson, L, Canada (NKI)
De Pereda, J, Spain (NKI)
Dewhirst, M.W., USA (AMC)
Diffley, J, UK (NKI)
Djovadi, F, France (AMC)

Echeverri, C, Germany (NKI)
Espeel, M, Belgium (AMC)
Estrela, J.M., Spain (AMC)

Farrell, P, UK (VUmc)
Feher, M, United Kingdom (AMC)
Ferreira, S, Portugal (AMC)
Fraser, P, UK (NKI)

Ganley, I, USA (NKI)
Gasser, S, Switzerland (NKI)
Gibberd, B, United Kingdom (AMC)
Goossens, A, Belgium (VUmc)
Granville, D, Canada (AMC)
Green, D, USA (NKI)
Grundy, D, UK (AMC)

Haughey, B, USA (NKI)
Hauptmann, M, USA (NKI)
Henikoff, S, USA (NKI)
Hetteema, E, UK (AMC)
Horn, M, Norway (AMC)
Huizinga, J, Canada (AMC)

Iliakis, S, Germany (NKI)

Jaattela, M, Denmark (AMC)

Kaaks, R, France (NKI)
Kassmann, C, Germany (AMC)
Klein, B, France (AMC)

Kliman, H.J., USA (AMC)
Klimstra, D, USA (AMC)
Koster, M, USA (NKI)
Kouzarides, T, UK (NKI)
Krek, W, Switzerland (NKI)

LaCharriere, O, France (VUmc)
Largaespada, D, USA (NKI)
Levine, A, USA (NKI)
Lloyd, M, UK (AMC)
Lukas, J, Denmark (NKI)

MacFarlane, M, UK (AMC)
Mancini, M, USA (NKI)
Martin, S, Ireland (AMC)
Miska, E, UK (NKI)
Misteli, T, USA (NKI)
Müller, J, Germany (NKI)

Narod, S, Canada (NKI)
Niedobitek, G, Germany (VUmc)

Omari, T, Australia (AMC)

Pantel, K, Germany (NKI)
Pauptit, R, UK (NKI)
Perrimon, N, USA (NKI)
Petit, P, France (AMC)
Petosa, C, France (NKI)

Radicella, P, France (NKI)

Sansom, O.O., UK (AMC)
Santoro, G.A., Italy
Sauerwein, W.A., Germany (VUmc)
Serrano, M, Spain (NKI)

Schofield, C, UK (AMC)
Schulz, T, Germany (VUmc)
Shipp, M, USA (NKI)
Sniekers, M, Belgium (AMC)
Sprick, M, Germany (AMC)
Stassi, G, Italy (AMC)
Steinberg, S, USA (AMC)
Syljuåsen, R, Denmark (NKI)

Thorley-Lawson, D, USA (VUmc)
Tomassino, M, France (VUmc)

Uittenbogaart, C.H., USA (AMC)

Van den Broek M, Switzerland (NKI)
Van Deursen, J, USA (NKI)
Vizzan Carralcazar, P, Spain (AMC)

Watkins, P.I., USA (AMC)
Wierzbicki, A.S., UK (AMC)

Yewdell, J, USA (NKI)
Young, L, UK (VUmc)

6. Scientific results

6.1. International papers 2004

1. Aalfs CM, Mollema E, Oort FJ, de Haes JCJM, Leschot NJ, Smets EMA. Genetic counseling for familial conditions during pregnancy: an analysis of patient characteristics. *Clin Genet* 2004; 66(2): 112-121. (AMC)
2. Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, Giaccone G, Kruyt FA. Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. *Brit J Cancer* 2004; 91(1): 171-177. (VUmc)
3. Abou El Hassan MAI, van der Meulen-Muileman I, Abbas S, Kruyt FA. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. *J Virol* 2004; 78: 12243-12251. (VUmc)
4. Adams DJ, Biggs PJ, Cox T, Davies R, Van der Weyden L, Jonkers J et al. Mutagenic insertion and chromosome engineering resource (MICER). *Nat Genet* 2004; 36: 867-71. (NKI)
5. Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A, Mansel RE, Neeman I, Geldof AA, Campbell MJ. Pomegranate extracts potently suppress proliferation, xenograft growth and invasion of human prostate cancer cells. *J Med Food* 2004; 7(3): 274-283. (VUmc)
6. Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V et al. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. *Br J Cancer* 2004; 90: 100-5. (NKI)
7. Albregts M, Hulshof MCCM, zum Vörde sive Vörding P, van Lanschot JJB, Richel DJ, Crezee H, Fockens P, van Dijk JDP, González González D. A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery. *Int J Hyperther* 2004; 20 (6): 647-659. (AMC)
8. Alcolea S, Jarry-Guichard T, de Bakker J, Gonzalèz D, Lamers WH, Coppens S, Barrio L, Jongsma HJ, Gros D, van Rijen HVM. Replacement of connexin40 by connexin45 in the mouse: impact on cardiac electrical conduction. *Circ Res* 2004; 94 (1): 100-109. (AMC)
9. Alderton GH, Joenje H, Varon R, Borglum AD, Jeggo PA, O'Driscoll M. Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. *Hum Mol Genet* 2004; 13: 3127-3138. (VUmc)
10. Aldred MA, Sanford ROC, Thomas NS, Barrow MA, Wilson LC, Brueton LA, Bonaglia MC, Hennekam RCM, Eng C, Dennis NR, Trembath RC. Molecular analysis of 20 patients with 2q37.3 monosomy: definition of minimum deletion intervals for key phenotypes [research letter]. *J Med Genet* 2004; 41(6): 433-439. (AMC)
11. Aleman BM, Russell NS, Bartelink H, van Leeuwen FE. Re: Radiation therapy in the treatment of Hodgkin's disease--do you see what I see?. *J Natl Cancer Inst* 2004; 96(3): 235-236. (VUmc + NKI)
12. Al-Madhoun A, Van der Wilt CL, Loves WJP, Padron JM, Eriksson S, Talianidis I, Peters GJ. Detection and alternatively spliced form of deoxycytidine kinase mRNA in the 2',2'-difluorodeoxycytidine (gemcitabine) resistant human ovarian cancer cell line AG6000. *Biochem Pharmacol* 2004; 68(4): 601-9. (VUmc)
13. Alonso J, Ferrer M, Gandek B, Ware JE, Jr., Aaronson NK, Mosconi P et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. *Qual Life Res* 2004; 13: 283-98. (NKI)
14. Annema JT, Hoekstra OS, Smit EF, Veselic M, Versteegh MI, Rabe KF. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. *Lung Cancer* 2004; 44(1): 53-60. (VUmc)
15. Anninga JK, Van de Vijver MJ, Cleton-Jansen AM, Kristel PMP, Taminiou AHM, Nooij M et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. *Eur J Cancer* 2004; 40: 963-70. (NKI)
16. Arens R, Schepers K, Nolte MA, Van Oosterwijk MF, Van Lier RAW, Schumacher TNM et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. *J Exp Med* 2004; 199: 1595-605. (NKI)
17. Arnold J, de Boer EC, O'Donnell A, Böhle A, Brandau S. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. *J Immunother* 2004; 27 (2): 116-123. (AMC)
18. Artignan X, Smitsmans MHP, Lebesque JV, Jaffray DA, Van Herk M, Bartelink H. Online ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on

prostate displacement. *Int J Radiat Oncol Biol Phys* 2004; 59: 595-601. (NKI)

19. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. *J Biol Chem* 2004; 279: 22250-7. (NKI)

20. Assies J, Lok A, Bockting CLH, Weverling GJ, Lieveise R, Duran M, Schene AH. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. *Prostag Leukotr Ess* 2004; 70 (4): 349-356. (AMC)

21. Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LECM, Warde P, Dubois JB, Jeanneret W, Keuppens F, Bernier J, Kuten A, Collette L, Pierart M, Bolla M. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. *Eur J Cancer* 2004; 40 (11): 1674-1681. (AMC)

22. Aten JA, Stap J, Krawczyk PM, van Oven CH, Hoebe RA, Essers J, Kanaar R. Dynamics of DNA double-strand breaks revealed by clustering of damaged chromosome domains. *Science* 2004; 303 (5654): 92-95. (AMC)

23. Aufenacker TJ, van Geldere D, van Mesdag T, Bossers AN, Dekker B, Scheijde E, Nieuwenhuizen R, Hiemstra E, Maduro JH, Juttman J-W, Hofstede D, Linden CTM, Gouma DJ, Simons, MP. The role of antibiotic prophylaxis in prevention of wound infection after Lichtenstein open mesh repair of primary inguinal hernia: a multicenter double-blind randomized controlled trial. *Ann Surg* 2004; 240 (6): 955-961. (AMC)

24. Auwerx J, Avner P, Baldock R, Ballabio A, Balling R, Barbacid M et al. The European dimension for the mouse genome mutagenesis program. *Nat Genet* 2004; 36: 925-7. (NKI)

25. Baas AF, Kuipers J, Van der Wel NN, Batlle E, Koerten HK, Peters PJ et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. *Cell* 2004; 116: 457-66. (NKI)

26. Bakx R, Busch ORC, Bemelman WA, Veldink GJ, Slors JFM, van Lanschot JJB. Morbidity of temporary loop ileostomies. *Digest Surg* 2004; 21(4), 277-281. (AMC)

27. Bakx R, Van Lanschot JJB, Zoetmulder FAN. Inferiorly based rectus abdominis myocutaneous flaps in surgical oncology: Indications, technique, and experience in 37 patients. *J Surg Oncol* 2004; 85: 93-7. (AMC/NKI)

28. Bakx R, Van Lanschot JJB, Zoetmulder FAN. Sacral resection in cancer surgery: surgical technique and experience in 26 procedures. *J Am Coll Surg* 2004; 198: 846-51. (AMC/NKI)

29. Bakx R, Van Tinteren H, Van Lanschot JJB, Zoetmulder FAN. Surgical treatment of locally

recurrent rectal cancer. *Eur J Surg Oncol* 2004; 30: 857-63. (AMC/NKI)

30. Baldanzi G, Mitola S, Cutrupi S, Filigheddu N, Van Blitterswijk WJ, Sinigaglia F et al. Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. *Oncogene* 2004; 23: 4828-38. (NKI)

31. Balm AJM, Rasch CRN, Schornagel JH, Hilgers FJM, Keus RB, Schultze-Kool L et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. *Head Neck* 2004; 26: 485-93. (NKI)

32. Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JHM, Van Tellinggen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. *Invest New Drugs* 2004; 22: 219-29. (NKI)

33. Bartelink H. Intraoperative radiotherapy for breast cancer: tail wagging the dog? *Lancet Oncol* 2004; 5: 207-8. (NKI)

34. Barth PG, Majoie CBLM, Gootjes J, Wanders RJA, Waterham HR, van der Knaap MS, de Klerk JBC, Smeitink J, Poll-The BT. Neuroimaging of peroxisome biogenesis disorders (Zellweger spectrum) with prolonged survival. *Neurologie* 2004; 62 (3): 439-444. (AMC)

35. Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz FM, Wanders RJA. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. *Am J Med Genet* 2004; 126A (4): 349-354. (AMC)

36. Bauer AJ, Boeckxstaens GEE. Mechanisms of postoperative ileus. *Neurogastroent Motil* 2004; 16 (Suppl. 16): 54-60. (AMC)

37. Beijnen JH, Schellens JHM. Drug interactions in oncology [review]. *Lancet Oncol* 2004; 5: 489-96. (NKI)

38. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. *Ann Oncol* 2004; 15(7): 1097-1108. (VUmc)

39. Belka C, Jendrossek V, Pruschy M, Vink S, Verheij M, Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. *Int J Radiat Oncol Biol Phys* 2004; 58: 542-54. (NKI)

40. Benninga MA, Voskuil WP, Akkerhuis GW, Taminau JAJM, Buller HA. Colonic transit times and behaviour profiles in children with defecation disorders. *Arch Dis Child* 2004; 89 (1): 13-16. (AMC)

41. Bennink RJ, Dinant S, Erdogan D, Heijnen BHM, Straatsburg IH, van Vliet AK, van Gulik TM. Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. *Eur J Nucl Med* 2004; 45(6): 965-971. (AMC)

42. Bennink RJ, Peeters M, Rutgeerts PJ, Mortelmans L. Evaluation of early treatment response and predicting the need for colectomy in active ulcerative colitis with Tc-99m-HMPAO white blood cell scintigraphy. *J Nucl Med* 2004; 45(10): 1698-1704. (AMC)
43. Bennink RJ, van den Elzen BDJ, Kuiken SD, Boeckxstaens GEE.. Noninvasive measurement of gastric accommodation by means of per technetate SPECT: limiting radiation dose without losing image quality. *J Nucl Med* 2004; (45): 147-152. (AMC)
44. Bennink RJ, van den Hoff MJB, van Hemert FJ, de Bruin K, Spijkerboer AL, van der Heyden J-L, Steinmetz N, van Eck-Smit BLF. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. *J Nucl Med* 2004; 45(5): 842-848. (AMC)
45. Bennink RJ, van Montfrans C, de Jonge WJ, de Bruin K, van Deventer SJ, te Velde AA. Imaging of intestinal lymphocyte homing by means of pinhole SPECT in a TNBS colitis mouse model. *Nucl Med Biol* 2004; 31(1): 93-101. (AMC)
46. Bennink RJ, van Tienhoven G, Rijks LJM, Noorduyt LA, Janssen AG, Sloof GW. In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. *J Nucl Med* 2004; 45(1): 1-7. (AMC)
47. Beral V, Bull D, Doll R, Peto R, Reeves G, Collaborative Group on Hormonal Factors in Breast Cancer et al. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. *Lancet* 2004; 363: 1007-16. (NKI)
48. Bergman AM, Kuiper CM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (Ara-C) in leukemia and solid tumor cell lines. *Nucleos Nucleot Nucl* 2004; 23: 1523-1526. (VUmc)
49. Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. *Biochem Pharmacol* 2004; 67(3): 503-511. (VUmc)
50. Bergman AM, Kuipers CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Fodstad O, Breistol K, Peters GJ. Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. *Nucleos Nucleot Nucl* 2004; 23: 1329-1333. (VUmc)
51. Bernad R, Van der Velde H, Fornerod M, Pickersgill H. Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. *Mol Cell Biol* 2004; 24: 2373-84. (NKI)
52. Bernards R. Wip-ing out cancer [comment]. *Nat Genet* 2004; 36: 319-20. (NKI)
53. Berns A. Good news for gene therapy. *N Engl J Med* 2004; 350: 1679-80. (NKI)
54. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. *Nature* 2004; 428: 431-7. (NKI)
55. Beumer JH, Rosing H, Hillebrand MJX, Nan-Offeringa LGAH, Foley K, Yule SM et al. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2004; 18: 2839-48. (NKI)
56. Bevers RFM, Kurth K-H, Schamhart DHJ. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. *Brit J Cancer* 2004; 91 (4): 607-612. (AMC)
57. Bhowmick P, Coad JE, Bhowmick S Pryor JL, Larson T, de la Rosette JJMCH, Bischof JC. In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia. *Int J Hyperther* 2004; 20(4): 421-439. (AMC)
58. Bierau J, Leen R, van Gennip AH, Caron HN, van Kuilenburg ABP. Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed-phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine. *J Chromatogr B* 2004; 805: 339-346. (AMC)
59. Biewenga P, de Blok S, Birnie E. Does diagnostic hysteroscopy in patients with stage I endometrial carcinoma cause positive peritoneal washings? *Gynecol Oncol* 2004; 93 (1): 194-198. (AMC)
60. Bijlsma MF, Spek CA, Peppelenbosch MP. Hedgehog: an unusual signal transducer. *Bioessays* 2004; 26(4): 387-394. (AMC)
61. Bilardo CM, Wolf H Stigter RH, Ville Y, Baez E, Visser GHA, Hecher K. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. *Ultrasound Obst Gyn* 2004; 23(2): 119-125. (AMC)
62. Bipat S, Glas AS, Slors JFM, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. *Radiology* 2004; 232 (3): 773-783. (AMC)
63. Bischof F, Hofmann M, Schumacher TNM, Vyth-Dreese FA, Weissert R, Schild H et al. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and

secondary challenge using MHC class II tetramers. *J Immunol* 2004; 172: 2878-84. (NKI)

64. Bisschop PHLT, Bandsma RHJ, Stellaard F, ter Harmsel A, Meijer AJ, Sauerwein HP, Kuipers F, Romijn JA. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. *Am J Clin Nutr* 2004; 79 (4): 570-576. (AMC)

65. Bjorner JB, Petersen MA, Groenvold M, Aaronson N, Ahlner-Elmqvist M, Arraras JI et al. Use of item response theory to develop a shortened version of the EORTC QLQ-C30 emotional functioning scale. *Qual Life Res* 2004; 13: 1683-97. (NKI)

66. Bleuming SA, Roberts DJ, Peppelenbosch MP, van den Brink GR. Homeostasis of the adult colonic epithelium: a role for morphogens. *Scand J Gastroentero* 2004; 39(2): 93-98. (AMC)

67. Blik J, Gicquel C, Maas S, Gaston V, Bouc Y, Mannens MMAM. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). *J Pediatr* 2004; 145(6): 796-799. (AMC)

68. Blokhuis TJ, Van der Schaaf MC, Van den Tol MP, Comans EFI, Manoliu RA, Van der Sijp JRM. Results of radio-frequency ablation of primary and secondary liver tumors: long-term follow-up with computer tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. *Scand J Gastroenterol Supp* 2004; 241: 93-7. (VUmc)

69. Bloks VW, Bakker-van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. *Diabetologia* 2004; 47(1): 104-112. (AMC)

70. Blom E, van de Vrugt HJ, de Vries Y, de Winter JP, Arwert F, Joenje H. Multiple TPR motifs characterize the Fanconi anemia FANCG protein. *DNA Repair (Amst)* 2004; 3(1): 77-84. (VUmc)

71. Blümer RME, Hessel NS, van Baren R, Kuyper CF, Aronson DC. Comparison between umbilical and transverse right upper abdominal incision for pyloromyotomy. *J Pediatr Surg* 2004; 39(7): 1091-1093. (AMC)

72. Boeckxstaens GEE, Tytgat GNJ. Discussion on antro-fundic dysfunction in functional dyspepsia. *Gastroenterology* 2004; 126(1): 381-382. (AMC)

73. Boeckxstaens GEE. TLOSRS: reproducible or not. *Neurogastro Ent Motil* 2004; 16(3): 269-270. (AMC)

74. Boekholdt SM, Peters RJG, Hack CE, Day NE, Luben R, Bingham SA, Wareham NJ, Reitsma PH, Khaw KT. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women - The EPIC-Norfolk prospective population study. *Arterioscl Throm Vas*

2004; 24(8): 1503-1508. (AMC)

75. Boogerd W, Van den Bent MJ, Koehler PJ, Heimans JJ, Van der Sande JJ, Aaronson NK, Hart AAM, Benraadt J, Vecht ChJ. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. *Eur J Cancer* 2004; 40: 2726-2733. (NKI/VUmc)

76. Boon EMJ, Keller JJ, Wormhoudt TAM, Giardiello FM, Offerhaus GJA, van der Neut R, Pals ST. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. *Brit J Cancer* 2004; 90(1): 224-229. (AMC)

77. Boonacker E, Stap J, Koehler A, van Noorden CJF. The need for metabolic mapping in living cells and tissues. *Acta Histochem* 2004; 106(2): 89-96. (AMC)

78. Borggreven PA, de Graaf FH, van der Valk P, Leemans CR. Post-traumatic cutaneous meningioma. *J Laryngol Otol* 2004; 118(3): 228-230. (VUmc)

79. Borjesson PK, Postema EJ, de Bree R, Roos JC, Leemans CR, Kairemo KJ, Van Dongen GA. Radioimmunodetection and radioimmunotherapy of head and neck cancer. *Oral Oncol* 2004; 40(8): 761-772. (VUmc)

80. Borst P, Balzarini J, Ono N, Reid G, De Vries H, Wielinga P et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. *Antiviral Res* 2004; 62: 1-7. (NKI)

81. Borst P, Rottenberg S. Cancer cell death by programmed necrosis? *Drug Resist Updat* 2004; 7: 321-4. (NKI)

82. Bos C, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH. Prostanoids and prostanoid receptors in signal transduction. *Int J Biochem Cell B* 2004; 26(7): 1187-1205. (AMC)

83. Bos LJ, Schwarz M, Bär W, Alber M, Mijnheer BJ, Lebesque JV et al. Comparison between manual and automatic segment generation in step-and-shoot IMRT of prostate cancer. *Med Phys* 2004; 31: 122-30.

84. Bos R, Van Diest PJ, Van der Groep P, Shvarts A, Greijer AE, Van der Wall E, Van Diest PJ. Expression of hypoxia-inducible factor -1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. *Breast Cancer Res* 2004; 4: R450-R459. (VUmc)

85. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. *EMBO J* 2004; 23: 2830-40. (NKI)

86. Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette JJMCH, Emberton M. 5-Alpha reductase inhibition provides superior benefits to alpha

- blockade by preventing AUR and BPH-related surgery. *Eur Urol* 2004; 45(5): 620-626. (AMC)
87. Braakhuis BJ, Leemans CR, Brakenhoff RH. A genetic progression model of oral cancer: current evidence and clinical implications. *J Oral Pathol Med* 2004; 33(6): 317-322. (VUmc)
88. Braakhuis BJ, Leemans CR, Brakenhoff RH. Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice. *J Pathol* 2004; 203(2): 620-621. (VUmc)
89. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. *J Natl Cancer Inst* 2004; 96(13): 998-1006. (VUmc)
90. Braat H, de Jong EC, van den Brande JMH, Kapsenberg ML, Peppelenbosch MP, van Tol EAF, van Deventer SJH. Dichotomy between *Lactobacillus rhamnosus* and *Klebsiella pneumoniae* on dendritic cell phenotype and function. *J Mol Med-JMM* 2004; 82(3): 197-205. (AMC)
91. Brada SJ, van de Loosdrecht AA, Koudstaal J, de Wolf JT, Vellenga E. Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome. *Leukemia Res* 2004; 28(9): 921-5. (VUmc)
92. Bramer J, Gubler FM, Maas M, Bras H, de Kraker J, vd Eijken JW, Schaap GR. Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma. *Pediatr Radiol* 2004; 34(8): 614-619. (AMC)
93. Brand HS, Lerner UH, Grubb A, Beertsen W, van Nieuw Amerongen A, Everts V. Family 2 cystatins inhibit osteoclast-mediated bone resorption in calvarial bone explants. *Bone* 2004; 35(3): 689-696. (AMC)
94. Brandon EFA, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, Schellens JHM. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. *Invest New Drugs* 2004; 22: 241-51. (NKI)
95. Brecht M, Steenvoorden ACM, Collard JG, Luf S, Erz D, Bartram CR et al. Activation of GEF-h1, a guanine nucleotide exchange factor for RhoA, by DNA transfection. *Int J Cancer* 2004; 113: 533-40. (NKI)
96. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. *Cancer Res* 2004; 64: 5804-11. (NKI)
97. Brinkman J, de Nef JJEM, Barth PG, Verschuur AC. Burkitt lymphoma in a child with Joubert syndrome. *Pediatr Blood Cancer* 2004. (AMC)
98. Brites P, Waterham HR, Wanders RJA. Functions and biosynthesis of plasmalogens in health and disease. *Biochim Biophys Acta* 2004; 1636: 219-231. (AMC)
99. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. *Breast Cancer Res Treat* 2004; 83(1): 91-93. (VUmc)
100. Broeks A, De Witte L, Nooijen A, Huseinovic A, Klijn JGM, Van Leeuwen FE et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. *Breast Cancer Res Treat* 2004; 83: 91-3. (NKI)
101. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA, Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. *Cancer Res* 2004; 64(1): 27-30. (VUmc)
102. Brokx HA, Kunst PW, Van Diest PJ, Postmus PE, Sutedja TG. Bronchial typical carcinoid tumors: histological study of intra- versus extraluminal growth pattern. *Lung Cancer* 2004; 44(1): 129-130. (VUmc)
103. Brouwer J, Bodar EJ, de Bree R, Langendijk JA, Castelijns JA, Hoekstra OS, Leemans CR. Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement. *Eur Arch Oto-Rhino-L* 2004; 261(8): 417-422. (VUmc)
104. Brouwer J, De Bree R, Comans EFI, Castelijns JA, Hoekstra OS, Leemans CR. Positron remission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior?. *Eur Arch Oto-Rhino-L* 2004; 261: 479-483. (VUmc)
105. Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, Corstens F, Oyen W, Van Dongen G, Boerman O. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. *Cancer Biother Radiopharm* 2004; 19(2): 155-163. (VUmc)
106. Broxterman HJ, Georgopapadakou NH. New cancer therapeutics: target-specific in, cytotoxics out?. *Drug Resist Update* 2004; 7(2): 79-87. (VUmc)
107. Bruins MJ, Luiking YC, Soeters PB, Lamers WH, Akkermans LMA, Deutz NEP. Effects of long-term intravenous and intragastric L-arginine intervention on jejunal motility and visceral nitric oxide production in the hyperdynamic compensated endotoxaemic pig. *Neurogastroent Motil* 2004; 16(6): 849-828. (AMC)
108. Buis DR, Peerdeman SM, Vandertop WP. Metastatic adenocarcinoma in the cerebellopontine angle, presenting as meningioma: a case report of rare occurrence. *Cancer Res* 2004; 64(16): 5753-5759. (VUmc)

- 109.** Bulkman NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, van den Brule AJ, Meijer CJ. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. *Int J Cancer* 2004; 110(1): 94-101. (VUmc)
- 110.** Burgers JA, Damhuis RAM. Prognostic factors in malignant mesothelioma. *Lung Cancer* 2004; 45 Suppl 1: S49-S54. (NKI)
- 111.** Buskens CJ, Westerterp M, Lagarde SM, Bergman JJGHM, ten Kate FJW, van Lanschot JJB. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. *Gastrointest Endosc* 2004; 60(5): 703-710. (AMC)
- 112.** Buwalda J, Blank LECM, Schouwenburg PF, Copper MP, Strackee SD, Voûte PA, Merks JHM, Caron HN. The AMORE protocol as salvage treatment for non-orbital head and neck rhabdomyosarcoma in children. *Eur J Surg Oncol* 2004; 30(8): 884-892. (AMC)
- 113.** Calvet L, Santos A, Valent A, Terrier-Lacombe MJ, Opolon P, Merlin JL et al. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. *Br J Cancer* 2004; 91: 1205-12. (NKI)
- 114.** Candeil L, Gourdiere I, Peyron D, Vezzio N, Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, Pommier Y, Pau B, Martineau P, Del Rio M. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. *Int J Cancer* 2004; 109(6): 848-854. (VUmc)
- 115.** Canfell K, Gray W, Snijders P, Murray C, Tipper S, Drinkwater K, Beral V. Factors predicting successful DNA recovery from archival cervical smear samples. *Cytopathol* 2004; 15: 276-282. (VUmc)
- 116.** Cano N, Sturm JM, Meijer AJ, El_Mir MY, Novaretti R, Reynier JP, Leverve XM. Effect of chronic renal failure with metabolic acidosis on alanine metabolism in isolated liver cells. *Clin Nutr* 2004; 23(3): 317-324. (AMC)
- 117.** Cao D, Hustinx SR, Sui G, Bala P, Sato N, Martin S, Maitra A, Murphy KM, Cameron JL, Yeo CHJ, Kern SE, Goggins M, Pandey A, Hruban RH. Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. *Cancer Biol Ther* 2004; 3(11): 1081-1089. (AMC)
- 118.** Cardous-Ubbink MC, Heinen RC, Langeveld NE, Bakker PJ, Voute PA, Caron HN, van Leeuwen FE. Long-term cause-specific mortality among five-year survivors of childhood cancer. *Pediatr Blood Cancer* 2004; 42(7): 563-573. (AMC/NKI/VUmc)
- 119.** Carette JE, Overmeer RM, Schagen FH, Alemany R, Barski OA, Gerritsen WR, van Beusechem VW. Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. *Cancer Res* 2004; 64(8): 2663-2667. (VUmc)
- 120.** Carlotti F, Bazuine M, Kekrainen T, Seppen J, Popnonec P, Maassen JA, Hoeben RC. Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. *Mol Ther* 2004; 9(2): 209-217. (AMC)
- 121.** Carstens MJ, Krempler A, Triplett AA, Van Lohuizen M, Wagner KU. Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. *J Biol Chem* 2004; 279: 35984-94. (NKI)
- 122.** Carvalho B, Ouwerkerk E, Meijer GA, Ylstra B. High resolution microarray comparative genomic hybridisation analysis using spotted oligonucleotides. *J Clin Pathol* 2004; 57(6): 644-646. (VUmc)
- 123.** Carvalho R, Milne ANA, van Rees BP, Caspers E, Cimes L, Figueiredo C, Offerhaus GJA, Weterman MAJ. Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. *J Pathol* 2004; 204(1): 75-83. (AMC)
- 124.** Carvalho RL, Jonker L, Goumans MJ, Larsson J, Bouwman P, Karlsson S et al. Defective paracrine signalling by TGF{beta} in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. *Development* 2004; 131: 6237-47. (NKI)
- 125.** Casanova M, Ferrari A, Bisogno G, Merks JHM, de Salvo GL. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. *Cancer* 2004; 101(7): 1664-1671. (AMC)
- 126.** Castedo M, Perfettini J-L, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. *Oncogene* 2004; 23: 2825-37. (NKI)
- 127.** Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. *Oncogene* 2004; 23: 4362-70. (NKI)
- 128.** Castedo M, Perfettini J-L, Roumier T, Yakushijin K, Horne D, Medema R et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. *Oncogene* 2004; 23: 4353-61. (NKI)
- 129.** Castro Kreder N, ten Cate R, Rodermond HM, van Bree C, Franken NAP, Zdzienicka MZ. Cellular Response to Pulsed Low-dose Rate Irradiation in X-ray Sensitive Hamster Mutant Cell Lines. *J Radiat Res* 2004; 45(3): 385-391. (AMC)

- 130.** Castro Kreder N, van Bree C, Franken NAP, Haveman J. Effects of gemcitabine on cell survival and chromosome aberrations after pulsed low dose-rate irradiation. *J Radiat Res* 2004; 45(1): 111-118. (AMC)
- 131.** Catalfamo M, Karpova T, McNally J, Costes SV, Lockett SJ, Bos E et al. Human CD8+ T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. *Immunity* 2004; 20: 219-30. (NKI)
- 132.** Celie PHN, Van Rossum-Fikkert SE, Van Dijk WJ, Brejc K, Smit AB, Sixma TK. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. *Neuron* 2004; 41: 907-14. (NKI)
- 133.** Cense HA, Sloof GW, Klaase JM, Bergman JJGHM, van Hemert FJ, Fockens P, van Lanschot JJB. Lymphatic drainage routes of the gastric cardia visualized by lymphoscintigraphy. *J Nucl Med* 2004; 45(2): 247-252. (AMC)
- 134.** Cense HA, Visser MRM, van Sandick JW, de Boer AGEM, Lamme B, Obertop H, van Lanschot JJB. Quality of life after colon interposition by necessity for esophageal cancer replacement. *J Surg Oncol* 2004; 88(1): 32-38. (AMC)
- 135.** Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA, Ossenkoppele GJ. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. *Cancer Res* 2004; 64(16): 5546-5550. (VUmc)
- 136.** Chen F, Medhurst AL, De Winter JP, Waisfisz Q, Roimans MA, Oostra AB, Meyer S, Zhang KJ, Xia B, Pals G, Arwert F, Zwaan CM, Joenje H. Apparent absence of BRCA2 protein in a proportion of acute myeloid leukemia cell lines. *Leukemia* 2004; 18(11): 1918-1920. (VUmc)
- 137.** Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. *J Neuro-Oncol* 2004; 69(1-3): 101-107. (VUmc)
- 138.** Cho BCJ, Mijnheer BJ, Bartelink H. Determining optimal two-beam axial orientations for heart sparing in left-sided breast cancer patients. *Med Phys* 2004; 31: 111-21. (NKI)
- 139.** Cho BCJ, Schwarz M, Mijnheer B, Bartelink H. Simplified intensity-modulated radiotherapy using pre-defined segments to reduce cardiac complications in left-sided breast cancer. *Radiother Oncol* 2004; 70: 231-41. (NKI)
- 140.** Chung YJ, Jonkers J, Kitson H, Fiegler H, Humphray S, Scott C et al. A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. *Genome Res* 2004; 14: 188-96. (NKI)
- 141.** Chuva De Sousa Lopes SM, Feijen A, Korving J, Korchynski O, Larsson J, Karlsson S et al. Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. *Dev Dyn* 2004; 231: 542-50. (NKI)
- 142.** Claij N, Te Riele H. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells. *Oncogene* 2004; 23: 260-6. (NKI)
- 143.** Clamp A, Adams M, Atkinson R, Boven E, Calvert AH, Cervantes A, Ganesan T, Lotz J, Vasey P, Cheverton P, Jayson GC. A phase IIA study of the topoisomerase-1 inhibitor, exatecan mesylate (DX-8951f) in patients with platinum and taxane resistant/refractory. *Gynecol Oncol* 2004; 95(1): 114-119. (VUmc)
- 144.** Cleton-Jansen AM, Buerger H, Ter Haar N, Philippo K, Van de Vijver MJ, Boecker W et al. Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. *Genes Chromosomes Cancer* 2004; 41: 109-16. (NKI)
- 145.** Cleton-Jansen AM, Timmerman MC, Van de Vijver MJ, Van Asperen CJ, Kroon HM, Eilers PHC et al. A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. *Lab Invest* 2004; 84: 191-202. (NKI)
- 146.** Cohen S, Morris R, Fernandez F, Ben Jelloul M, Kakaris M, Parthasarathy V et al. Towards complete validated models in the next generation of ARP/wARP. *Acta Crystallogr D Biol Crystallogr* 2004; 60: 2222-9. (NKI)
- 147.** Collard JG. Cancer: Kip moving. *Nature* 2004; 428: 705-8. (NKI)
- 148.** Collette L, van Andel G, Bottomley A, Oosterhof GO, Albrecht W, Reijke TM, Fossa SD. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. *J Clin Oncol* 2004; 22(19): 3877-3885. (AMC)
- 149.** Colnot DR, Nieuwenhuis AJC, Kuik DJ, Leemans CR, Dijkstra J, Snow GB, Van Dongen GAMS, Brakenhoff RH. Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients. *Clin Cancer Res* 2004; 10: 7827-7833. (VUmc)
- 150.** Creutzig U, Kaspers GJL. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol* 2004; 22: 3432-3433. (VUmc)

151. Croles N, Smorenburg CH, Van Groeningen CJ, Giaccone G, Boven E. FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer. *Neth J Med* 2004; 62: 242-245. (VUmc)
152. Crommentuyn KML, Mulder JW, Sparidans RW, Huitema ADR, Schellens JHM, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. *Clin Infect Dis* 2004; 38: e73-e75. (NKI)
153. Crommentuyn KML, Rosing H, Hillebrand MJX, Huitema ADR, Beijnen JH. Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2004; 804: 359-67. (NKI)
154. Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. *J Clin Pathol* 2004; 57: 695-701. (NKI)
155. Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M et al. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. *Biochem Pharmacol* 2004; 67: 31-9. (NKI)
156. Dai J, Li J, Bos E, Porcionatto M, Premont RT, Bourgoin S et al. ACAP1 promotes endocytic recycling by recognizing recycling sorting signals. *Dev Cell* 2004; 7: 771-6. (NKI)
157. Dai M, Clifford GM, Le Calvez F, Castellsague X, Snijders P, Pawlita M, Herrero R, Hainaut P, Franceschi S for the IARC Multi-center Oral Cancer Study Group. Human Papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. *Cancer Res* 2004; 64: 468-471. (VUmc)
158. Danen-van Oorschot AAAM, Voskamp P, Seelen MCMJ, Van Miltenburg MHAM, Bolk MW, Tait SW et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. *Cell Death Differ* 2004; 11: 564-73. (NKI)
159. Dannenberg J, Schuijff L, Dekker M, Van der Valk M, Te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. *Genes Dev* 2004; 18: 2952-62. (NKI)
160. Dansen TB, Kops GJPL, Denis SW, Jelluma N, Wanders RJA, Bos JL, Burgering BMT, Wirtz KWA. Regulation of sterol carrier protein gene expression by the forkhead transcription factor FOXO3a. *J Lipid Res* 2004; 45(1): 81-88. (AMC)
161. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernardis R et al. Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition. *J Virol* 2004; 78: 2601-5. (NKI)
162. De Berardinis E, Antonini G, Peters GJ, Loves WJP, Van der Born K, Codacci-Pisanelli G, Di Silverio F. Intravesical administration of gemcitabine in superficial bladder cancer: A phase I study with pharmacodynamic evaluation. *Brit J Urol* 2004; 93: 491-494. (VUmc)
163. De Blok W, Van Rooij K. De kwestie: "Om aankomend verpleegkundigen enthousiast te maken voor de oncologische zorg, is het wenselijk dat studenten verpleegkunde stage lopen op een oncologieafdeling". *Oncologica* 2004; 21: 53. (NKI)
164. De Boer AGEM, Van Lanschot JJB, Stalmeier PFM, Van Sandick JW, Hulscher JBF. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? *Qual Life Res* 2004; 13(2): 311-320. (AMC)
165. De Boer AGEM, Van Lanschot JJB, Van Sandick JW, Hulscher JBF, Stalmeier PFM, De Haes JCJM, Tilanus HW, Obertop H, Sprangers MAG. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. *J Clin Oncol* 2004; 22(20): 4202-4208. (AMC)
166. De Boer EJ, Den Tonkelaar I, Burger CW, Looman CWN, Van Leeuwen FE, Te Velde ER. The number of retrieved oocytes does not decrease during consecutive gonadotrophin-stimulated IVF cycles. *Hum Reprod* 2004; 19: 899-904. (NKI)
167. De Boer L, Kant SG, Karperien M, Van Beers L, Tjon J, Vink GR, van Tol D, Dauwerse H, Cessie S, Beemer FA, Van der Burgt I, Hamel BCJ, Hennekam RCM, Kuhnle U, Mathijssen IB, Veenstra-Knol HE, Stumpel CT, Breuning MH, Wit JM. Genotype-phenotype correlation in patients suspected of having sotos syndrome. *Horm Res* 2004; 62(4): 197-207. (AMC)
168. De Bree E, Koops W, Kroger R, Van Ruth S, Witkamp AJ, Zoetmulder FAN. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. *J Surg Oncol* 2004; 86: 64-73.
169. De Bree E, Zoetmulder FAN, Keus RB, Peterse HL, Van Coevorden F. Incidence and treatment of recurrent plantar fibromatosis by surgery and postoperative radiotherapy. *Am J Surg* 2004; 187: 33-8. (NKI)
170. De Bree R, Leemans CR. New developments for optimal management of head and neck cancer. *Onkologie* 2004; 27(4): 339-342. (VUmc)
171. De Bree R, Middelweerd MJ, van der Waal I. Severe granulomatous inflammatory response induced by injection of polyacrylamide gel into the

facial tissue. *Arch Facial Plast Surg* 2004; 6(3): 204-206. (VUmc)

172. De Bree R, Quak JJ, Kummer JA, Simsek S, Leemans CR. Severe atherosclerosis of the radial artery in a free radial forearm flap precluding its use. *Oral Oncol* 2004; 40: 99-102. (VUmc)

173. De Bruin M, Peters GJ, Oerlemans R, Assaraf YG, Masterson AJ, Adema AD, Dijkmans BA, Pinedo HM, Jansen G. Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and Interleukin-8 in human monocytic-macrophage THP1 and U937 cells. *Mol Pharmacol* 2004; 66(4): 1054-1060. (VUmc)

174. De Bruin M, Smid K, Van der Ent MA, Fukushima M, Pinedo HM, Peters GJ. Upregulation of platelet derived endothelial cell growth factor/thymidine phosphorylase by interferon alpha. *Nucleos Nucleot Nucl* 2004; 23: 1367-1370. (VUmc)

175. De Bruin M, Van Capel T, Smid K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase. *Eur J Pharmacol* 2004; 491(2-3): 93-99. (VUmc)

176. De Bruin M, Van Capel T, Smid K, Van der Born K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. Role of platelet derived endothelial cell growth factor / thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate. *Nucleos Nucleot Nucl* 2004; 23: 1485-1490. (VUmc)

177. De Castro SMM, Busch ORC, Gouma DJ. Management of bleeding and leakage after pancreatic surgery. *Best Pract Res Cl GA* 2004; 18(5): 847-864. (AMC)

178. De Castro SMM, Kuhlmann KFD, van Heek NT, Busch ORC, Offerhaus GJA, van Gulik TM, Obertop H, Gouma DJ. Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. *J Gastrointest Surg* 2004; 8(7): 775-784. (AMC)

179. De Castro SMM, Tilleman EHBM, Busch ORC, van Delden OM, Laméris JS, van Gulik TM, Obertop H, Gouma DJ. Diagnostic laparoscopy for primary and secondary liver malignancies: impact of improved imaging and changed criteria for resection. *Ann Surg Oncol* 2004; 11(5): 522-529. (AMC)

180. De Castro SMM, van Heek NT, Kuhlman KFD, Busch ORC, Offerhaus GJA, van Gulik TM, Obertop H, Gouma DJ. Surgical management of neoplasms of the ampulla of Vater: local resection or pancreatoduodenectomy and prognostic factors for survival. *Surgery* 2004; 136(5): 994-1002. (AMC)

181. De Geus-Oei LF, Van Eerd-Vismale J, Molthoff C, Corstens F, Oyen W, Boerman O. Tracers to

monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals. *Cancer Biother Radiopharm* 2004; 19: 457-465. (VUmc)

182. De Graaf M, Nevalainen TJ, Scheeren HW, Pinedo HM, Haisma HJ, Boven E. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. *Biochem Pharmacol* 2004; 68(11): 2273-2281. (VUmc)

183. De Graaf M, Pinedo HM, Oosterhoff D, van der Meulen-Muileman IH, Gerritsen WR, Haisma HJ, Boven E. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. *Hum Gene Ther* 2004; 15(3): 229-238. (VUmc)

184. De Haar SF, Jansen DC, Schoenmaker T, de Vree H, Everts V, Beertsen W. Loss-of-function mutations in cathepsin C in two families with Papillon-Lefevre syndrome are associated with deficiency of serine proteinases in PMNs. *Hum Mutat* 2004; 23(5): 524-?. (AMC)

185. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JSA, Lebesque JV. Significance of plasma transforming growth factor-[beta] levels in radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004; 58: 1378-87. (NKI)

186. De Jaeger K, Seppenwoolde Y, Lebesque JV, Kampinga HH. In reply to Dr. Barthelemy-Brichant [letter]. *Int J Radiat Oncol Biol Phys* 2004; 60: 1339-40. (NKI)

187. De Jong AE, Morreau H, Van Puijenbroek M, Eilers PHC, Wijnen J, Nagengast FM et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. *Gastroenterology* 2004; 126: 42-8. (NKI)

188. De Jong D, Van 't Veer LJ. Tools for molecular risk-stratification for clinical purposes: CLL as a prototype. *Eur J Hum Genet* 2004; 12: 423. (NKI)

189. De Jong HWAM, Boellaard R, Lenox M, Michel C, Lammertsma AA. Correction for emission contamination in transmission scans for the High Resolution Research Tomograph. *IEEE T Nucl Sci* 2004; 51(3): 673-676. (VUmc)

190. De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van de Weyer EP et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. *J Nucl Med* 2004; 45: 1168-71. (NKI)

191. De Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. *J Pharmacokinet Pharmacodyn* 2004; 31: 135-56. (NKI)

- 192.** De Jonge ME, Van Dam SM, Hillebrand MJX, Rosing H, Huitema ADR, Rodenhuis S et al. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramidate (thiotepa) and N,N',N"-triethylenephosphoramidate (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *J Mass Spectrom* 2004; 39: 262-71. (NKI)
- 193.** De Jonge ME, Van den Bongard HJGD, Huitema ADR, Mathot RAA, Rosing H, Baas P et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. *Clin Cancer Res* 2004; 10: 2237-44. (NKI)
- 194.** De Jonge WJ, The FO, van der Coelen D, Bennink RJ, Reitsma PH, van Deventer SJH, van den Wijngaard RMJGJ, Boeckxstaens GEE. Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. *Gastroenterology* 2004; 127(2): 535-545. (AMC)
- 195.** De Kraker J, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade M-F. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. *Lancet* 2004; 364: 1229-1235. (AMC)
- 196.** De Kreuk AM, Zevenbergen A, Jonuleit T, Schuurhuis GJ, Huijgens PC, Hendriks ECM, van Oostveen JW, Lemke HD, Jonkhoff AR. Preservation of G-CSF mobilized whole blood in an automated closed hollow fiber bioreactor. *Cytotherapy* 2004; 6: 380-384. (VUmc)
- 197.** De Lange SM, Van Groeningen CJ, Kroep JR, Van Bochove A, Snijders JF, Peters GJ, Pinedo HM, Giaccone G. Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. *Ann Oncol* 2004; 15(3): 484-488. (VUmc)
- 198.** De Lorijn F, van Wijk MP, Reitsma JB, van Ginkel R, Taminiou JAJM, Benninga MA. Prognosis of constipation: clinical factors and colonic transit time. *Arch Dis Child* 2004; 89(8): 723-727. (AMC)
- 199.** De Melker AA, Van der Horst G, Borst J. c-Cbl directs EGF receptors into an endocytic pathway that involves the ubiquitin-interacting motif of Eps15. *J Cell Sci* 2004; 117: 5001-12. (NKI)
- 200.** De Melker AA, Van der Horst G, Borst J. Ubiquitin ligase activity of c-Cbl guides the EGF receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. *J Biol Chem* 2004; 279: 55465-73. (NKI)
- 201.** De Metz J, Romijn JA, Endert E, Ackermans MT, Weverling GJ, Busch ORC, de Wit LT, Gouma DJ, ten Berge IJM, Sauerwein HP. Interferon-gamma increases monocyte HLA-DR expression without effects on glucose and fat metabolism in postoperative patients. *J Appl Physiol* 2004 ; 96 : 597-603. (AMC)
- 202.** De Reijke ThM, Klarskov P. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. *BJU Int* 2004; 93(6): 757-762. (AMC)
- 203.** De Reijke ThM. Editorial comment on: European collaborative group on prostate brachytherapy: preliminary report in 1175 patients [*Eur Urol*, 46 (5), 565-570]. *Eur Urol* 2004; 46(5): 570-ev. (AMC)
- 204.** De Ridder L, Bosman DK, Benninga MA, ten Kate FJW, de Haas V, Taminiou JAJM. Endoscopic diagnosis of leukemia in a child with acute abdominal pain. *Endoscopy* 2004; 36(10): 933. (AMC)
- 205.** De Ruijter AJM, Kemp S, Kramer G, Meinsma RJ, Kaufmann JO, Caron HN, van Kuilenburg ABP. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. *Biochem Pharmacol* 2004; 68(7): 1279-1288. (AMC)
- 206.** De Vos tot Nederveen Cappel RJ, Van Hillegersberg R, Rodenhuis S, Peterse JL, Van Coevorden F. Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib. *Dig Surg* 2004; 21: 77-9. (NKI)
- 207.** De Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. *Int J Cancer* 2004; 109: 468-71. (NKI)
- 208.** De Vries M, Veerman AJP, Zwaan CHM. First clinical experiences with rituximab in children with relapsed/refractory B-cell Acute Lymphoblastic Leukemia/Burkitt Lymphoma: report on 3 children treated on compassionate use basis. *Brit J Haematol* 2004; 125: 414-415. (VUmc)
- 209.** De Witte MA, Schumacher TNM. Generating CTL by HLA transplant. *Blood* 2004; 103: 4381-2. (NKI)
- 210.** Dekker N, Speijer D, Grun HC, van den Berg M, de Haan A, Hochstenbach FMH. Role of the alpha-glucanase Agn1p in fission-yeast cell separation. *Mol Biol Cell* 2004; 15(8): 3903-3914. (AMC)
- 211.** Den Brok MWJ, Van der Schoot SC, Nuijen B, Hillebrand MJX, Beijnen JH. 2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing. *Int J Pharm* 2004; 278: 303-9. (NKI)
- 212.** Di Lorenzo C, Benninga MA, Forbes D, Morais MB, Morera C, Rudolph C, Staiano A, Sullivan PB, Tobin J. Functional gastrointestinal disorders, gastroesophageal reflux and neurogastroenterology: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastr Nutr* 2004; 39(Suppl.2): S616-S625. (AMC)

- 213.** Dietrich CG, Geier A, Salein N, Lammert F, Roeb E, Oude Elferink RPJ, Matern S, Gartung C. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. *Gastroenterology* 2004; 126(4): 1044-1053. (AMC)
- 214.** Dietrich CG, Geier A, Wasmuth HE, de Waart DR, Oude Elferink RPJ, Matern S, Gartung C. Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen. *Gut* 2004; 53(12): 1850-1855. (AMC)
- 215.** Diks SH, Richel DJ, Peppelenbosch MP. LPS signal transduction: the picture is becoming more complex. *Curr Top Med Chem* 2004; 4(11): 1115-1126. (AMC)
- 216.** Dirkx MLP, van Sörnsen JR, de Koste, Senan S. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer. *Lung Cancer* 2004; 45: 57-65. (VUmc)
- 217.** Divecha N, Halstead JR. Of yeast and men. *EMBO Rep* 2004; 5: 865-6. (NKI)
- 218.** Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. *Nature* 2004; 430: 1034-9. (NKI)
- 219.** Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, Kluin-Nelemans HC, Meijer CJ, Raaphorst FM. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. *Am J Pathol* 2004; 164(3): 873-881. (VUmc)
- 220.** Dunker MS, Bemelman WA, Vijn PCM, Jansen FW, Peters AAW, Janss RAJ. Long-term outcomes and quality of life after laparoscopic adhesiolysis for chronic abdominal pain. *J Am Assoc Gyn Lap* 2004; 11(1): 36-41. (AMC)
- 221.** Edel MJ, Shvarts A, Medema JP, Bernards R. An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression. *Oncogene* 2004; 23: 4959-65. (NKI)
- 222.** Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? *Int J Radiat Oncol Biol Phys* 2004; 60: 1425-39. (NKI)
- 223.** Engelsma D, Bernad R, Calafat J, Fornerod M. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. *EMBO J* 2004; 23: 3643-52. (NKI)
- 224.** Engering A, Van Vliet SJ, Hebeda K, Jackson DG, Prevo R, Singh SK, Geijtenbeek TB, van Krieken H, Van Kooyk Y. Dynamic populations of dendritic cell-specific ICAM-3 grabbing nonintegrin-positive immature dendritic cells and liver/lymph node-specific ICAM-3 grabbing nonintegrin-positive endothelial cells in the outer zones of the paracortex of human lymph nodes. *Am J Pathol* 2004; 164(5): 1587-1595. (VUmc)
- 225.** Enserink JM, Price LS, Methi T, Mahic M, Sonnenberg A, Bos JL et al. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. *J Biol Chem* 2004; 279: 44889-96. (NKI)
- 226.** Erdogan D, Heijnen BHM, Bennink RJ, Kok M, Dinant S, Straatsburg IH. Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. *Liver Int* 2004; 24(2): 117-123. (AMC)
- 227.** Estourgie SH, Nieweg OE, Kroon BBR. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. *Br J Surg* 2004; 91: 1370. (NKI)
- 228.** Estourgie SH, Nieweg OE, Kroon BBR. The sentinel node procedure in patients with melanoma [editorial]. *Eur J Surg Oncol* 2004; 30: 713-4. (NKI)
- 229.** Estourgie SH, Nieweg OE, Valdés Olmos RA, Rutgers EJT, Kroon BBR. Internal mammary chain drainage of breast cancer: reply. *Ann Surg* 2004; 240: 558. (NKI)
- 230.** Estourgie SH, Nieweg OE, Valdés Olmos RA, Rutgers EJT, Kroon BBR. Lymphatic drainage patterns from the breast. *Ann Surg* 2004; 239: 232-7. (NKI)
- 231.** Everts B, Van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. *Cancer Gene Ther* 2004. (NKI)
- 232.** Fabry HF, Mutsaers PG, Meijer S, Torrens H, Pijpers R, van Leeuwen PA, Van der Sijp JRM. Clinical relevance of parasternal uptake in sentinel node procedure for breast cancer. *J Surg Oncol* 2004; 87(1): 13-18. (VUmc)
- 233.** Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. *J Infect Dis* 2004; 190: 53-62. (VUmc)
- 234.** Fahner PJ, Legemate DA, Van Bavel E, Borstlap J, Pfaffendorf M, Van Marle J, Van Gulik TM. Morphological and functional alterations in glycerol preserved rat aortic allografts. *Int J Artif Organs* 2004; 27(11): 979-989. (AMC)
- 235.** Fanchon S, Bourd K, Septier D, Everts V, Beertsen W, Menashi S, Goldberg M. Involvement of matrix metalloproteinases in the onset of dentin mineralization. *Eur J Oral Sci* 2004; 112(2): 171-176. (AMC)
- 236.** Faneyte IF, Kristel PM, Van de Vijver MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed

- breast cancer. *Anticancer Res* 2004; 24: 2931-9. (NKI)
- 237.** Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, De Vries EGE, Rodenhuis S et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. *Clin Cancer Res* 2004; 10: 4457-63. (NKI)
- 238.** Farabegoli F, Hermsen MA, Ceccarelli C, Santini D, Weiss MM, Meijer GA, Van Diest PJ. Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma. *Modern Pathol* 2004; 17(4): 449-455. (VUmc)
- 239.** Fehlauer F, Stalpers LJ, Panayiotides J, Kaaijk P, Gonzalez GD, Leenstra S, van d, V, Sminia P. Effect of single dose irradiation on human glioblastoma spheroids in vitro. *Oncol Rep* 2004; 11(2): 477-485. (AMC/VUmc)
- 240.** Fei BY, Xia B, Deng CS, Xia XQ, Xie M, Crusius JB, Pena AS. Association of tumor necrosis factor genetic polymorphism with chronic atrophic gastritis and gastric adenocarcinoma in Chinese Han population. *World J Gastroenterol* 2004; 10(9): 1256-1261. (VUmc)
- 241.** Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, Evertse BW, Ossenkoppele GJ, Schuurhuis GJ. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. *Leukemia* 2004; 18(8): 1380-1390. (VUmc)
- 242.** Ferdinandusse S, Denis SW, van Roermund CWT, Wanders RJA, Dacremont G. Identification of the peroxisomal beta-oxidation enzymes involved in the degradation of long-chain dicarboxylic acids. *J Lipid Res* 2004; 45(6): 1104-1111. (AMC)
- 243.** Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, Vaccarella SV, Jara AT, Puschel KI, Robles SC, Herrero R, Franceschi SF, Ojeda JM. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. *Cancer Epidem Biomar* 2004; 13: 2217-2276. (VUmc)
- 244.** Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Duran N, Peppelenbosch MP. Molecular mechanism of violacein-mediated human leukemia cell death. *Blood* 2004; 104(5): 1459-1464. (AMC)
- 245.** Ferrer M, De Winter JP, Mastenbroek DC, Curiel DT, Gerritsen WR, Giaccone G, Kruyt FA. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. *Cancer Gene Ther* 2004; 11(8): 539-546. (VUmc)
- 246.** Fijneman RJ, Vos M, Berkhof J, Demant P, Kraal G. Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3. *Cancer Res* 2004; 64(10): 3458-3464. (VUmc)
- 247.** Fons G, Rahe B ter, Sloof G, de Hullu J, van der Velden J. Failure in the detection of the sentinel lymph node with a combined technique of radioactive tracer and blue dye in a patient with cancer of the vulva and a single positive lymph node. *Gynec Oncol* 2004; 92(3): 981-984. (AMC)
- 248.** Fontao L, Tasanen K, Huber M, Hohl D, Koster J, Bruckner-Tuderman L et al. Molecular consequences of deletion of the cytoplasmic domain of bullous pemphigoid 180 in a patient with predominant features of epidermolysis bullosa simplex. *J Invest Dermatol* 2004; 122: 65-72. (NKI)
- 249.** Fossa SD, Mickisch GHJ, De Mulder PHM, Horenblas S, Van Oosterom AT, Van Poppel H et al. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. *Cancer* 2004; 101: 533-40. (NKI)
- 250.** Fotoohi K, Jansen G, Assaraf YG, Rothem L, Stark M, Kathmann I, Gregorczyk J, Peters GJ, Albertioni F.. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. *Blood* 2004; 104(13): 4194-4201. (VUmc)
- 251.** Fracasso PM, Goldstein LJ, De Alwis DP, Rader JS, Arquette MA, Goodner SA et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. *Clin Cancer Res* 2004; 10: 7220-8. (NKI)
- 252.** Franco S, Van de Vrugt HJ, Fernandez P, Aracil M, Arwert M, Arwert F, Blasco MA. Telomerase dynamics in Fancg-deficient mouse and human cells. *Blood* 2004; 15: 3927-3935. (VUmc)
- 253.** Franken NAP, ten Cate R, van Bree C, Haveman J. Induction of the early response protein EGR-1 in human tumour cells after ionizing radiation is correlated with a reduction of repair of lethal lesions and an increase of repair of sublethal lesions. *Int J Oncol* 2004; 24(4): 1027-1031. (AMC)
- 254.** Franken NAP, van Bree C, Haveman J. Differential response to radiation of TP53-inactivated cells by overexpression of dominant-negative mutant TP53 or HPVE6. *Radiat Res* 2004; 161(5): 504-510. (AMC)
- 255.** Frederiks WM, Mook ORF. Metabolic mapping of proteinase activity with emphasis on in situ zymography of gelatinases: review and protocols. *J Histochem Cytochem* 2004; 52(6): 711-722. (AMC)
- 256.** Gargica S, Hauser S, Kolfschoten I, Osterloh L, Agami R, Gaubatz S. Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein. *EMBO J* 2004; 23: 4627-38. (NKI)
- 257.** Gallegos Hernandez JF, Tanis PJ, Deurloo EE, Nieweg OE, Rutgers EJT, Kroon BBR et al. Radio-

guided surgery improves outcome of therapeutic excision in non-palpable invasive breast cancer. *Nucl Med Commun* 2004; 25: 227-32. (NKI)

258. Gao Y, Hansson M, Calafat J, Tapper H, Olsson I. Sorting soluble tumor necrosis factor (TNF) receptor for storage and regulated secretion in hematopoietic cells. *J Leukoc Biol* 2004; 76: 870-85. (NKI)

259. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol* 2004; 15: 19-27. (NKI)

260. Geldof AA, Tjon A, Sminia P, Lammertsma AA. In vitro Positron Emission Tomography (PET) as a tool to validate imaging of cancer cell physiology and response to treatment. *Anticancer Res* 2004; 24: 3497-3498. (VUmc)

261. Genc M, Castro Kreder N, Barten-van Rijbroek AD, Stalpers LJA, Haveman J. Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids. *J Cancer Res Clin* 2004; 130(1): 45-51. (AMC)

262. Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van Beusechem VW. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. *Cancer Res* 2004; 64(16): 5753-5759. (VUmc)

263. Gerdes VEA, Kraaijenhagen RA, Vogels EWM, ten Cate H, Reitsma PH. Factor XI gene analysis in thrombophilia and factor XI deficiency [letter]. *J Thromb Haemost* 2004; 2(6): 1015-1017. (AMC)

264. Gerdes VEA, Kremer Hovinga JA, ten Cate H, MacGillavry MR, Leijte A, Reitsma PH, Brandjes DPM, Büller HR. Homocysteine and markers of coagulation and endothelial cell activation. *J Thromb Haemost* 2004; 2(3): 445-451. (AMC)

265. Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh WJ, Smith R, Averbuch S, Fandi A. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. *Ann Oncol* 2004; 15(5): 831-838. (VUmc)

266. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. *J Clin Oncol* 2004; 22(5): 777-784. (VUmc)

267. Giaccone G, Smit EF, de Jonge M, Dansin E, Briasoulis E, Ardizzoni A, Douillard JY, Spaeth D, Lacombe D, Baron B, Bachmann P, Fumoleau P. Glufosfamide administered by 1-hour infusion as a

second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development Group. *Eur J Cancer* 2004; 40(5): 667-672. (VUmc)

268. Giaccone G. Clinical potential of proteasome inhibition in solid tumours. *Eur J Cancer* 2004; suppl 2: 25-28. (VUmc)

269. Giaccone G. The role of gefitinib in lung cancer treatment. *Clin Cancer Res* 2004; 10(12 Pt 2): 4233s-4237s. (VUmc)

270. Giardiello FM, Casero RA, Hamilton SR, Hyland LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJA, Yang VW. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. *Gastroenterology* 2004; 126(2): 425-431. (AMC)

271. Gieling RG, Ruijter JM, Maas AAW, van der Bergh Weerman MA, Dingemans KP, ten Kate FJW, Lekanne Dit Deprez RH, Moorman AFM, Lamers WH. Hepatic response to right ventricular pressure overload. *Gastroenterology* 2004; 127(4): 1210-1221. (AMC)

272. Gietema HA, Vuylsteke RJ, de Jonge IA, van Leeuwen PA, Molenkamp BG, Van der Sijp JRM,, Meijer S, Van Diest PJ. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry. *J Clin Pathol* 2004; 57(6): 618-620. (VUmc)

273. Gootjes J, Elpeleg ON, Eyskens F, Mandel H, Mitanchez D, Shimozawa N, Suzuki Y, Waterham HR, Wanders RJA. Novel mutations in the PEX2 gene of four unrelated patients with a peroxisome biogenesis disorder. *Pediatr Res* 2004; 55(3): 431-436. (AMC)

274. Gootjes J, Schmohl F, Mooijer PAW, Dekker C, Mandel H, Topcu M, Huemer M, von Schütz M, Marquardt T, Smeitink JA, Waterham HR, Wanders RJA. Identification of the molecular defect in patients with peroxisomal mosaicism using a novel method involving culturing of cells at 40 degrees C: implications for other inborn errors of metabolism. *Hum Mutat* 2004; 24(2): 130-139. (AMC)

275. Gootjes J, Schmohl F, Waterham HR, Wanders RJA. Novel mutations in the PEX12 gene of patients with a peroxisome biogenesis disorder. *Eur J Hum Genet* 2004; 12(2): 115-120. (AMC)

276. Gootjes J, Skovby F, Christensen E, Wanders RJA, Ferdinandusse S. Reinvestigation of trihydroxycholestanic acidemia reveals a peroxisome biogenesis disorder. *Neurology* 2004; 62(11): 2077-2081. (AMC)

277. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. *J Clin Oncol* 2004; 22(12): 2388-2394. (AMC)

- 278.** Graaf MR, Richel DJ, van Noorden CJF, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. *Cancer Treat Rev* 2004; 30(7): 609-641. (AMC)
- 279.** Graham JM, Hennekam RCM, Dobyns WB, Roeder E, Busch D. MICRO syndrome: an entity distinct from COFS syndrome. *Am J Med Genet* 2004; 128A(3): 235-245. (AMC)
- 280.** Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. *J Clin Pathol* 2004; 10: 1009-1014. (VUmc)
- 281.** Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. *Ann Oncol* 2004; 15: 419-26. (NKI)
- 282.** Griparic L, Van der Wel NN, Orozco IJ, Peters PJ, Van der Blik AM. Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria. *J Biol Chem* 2004; 279: 18792-8. (NKI)
- 283.** Groen AK, Oude Elferink RPJ, Verkade HJJ, Kuipers F. The ins and outs of reverse cholesterol transport. *Ann Med* 2004; 36(2): 135-145. (AMC)
- 284.** Grun HC, Hochstenbach FMH, Humbel BM, Verkleij AJ, Sietsma JH, Klis FM, Kamerling JP, Vliegthart JFG. The structure of cell wall alpha-glucan from fission yeast. *Glycobiology* 2004; 15(3): 1-13. (AMC)
- 285.** Gu Z, Valianpour F, Chen S, Vaz FM, Hakkaart GAJ, Wanders RJA, Greenberg ML. Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome. *Molecular Microbiology* 2004; 51(1): 149-158. (AMC)
- 286.** Haarman EG, Kaspers GJ, Pieters R, Rottier MM, Veerman AJ. Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticoid resistance in childhood leukemia. *Leukemia* 2004; 18(3): 530-537. (VUmc)
- 287.** Haas RLM, De Jong D, Valdés Olmos RA, Hoefnagel CA, Van den Heuvel I, Zerp SF et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. *Int J Radiat Oncol Biol Phys* 2004; 59: 782-7. (NKI)
- 288.** Hage JJ, Woerdeman LAE. Lower limb necrosis after use of the anterolateral thigh free flap: is preoperative angiography indicated? *Ann Plast Surg* 2004; 52: 315-8. (NKI)
- 289.** Hagenbeek TJ, Naspetti M, Malergue F, Garcon F, Nunes JA, Cleutjens KB et al. The Loss of PTEN Allows TCR $\alpha\beta$ Lineage Thymocytes to Bypass IL-7 and Pre-TCR-mediated Signaling. *J Exp Med* 2004; 200: 883-94. (NKI)
- 290.** Hansen JB, Jorgensen C, Petersen RK, Hallenborg P, De Matteis R, Boye HA et al. Retinoblastoma protein functions as a molecular switch determining white versus brown adipocyte differentiation. *Proc Natl Acad Sci U S A* 2004; 101: 4112-7. (NKI)
- 291.** Hansen JB, Te Riele H, Kristiansen K. Novel function of the retinoblastoma protein in fat: regulation of white versus brown adipocyte differentiation. *Cell Cycle* 2004; 3: 774-8. (NKI)
- 292.** Hansma AH, van Hensbergen Y, Kuenen BC, Van Diest PJ, Hanemaaijer R, Meijer S, Pinedo HM, Hoekman K. A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour. *J Clin Pathol* 2004; 57(5): 536-538. (VUmc)
- 293.** Haralambieva E, Schuurings E, Rosati S, van Noesel C, Jansen P, Appel I, Guikema JEJ, Wabinga H, Bleggi-Torres LF, Lam K, van den Berg E, Mellink CHM, van Zelderen-Bhola S, Kluin P. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. *Genes Chromosomes & Cancer* 2004; 40(1): 10-18. (AMC)
- 294.** Haramis A-P, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJA, Clevers H. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. *Science* 2004; 303(5664): 1684-1686. (AMC)
- 295.** Hardwick JCH, van den Brink GR, Bleuming SA, Ballester I, van den Brande JMH, Keller JJ, Offerhaus GJA, van Deventer SJH, Peppelenbosch MP. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. *Gastroenterology* 2004; 126(1): 111-121. (AMC)
- 296.** Hardwick JCH, van Santen HM, van den Brink GR, van Deventer SJH, Peppelenbosch MP. DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. *Carcinogenesis* 2004; 25(7): 1293-1298. (AMC)
- 297.** Haringhuizen A, van Tinteren H, Vaessen HFR, Baas P, van Zandwijk N. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. *Ann Oncol* 2004; 15: 786-92. (NKI)
- 298.** Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein, Kranenbarg E, Songun I, Welvaart K, Van Krieken JH, Meijer S, Plukker JT, Van Elk PJ, Obertop H, Gouma DJ, Van Lanschot JJ, Taat CW, De Graaf PW, Von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol* 2004; 22(11): 2069-2077. (AMC/VUmc)
- 299.** Hartman EE, Oort FJ, Aronson DC, Hanneman MJG, van der Zee DC, Rieu PNMA, Madern GC, de Langen ZJ, van Heurn E, van Silfhout-Bezemer M, Looijaard N, Sprangers MAG. Critical factors affecting quality of life of adult patients with anorectal malformations or Hirschsprung's disease.

Am J Gastroenterol 2004; 99(5): 907-913. (AMC)

300. Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, Poland DCW, Van Dijk W, Kuwano H, Kochibe N, Yazawa S. Alpha-1-acid glycoprotein fucosylation as a marker of cancer progression and prognosis. *Cancer* 2004; 101(12): 2825-2836. (VUmc)

301. Hasle H, Baumann I, Bergsträsser E, Fenu S, Fischer A, Kardos G, Kerndrup G, Locatelli F, Rogge T, Schultz KR, Stary J, Trebo M, Van den Heuvel-Eibrink MM, Harbott J, Nöllke P, Niemeyer CM. The international prognostic scoring system (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). For the European Working Group on childhood MDS (EWOG-MDS). *Leukemia* 2004; 18: 2008-2015. (VUmc)

302. Haveman J, Castro Keder N, Rodermond HM, Van Bree C, Franken NAP, Stalpers LJA, Zdienicka MM, Peters GJ. Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil. *Oncol Rep* 2004; 12(1): 187-92. (AMC/VUmc)

303. Haveman J, van der Zee J, Wondergem J, Hoozeveldt JF, Hulshof MCCM. Effects of hyperthermia on the peripheral nervous system: a review. *Int J Hypertherm* 2004; 20(4): 371-391. (AMC)

304. Heideman DA, van Beusechem VW, Bloemena E, Snijders PJ, Craanen ME, Offerhaus GJ, Derksen PW, de Bruin M, Witlox MA, Molenaar B, Meijer CJ, Gerritsen WR. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. *J Gene Med* 2004; 6(3): 317-327. (AMC/VUmc)

305. Heijnsdijk EAM, de Visser H, Dankelman J, Gouma DJ. Slip and damage properties of jaws of laparoscopic graspers. *Surg Endosc-Ultras* 2004; 18(6): 974-979. (AMC)

306. Heijnsdijk EAM, Padeloup A, van der Pijl AJ, Dankelman J, Gouma DJ. The influence of force feedback and visual feedback in grasping tissue laparoscopically. *Surg Endosc-Ultras* 2004; 18(6): 980-985. (AMC)

307. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. *J Clin Oncol* 2004; 22(5): 785-794 (VUmc).

308. Herder GJ, Golding RP, Hoekstra OS, Comans EF, Teule GJ, Postmus PE, Smit EF. The performance of (18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. *Eur J Nucl Med Mol I* 2004; 31(9): 1231-1236. (VUmc)

309. Hess CJ, Denkers F, Ossenkoppele GJ, Waisfisz Q, McElgunn CJ, Eldering E, Schouten JP, Schuurhuis

GJ. Gene expression profiling of minimal residual disease in acute myeloid leukemia by novel multiplex-PCR based method. *Leukemia* 2004; 18(12): 1981-1988. (VUmc)

310. Hesselink AT, van den Brule AJ, Brink AA, Berkhof J, van Kemenade FJ, Verheijen RH, Snijders PJ. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. *Cancer* 2004; 102(1): 11-18. (VUmc)

311. Hochberg D, Middeldorp JM, Cataline M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. *P Natl Acad Sci USA* 2004; 101(1): 239-244. (VUmc)

312. Hoefnagel CA, De Kraker J. Nuclear medicine in pediatric oncology. *Nucl Med Rev Cent East Eur* 2004; 7: 69-75. (NKI)

313. Hoekman K, Pinedo HM. Angiogenesis: a potential target for therapy of soft tissue sarcomas. *Cancer Treat Res* 2004; 120: 169-80. (VUmc)

314. Hogenboom S, Tuyp JJM, Espeel M, Koster J, Wanders RJA, Waterham HR. Human mevalonate pyrophosphate decarboxylase is localized in the cytosol. *Mol Genet Metab* 2004; 81(3): 216-224. (AMC)

315. Hogenboom S, Tuyp JJM, Espeel M, Koster J, Wanders RJA, Waterham HR. Mevalonate kinase is a cytosolic enzyme in humans. *J Cell Sci* 2004; 117(4): 631-639. (AMC)

316. Hogenboom S, Tuyp JJM, Espeel M, Koster J, Wanders RJA, Waterham HR. Phosphomevalonate kinase is a cytosolic protein in humans. *J Lipid Res* 2004; 45(4): 697-705. (AMC)

317. Hogewoning CJ, Bleeker MC, Voorhorst FJ, Berkhof J, Snijders PJ, Meijer CJ. Tobacco, condom use and regression of CIN lesions. *Int J Cancer* 2004; 112(1): 165. (VUmc)

318. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. *New Engl J Med* 2004; 351: 533-542. (VUmc)

319. Hollestelle MJ, Geertzen HGM, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. *Throm Haemostasis* 2004; 91(2): 267-275. (AMC)

320. Homs MY, Steyerberg EW, Eijkenboom WMH, Tilanus HW, Stalpers LJ, Bartelsman JF et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. *Lancet* 2004; 364: 1497-1504. (AMC/NKI)

321. Honing H, Van den Berg TK, Dijkstra CD, Van der Kammen RA, Collard JG, De Vries HE. RhoA

activation promotes transendothelial migration of monocytes via ROCK. *J Leukoc Biol* 2004; 75: 523-8. (NKI + VUmc)

322. Hooft L, Hoekstra OS, Boers M, Van Tulder MW, Van Diest P, Lips P. Practice, efficacy, and costs of thyroid nodule evaluation: a retrospective study in a Dutch university hospital. *Thyroid* 2004; 14(4): 287-293. (VUmc)

323. Hooft L, van der Veldt AAM, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJJ, Molthoff CFM. 18F-fluorodeoxyglucose uptake in recurrent thyroid cancer is related to HK I expression in the primary tumor. *J Clin Endocr Metab* 2004; 90(1): 328-334. (VUmc)

324. Hoogeman MS, Van Herk M, De Bois J, Muller-Timmermans P, Koper PC, Lebesque JV. Quantification of local rectal wall displacements by virtual rectum unfolding. *Radiother Oncol* 2004; 70: 21-30. (NKI)

325. Hooijberg JH, Jansen G, Assaraf YG, Kathmann I, Pieters R, Laan AC, Veerman AJ, Kaspers GJ, Peters GJ. Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). *Biochem Pharmacol* 2004; 67(8): 1541-1548. (VUmc)

326. Hooijberg JH, Peters GJ, Kaspers GJL, Wielinga PR, Veerman AJP, Pieters R, Jansen G. Online fluorescent method to assess BCRP/ABCG2 activity in suspension cells. *Nucleos Nucleot Nucl* 2004; 23: 1451-1454. (VUmc)

327. Hopper C, Kubler A, Lewis H, Tan IB, Putnam G. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. *Int J Cancer* 2004; 111: 138-46. (NKI)

328. Horn T, Kortmann BB, Holm NR, Smedts F, Nordling J, Kiemeny LA, Rosette JJ. Routine bladder biopsies in men with bladder outlet obstruction. *Urology* 2004; 63(3): 451-456. (AMC)

329. Hornberg JJ, Tijssen MR, Lankelma J. Synergistic activation of signalling to extracellular signal-regulated kinases 1 and 2 by epidermal growth factor and 4beta-phorbol 12-myristate 13-acetate. *Eur J Biochem* 2004; 271(19): 3905-3913. (VUmc)

330. Horsch A, Prinz M, Schneider S, Sipilä O, Spinnler K, Vallee JP, Verdonck-de Leeuw AA. TNF-alpha receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells. *Leukemia* 2004; 18(6): 1149-1153. (VUmc)

331. Houtenbos I, Westers TM, de Gruijl TD, Scheper RJ, Ossenkoppele GJ, van de Loosdrecht AA. TNF-alpha receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells. *Leukemia* 2004; 18(6): 1149-1153. (VUmc)

332. Houtzager BA, Grootenhuys MA, Caron HN, Last BF. Quality of life and psychological adaptation

in siblings of paediatric cancer patients, 2 years after diagnosis. *Psycho-Oncology* 2004; 13(8): 499-511. (AMC)

333. Houtzager BA, Oort FJ, Hoekstra-Weebers JEHM, Caron HN, Grootenhuys MA, Kast BF. Coping and family functioning predict longitudinal psychological adaptation of siblings of childhood cancer patients. *J Pediatr Psychol* 2004; 29(8): 591-605. (AMC)

334. Hovinga J, Franco RF, Zago MA, ten Cate H, Westendorp RGJ, Reitsma PH. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. *J Thromb Haemost* 2004; 2(1): 54-57. (AMC)

335. Hovingh GK, Kuivenhoven JA, Bisoendial RJ, Groen AK, van Dam MJ, van Tol A, Wellington CL, Hayden MR, Smelt AHM, Kastelein JJP. HDL deficiency and atherosclerosis: lessons from Tangier disease [letter]. *J Intern Med* 2004; 255(2): 299-301. (AMC)

336. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Klöppel G, Longnecker DS, Lüttinges J, Maitra A, Offerhaus GJA, Shimizu M, Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *Am J Surg Pathol* 2004; 28(8): 977-987. (AMC)

337. Hubeek I, Litvinova E, Peters GJ, Broekhuizen R, Haarman EG, Huismans DR, Cloos J, Zwaan CM, Fleischhack G, Creutzig U, Kaspers GJL. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. *Int J Oncol* 2004; 25(6): 1823-1829. (VUmc)

338. Hubeek I, Peters GJ, Broekhuizen AJF, Kaspers GJL. Modulation of cytarabine induced cytotoxicity using novel deoxynucleotide analogs in the HL60 cell line. *Nucleos Nucleot Nucl* 2004; 23(8-9): 1513-1516. (VUmc)

339. Hubeek I, Peters GJ, Broekhuizen AJF, Talianidis I, Schouten van Meeteren AYN, van Wering ER, Gibson B, Creutzig U, Kaspers GJL. Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity. *Nucleos Nucleot Nucl* 2004; 23(8-9): 1351-1356. (VUmc)

340. Huidobro C, Bolmsjo M, Larson T, de la Rosette JJMCH, Wagrell L, Schelin S, Gorecki T, Mattiasson A. Evaluation of microwave thermotherapy with histopathology, magnetic resonance imaging and temperature mapping. *J Urology* 2004; 171(2 pt 1): 672-678. (AMC)

341. Hulsebos TJM, Troost D, Leenstra S. Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours. *Brit J Neurosurg* 2004; 75(5): 723-726. (AMC)

- 342.** Hulshof MCCM, Raaymakers BW, Lagendijk JJW, Koot RW, Crezee H, Stalpers LJA, González González D. A feasibility study of interstitial hyperthermia plus external beam radiotherapy in glioblastoma multiforme using the Multi Electrode Current Source (MECS) system. *Eur J Cancer* 2004; 40(5): 451-463. (AMC)
- 343.** Hulsman RL, Mollema E, Hoos AM, de Haes JCJM, Donnison-Speijer JD. Assessment of medical communication skills by computer: assessment method and student experiences. *Med Educ* 2004; 38(8): 813-824. (AMC)
- 344.** Hussain S, Wilson JB, Medhurst AL, Hejna J, Witt E, Ananth S, Davies A, Masson JY, Moses R, West SC, De Winter JP, Ashworth A, Jones NJ, Mathew CG. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. *Hum Mol Genet* 2004; 13: 1241-1248. (VUmc)
- 345.** Hustinx SR, Cao D, Maitra A, Sato N, Martin S, Sudhir D, Iacobuzio-Donahue C, Cameron JL, Yeo CHJ, Kern SE, Goggins M, Mollenhauer J, Pandey A, Hruban RH. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. *Cancer Biol Ther* 2004; 3(12): 1254-1261. (AMC)
- 346.** Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. *J Biol Chem* 2004; 279: 25527-25534 (VUmc).
- 347.** Itoh F, Itoh S, Goumans MJ, Valdimarsdottir G, Iso T, Dotto GP et al. Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. *EMBO J* 2004; 23: 541-51. (NKI)
- 348.** Jairath D, Hage JJ. Deep circumflex iliac artery (DCIA) free flap without DCIA: report of a unique case. *J Reconstr Microsurg* 2004; 20: 519-21. (NKI)
- 349.** Jansen GA, Waterham HR, Wanders RJA. Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). *Hum Mutat* 2004; 23(3): 209-218. (AMC)
- 350.** Jansen M, de Witt Hamer PhC, Witmer AN, Troost D, van Noorden CJF. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. *Brain Res Rev* 2004; 45(3): 143-163. (AMC)
- 351.** Janssen HL, Hoebbers FJP, Sprong D, Goethals L, Williams KJ, Stratford IJ et al. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. *Radiother Oncol* 2004; 70: 91-7. (NKI)
- 352.** Janssen JJ, Hochhaus A, van Oostveen JW, Waisfisz Q, Schuurhuis CJ, Ossenkoppele GJ. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene. *Leukemia* 2004; 18(5): 1020-1021. (VUmc)
- 353.** Jaspers MWM, Steen T, van den Bos C, Geenen M. The think aloud method: a guide to user interface design. *Int J Med Inform* 2004; 73(11-12): 781-795. (AMC)
- 354.** Jiang XG, Wijkstra H, Meuleman EJ, Wagner G. The methodology of corpus cavernosum electromyography revisited. *Eur Urol* 2004; 46(3): 370-376. (AMC)
- 355.** Joerger M, Schellens JHM, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. *Methods Find Exp Clin Pharmacol* 2004; 26: 531-45. (NKI)
- 356.** Jones DR, Divecha N. Linking lipids to chromatin. *Curr Opin Genet Dev* 2004; 14: 196-202. (NKI)
- 357.** Jones EA. Fatigue complicating chronic liver disease. *Metab Brain Dis* 2004; 19(3/4): 421-429. (AMC)
- 358.** Jones EA. Technical medical interventions and the health of populations [letter]. *Quart J Med* 2004; 97(5): 309. (AMC)
- 359.** Jong K, Marchiori E, Meijer G, van der Vaart A, Ylstra B. Breakpoint identification and smoothing of array comparative genomic hybridization data. *Bioinformatics* 2004; 20(18): 3636-3637. (VUmc)
- 360.** Jonker JW, Schinkel AH. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3). *J Pharmacol Exp Ther* 2004; 308: 2-9. (NKI)
- 361.** Jonkers J, Berns A. Oncogene addiction: Sometimes a temporary slavery. *Cancer Cell* 2004; 6: 530-3. (NKI)
- 362.** Jonkers RE, Lettinga KD, Pels Rijcken TH, Prins JM, Roos CM, van Delden OM, Verbon A, Bresser P, Jansen HM. Abnormal radiological findings and a decreased carbon monoxide transfer factor can persist long after the acute phase of Legionella pneumophila pneumonia. *Clin Infect Dis* 2004; 38(5): 605-611. (AMC)
- 363.** Joshi U, Hoekstra OS, Boellaard R, Comans EF, Raijmakers PG, Pijpers RJ, Miller SD, Teule GJ, van Lingen A. Initial experience with a prototype dual-crystal (LSO/NaI) dual-head coincidence camera in oncology. *Eur J Nucl Med Mol I* 2004; 31(4): 596-598. (VUmc)
- 364.** Joshi U, vd Hoeven JJM, Comans EFI, Herder GJ, Teule GJJ, Hoekstra OS. In search of an unknown primary tumour presenting with extracervical metastasis: the diagnostic performance of FDG PET. *Brit J Radiol* 2004; 77(924): 1000-1006. (VUmc)
- 365.** Kaas R, Kroger R, Hendriks JHCL, Besnard APE, Koops W, Pameijer FA et al. The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers. *Eur Radiol* 2004; 14: 1647-53. (NKI)
- 366.** Kalb R, Duerr M, Wagner M, Herterich S, Gross M, Digweed M, Joenje H, Hoehn H, Schindler D.

Lack of sensitivity of primary Fanconi's anemia fibroblasts to UV and ionizing radiation. *Radiat Res* 2004; 161: 318-325. (VUmc)

367. Kartachova M, Haas RLM, Valdés Olmos RA, Hoebers FJP, Van Zandwijk N, Verheij M. In vivo imaging of apoptosis by (99m)Tc-Annexin V scintigraphy: visual analysis in relation to treatment response. *Radiother Oncol* 2004; 72: 333-9. (NKI)

368. Kaufman Y, Drori S, Cole PD, Kamen BA, Sirotta J, Ifergan I, Arush MW, Elhasid R, Sahar D, Kaspers GJ, Jansen G, Matherly LH, Rechavi G, Toren A, Assaraf YG. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. *Cancer* 2004; 100: 773-782. (VUmc)

369. Kemper EM, Boogerd W, Thuis I, Beijnen JH, Van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? [review]. *Cancer Treat Rev* 2004; 30: 415-23. (NKI)

370. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, Van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. *Cancer Chemother Pharmacol* 2004; 53: 173-8. (NKI)

371. Kemper EM, Verheij M, Boogerd W, Beijnen JH, Van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. *Eur J Cancer* 2004; 40: 1269-74. (NKI)

372. Kenemans P, Verstraeten RA, Verheijen RH. Oncogenic pathways in hereditary and sporadic breast cancer. *Maturitas* 2004; 49(1): 34-43. (VUmc)

373. Kerbusch T, Groenewegen G, Mathot RAA, Herben VMM, Ten Bokkel Huinink WW, Swart M et al. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. *Br J Cancer* 2004; 90: 2268-77. (NKI)

374. Kessels HWHG, De Visser KE, Tirion FH, Coccoris M, Kruisbeek AM, Schumacher TNM. The impact of self-tolerance on the polyclonal CD8(+) T cell repertoire. *J Immunol* 2004; 172: 2324-31. (NKI)

375. Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNFalpha polymorphism frequencies in HPV-associated cervical dysplasia. *Gynecol Oncol* 2004; 92(2): 675-679. (VUmc)

376. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJA, Griffin C, Cameron JL, Yeo CHJ, Kern S, Hruban RH. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res* 2004; 64(7): 2634-2638.

377. Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients

after radiotherapy. *J Clin Oncol* 2004; 22(5): 966-967. (VUmc)

378. Klein Zeggelink WFA, Hart AAM, Gilhuijs KGA. Assessment of analysis-of-variance-based methods to quantify the random variations of observers in medical imaging measurements: guidelines to the investigator. *Med Phys* 2004; 31: 1996-2007. (NKI)

379. Klerk CPW, Büller HR. Thrombosis prophylaxis in cancer patients with a central venous catheter [reply]. *Arch Intern Med* 2004; 164: 459-460. (AMC)

380. Knapp S, Gibot S, de Vos AF, Versteeg HH, Colonna M, van der Poll T. Cutting edge: Expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. *J Immunol* 2004; 173(12): 7131-7134. (AMC)

381. Koedoot CG, Oort FJ, de Haan RJ, Bakker PJM, de Graeff A, de Haes JCJM. The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are. palliative chemotherapy and watchful-waiting. *Eur J Cancer* 2004; 40(2): 225-235. (AMC)

382. Koehler A, Alpermann T, Lauritzen B, van Noorden CJF. Clonal xenobiotic resistance during pollution-induced toxic injury and hepatocellular carcinogenesis in liver of female flounder (*Platichthys flesus* (L.)). *Acta Histochem* 2004; 106(2): 155-170. (AMC)

383. Koeppen S, Verstappen CC, Korte R, Scheulen ME, Strumberg D, Postma TJ, Heimans JJ, Huijgens PC, Kiburg B, Renzing-Kohler K, Diener HC. Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. *J Cancer Res Clin Oncol* 2004; 130(3): 153-160. (VUmc) (VUmc)

384. Kok K, Stokkers P, Reitsma PH. Genomics and proteomics: implications for inflammatory bowel diseases. *Inflamm Bowel Dis* 2004; 10(Suppl.1): S1-S6. (AMC)

385. Komen JC, Duran M, Wanders RJA. Omega-hydroxylation of phytanic acid in rat liver microsomes: implications for Refsum disease. *J Lipid Res* 2004; 45(7): 1341-1346. (AMC)

386. Koot RW, de Heer K, Oort FJ, Hulshof MCCM, Bosch DA, de Haes JCJM. Quality of life after brachytherapy in patients with glioblastoma multiforme. *Eur J Cancer* 2004; 40(7): 1013-1020. (AMC)

387. Koper PCM, Heemsbergen WD, Hoogeman MS, Jansen PP, Hart GAM, Wijnmaalen AJ et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. *Int J Radiat Oncol Biol Phys* 2004; 58: 1072-82. (NKI)

388. Koper PCM, Jansen P, Van Putten W, Van Os M, Wijnmaalen AJ, Lebesque JV et al. Gastro-intestinal

and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. *Radiother Oncol* 2004; 73: 1-9. (NKI)

389. Koppe M, Schaijk F, Roos J, Leeuwen P, Heider KH, Kuthan H e.a. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)re-labeled humanized monoclonal antibody BIWA4 (Bivatuzumab) in patients with early-stage breast cancer. *Cancer Biother Radiopharm* 2004; 19(6): 720-729. (VUmc)

390. Korswagen LA, Moll AC, Imhof SM, Schouten-van Meeteren AY. A second primary tumor in a patient with retinoma. *Ophthalmic Genetics* 2004; 25(1): 45-48. (VUmc)

391. Koshy A, Bosma PJ, Oude Elferink RPJ. Crigler-Najjar syndrome type 1 associated with combined 1070A->G, Q357R and (TA)₇ mutation in Kuwaiti Bedouin families indicate a founder effect in Arabs. *J Clin Gastroenterol* 2004; 38(5): 465-467. (AMC)

392. Koster J, Van Wilpe S, Kuikman I, Litjens SHM, Sonnenberg A. Role of binding of plectin to the integrin {beta}4 subunit in the assembly of hemidesmosomes. *Mol Biol Cell* 2004; 15: 1211-23. (NKI)

393. Krak NC, Hoekstra OS, Lammertsma AA. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. *Eur J Nucl Med Mol I* 2004; 31 Suppl 1: S103-11. (VUmc)

394. Kremer LCM, Caron HN. Anthracycline cardiotoxicity in children. *New Engl J Med* 2004; 351(2): 120-121. (AMC)

395. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *New Engl J Med* 2004; 351(5): 427-437. (NKI/VUmc)

396. Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, Van Groeningen CJ. Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. *Ann Oncol* 2004; 15(2): 230-235. (VUmc)

397. Kroon BK, Horenblas S, Estourgie SH, Lont AP, Valdés Olmos RA, Nieweg OE. How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. *J Urol* 2004; 171: 2191-4. (NKI)

398. Kroon BK, Horenblas S, Nieweg OE. Contemporary management of penile squamous cell carcinoma. *J Surg Oncol* 2004; 89: 43-50. (NKI)

399. Kroon BK, Horenblas S, Nieweg OE. Re: Gipponi M, Solari N, Di Somma FC, et al.: New fields of application of the sentinel lymph node biopsy in the pathologic staging of solid neoplasms: review of literature and surgical perspectives. *J Surg Oncol*

2004; 85:171-179. *J Surg Oncol* 2004; 87: 107. (NKI)

400. Kruse JJCM, Te Poele JAM, Russell NS, Boersma LJ, Stewart FA. Microarray analysis to identify molecular mechanisms of radiation-induced microvascular damage in normal tissues. *Int J Radiat Oncol Biol Phys* 2004; 58: 420-6. (NKI)

401. Kruse JJCM, Te Poele JAM, Velds A, Kerkhoven RM, Boersma LJ, Russell NS et al. Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. *Radiat Res* 2004; 161: 28-38. (NKI)

402. Kuhlmann KFD, De Castro SM, Wesseling JG, ten Kate FJW, Offerhaus GJA, Busch ORC, van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. *Eur J Cancer* 2004; 40(4): 549-558. (AMC)

403. Kuijpers TW, Maianki NA, Tool ATJ, Becker K, Plecko B, Valianpour F, Wanders RJA, Pereira R, van Hove J, Verhoeven AJ, Roos D, Baas F, Barth PG. Neutrophils in Barth syndrome (BTHS) avidly bind annexin-V in the absence of apoptosis. *Blood* 2004; 103(10): 3915-3923. (AMC)

404. Kuijpers TW, Nannenberg EA, Alders M, Bredius R, Hennekam RCM. Congenital aplastic anemia caused by mutations in the SBDS gene: a rare presentation of Shwachman-Diamond syndrome. *Pediatrics* 2004; 114(3): e387-e391. (AMC)

405. Kuiken SD, van den Berg SJ, Tytgat GNJ, Boeckxstaens GEE. Oral S(+)-ketamine does not change visceral perception in health. *Digest Dis Sci* 2004; 49(11-12): 1745-1751. (AMC)

406. Kuipers GK, Slotman O, Reitsma-Wijker CA, van Aniel RJ, Poldervaart HA, Lafleur MVM. Influence of anoxia on the induction of mutations by phenylalanine radicals during gamma-irradiation of plasmid DNA in aqueous solution. *Mutation Res/Fund Mol M* 2004; 568(2): 171-177. (VUmc)

407. Kukreja J, Jaklitsch MT, Wiener DC, Sugarbaker DJ, Burgers S, Baas P. Malignant pleural mesothelioma: overview of the North American and European experience. *Thorac Surg Clin* 2004; 14: 435-45. (NKI)

408. Kuppens IELM, Beijnen J, Schellens JHM. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. *Clin Colorectal Cancer* 2004; 4: 163-80. (NKI)

409. Kuppens IELM, Boot H, Beijnen JH, Schellens JHM, Labadie J. Capecitabine induces severe angina-like chest pain [letter]. *Ann Intern Med* 2004; 140: 494-5. (NKI)

410. Kurian MA, Ryan S, Besley GTN, Wanders RJA, King MD. Straight-chain acyl-CoA oxidase deficiency presenting with dysmorphia, neurodevelopmental autistic-type regression and a

selective pattern of leukodystrophy. *J Inher Metab Dis* 2004; 27(1): 105-108. (AMC)

411. Lagerveld BW, Koot RA, Smits GA. Thermal artifacts in bladder tumors following loop endoresection: electrovaporization v electrocauterization. *J Endourol* 2004; 18(6): 583-586. (AMC)
412. Lamfers ML, Hemminki A. Multicellular tumor spheroids in gene therapy and oncolytic virus therapy. *Curr Opin Mol Ther* 2004; 6(4): 403-11. (VUmc)
413. Lan L, Hayashi T, Rabeya RM, Nakajima S, Kanno S, Takao M et al. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. *DNA Repair (Amst)* 2004; 3: 135-43. (NKI)
414. Langendijk JA, Leemans ChR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. *J Clin Oncol* 2004; 22: 4604-4612. (VUmc)
415. Langendijk JA, Poorter R, Leemans CR, de Bree R, Doornaert P, Slotman BJ. Radiotherapy of squamous cell carcinoma of the nasal vestibule. *Int J Radiat Oncol Biol Phys* 2004; 59(5): 1319-1325. (VUmc)
416. Langeveld NE, Grootenhuis MA, Voûte PA, de Haan RJ, van den Bos C. Quality of life, self-esteem and worries in young adult survivors of childhood cancer. *Psycho-oncology* 2004; 13(12): 867-881. (AMC)
417. Langeveld NE, Grootenhuis MA, Voûte PA, de Haan RJ. Posttraumatic stress symptoms in adult survivors of childhood cancer. *Pediatr Blood Cancer* 2004; 42(7): 604-610. (AMC)
418. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. *EMBO J* 2004; 23: 4018-28. (NKI)
419. Lee S, Varnai P, Balla A, Jalink K, Rhee S, Balla T. The pleckstrin-homology domain of PLCdelta 4 is not critical determinant of the membrane localization of the enzyme. *J Biol Chem* 2004; M312772200. (NKI)
420. Leemans JC, te Velde AA, Florquin S, Bennink RJ, Bruin KF, van Lier RAW, van der Poll T, Hamann J. The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. *J Immunol* 2004; 172(2): 1125-1131. (AMC)
421. Lefman J, Zhang P, Hirai T, Weis RM, Juliani J, Bliss D et al. Three-dimensional electron microscopic imaging of membrane invaginations in *Escherichia coli* overproducing the chemotaxis receptor Tsr. *J Bacteriol* 2004; 186: 5052-61. (NKI)

422. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. *Mol Cell Biol* 2004; 24(17): 7612-7621. (NKI/VUmc)
423. Lerut TE, van Lanschot JJB. Chronic symptoms after subtotal or partial oesophagectomy: diagnosis and treatment. *Best Pract Res CL GA* 2004; 18(5): 901-915. (AMC)
424. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. *Nature* 2004; 428: 337-41. (NKI)
425. Leveille F, Blom E, Medhurst AL, Bier P, Laghmani eH, Johnson M, Roomans MA, Soback A, Waisfisz Q, Arwert F, Patel KJ, Hoatlin ME, Joenje H, De Winter JP. The Fanconi anemia gene product FANCF is a flexible adaptor protein. *J Biol Chem* 2004; 279(38): 39421-39430. (VUmc)
426. Levitus M, Rooimans MA, Steltenpool J, Cool NF, Oostra AB, Mathew CG, Hoatlin ME, Waisfisz Q, Arwert F, De Winter JP, Joenje H. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. *Blood* 2004; 103(7): 2498-2503. (VUmc)
427. Lim W, Olschwang S, Keller JJ, Westerman AM, Menko FH, Boardman LA, Scott RJ, Trimbath J, Giardello FM, Gruber SB, Gille JJP, Offerhaus GJA, de Rooij FWM, Wilson JHP, Spigelman AD, Phillips RKS, Houlston RS. Relative frequency and morphology of cancers in STK11 mutation carriers. *Gastroenterology* 2004; 126(7): 1788-1794. (AMC)
428. Lisman Quirine Pomorski T, Vogelzangs C, Urli-Stam D, de Cocq van Delwijnen W, Holthuis JCM. Protein sorting in the late Golgi of *Saccharomyces cerevisiae* does not require mannosylated sphingolipids. *J Biol Chem* 2004; 279(2): 1020-1029. (AMC)
429. Lisman Quirine Urli-Stam D, Holthuis JCM. HOR7, a multicopy suppressor of the Ca²⁺-induced growth defect in sphingolipid mannosyltransferase-deficient yeast. *J Biol Chem* 2004; 279(35): 36390-36396. (AMC)
430. Ljumanovic R, Langendijk JA, Schenk B, Van Watingen M, Knol DL, Leemans CR, Castelijns JA. Supraglottic carcinoma treated with curative radiation therapy: identification of prognostic groups with MR imaging. *Radiology* 2004; 232(2): 440-448. (VUmc)
431. Logan N, Delavaine L, Graham A, Reilly C, Wilson J, Brummelkamp TR et al. E2F-7: a distinctive E2F family member with unusual organization of DNA binding domains. *Oncogene* 2004; 23: 5138-50. (NKI)
432. Lohuis PJ, Klop WM, Tan IB, Van den Brekel MWM, Hilgers FJM, Balm AJM. Effectiveness of therapeutic (N1, N2) selective neck dissection (levels II to V) in patients with laryngeal and

- hypopharyngeal squamous cell carcinoma. *Am J Surg* 2004; 187: 295-9. (NKI)
433. Lont AP, Gallee MP, Snijders P, Horenblas S. Sarcomatoid squamous cell carcinoma of the penis: a clinical and pathological study of 5 cases. *J Urology* 2004; 172: 932-935. (NKI/VUmc)
434. Los AP, Van Baal J, De Widt J, Divecha N, Van Blitterswijk WJ. Structure-activity relationship of diacylglycerol kinase theta. *Biochim Biophys Acta - Mol Cell Biol Lipids* 2004; 1636: 169-74. (NKI)
435. Lotz HT, Remeijer P, Van Herk M, Lebesque JV, De Bois JA, Zijp LJ et al. A model to predict bladder shapes from changes in bladder and rectal filling. *Med Phys* 2004; 31: 1415-23. (NKI)
436. Louwe RJ, McDermott LN, Sonke J-J, Tielenburg R, Wendling M, Van Herk MB et al. The long-term stability of amorphous silicon flat panel imaging devices for dosimetry purposes. *Med Phys* 2004; 31: 2989-95. (NKI)
437. Louwe RJW, Tielenburg R, Van Ingen KM, Mijnheer BJ, Van Herk MB. The stability of liquid-filled matrix ionization chamber electronic portal imaging devices for dosimetry purposes. *Med Phys* 2004; 31: 819-27. (NKI)
438. Lowe SH, Sankatsing SUC, Repping S, van der Veen F, Reiss P, Lange JMA, Prins JM. Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. *AIDS* 2004; 18(10): 1353-1362. (AMC)
439. Lowenberg M, Peppelenbosch MP, Hommes DW. Therapeutic modulation of signal transduction pathways. *Inflamm Bowel Dis* 2004; 10(Suppl. 1): S52-S57. (AMC)
440. Lund AH, Van Lohuizen M. Epigenetics and cancer. *Genes Dev* 2004; 18: 2315-35. (NKI)
441. Lund AH, Van Lohuizen M. Polycomb complexes and silencing mechanisms. *Curr Opin Cell Biol* 2004; 16: 239-46. (NKI)
442. Lutz M, Kriegelstein K, Schmitt S, Ten Dijke P, Sebald W, Wizenmann A et al. Nerve growth factor mediates activation of the Smad pathway in PC12 cells. *Eur J Biochem* 2004; 271: 920-31. (NKI)
443. Lynch TJ, Adjei AA, Bunn PA, Jr., DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. *Clin Cancer Res* 2004; 10(12 Pt 2): 4199s-4204s. (VUmc)
444. Maartense S, Bemelman WA, Gerritsen van der Hoop A, Meijer DW, Gouma DJ. Hand-assisted laparoscopic surgery (HALS): a report of 150 procedures. *Surg Endosc-Ultras* 2004; 18(3): 397-401. (AMC)
445. Maartense S, Dunker MS, Slors JFM, Cuesta MA, Gouma DJ, van Deventer SJH, van Bodegraven AA, Bemelman WA. Hand-assisted laparoscopic versus open restorative proctocolectomy with ileal pouch anal anastomosis: a randomized trial. *Ann Surg* 2004; 240(6): 984-992. (AMC)
446. Madersbacher St, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH) guidelines. *Eur Urol*. 2004; 46(5): 547-554. (AMC)
447. Maiburg BHJ, Rethans JJE, van Erk IM, Mathus-Vliegen EMH, van Ree JW. Fielding incognito standardised patients as 'known' patients in a controlled trial in general practice. *Med Educ* 2004; 38(12): 1229-1235. (AMC)
448. Malliri A, Van Es S, Huveneers S, Collard JG. The Rac exchange factor Tiam1 is required for the establishment and maintenance of cadherin-based adhesions. *J Biol Chem* 2004; 279: 30092-8. (NKI)
449. Marberger M, Harkaway R, de la Rosette JJMCH. Optimising the medical management of benign prostatic hyperplasia. *Eur Urol* 2004; 45(4): 411-419. (AMC)
450. Marsman M, Jordens I, Kuijl C, Janssen L, Neefjes J. Dynein-mediated vesicle transport controls intracellular Salmonella replication. *Mol Biol Cell* 2004; 15: 2954-64. (NKI)
451. Marsman WA, Birjmohun RS, van Rees BP, Caspers E, Offerhaus GJA, Bosma PJ, van Lanschot JJB. Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia. *Clin Cancer Res* 2004; 10(24): 8479-8484. (AMC)
452. Marsman WA, Buskens CJ, Wesseling JG, Offerhaus GJA, Bergman JJGHM, Tytgat GNJ, van Lanschot JJB, Bosma PJ. Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo. *Cancer Gene Ther* 2004; 11(4): 289-296. (AMC)
453. Marsman WA, van Sandick JW, Tytgat GNJ, ten Kate FJW, van Lanschot JJB. The presence and mucin histochemistry of cardiac type mucosa at the esophagogastric junction. *Am J Gastroenterol* 2004; 99(2): 212-217. (AMC)
454. Marsman WA, van Wissen M, Bergman JJGHM, van Lanschot JJB, Obertop H, Tytgat GNJ, Fockens P. Outcome of patients with esophageal carcinoma and suspicious celiac lymph nodes as determined by endoscopic ultrasonography. *Endoscopy* 2004; 36(11): 961-965. (AMC)
455. Mathus-Vliegen EMH, Smit CF, Devriese PPEOM. Artefacts in 24-h pharyngeal and oesophageal pH monitoring: is simplification of pH data analysis feasible. *Scand J Gastroentero* 2004; 39(1): 14-19. (AMC)
456. Mathus-Vliegen EMH, Van Ierland-Van Leeuwen ML, Terpstra A. Lipase inhibition by

orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity. *Aliment Pharm Therap* 2004; 19(5): 601-611.

457. Mauritz R, Beumer IJ, Marsh S, McLeod HL, Smid K, Van Groeningen CJ, Pinedo HM, Peters CJ. Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. *Nucleos Nucleot Nucl* 2004; 23: 1381-1384. (VUmc)

458. Mauritz R, Schwabe W, Haeusler P, Noordhuis P, Smid K, McLeod HL, Behnke D, Van Groeningen CJ, Peters CJ. Comparison of mRNA expression levels determined with Taq-man and competitive template RT-PCR. *Nucleos Nucleot Nucl* 2004; 23: 1471-1474. (VUmc)

459. Mayatepek E, Ferdinandusse S, Meissner T, Wanders RJA. Analysis of cysteinyl leukotrienes and their metabolites in bile of patients with peroxisomal or mitochondrial beta-oxidation defects. *Clin Chim Acta* 2004; 345(1-2): 89-92. (AMC)

460. McDermott LN, Louwe RJW, Sonke JJ, Van Herk MB, Mijneer BJ. Dose-response and ghosting effects of an amorphous silicon electronic portal imaging device. *Med Phys* 2004; 31: 285-95. (NKI)

461. Medema RH. Optimizing RNA interference for application in mammalian cells. *Biochem J* 2004; 380: 593-603. (NKI)

462. Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan CM, Ling C, Rooimans MA, Bier P, Hoatlin ME, Pals G, De Winter JP, Wang W, Joenje H. X-linked inheritance of Fanconi anaemia complementation group B. *Nat Genet* 2004; 36(11): 1219-1224. (VUmc)

463. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. *Int J Biochem Cell B* 2004; 6(12), 445-2462. (AMC)

464. Meijer AJ, Dubbelhuis PF. Amino acid signalling and the integration of metabolism. *Biochem Bioph Res Co* 2004; 313(2): 397-403. (AMC)

465. Meijer G. The future of Cellular Oncology. *Cell Oncol* 2004; 26(5-6): 271-273. (VUmc)

466. Meijer JW, Mulder CJ, Goerres MG, Boot H, Schweizer JJ. Coeliac disease and (extra)intestinal T-cell lymphomas: definition, diagnosis and treatment. *Scand J Gastroenterol Suppl* 2004; 78-84. (NKI)

467. Mellink CHM, Alders M, van der Lelie H, Hennekam RCM, Kuijpers TW. SBDS mutations and isochromosome 7q in a patient with Shwachman-Diamond syndrome: no predisposition to malignant transformation. *Cancer Genet Cytogen* 2004; 154(2): 144-149. (AMC)

468. Mels AK, Mayen I, Egmond MM, Beelen RH, Meijer S, Richters CD. Reduction of liver metastases outgrowth by tumour antigen-pulsed dendritic cell

vaccination. *Comp Hepatol* 2004; 3 Suppl 1: S54.:S54. (VUmc)

469. Menko FH, Kaspers GL, Meijer GA, Claes K, Van Hagen JM, Gille JJ. A Homozygous MSH6 Mutation in a Child with Cafe-au-Lait Spots, Oligodendroglioma and Rectal Cancer. *Familial Cancer* 2004; 3(2): 123-127. (VUmc)

470. Merks JH, Ceelie H, Caron HN, Hennekam RCM. Neuroblastoma, maternal valproic acid use, in-vitro fertilization and family history of mosaic chromosome 22: coincidence or causal relationship [letter]. *Clin Dysmorphol* 2004; 13(3): 197-198. (AMC)

471. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. *Cancer Cell* 2004; 5: 597-605. (NKI)

472. Milne ANA, Carvalho R, van Rees BP, van Lanschot JJB, Offerhaus GJA, Weterman MAJ. Do collision tumors of the gastroesophageal junction exist? A molecular analysis. *Am J Surg Pathol* 2004; 28(11): 1492-1498. (AMC)

473. Mizuno N, Suzuki M, Kusuvara H, Suzuki H, Takeuchi K, Niwa T et al. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. *Drug Metab Dispos* 2004; 32: 898-901. (NKI)

474. Mochtar MH. The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. *Hum Reprod* 2004; 19(8): 1713-1718. (AMC)

475. Molano M, Meijer CJ, Morre SA, Pol R, van den Brule AJ. Combination of PCR targeting the VD2 of omp1 and reverse line blot analysis for typing of urogenital Chlamydia trachomatis serovars in cervical scrape specimens. *J Clin Microbiol* 2004; 42(7): 2935-2939. (VUmc)

476. Molenaar S, Oort F, Sprangers M, Rutgers E, Luiten E, Mulder J et al. Predictors of patients' choices for breast-conserving therapy or mastectomy: a prospective study. *Br J Cancer* 2004; 90: 2123-30. (NKI)

477. Moll AC, Hoekstra OS, Imhof SM, Comans EF, Schouten-van Meeteren AY, van d, V, Boers M. Fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to detect vital retinoblastoma in the eye: preliminary experience. *Ophthalmic Genetics* 2004; 25(1): 31-35. (VUmc)

478. Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, Sankaranarayanan R, Schiller J, Singer A, Wright TC, Jr., Kinney W, Meijer CJ, Linder J, McGoogan E, Meijer C, Wright T. Cervical cancer control, priorities and new directions. *Int J Cancer* 2004; 108(3): 329-333. (VUmc)

- 479.** Monteiro RM, Sousa Lopes SM, Korchynskiy O, Ten Dijke P, Mummery CL. Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins. *J Cell Sci* 2004; 117: 4653-63. (NKI)
- 480.** Mook ORF, Frederiks WM, van Noorden CJF. The role of gelatinases in colorectal cancer progression and metastasis. *Biochim Biophys Acta* 2004; 1705(2): 69-89. (AMC)
- 481.** Moolenaar WH, Van Meeteren LA, Giepmans BNG. The ins and outs of lysophosphatidic acid signaling. *BioEssays* 2004; 26: 870-81. (NKI)
- 482.** Morris RJ, Zwart PH, Cohen S, Fernandez FJ, Kakaris M, Kirillova O et al. Breaking good resolutions with ARP/wARP. *J Synchrotron Rad* 2004; 11: 56-9. (NKI)
- 483.** Moser EC, Noordijk EM, Van Glabbeke M, Teodorovic I, De Wolf-Peeters C, Carde P et al. Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials. *Eur J Cancer* 2004; 40: 474-80. (NKI)
- 484.** Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W et al. Mammalian SIRT1 represses forkhead transcription factors. *Cell* 2004; 116: 551-63. (NKI)
- 485.** Mukherji SK, Schmalfluss IM, Castelijns J, Mancuso AA. Clinical applications of tumor volume measurements for predicting outcome in patients with squamous cell carcinoma of the upper aerodigestive tract. *Am J Neuroradiol* 2004; 25(8): 1425-1432. (VUmc)
- 486.** Mulder J, Ariaens A, Van den Boomen D, Moolenaar WH. p116Rip Targets Myosin Phosphatase to the Actin Cytoskeleton and Is Essential for RhoA/ROCK-regulated Neuriteogenesis. *Mol Biol Cell* 2004; 15: 5516-27. (NKI)
- 487.** Muller MA, Pajkrt E, Bleker OP, Bonsel GJ, Bilardo CM. Disappearance of enlarged nuchal translucency before 14 weeks' gestation: relationship with chromosomal abnormalities and pregnancy outcome. *Ultrasound Obst Gyn* 2004; 24(2): 169-174. (AMC)
- 488.** Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. *Int J Cancer* 2004; 111(2): 278-285. (VUmc)
- 489.** Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM, Siegenbeek van Heukelom LH, Ossenkoppele GJ, Oudejans JJ. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. *Leukemia* 2004; 18(3): 589-596. (VUmc)
- 490.** Mussmann R, Engstler M, Gerrits H, Kieft R, Bentin Toaldo C, Onderwater J et al. Factors affecting level and localization of the transferrin receptor in *Trypanosoma brucei*. *J Biol Chem* 2004; 279: 40690-8. (NKI)
- 491.** Naderi N, Mochtar CA, de la Rosette JJMCH. Real life practice in the management of benign prostatic hyperplasia. *Curr Opin Urol* 2004; 14(1): 41-4. (AMC)
- 492.** Naderi N, Nieuwenhuijzen JA, Bex A, Kooistra A, Horenblas S. Port site metastasis after laparoscopic nephro-ureterectomy for transitional cell carcinoma. *Eur Urol* 2004; 46: 440-1. (NKI)
- 493.** Navarro CL, Sandre-Giovannoli A Bernard R, Boccaccio I, Boyer A, Genevieve D, Hadj-Rabia S, Gaudy-Marqueste C, Smitt HS, Vabres P, Faivre L, Verloes A, van Essen T, Flori E, Hennekam RCM, Beemer FA, Laurent N, Merrer M, Cau P, Levy N. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. *Hum Mol Genet* 2004; 13(20): 2493-2503. (AMC)
- 494.** Nielsen CM, Williams J, van den Brink GR, Lauwers GY, Roberts DJ. Hh pathway expression in human gut tissues and in inflammatory gut diseases. *Lab Invest* 2004; 84(12): 1631-1642. (AMC)
- 495.** Niemann CU, Cowland JB, Klausen P, Askaa J, Calafat J, Borregaard N. Localization of serglycin in human neutrophil granulocytes and their precursors. *J Leukoc Biol* 2004; 76: 406-15. (NKI)
- 496.** Nieuwenhuijzen JA, Horenblas S, Meinhardt W, Van Tinteren H, Moonen LMF. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. *BJU Int* 2004; 94: 793-7. (NKI)
- 497.** Nieuwenhuis EJ, Van der Waal I, Leemans CR, Kummer A, Pijpers R, Castelijns JA ea. Histopathologic validation of the sentinel node concept in oral and oropharyngeal squamous cell carcinoma. *Head Neck* 2004; 27(2): 150-158. (VUmc)
- 498.** Nieweg OE, Bartelink H. Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer. *Eur J Cancer* 2004; 40: 179-81. (NKI)
- 499.** Nieweg OE, Estourgie SH, Van Rijk MC, Kroon BBR. Rationale for superficial injection techniques in lymphatic mapping in breast cancer patients. *J Surg Oncol* 2004; 87: 153-6. (NKI)
- 500.** Nieweg OE, Estourgie SH. What is a sentinel node and what is a false-negative sentinel node? *Ann Surg Oncol* 2004; 11: 169S-73S. (NKI)
- 501.** Nieweg OE, Tanis PJ. Letter to the editor concerning 'intra-dermal radioisotope injection optimises sentinel lymph node identification in breast cancer'. *Eur J Surg Oncol* 2004; 30: 708-9. (NKI)
- 502.** Nieweg OE, Van Rijk MC, Tanis PJ, Estourgie SH. Commentary on Barranger et al., Contralateral

axillary lymph node drainage in breast cancer: a case report: unusual lymph drainage pathways in patients with breast cancer. *J Surg Oncol* 2004; 87: 105-6. (NKI)

503. Nieweg OE. Commentary (Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: A long term follow-up analysis). *J Surg Oncol* 2004; 88: 7. (NKI)

504. Nijenhuis AV, Van Bergeijk L, Huijgens PC, Zweegman S. Acquired factor xiii deficiency due to an inhibitor: a case report and review of the literature. *Haematologica* 2004; 89(5): ECR1. (VUmc)

505. Nijsten SMJJG, Minken AWH, Lambin P, Bruinvis IAD. Verification of treatment parameter transfer by means of electronic portal dosimetry. *Med Phys* 2004; 31: 341-7. (NKI)

506. Nio D, Balm R, Maartense S, Guijt M, Bemelman WA. The efficacy of robot-assisted versus conventional laparoscopic vascular anastomoses in an experimental model. *Eur J Vasc Endovasc* 2004; 27(3): 283-286. (AMC)

507. Nio D, Bemelman WA, Busch ORC, Vrouwenraets BC, Gouma DJ. Robot-assisted laparoscopic cholecystectomy versus conventional laparoscopic cholecystectomy: a comparative study. *Surg Endosc-Ultras* 2004; 18(3): 379-382. (AMC)

508. Nisio M Di, Squizzato A, Klerk CPW, Richel DJ, Büller HR. Antithrombotic therapy and cancer. *Curr Opin Hematol* 2004; 11(3): 187-191. (AMC)

509. Nolte-'t Hoen EN, Wagenaar-Hilbers JP, Peters PJ, Gadella BM, Van Eden W, Wauben MH. Uptake of membrane molecules from T cells endows antigen-presenting cells with novel functional properties. *Eur J Immunol* 2004. (NKI)

510. Noorda EM, Takkenberg B, Vrouwenraets BC, Nieweg OE, Van Geel BN, Eggermont AMM et al. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. *Ann Surg Oncol* 2004; 11: 491-9. (NKI)

511. Noorda EM, Vrouwenraets BC, Nieweg OE, Van Coevorden F, Kroon BBR. Isolated Limb Perfusion: What Is the Evidence for Its Use? *Ann Surg Oncol* 2004; 11: 837-45. (NKI)

512. Noorda EM, Vrouwenraets BC, Nieweg OE, Van Geel BN, Eggermont AMM, Kroon BBR. Isolated limb perfusion for unresectable melanoma of the extremities. *Arch Surg* 2004; 139: 1237-42. (NKI)

513. Noordhuis P, Holwerda U, Van Der Wilt CL, Van Groenigen CJ, Smid K, Meijer S, Pinedo HM, Peters GJ. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. *Ann Oncol* 2004; 15(7): 1025-1032. (VUmc)

514. Noordhuis P, Holwerda U, Van Laar JAM, Van der Wilt CL, Peters GJ. A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into

DNA of solid tumors. *Nucleos Nucleot Nucl* 2004; 23: 1481-1484. (VUmc)

515. Olivier RI, van Beurden M, Lubsen MAC, Rookus MA, Mooij TM, van de Vijver MJ, van 't Veer LJ. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. *Brit J Cancer* 2004; 90(8): 1492-1497. (AMC/NKI)

516. Oosterhoff D, Van Beusechem VW. Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. *J Exp Ther Oncol* 2004; 4: 37-57. (VUmc)

517. Opdam FJM, Kamp M, De Bruijn R, Roos E. Jak kinase activity is required for lymphoma invasion and metastasis. *Oncogene* 2004; 23: 6647-53. (NKI)

518. Osborne RH, Sali A, Aaronson NK, Elsworth GR, Mdzewski B, Sinclair AJ. Immune function and adjustment style: do they predict survival in breast cancer?. *Psychooncology* 2004; 13(3): 199-210. (NKI/VUmc)

519. Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der HB, Delforge M, Lowenberg B, Verhoef GE. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. *Blood* 2004; 103(8): 2908-2913. (VUmc)

520. Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, Perilongo G, Shafford E, Plaschkes J. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. *Pediatr Blood Cancer* 2004; 42(1): 74-83. (AMC)

521. Otten JMMB, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, Prins MH. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. *Arch Intern Med* 2004; 164(2): 190-194. (AMC)

522. Oude Elferink RPJ, Ottenhoff R, Fricker G, Seward DJ, Ballatori N, Boyer J. Lack of biliary lipid excretion in the little skate, *Raja erinacea*, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. *Am J Physiol-Gastr L* 2004; 286(5): G762-G768. (AMC)

523. Oude Elferink RPJ. Milestones in liver disease. The start of a new era in bile physiology [commentary on *J Biol Chem* 1989; 264; 11693-11698]. *J Hepatol* 2004; 41: 902-904. (AMC)

524. Ovejero C, Cavard C, Périanin A, Hakvoort TBM, Vermeulen JLM, Godard C, Fabre M, Chafey P, Suzuki K, Romagnolo B, Yamagoe S, Perret C. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. *Hepatology* 2004; 40(1): 167-

176. (AMC)

525. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JRM, Hubscher S, Reynolds G et al. Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. *J Clin Oncol* 2004; 22: 1546-52. (VUmc)

526. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. *Nat Cancer Rev* 2004; 4: 448-456. (VUmc)

527. Pasic A, Brokx HA, Noordegraaf AV, Paul RM, Postmus PE, Sutedja TG. Cost-effectiveness of early intervention: comparison between intraluminal bronchoscopic treatment and surgical resection for T1N0 lung cancer patients. *Respiration* 2004; 71(4): 391-396. (VUmc)

528. Pasic A, Comans EF, Paul MA, Postbus PE, Sutedja TG. Borderline early squamous cell lung cancer. *Breathe* 2004; 1: 157-159. (VUmc)

529. Pasic A, Postmus PE, Sutedja TG. What is early lung cancer? A review of the literature. *Lung Cancer* 2004; 45(3): 267-277. (VUmc)

530. Pasic A, van Vliet E, Breuer RH, Risse EJ, Snijders PJ, Postmus PE, Sutedja TG. Smoking behavior does not influence the natural course of pre-invasive lesions in bronchial mucosa. *Lung Cancer* 2004; 45(2): 153-154. (VUmc)

531. Pawlikowska L, Groen A, Eppens EF, Kunne C, Ottenhoff R, Looije N, Knisely AS, Killeen NP, Bull LN, Oude Elferink RPJ, Freimer FB. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. *Hum Mol Genet* 2004; 13(8): 881-892. (AMC)

532. Peeters AJ, Van Gogh CD, Goor KM, Verdonck-De Leeuw IM, Langendijk JA, Mahieu HF. Health status and voice outcome after treatment for T1a glottic carcinoma. *Eur Arch Oto-Rhino-L* 2004; 261(10): 534-540. (VUmc)

533. Peppelenbosch MP, van Deventer SJH. T cell apoptosis and inflammatory bowel disease. *Gut* 2004; 53(11): 1556-1558. (AMC)

534. Perez EA, Pusztai L, Van de Vijver M. Improving patient care through molecular diagnostics. *Semin Oncol* 2004; 31: 14-20. (NKI)

535. Perez-Amodio S, Beertsen W, Everts V. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts. *J Bone Miner Res* 2004; 19(10): 1722-1731. (AMC)

536. Perilongo G, Shafford E, Maibach R, Aronson D, Brugières L, Brock P, Childs M, Czauderna P, Mackinlay G, Otte JB, Pritchard J, Rondelli R, Scopinaro M, Staalman C, Plaschkes J. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. *Eur J Cancer* 2004; 40(3): 411-421. (AMC)

537. Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvers A, Schornagel JH, Beijnen JH, Fumoleau P, Schellens JH. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. *Clin Cancer Res* 2004; 10(12 Pt 1): 4072-4076. (NKI/VUmc)

538. Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. *J Chemother* 2004; 16(suppl 4): 25-30. (VUmc)

539. Peters GJ, van Kuilenburg ABP, de Abreu RA. Purine and pyrimidine metabolism: new challenges. *Nucleos Nucleot Nucl* 2004; 23(8 en 9): 1077-1079. (AMC)

540. Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadie M, Machet L, Casasnovas O, Vergier B, Teitell MA. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. *Am J Clin Pathol* 2004; 122(2): 307-313. (VUmc)

541. Petrella T, Teitell MA, Spiekermann C, Meijer CJ, Franck F, Enache I. A CD56-negative case of blastic natural killer-cell lymphoma (a granular CD4+/CD56+ haematodermic neoplasm. *Brit J Dermatol* 2004; 150(1): 174-176. (VUmc)

542. Pichler A, Knipscheer P, Saitoh H, Sixma TK, Melchior F. The RanBP2 SUMO E3 ligase is neither. *Nat Struct Mol Biol* 2004; 11: 984-91. (NKI)

543. Piek E, Van Dinther M, Parks WT, Sallee JM, Bottinger EP, Roberts AB et al. RLP, a novel Ras-like protein, is an immediate-early transforming growth factor-beta (TGF-beta) target gene that negatively regulates transcriptional activity induced by TGF-beta. *Biochem J* 2004; 383: 187-99. (NKI)

544. Piek JM, Dorsman JC, Shvarts A, Ansink AC, Massuger LF, Scholten P, Van Diest PJ, Dijkstra JC, Weegenaar J, Kenemans P, Verheijen RH. Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma. *Gynecol Oncol* 2004; 92(3): 819-826. (VUmc)

545. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. *Am J Obstet Gynecol* 2004; 191: 718-732. (VUmc)

546. Pietersen AM, Rutjes SA, van Tongeren J, Vogels R, Wesseling JG, Noteborn MHM. The tumor-selective viral protein apoptin effectively kills human biliary tract cancer cells. *J Mol Med-JMM* 2004; 82(1): 56-63. (AMC)

547. Pijnappel RM, Van den Donk M, Holland R, Mali WPTM, Peterse JL, Hendriks JHCL et al. Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions. *Br J Cancer* 2004; 90: 595-600. (NKI)

- 548.** Pijpers R, Buist MR, van Lingen A, Dijkstra J, Van Diest PJ, Teule GJ, Kenemans P, Verheijen RH. The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy. *Eur J Nucl Med Mol I* 2004; 31(11): 1479-1486. (AMC/VUmc)
- 549.** Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D, Veerman AJ, Kamps WA, Vellenga E, de Graaf SS, de Bont ES. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. *Clin Pharmacol Ther* 2004; 76: 220-229. (VUmc)
- 550.** Ploeger LS, Belien JA, Poulin NM, Grizzle W, Van Diest PJ. Confocal 3D DNA cytometry: assessment of required coefficient of variation by computer simulation. *Cell Oncol* 2004; 26(3): 93-99. (VUmc)
- 551.** Plomp AS, Hu X, de Jong PTVM, Bergen AAB. Does autosomal dominant pseudoxanthoma elasticum exist. *Am J Med Genet* 2004; 126A(4): 403-412. (AMC)
- 552.** Plösch T, Bloks VW, Terasawa Y, Berdy S, Siegler K, Sluijs F, Kema IP, Groen AK, Shan B, Kuipers F, Schwartz M. Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor. *Gastroenterology* 2004; 126(1): 290-300. (AMC)
- 553.** Pluim D, Van Waardenburg RCAM, Beijnen JH, Schellens JHM. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. *Cancer Chemother Pharmacol* 2004; 54: 71-8. (NKI)
- 554.** Poland DC, Kulik W, Van Dijk W, Hallemeesch MM, Jakobs C, De Meer K. Distinct glycoforms of human alpha1-acid glycoprotein have comparable synthesis rates: a [¹³C]valine-labelling study in healthy humans. *Glycoconjugate J* 2004; 20: 99-105. (VUmc)
- 555.** Polkowski WP, Skomra DG, Mielko J, Wallner GT, Szumillo J, Zinkiewicz K, Korobowicz EM, van Lanschot JJB. E-cadherin expression as predictive marker of proximal resection line involvement for advanced carcinoma of the gastric cardia. *Eur J Surg Oncol* 2004; 30(10): 1084-1092. (AMC)
- 556.** Poll-The B-T, Gootjes J, Duran M, de Klerk JBC, Maillette de Buy Wenniger-Pris LJM, Admiraal RJC, Waterham HR, Wanders RJA, Barth PG. Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients. *Am J Med Genet* 2004; 126A(4): 333-338. (AMC)
- 557.** Poll-The BT, Wanders RJA, Ruiters JPN, Ofman R, Majoie CBLM, Barth PG, Duran M. Spastic diplegia and periventricular white matter abnormalities in 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency, a defect of isoleucine metabolism: differential diagnosis with hypoxic-ischemic brain diseases. *Mol Genet Metab* 2004; 81(4): 295-299. (AMC)
- 558.** Ponsioen B, Zhao J, Riedl J, Zwartkruis F, Van der Krogt G, Zaccolo M et al. Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. *EMBO Rep* 2004; 5: 1176-80. (NKI)
- 559.** Poole IC Le, Wankowicz-Kalinska A, van den Wijngaard RMJGJ, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. *J Invest Derm Symp P* 2004; 9(1): 68-72. (AMC)
- 560.** Poortmans P, Bartelink H, Horiot JC, Struikmans H, Van den Bogaert W, Fourquet A et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial. *Radiother Oncol* 2004; 72: 25-33. (NKI)
- 561.** Pos FJ, Horenblas S, Lebesque J, Moonen L, Schneider C, Sminia P, Bartelink H. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. *Int J Radiat Oncol Biol Phys* 2004; 59: 696-705. (NKI/VUmc)
- 562.** Postema RJ, Van Velthuysen MLF, Van den Brekel MWM, Balm AJM, Peterse JL. Accuracy of fine-needle aspiration cytology of salivary gland lesions in the netherlands cancer institute. *Head Neck* 2004; 26: 418-24. (NKI)
- 563.** Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P et al. Developments in the CCP4 molecular-graphics project. *Acta Crystallogr D Biol Crystallogr* 2004; 60: 2288-94. (NKI)
- 564.** Powelka AM, Sun J, Li J, Gao M, Shaw LM, Sonnenberg A et al. Stimulation-dependent recycling of integrin beta1 regulated by ARF6 and Rab11. *Traffic* 2004; 5: 20-36. (NKI)
- 565.** Price LS, Hajdo-Milasinovic A, Zhao J, Zwartkruis FJT, Collard JG, Bos JL. Rap1 regulates E-cadherin-mediated cell-cell adhesion. *J Biol Chem* 2004; 279: 35127-32. (NKI)
- 566.** Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European neuroblastoma study group. *Pediatr Blood Cancer* 2004; 44(4): 1-10. (AMC)
- 567.** Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. *J Clin Endocr Metab* 2004; 89(1): 15-20. (AMC)
- 568.** Qu C, Edwards EW, Tacke F, Angeli V, Llodra J, Sanches-Schmitz G, Garin A, Haque NS, Peters W, Van Rooijen N, Sanchez-Torres C, Bromberg J, Charo IF, Jung S, Lira SA, Randolph GJ. Analysis of chemokine pathways that affect migration of monocyte-derived dendritic cells to lymph nodes: identification of a novel function for CCR8. *J Exp Med* 2004; 200: 1231-1241. (VUmc)

569. Raaphorst FM, Vermeer M, Fieret E, Blokzijl T, Dukers D, Sewalt RG, Otte AP, Willemze R, Meijer CJ. Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas. *Am J Pathol* 2004; 164(2): 533-542. (VUmc)
570. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. *Clin Cancer Res* 2004; 10: 3386-95. (NKI)
571. Rademaker-Lakhai JM, Van den Bongard D, Pluim D, Beijnen JH, Schellens JHM. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. *Clin Cancer Res* 2004; 10: 3717-27. (NKI)
572. Rades D, Fehlauer F, Stalpers LJA, Wildfang I, Zschenker O, Schild SE, Schmoll HJ, Karstens JH, Alberti W. A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. *Cancer* 2004; 101(11): 2687-2692. (AMC)
573. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. *Leukemia* 2004; 18: 521-529. (VUmc)
574. Raupp P, Varady E, Duran M, Wanders RJA, Waterham HR, Houten SM. Novel genotype of mevalonic aciduria with fatalities in premature siblings [case report]. *Arch Dis Child* 2004; 89: F90-F91. (AMC)
575. Rauws EAJ, Gouma DJ. Endoscopic and surgical management of bile duct injury after laparoscopic cholecystectomy. *Best Pract Res CL GA* 2004; 18(5): 829-846. (AMC)
576. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van 't Veer L, Garber JE et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 2004; 22: 1055-62. (NKI)
577. Reinhardt D, Diekamp S, Fleischhack G, Corbacioglu S, Jürgens H, Lieber T, Kaspers GJL, Creutzig U, Zwaan ChM. Therapie mit gemtuzumab ozogamicin (Mylotarg(r)) bei Kindern mit refraktärer oder rezidivierter akuter myeloischer leukämie. *Onkologie* 2004; 27: 269-272. (VUmc)
578. Reits E, Neijssen J, Herberts C, Benckhuijsen W, Janssen L, Drijfhout JW et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. *Immunity* 2004; 20: 495-506. (NKI)
579. Reitsma PH. Is hypercoagulability an issue in arterial thrombosis? *No. J Thromb Haemost* 2004; 2(5): 692-694. (AMC)
580. Rentinck MEM, Schrijver HM, Kneppers E, Zijlmans JCM, Van Groeningen CJ. Carcinomatous meningitis in cancer of the uterine cervix. *J Neuro-Oncol* 2004; 70: 87-90. (VUmc)
581. Repping S, Korver CM, Oates RD, Silber S, van der Veen F, Page DC, Rozen S. Are sequence family variants useful for identifying deletions in the human Y chromosome [letter]. *Am J Hum Genet* 2004; 75(1): 514-517. (AMC)
582. Richel DJ, Vervenne WL. Systemic treatment of oesophageal cancer. *Eur J Gastroen Hepat* 2004; 16(3): 249-254. (AMC)
583. Richel O, zum Vorde Sive Vording PJ, Rietbroek RC, van Dijk JDP, Schilthuis MS, Westermann AM. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer. *Gynecol Oncol* 2004; 95(3): 680-685. (AMC)
584. Rijk PC, Tigchelaar-Gutter W, Bernoski F.-P, van Noorden CJF. Histologic changes in articular cartilage after medial meniscus replacement in rabbits. *J Arthro Rel Surg* 2004; 20(9): 911-917. (AMC)
585. Rijnveld AW, Weijer S, Florquin S, Esmon CT, Meijers JCM, Speelman P, Reitsma PH, ten Cate H, van der Poll T. Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. *Blood* 2004; 103(5): 1702-1709. (AMC)
586. Ringrose JH, Meijring HD, Speijer D, Feltkamp TEW, van Els CACM, de Jong APJM, Dankert J. Major histocompatibility complex class I peptide presentation after Salmonella enterica serovar typhimurium infection assessed via stable isotope tagging of the B27-presented peptide repertoire. *Infect Immun* 2004; 72(9): 5097-5105. (AMC)
587. Rittersma SZH, Boekholdt SM, Koch KT, Geuzebroek R, Bax M, Schotborgh CE, Eckmann H, Peters RJG, Piek JJ, Tijssen JGP, Reitsma PH, de Winter RJ. Thrombospondin gene polymorphisms and the risk of angiographic coronary in-stent restenosis: letter. *Am J Med* 2004; 116(7): 499-500. (AMC)
588. Robanus-Maandag E, Giovannini M, Van der Valk M, Niwa-Kawakita M, Abramowski V, Antonescu C et al. Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin. *Oncogene* 2004; 23: 6541-7. (NKI)
589. Rodriguez E, Baas P, Friedberg JS. Innovative therapies: photodynamic therapy. *Thorac Surg Clin* 2004; 14: 557-66. (NKI)

- 590.** Ronckers C, Land C, Hayes R, Verduijn P, Van Leeuwen F. Factors impacting questionnaire response in a Dutch retrospective cohort study. *Ann Epidemiol* 2004; 14: 66-72. (NKI)
- 591.** Rookus MA, Van Leeuwen FE. Effects of estrogen-only treatment in postmenopausal women [comment]. *JAMA* 2004; 292: 683. (NKI)
- 592.** Rosen H, Calafat J, Holmberg L, Olsson I. Sorting of Von Willebrand factor to lysosome-related granules of haematopoietic cells. *Biochem Biophys Res Commun* 2004; 315: 671-8. (NKI)
- 593.** Rosendaal FR, Reitsma PH. Genetic studies in complex disease. *J Thromb Haemost* 2004; 2(2): 342-345. (AMC)
- 594.** Rothbarth J, Tollenaar RAEM, Schellens JHM, Nortier JWR, Schultze Kool LJ, Kuppen PJK et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. *Eur J Cancer* 2004; 40: 1812-24. (NKI)
- 595.** Roz L, Adriani F, Ferreira CG, Giaccone G, Sozzi G. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. *Oncogene* 2004; 23(56): 9102-9110. (VUmc)
- 596.** Ruijter JM, Gieling RG, Markman MWM, Hagoort J, Lamers WH. Stereological measurement of porto-central gradients in gene expression in mouse liver. *Hepatology* 2004; 39(2): 343-352. (AMC)
- 597.** Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, Berns A et al. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. *Development* 2004; 131: 2737-48. (NKI)
- 598.** Russell NS, Bartelink H. Sophisticated radiotherapy with optimal surgery is the way forward. *Curr Opin Oncol* 2004; 16: 529-35. (NKI)
- 599.** Rutgers EJT, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. *Breast Cancer Res* 2004; 6: 165-9. (NKI)
- 600.** Rutgers EJT. Follow-up care in breast cancer. *Expert Rev Anticancer Ther* 2004; 4: 212-8. (NKI)
- 601.** Rutgers EJT. Sentinel node micrometastasis in breast cancer. *Br J Surg* 2004; 91: 1241. (NKI)
- 602.** Rutgers EJT. Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more? *Eur J Cancer* 2004; 40: 182-6. (NKI)
- 603.** Sachs MD, Ramamurthy M, Poel H, Wickham TJ, Lamfers M, Gerritsen W, Chowdhury W, Li Y, Schoenberg MP, Rodriguez R. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. *Cancer Gene Ther* 2004; 11(7): 477-86. (VUmc)
- 604.** Sankatsing SU, Beijnen JH, Schinkel AH, Lange JMA, Prins JM. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. *Antimicrob Agents Chemother* 2004; 48: 1073-81. (NKI)
- 605.** Sankatsing SU, Hoggard PG, Huitema AD, Sparidans RW, Kewn S, Crommentuyn KML et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. *Clin Pharmacokinet* 2004; 43: 823-32. (NKI)
- 606.** Sarno A, Bocciolini C, Deganello A, Coscarelli S, Gallo O. Does unnecessary elective neck treatment affect the prognosis of NO laryngeal cancer patients?. *Acta Oto-Laryngol* 2004; 124: 980-985. (VUmc)
- 607.** Savouret C, Garcia-Cordier C, Megret J, Te Riele H, Junien C, Gourdon G. MSH2-Dependent Germinal CTG Repeat Expansions Are Produced Continuously in Spermatogonia from DM1 Transgenic Mice. *Mol Cell Biol* 2004; 24: 629-37. (NKI)
- 608.** Schaap FG, Rensen PCN, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RAFM, Havekes LM, Groen AK, Willems van Dijk K. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. *J Biol Chem* 2004; 279(27): 27941-27947. (AMC)
- 609.** Scheijen B, Bronk M, Van der Meer T, De Jong D, Bernardis R. High incidence of thymic epithelial tumors in E2F2 transgenic mice. *J Biol Chem* 2004; 279: 10476-83. (NKI)
- 610.** Schimmel KJM, Richel DJ, van den Brink RBA, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. *Cancer Treat Rev* 2004; 30(2): 181-191. (AMC)
- 611.** Schmoll HJ, Souchon R, Kregge S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PHM, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoetl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GON, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjuladin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). *Ann Oncol* 2004; 15(9): 1377-1399. (AMC)
- 612.** Schoelmerich J, Gouma DJ. Preface. *Best Pract Res CL GA* 2004; 18(5): 797. (AMC)

- 613.** Schoemaker NE, Kuppens IELM, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. *Br J Cancer* 2004; 91: 1434-41. (NKI)
- 614.** Schoenmakers SHHF, Groot AP, Florquin S, Reitsma PH, Spek CA. Blood cell-derived tissue factor influences host response during murine endotoxemia. *Blood Cell Mol Dis* 2004; 32(2): 325-333. (AMC)
- 615.** Schoenmakers SHHF, Versteeg HH, Groot AP, Reitsma PH, Spek CA. Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. *J Thromb Haemost* 2004; 2(12): 2185-2193. (AMC)
- 616.** Schoneveld OJLM, Gaemers IC, Das AT, Hoogenkamp M, Renes J, Ruijter JM, Lamers WH. Structural requirements of the glucocorticoid-response unit of the carbamoyl-phosphate synthase gene. *Biochem* 2004; 382(Pt 2): 463-470. (AMC)
- 617.** Schoneveld OJLM, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. *Biochim Biophys Acta* 2004; 1680(2): 114-128. (AMC)
- 618.** Schoots IG, Koffeman GI, Legemate DA, Levi M, van Gulik TM. Systematic review of survival after acute mesenteric ischaemia according to disease aetiology. *Brit J Surg* 2004; 91(1): 17-27. (AMC)
- 619.** Schoots IG, Levi MM, van Vliet AK, Declerck PJ, Maas AM, van Gulik TM. Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. *Thromb Haemostasis* 2004; 91(3): 497-505. (AMC)
- 620.** Schoots IG, Levi MM, van Vliet AK, Maas AM, Roossink EHP, van Gulik TM. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. *Crit Care Med* 2004; 32(6): 1375-1383. (AMC)
- 621.** Schouten-van Meeteren AY, Moll AC, Imhof SM, Dommering CJ. Regarding chemoreduction for retinoblastoma and intracranial neoplasms-reply. *Arch Ophthalmol* 2004; 122: 1571. (VUmc)
- 622.** Schouwink H, Baas P. Foscan-mediated photodynamic therapy and operation for malignant pleural mesothelioma [letter]. *Ann Thorac Surg* 2004; 78: 388. (NKI)
- 623.** Schrama D, Xiang R, Eggert AO, Andersen MH, Pedersen Ls LO, Kampgen E et al. Shift from systemic to site-specific memory by tumor-targeted IL-2. *J Immunol* 2004; 172: 5843-50. (NKI)
- 624.** Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, Van den Weyngaert D, Nguyen H, Le Boudier C, Castelijns JA, Kaanders J, De Mulder P, Vermorken JB. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. *Ann Oncol* 2004; 15: 638-645. (VUmc)
- 625.** Schroder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, Debois M, Collette L. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study. *J Urology* 2004; 172(3): 923-927. (AMC)
- 626.** Schröder FH, Whelan P, Reijke ThM de, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. *Eur Urol* 2004; 45(4): 457-464. (AMC)
- 627.** Schuurman B, Postmus PE, van Mourik JC, Risse EK, Sutedja TG. Combined use of autofluorescence bronchoscopy and argon plasma coagulation enables less extensive resection of radiographically occult lung cancer. *Respiration* 2004; 71(4): 410-411. (VUmc)
- 628.** Schwarz M, Lebesque JV, Mijnheer BJ, Damen EMF. Sensitivity of treatment plan optimisation for prostate cancer using the equivalent uniform dose (EUD) with respect to the rectal wall volume parameter. *Radiother Oncol* 2004; 73: 209-18. (NKI)
- 629.** Sears J, Ujihara M, Wong S, Ott C, Middeldorp J, Aiyar A. The amino terminus of Epstein-barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. *J Virol* 2004; 78(21): 11487-11505. (VUmc)
- 630.** Senan S, Chapet O, Lagerwaard FJ, Ten Haken RK. Defining target volumes for non-small cell lung carcinoma. *Semin Radiat Oncol* 2004; 14: 308-314. (VUmc)
- 631.** Senan S, De Ruyscher D, Giraud P, Mirimanoff R, Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. *Radiother Oncol* 2004; 71(2): 139-146. (VUmc)
- 632.** Senan S, Van De Pol M. Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma. *Lung Cancer* 2004; 45 Suppl 1: S93-6. (VUmc)
- 633.** Senan S. PET-CT for radiotherapy planning in lung cancer. *Lung Cancer* 2004; 46(S1): S31-S34. (VUmc)
- 634.** Senan S. Reply to "Radiation pneumonitis and docetaxel". *Lung Cancer* 2004; 43(1): 117-118. (VUmc)

- 635.** Seppenwoolde Y, De Jaeger K, Boersma LJ, Belderbos JSA, Lebesque JV. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004; 60: 748-58. (NKI)
- 636.** Seppenwoolde Y, De Jaeger K, Lebesque JV. (Lung V20 measurements) Response to Drs. Garces and Miller [correspondence]. *Int J Radiat Oncol Biol Phys* 2004; 58: 1636-7. (NKI)
- 637.** Sewnath ME, van der Poll T, van Noorden CJF, ten Kate FJW, Gouma DJ. Cholestatic interleukin-6-deficient mice succumb to endotoxin-induced liver injury and pulmonary inflammation. *Am J Resp Crit Care* 2004; 169(3): 413-420. (AMC)
- 638.** Shen C, Bullens D, Kasran A, Maerten P, Boon L, Aerts JMFG, van Assche G, Geboes K, Rutgeers P, Ceuppens JL. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. *Int Immunol* 2004; 4(7): 939-951. (AMC)
- 639.** Shimozawa N, Tsukamoto T, Nagase T, Takemoto Y, Koyama N, Suzuki Y, Komori M, Osumi T, Gootjes J, Wanders RJA, Kondo N. Identification of a new complementation group of the peroxisome biogenesis disorders and PEX14 as the mutated gene. *Hum Mutat* 2004; 23(6): 552-558. (AMC)
- 640.** Sigmond J, Kroep JR, Loves W, Codacci-Pisanelli G, Peters GJ. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cyclor PCR in relation to enzyme activity and gemcitabine sensitivity. *Cancer Lett* 2004; 213(2): 173-179. (VUmc)
- 641.** Silva MFB, Ijst L, Allers P, Jakobs C, Duran M, Tavares de Almeida I, Wanders RJA. Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. *Drug Metab Dispos* 2004; 32(11): 1304-1310. (AMC)
- 642.** Sjarif DR, Hellerud C, Ploos Van Amstel JK, Kleijer WJ, Sperl W, Lacombe D, Sass JO, Beemer FA, Duran M, Poll-The B-T. Glycerol kinase deficiency: residual activity explained by reduced transcription and enzyme conformation. *Eur J Hum Genet* 2004; 12(6): 424-432. (AMC)
- 643.** Slotman BJ, van der WG, Kregar S, Langendijk HA, Willems DL. Patients' appreciation of single fraction radiotherapy for painful bone metastases. *Palliative Med* 2004; 18(1): 72-73. (VUmc)
- 644.** Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, van den Brule AJ, Franceschi S, Peeling RW. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. *Int J Cancer* 2004; 111(3): 431-439. (VUmc)
- 645.** Smitsmans MHP, Wolthaus JW, Artignan X, De Bois J, Jaffray DA, Lebesque JV et al. Automatic localization of the prostate for on-line or off-line image-guided radiotherapy. *Int J Radiat Oncol Biol Phys* 2004; 60: 623-35. (NKI)
- 646.** Snijders PJ, Breuer RH, Sutedja TG, Egging M, Voorhorst FJ, Steenbergen RD, van der Linden HC, Risse EK, Berkhof J, de Vries EG, van der Zee AG, Postmus PE, Meijer CJ, Smit EF. Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ). *Int J Cancer* 2004; 109(3): 412-417. (VUmc)
- 647.** Sommeijer DW, Beganovic A, Schalkwijk CG, Ploegmakers H, van der Loos CM, van Aken BE, ten Cate H, van der Wal AC. More fibrosis and thrombotic complications but similar expression patterns of markers for coagulation and inflammation in symptomatic plaques from DM2 patients. *J Histochem Cytochem* 2004; 52(9): 1141-1149. (AMC)
- 648.** Sommeijer DW, MacGillavry MR, Meijers JCM, van Zanten AP, Reitsma PH, ten Cate H. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. *Diabetes Care* 2004; 27(2): 468-473. (AMC)
- 649.** Sonke JJ, Ploeger LS, Brand B, Smitsmans MHP, Van Herk M. Leaf trajectory verification during dynamic intensity modulated radiotherapy using an amorphous silicon flat panel imager. *Med Phys* 2004; 31: 389-95. (NKI)
- 650.** Soto-Cerrato V, Glagostera E, Montaner B, Scheffer GL, Perez-Tomas R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. *Biochem Pharmacol* 2004; 68: 1345-1352. (VUmc)
- 651.** Sparidans RW, Schellens JHM, Lopez-Lazaro L, Jimeno JM, Beijnen JH. Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole. *Biomed Chromatogr* 2004; 18: 16-20. (NKI)
- 652.** Spek CA. Tissue factor: from 'just one of the coagulation factors' to a major player in physiology. *Blood Coagul Fibrin* 2004; 15(Suppl.1): S3-S10. (AMC)
- 653.** Spiekerkoetter U, Tokunaga C, Wendel U, Mayatepak E, Exil V, Duran M, Wijburg FA, Wanders RJA, Strauss AW. Changes in blood carnitine and acylcarnitine profiles of very long-chain acyl-CoA dehydrogenase-deficient mice subjected to stress. *Eur J Clin Invest* 2004; 34(3): 191-196. (AMC)
- 654.** Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. *Leukemia* 2004; 18: 78-83. (NKI)
- 655.** Steenbakkens RJ, Duppen JC, Betgen A, Lotz HT, Remeijer P, Fitton I et al. Impact of knee support and shape of tabletop on rectum and

prostate position. *Int J Radiat Oncol Biol Phys* 2004; 60: 1364-72. (NKI)

656. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, Snijders PJ. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. *J Natl Cancer Inst* 2004; 96(4): 294-305. (VUmc)

657. Stevens SJC, Brink AATP, Middeldorp JM. Profiling of Epstein-Barr virus latent RNA expression in clinical specimens by gene-specific multi-primed cDNA synthesis and PCR. *Methods Mol Biol* 2004; 292: 27-37. (VUmc)

658. Stevens SJC, Verkuijlen SAWM, Middeldorp JM. Quantitative detection of Epstein-Barr virus DNA in clinical specimens by rapid real-time PCR targeting a highly conserved region of EBNA-1. *Methods Mol Biol* 2004; 292: 15-25. (VUmc)

659. Stokvis E, Nan-Offeringa LGAH, Ouwehand M, Tibben MM, Rosing H, Schnaars Y et al. Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2004; 18: 1465-71. (NKI)

660. Stokvis E, Ouwehand M, Nan LG, Kemper EM, Van Tellingen O, Rosing H et al. A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry. *J Mass Spectrom* 2004; 39: 1506-12. (NKI)

661. Stokvis E, Rosing H, Causon RC, Schellens JHM, Beijnen JH. Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection. *J Mass Spectrom* 2004; 39: 1122-30. (NKI)

662. Stokvis E, Rosing H, Crul M, Rieser MJ, Heck AJR, Schellens JHM et al. Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. *J Mass Spectrom* 2004; 39: 277-88. (NKI)

663. Stokvis E, Rosing H, Lopez-Lazaro L, Beijnen JH. Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection. *J Mass Spectrom* 2004; 39: 431-6. (NKI)

664. Stokvis E, Rosing H, Lopez-Lazaro L, Schellens JHM, Beijnen JH. A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. *Biomed Chromatogr* 2004; 18: 403-7. (NKI)

665. Stokvis E, Rosing H, Lopez-Lazaro L, Schellens JHM, Beijnen JH. Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance. *Biomed Chromatogr* 2004; 18: 400-2. (NKI)

666. Strackee SD, Kroon FH, Spierings PT, Jaspers JE. Development of a modeling and osteotomy jig system for reconstruction of the mandible with a free vascularized fibula flap. *Plast Reconstr Surg* 2004; 114: 1851-8. (NKI)

667. Streng S, Froster UG, Wanders RJA, Gartner J, Maier EM, Muntau AC, Faber R. First-trimester increased nuchal translucency as a prenatal sign of Zellweger syndrome [letter]. *Prenatal Diag* 2004; 24(2): 151-153. (AMC)

668. Swennen MHJ, Bromberg JEC, Witkamp ThD, Terhaard CHJ, Postma TJ, Taphoorn MJB. . 2004. Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma. *J Neuro-Oncol* 2004; 66: 333-339. (VUmc)

669. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F et al. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? *Cancer Res* 2004; 64: 840-3. (NKI)

670. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. *Neuroendocrinology* 2004; 80 Suppl 1: 3-7. (NKI)

671. Taat F, Bosman DK, Aronson DC. Hepatoblastoma in a girl with biliary atresia: coincidence or co-incidence. *Pediatr Blood Cancer* 2004; 43(5): 603-605. (AMC)

672. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. *Clin Cancer Res* 2004; 10(11): 3607-3613. (VUmc)

673. Tait SWG, Werner AB, De Vries E, Borst J. Mechanism of action of *Drosophila* Reaper in mammalian cells: reaper globally inhibits protein synthesis and induces apoptosis independent of mitochondrial permeability. *Cell Death Differ* 2004; 11: 800-11. (NKI)

674. Taminiau JAJM, Bijlsma PB, Benninga MA. Lower functional gastrointestinal disorders in a paediatric population. *J Pediatr Gastr Nutr* 2004; 39(Suppl. 3): S758-S759. (AMC)

675. Tannock IF, Ahles TA, Ganz PA, Van Dam FSAM. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. *J Clin Oncol* 2004; 22: 2233-9. (NKI)

676. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumors. *Lancet Neurology* 2004; 3(3): 159-168. (VUmc)

- 677.** Te Vrugte D, Lloyd-Evans E, Veldman RJ, Neville DC, Dwek RA, Platt FM et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. *J Biol Chem* 2004; 279: 26167-75. (NKI)
- 678.** Temmink OH, Comijn EM, Fukushima M, Peters GJ. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. *Nucleos Nucleot Nucl* 2004; 23: 1491-1494. (VUmc)
- 679.** Ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. *Ann Oncol* 2004; 15: 100-3. (NKI)
- 680.** Ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. *Trends Biochem Sci* 2004; 29: 265-73. (NKI)
- 681.** Ten Hove T, The Olle F, Berkhout M, Bruggeman JP, Vyth-Dreese FA, Slors JFM, van Deventer SJH, te Velde AA. Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease. *J Leukocyte Biol* 2004; 75(6): 1010-1015. (AMC/NKI)
- 682.** Tepel J, Hinz S, Klomp HJ, Kapischke M, Kremer B. Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. *Eur J Surg Oncol* 2004; 30: 551-5. (NKI)
- 683.** Ter Borg PCJ, Hollemans M, Van Buuren HR, Vleggaar FP, Groeneweg M, Hop WCJ, Laméris JS. Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9 years. *Radiology* 2004; 231(2): 537-545. (AMC)
- 684.** Ter Rahe BSM, Majoie CBLM, Akkerman EM, den Heeten GJ, Poll-The B-T, Barth PG. Peroxisomal biogenesis disorder: comparison of conventional MR imaging with diffusion-weighted and diffusion-tensor imaging findings. *Am J Neuroradiol* 2004; 25(6): 1022-1027. (AMC)
- 685.** Terhaard CHJ, Lubsen H, Van der Tweel I, Hilgers FJM, Eijkenboom WMH, Marres HAM et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. *Head Neck* 2004; 26: 681-92. (NKI)
- 686.** Tertoolen LGJ, De Vries-Smits LMM, Frye RA, Medema RH, Burgering BMT. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). *J Biol Chem* 2004; 279: 28873-9. (NKI)
- 687.** Theodorou V, Boer M, Weigelt B, Jonkers J, Van der Valk M, Hilkens J. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. *Oncogene* 2004; 23: 6047-55. (NKI)
- 688.** Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Munoz N, Snijders PJ, Meijer CJ, Franceschi S. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. *Brit J Cancer* 2004; 90(3): 638-645. (VUmc)
- 689.** Thunnissen FBJM, Tilanus MGJ, Ligtenberg MJL, Nederlof PM, Dinjens WNM, Meulemans E et al. Quality control in diagnostic molecular pathology in the Netherlands; proficiency testing for patient identification in tissue samples. *J Clin Pathol* 2004; 57: 717-20. (NKI)
- 690.** Tilleman EHBM, Kuiken BW, Phoa SSKS, Castro S de, Busch ORC, Obertop H, Gouma DJ. Limitation of diagnostic laparoscopy for patients with a periampullary carcinoma. *Eur J Surg Oncol* 2004; 30(6): 658-662. (AMC)
- 691.** Timmers GJ, Dijkstra Bloem Y, Simoons-Smit AM, van Winkelhoff AJ, Touw DJ, Vandenbroucke-Grauls CM, Huijgens PC. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. *Bone Marrow Transplant* 2004; 33(8): 847-853. (VUmc)
- 692.** Tomas JT, Wolff RA, Hullett DA, Stark VE, Van Rooijen N, Hock JR. Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth factor-beta-1 in healing rat vein grafts. *J Vasc Surg* 2004; 39: 878-888. (VUmc)
- 693.** Topcu M, Jobard F, Halliez S, Coskun T, Yalcinkaya C, Gerceker FO, Wanders RJA, Prud'homme J-F, Lathrop M, Özguz M, Fischer J. L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1. *Hum Mol Genet* 2004; 13(22): 2803-2811. (AMC)
- 694.** Torrença H, Fabry H, Van der Sijp JRM, Van Diest PJ, Pijpers R, Meijer S. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: A long term follow-up analysis. *J Surg Oncol* 2004; 88(1): 4-7. (VUmc)
- 695.** Torrença H, Meijer S, Fabry H, van der Sijp JRM. Sentinel node biopsy in breast cancer patients: triple technique as a routine procedure. *Ann Surg Oncol* 2004; 11(3 Suppl): 231S-235S. (VUmc)
- 696.** Travis MA, Van der Flier A, Kammerer RA, Mould AP, Sonnenberg A, Humphries MJ. Interaction of filamin A with the integrin beta 7 cytoplasmic domain: role of alternative splicing and phosphorylation. *FEBS Lett* 2004; 569: 185-90. (NKI)
- 697.** Triesscheijn M, Ruevekamp M, Aalders M, Baas P, Stewart FA. Comparative Sensitivity of Microvascular Endothelial Cells, Fibroblasts and Tumour Cells after in vitro Photodynamic Therapy with mTHPC. *Photochem Photobiol* 2004; 80: 236-41. (NKI)

- 698.** Trimbos JB, Franchi F, Zanaboni F, van der Velden J. 'State of the art' of radical hysterectomy; current practice in European oncology centres. *Eur J Cancer* 2004; 40(3): 375-378. (AMC)
- 699.** Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. *Crit Rev Oncol Hemat* 2004; 52(2): 81-101. (AMC)
- 700.** Tytgat GN, Bartelink H, Bernards R, Giaccone G, van Lanschot JJ, Offerhaus GJ, Peters GJ. Cancer of the esophagus and gastric cardia: recent advances. *Dis Esophagus* 2004; 17(1): 10-26 (AMC/NKI/VUmc).
- 701.** Uhlenbrock K, Eberth A, Herbrand U, Daryab N, Stege P, Meier F et al. The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. *J Cell Sci* 2004; 117: 4863-71. (NKI)
- 702.** Ulbert S, Eide L, Seeberg E, Borst P, Base J, found in nuclear DNA of *Trypanosoma brucei*, is not a target for DNA glycosylases. *DNA Repair* 2004; 3: 145-54. (NKI)
- 703.** Underberg RWM, Lagerwaard FJ, Cuijpers JP, Slotman BJ, Van Sörnsen JR, Senan S. 4-Dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. *Int J Radiat Oncol Biol Phys* 2004; 60: 1283-1290. (VUmc)
- 704.** Uyl-de Groot CA, Gelderblom-den Hartog J, Derksen JGM, Symons EA, Buijt I, van der Velden J, Lindert ACM. Cost-effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial. *Eur J Obstet Gyn R B* 2004; 114(1): 77-82. (AMC)
- 705.** Valdes Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? [editorial]. *Eur J Nucl Med Mol Imaging* 2004; 31: 929-31. (NKI)
- 706.** Valdés Olmos RA, Horenblas S, Kartachova M, Hoefnagel CA, Sivo F, Baars PC. ^{99m}Tc-labelled heat-denatured erythrocyte SPET-CT matching to differentiate accessory spleen from tumour recurrence. *Eur J Nucl Med Mol Imaging* 2004; 31: 150. (NKI)
- 707.** Valianpour F, Abeling NGGM, Duran M, Huijmans JGM, Kulik W. Quantification of free sialic acid in urine by HPLC-electrospray tandem mass spectrometry: a tool for the diagnosis of sialic acid storage disease. *Clin Chem* 2004; 50(2): 403-409. (AMC)
- 708.** Valk-Lingbeek ME, Bruggeman SWM, Van Lohuizen M. Stem cells and cancer; the polycomb connection. *Cell* 2004; 118: 409-18. (NKI)
- 709.** Van Amerongen R, Van der Gulden H, Bleeker F, Jonkers J, Berns A. Characterization and functional analysis of the murine Frat2 gene. *J Biol Chem* 2004; 279: 26967-74. (NKI)
- 710.** Van Andel G, Visser AP, Zwinderman AH, Hulshof MCCM, Horenblas S, Kurth K-H. A prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients. *Prostate* 2004; 58 (4): 354-365. (AMC/NKI)
- 711.** Van As CJ, Op de Coul BMR, Eysholdt U, Hilgers FJM. Value of digital high-speed endoscopy in addition to videofluoroscopic imaging of the neoglottis in tracheoesophageal speech. *Acta Otolaryngol* 2004; 124: 82-9. (NKI)
- 712.** Van Barneveld TA, Sasco AJ, van Leeuwen FE. A cohort study of cancer mortality among Biology Research Laboratory workers in The Netherlands. *Cancer Causes Control* 2004; 15(1): 55-66. (NKI/VUmc)
- 713.** Van Beek J, Zur Hausen A, Klein Kranenburg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ, Bloemena E. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. *J Clin Oncol* 2004; 22(4): 664-670. (VUmc)
- 714.** Van Berkel AM, Cahen DL, van Westerloo DJ, Rauws EAJ, Huibregtse K., Bruno MJ. Self-expanding metal stents in benign biliary strictures due to chronic pancreatitis. *Endoscopy* 2004; 36(5): 381-384. (AMC)
- 715.** Van Bezooijen RL, Roelen BAJ, Visser A, Van der Wee-Pals L, De Wilt E, Karperien M et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. *J Exp Med* 2004; 199: 805-14. (NKI)
- 716.** Van Bree C, Franken NAP, Rodermond HM, Stalpers LJA, Haveman J. Repair of potentially lethal damage does not depend on functional TP53 in human glioblastoma cells. *Radiat Res* 2004; 161(5): 511-516. (AMC)
- 717.** Van Dalen EC, van der Pal HJH, Bakker PJM, Caron HN, Kremer LCM. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. *Eur J Cancer* 2004; 40(5): 643-652. (AMC)
- 718.** Van Dalen T, Hennipman A, Van Coevorden F, Hoekstra HJ, Van Geel BN, Slootweg P et al. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. *Ann Surg Oncol* 2004; 11: 483-90. (NKI)
- 719.** Van Dartel M, Hulsebos TJM. Amplification and overexpression of genes in 17p11.2 - p12 in osteosarcoma. *Cancer Genet Cytogen* 2004; 153(1): 77-80. (AMC)
- 720.** Van Dartel M, Hulsebos TJM. Characterization

of PMP22 expression in osteosarcoma. *Cancer Genet Cytogen* 2004; 152(2): 113-118. (AMC)

721. Van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJM. Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in high-grade osteosarcoma. *Cancer Genet Cytogen* 2004; 152(1): 8-14. (AMC)

722. Van de Kerkhove MP, Hoekstra R, Chamuleau RAFM, van Gulik TM. Clinical application of bioartificial liver support systems. *Ann Surg* 2004; 240(2): 216-230. (AMC)

723. Van de Kerkhove MP, Hoekstra R, van Gulik TM, Chamuleau RAFM. Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research. *Biomaterials* 2004; 25(9): 1613-1625. (AMC)

724. Van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ. Antibody targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B cell non-Hodgkin lymphoma. *Curr Opin Hematol* 2004; 11(6): 419-425. (VUmc)

725. Van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ. Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. *Anti-Cancer Drugs* 2004; 15(3): 189-201. (VUmc)

726. Van de Pol M, Levendag PC, De Bree RR, Huib FJ, Smelee LE, Nijdam WM et al. Radical radiotherapy compared with surgery for advanced squamous cell carcinoma of the base of tongue. *Brachytherapy* 2004; 3: 78-86. (NKI)

727. Van de Wetering MD, Caron HN, Biezeveld MH, Taminiou JAJM, ten Kate FJW, Spanjaard L, Kuijpers TW. Severity of enterocolitis is predicted by IL-8 in paediatric oncology patients. *Eur J Cancer* 2004; 40(4): 571-578. (AMC)

728. Van den Berg H, Furstner FA, van den Bos C, Behrendt H. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. *Pediatr Blood Cancer* 2004; 42 (3): 210-215. (AMC)

729. Van den Berg H, Hopman AH, Kraakman KC, De Jong D. Spontaneous remission in congenital leukemia is not related to (mosaic) trisomy 21: case presentation and literature review. *Pediatr Hematol Oncol* 2004; 21: 135-44. (NKI)

730. Van den Berg H, Hopman AH, Kraakman KC, de Jong D. Spontaneous remission in congenital leukemia is not related to (mosaic) trisomy 21: case presentation and literature review. *Pediatr Hematol Oncol* 2004; 21(2): 135-144. (AMC)

731. Van den Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. *Ann Oncol* 2004; 15(1): 175-176. (AMC)

732. Van den Berg R, Schepers A, De Bruine FT, Liauw L, Mertens BJ, Van der Mey AG, Van Buchem

MA. The value of MR angiography techniques in the detection of head and neck paragangliomas. *Eur J Radiol* 2004; 52(3): 240-245. (VUmc)

733. Van den Berg R, Verbist BM, Mertens BJ, Van der Mey AG, Van Buckem MA. Head and neck paragangliomas: improved tumor detection using contrast-enhanced 3D time-of-flight MR angiography as compared with fat-suppressed MR imaging techniques. *Am J Neuroradiol* 2004; 25(5): 863-870. (VUmc)

734. Van den Berg RJBHN, Donker-Koopman W, van Boom JH, Aerts HMFG, Noort D. Design and synthesis of 2-acetamidomethyl derivatives of isofagomine as potential inhibitors of human lysosomal beta-hexosaminidases. *Bioorgan Med Chem* 2004; 12 (5), 891-902. (AMC)

735. Van den Blink B, Branger J, Weijer S, Gupta A, van Deventer SJH, Peppelenbosch MP, van der Poll T. P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia. *J Clin Immunol* 2004; 24 (1): 37-41. (AMC)

736. Van den Bongard HJGD, Kemper EM, Van Tellingen O, Rosing H, Mathot RAA, Schellens JHM et al. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. *Anal Biochem* 2004; 324: 11-5. (NKI)

737. Van den Bongard HJGD, Sparidans RW, Critchley DJP, Beijnen JH, Schellens JHM. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. *Invest New Drugs* 2004; 22: 151-8. (NKI)

738. Van den Bos C, Heinen RC, Sukel M, van der Pal HJH, Geenen MM. Screening for late effects in survivors of childhood cancer: growth hormone deficiency from a pediatric oncologist's point of view. *Growth Horm IGF Res* 2004; 14 (suppl A): S125-S128. (AMC)

739. Van den Brink DM, van Miert JN, Dacremont G, Rontani J-F, Jansen GA, Wanders RJA. Identification of fatty aldehyde dehydrogenase in the breakdown of phytol to phytanic acid. *Mol Genet Metab* 2004; 82(1): 33-37. (AMC)

740. Van den Brink GR, Bleuming SA, Hardwick JCH, Schepman BL, Offerhaus GJA, Keller JJ, Nielsen C, Gaffield W, van Deventer SJH, Roberts DJ, Peppelenbosch MP. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation [letter]. *Nat Genet* 2004; 36(3): 277. (AMC)

741. Van den Brink GR. Linking pathways in colorectal cancer. *Nat Genet* 2004; 36(10): 1038-1039. (AMC)

742. Van den Broek GB, Rasch CR, Pameijer FA, Peter E, Van den Brekel MWM, Tan IB et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for

- advanced head and neck carcinoma. *Cancer* 2004; 101: 1809-17. (NKI)
- 743.** Van den Broek WT, Makay O, Berends FJ, Yuan JZ, Houdijk AP, Meijer S, Cuesta MA. Laparoscopically assisted transhiatal resection for malignancies of the distal esophagus. *Surg Endosc* 2004; 18(5): 812-817. (VUmc)
- 744.** Van den Broek WT, van der Ende ED, Bijnen AB, Breslau PJ, Gouma DJ. Which children could benefit from additional diagnostic tools in case of suspected appendicitis? *J Pediatr Surg* 2004; 39(4): 570-574. (AMC)
- 745.** Van den Heuvel-Eibrink MM, Graf N, Pein F, Sandstedt B, van Tinteren H, van der Vaart KE, de Kraker J. Intracranial relapse in Wilms tumor patients. *Pediatr Blood Cancer* 2004; 43(7): 737-741. (AMC)
- 746.** Van den Hoff MJB, Lekanne Dit Deprez RH, Ruijter JM, de Boer PAJ, Tesink-Taekema S, Buffing AAM, Lamers WH, Moorman AFM. Increased cardiac workload by closure of the ductus arteriosus leads to hypertrophy and apoptosis rather than to hyperplasia in the late fetal period. *N-S Arch Pharmacol* 2004; 370(3): 193-202. (AMC)
- 747.** Van der Groep P, Bouter A, Van der Zanden R, Menko FH, Buerger H, Verheijen RH, Van der Wall E, Van Diest PJ. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. *J Natl Cancer Inst* 2004; 96(9): 712-713. (VUmc)
- 748.** Van der Hage JA, Van den Broek LJCM, Legrand C, Clahsen PC, Bosch CJA, Robanus-Maandag EC et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. *Br J Cancer* 2004; 90: 1543-50. (NKI)
- 749.** Van der Heijden JF, Rekké B, Hutten BA, van der Meer FJM, Remkes MGH, Vermeulen M, Büller HR, Reitsma PH. Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. *J Thromb Haemost* 2004; 2(7): 1104-1109. (AMC)
- 750.** Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, Meijer S, van der WE, Buter J, Pinedo HM, Teule GJ, Lammertsma AA. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. *J Clin Oncol* 2004; 22(7): 1253-1259. (VUmc)
- 751.** Van der Horst A, Tertoolen LG, Vries-Smits LM, Frye RA, Medema RH, Burgering BM. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). *J Biol Chem* 2004; 279: 28873-9. (NKI)
- 752.** Van der Houwen C, Rietbroek RC, Lok CAR, Kate-Booij MJ ten, Lammes FB, Ansink AC. Feasibility of central co-ordinated EMA/CO for gestational trophoblastic disease in the Netherlands. *Brit J Obstet Gynaec* 2004; 111(4): 143-147. (AMC)
- 753.** Van der Poel HG. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells. *J Urol* 2004; 172: 1333-7. (NKI)
- 754.** Van der Poel HG. Smart drugs in prostate cancer. *Eur Urol* 2004; 45: 1-17. (NKI)
- 755.** Van der Pol M, Levendag PC, De Bree RR, Huib FJ, Smeele LE, Nijdam WM, Jansen PP, Meeuwis CA, Rene LC. Radical radiotherapy compared with surgery for advanced squamous cell carcinoma of the base of tongue. *Brachytherapy* 2004; 3(2): 78-86. (VUmc)
- 756.** Van der Slot AJ, Zuurmond AM, van den Bogaerd AJ, Ulrich MMW, Middelkoop E, Boers W, Runday HK, de Groot, J Huizinga TWJ, Bank RA. Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. *Matrix Biol* 2004; 23(4): 251-257. (AMC)
- 757.** Van der Steen LPE, Hage JJ, Kon M, Monstrey SJ. Validity of a structured method of selecting abstracts for a plastic surgical scientific meeting. *Plast Reconstr Surg* 2004; 113: 353-9. (NKI)
- 758.** Van der Steen LPE, Hage JJ, Loonen MPJ, Kon M. Full publication of papers presented at the 1995 through 1999 European Association of Plastic Surgeons annual scientific meetings: a systemic bibliometric analysis. *Plast Reconstr Surg* 2004; 114: 113-20. (NKI)
- 759.** Van der Velden J, Schilthuis MS, Hyde SE, ten Kate FJW, Burger MPM. Squamous cell cancer of the vulva with occult lymph node metastases in the groin: the impact of surgical technique on recurrence pattern and survival. *Int J Gynecol Cancer* 2004; 14(4): 633-638. (AMC)
- 760.** Van der Vliet HJJ, Molling JW, Von Blomberg BME, Nishi N, Kölgen W, Van den Eertwegh AJM, Pinedo HM, Giaccone G, Scheper RJ. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. *Clin Immunol* 2004; 112(1): 8-23. (VUmc)
- 761.** Van Dongen GA, Visser GW, Vrouwenraets MB. Photosensitizer-antibody conjugates for detection and therapy of cancer. *Adv Drug Deliver Rev* 2004; 56(1): 31-52. (VUmc)
- 762.** Van Dorsten FA, van der Graaf M, Engelbrecht MR, Leenders GJ van, Verhofstad A, Rijpkema M, de la Rosette JJMCH, Barentsz JO, Heerschap A. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. *JMRI-J Magn Reson Im* 2004; 20(2): 279-287. (AMC)
- 763.** Van Eeden S, de Leng WWJ, Offerhaus GJA, Morsink FHM, Weterman MAJ, Krijger RR de, Klöppel G, Klimstra DS. Ductuloinsular tumors of

the pancreas: endocrine tumors with entrapped nonneoplastic ductules. *Am J Surg Pathol* 2004; 28(6): 813-820. (AMC)

764. Van Eeden S, Offerhaus GJA, Morsink FHM, van Rees BP, Busch ORC, van Noesel CJM. Pyogenic granuloma: an unrecognized cause of gastrointestinal bleeding. *Virchows Arch* 2004; 444(6): 590-593. (AMC)

765. Van Esch S, Zweers MM, Jansen MAM, De Waart DR, Van Manen JG, Krediet RT. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. *Periton Dialysis Int* 2004; 24(6): 554-561. (AMC)

766. Van Etten B, Brunstein F, van Ijken MGA, Marinelli AWKS, Verhoef C, van der Sijp JRM, Guetens G, de Boeck G, de Bruijn EA, de Wilt JHW, Eggermont AMM. Isolated hypoxic hepatic perfusion (IHHP) with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques. *Ann Surg Oncol* 2004; 11(6): 598-605. (VUmc)

767. Van Galen JC, Dukers DF, Giroth C, Sewalt RG, Otte AP, Meijer CJ, Raaphorst FM. Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. *Eur J Immunol* 2004; 34(7): 1870-1881. (VUmc)

768. Van Gelder RE, Birnie E, Florie J, Schutter MP, Bartelsman JFWM, Snel P, Laméris JS, Bonsel GJ, Stoker J. CT colonography and colonoscopy: assessment of patient preference in a 5-week follow-up study. *Radiology* 2004; 233(2): 328-337. (AMC)

769. Van Gelder RE, Nio CY, Florie J, Bartelsman JFWM, Snel P, Jager SW, van Deventer SJH, Laméris JS, Bossuyt PMM. Computed tomographic colonography compared with colonoscopy in patients at increased risk for colorectal cancer. *Gastroenterology* 2004; 127(1): 41-48. (AMC)

770. Van Gelder RE, Venema HW, Florie J, Nio CY, Serlie IWO, Schutter MP, van Rijn JC, Vos FM, Glas AS, Bossuyt PMM, Bartelsman JFWM, Laméris JS, Stoker J. CT colonography: Feasibility of substantial dose reduction - Comparison of medium to very low doses in identical patients. *Radiology* 2004; 232(2): 611-620. (AMC)

771. Van Grieken NCT, Meijer GA, Kale I, Bloemena E, Lindeman J, Offerhaus GJA, Meuwissen SGM, Baak JPA, Kuipers EJ. Quantitative assessment of gastric antrum atrophy shows restitution to normal histology after *Helicobacter pylori* eradication. *Digestion* 2004; 69(1): 27-33. (AMC/VUmc)

772. Van Heek NT, Maitra A, Koopmann J, Fedarko N, Jain A, Rahman A, Iacobuzio-Donahue CA, Adsay V, Ashfaq R, Yeo CHJ, Cameron JL, Offerhaus GJA, Hruban RH, Berg KD, Goggins M. Gene expression profiling identifies markers of ampullary adenocarcinoma. *Cancer Biol Ther* 2004; 3(7): 651-656. (AMC)

773. Van Heek NT, Ubbink DTH, Legemate DA. Systematic review of studies on elective endovascular repair versus conventional surgery for abdominal aortic aneurysms [letter]. *Radiology* 2004; 232(3): 933-934. (AMC)

774. Van Hensbergen Y, Broxterman HJ, Rana S, Van Diest PJ, Duyndam MC, Hoekman K, Pinedo HM, Boven E. Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. *Clin Cancer Res* 2004; 10(3): 1180-1191. (VUmc)

775. Van Herk M. Errors and margins in radiotherapy. *Semin Radiat Oncol* 2004; 14: 52-64. (NKI)

776. Van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, Snow GB, Brakenhoff RH. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. *Clin Cancer Res* 2004; 10(11): 3614-3620. (NKI/VUmc)

777. Van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. *Lung Cancer* 2004; 43(1): 63-69. (VUmc)

778. Van Kleffens T, Van Baarsen B, Hoekman K, Van Leeuwen E. Clarifying the term 'palliative' in clinical oncology. *Eur J Cancer Care* 2004; 13(3): 263-271. (VUmc)

779. Van Kooten EO, Hage JJ, Meinhardt W, Horenblas S, Mooi WJ. Acquired smooth-muscle hamartoma of the scrotum: a histological simulator? *J Cutan Pathol* 2004; 31: 388-92. (NKI)

780. Van Kuilenburg ABP, Meinsma R, Beke D, Assmann B, Ribes A, Lorente I, Busch R, Mayatepak E, Abeling NGGM, van Cruchten A, Stroomer AEM, van Lenthe H, Zoetekouw L, Kulik W, Hoffmann GF, Voit T, Wevers RA, Rutsch F, van Gennip AH. beta-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. *Hum Mol Genet* 2004; 13(22): 2793-2801. (AMC)

781. Van Kuilenburg ABP, Meinsma R, van Gennip AH. Pyrimidine degradation defects and severe 5-fluorouracil toxicity. *Nucleos Nucleot Nucl* 2004; 23(8 en 9): 1371-1375. (AMC)

782. Van Kuilenburg ABP, Stroomer AEM, van Lenthe H, Abeling NGGM, van Gennip AH. New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? *Biochem* 2004; 379 (Pt1): 119-124. (AMC)

783. Van Kuilenburg ABP, van Lenthe H, Löffler M, van Gennip AH. Analysis of pyrimidine synthesis "de novo" intermediates in urine and dried urine filter- paper strips with HPLC-electrospray tandem mass spectrometry. *Clin Chem* 2004; 50(11): 2117-2124. (AMC)

- 784.** Van Kuilenburg ABP, van Lenthe H, van Cruchten A, Kulik W. Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry. *Clin Chem* 2004; 50(1): 236-238. (AMC)
- 785.** Van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil [review]. *Eur J Cancer* 2004; 40(7): 939-950. (AMC)
- 786.** Van Limpt VAME, Schramm A, Lakeman A, van Sluis P, Chan A, van Noesel M, Baas F, Caron H, Eggert A, Versteeg R. The Phox2B homeobox gene is mutated in sporadic neuroblastomas. *Oncogene* 2004; 23(57): 9280-9288. (AMC)
- 787.** Van Loon J, Hage JJ, Woerdeman LAE, Smeulders MJ. How soft are Soft Touch((R)) breast implants? [letter]. *Br J Plast Surg* 2004; 57: 176-7. (NKI)
- 788.** Van Meeteren LA, Frederiks F, Giepmans BNG, Fernandes PMF, Billington SJ, Jost BH et al. Spider and Bacterial Sphingomyelinases D Target Cellular Lysophosphatidic Acid Receptors by Hydrolyzing Lysophosphatidylcholine. *J Biol Chem* 2004; 279: 10833-6. (NKI)
- 789.** Van Montfrans C, te Velde AA, van Deventer SJH, Rodriguez Pena MS. Gene therapy in the treatment of intestinal inflammation. *Int J Colorectal Dis* 2004; 19(2): 79-86. (AMC)
- 790.** Van Muilekom E. Gastro-intestinale stromaceltumoren: een overzicht. *Oncologica* 2004; 21: 44-7. (NKI)
- 791.** Van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. *Gene* 2004; 325(1): 1-15. (AMC)
- 792.** Van Oijen M, Bins A, Elias S, Sein J, Weder P, De Gast G et al. On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. *Clin Cancer Res* 2004; 10: 4754-60. (NKI)
- 793.** Van Oost FJ, van der Hoeven JJ, Hoekstra OS, Voogd AC, Coebergh JW, Van De Poll-Franse LV. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. *Eur J Cancer* 2004; 40(10): 1545-1553. (VUmc)
- 794.** Van Oosten BW, Killestein J, Mathus-Vliegen EMH, Polman CH. Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. *Multiple Sclerosis* 2004; 10(3): 330-331. (AMC)
- 795.** Van Rheenen J, Langeslag M, Jalink K. Correcting confocal acquisition to optimize imaging of fluorescence resonance energy transfer by sensitized emission. *Biophys J* 2004; 86: 2517-29. (NKI)
- 796.** Van Riel JM, Van Groeningen CJ, de Greve J, Gruia G, Pinedo HM, Giaccone G. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. *Ann Oncol* 2004; 15(1): 59-63. (VUmc)
- 797.** Van Rietschoten JGI, Westland R, van den Bogaard R, Nieste-Otter MA, van Veen A, Jonkers RE, van der Kraan TCTM, den Hartog MT, Wierenga EA. A novel polymorphic GATA site in the human IL-12Rbeta2 promoter region affects transcriptional activity. *Tissue Antigens* 2004; 63(6): 538-546. (AMC)
- 798.** Van Rijn J, van den BJ, Schipper RG, de Jong S, Cuijpers V, Verhofstad AA, Teerlink T. Induction of hyperammonia in irradiated hepatoma cells: a recapitulation and possible explanation of the phenomenon. *Brit J Cancer* 2004; 91(1): 150-152 (VUmc).
- 799.** Van Rijswijk CS, Geirnaerd MJ, Hogendoorn PCW, Taminiau AHM, Van Coevorden F, Zwinderman AH et al. Soft-Tissue Tumors: Value of Static and Dynamic Gadopentetate Dimeglumine-enhanced MR Imaging in Prediction of Malignancy. *Radiology* 2004; 233: 493-502. (NKI)
- 800.** Van Roermund CWT, de Jong M, Ijlst L, van Marle J, Dansen TB, Wanders RJA, Waterham HR. The peroxisomal lumen in *Saccharomyces cerevisiae* is alkaline. *J Cell Sci* 2004; 117(Pt 18): 4231-4237. (AMC)
- 801.** Van Rongen E, Roubos EW, Van Aernsbergen LM, Brussaard G, Havenaar J, Koops FB et al. Mobile phones and children: is precaution warranted? *Bioelectromagnetics* 2004; 25: 142-4. (NKI)
- 802.** Van Ruth S, Mathot RA, Sparidans RW, Beijnen JH, Verwaal VJ, Zoetmulder FAN. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. *Clin Pharmacokinet* 2004; 43: 131-43. (NKI)
- 803.** Van Santen HM, Aronson DC, Vulmsa T, Tummers RFHM, Geenen MM, de Vijlder JJM, van den Bos C. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. *Eur J Cancer* 2004; 40(11): 1743-1751. (AMC)
- 804.** Van Someren EJW, Swart-Heikens J, Endert E, Bisschop PHLT, Swaab DF, Bakker PJM, Romijn JA, Fliers E. Long-term effects of cranial irradiation for childhood malignancy on sleep in adulthood. *Eur J Endocrinol* 2004; 150(4): 503-510. (AMC)
- 805.** Van Stijn A, Kok A, van Stalborch MA, Der Pol MA, Feller N, Westra AH, Ossenkoppele GJ, Schuurhuis GJ. Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile. *Leukemia* 2004; 18(4): 875-877. (VUmc)
- 806.** Van Tine BA, Kappes JC, Banerjee NS, Knops J, Lai L, Steenbergen RD, Meijer CL, Snijders PJ, Chatis P, Broker TR, Moen PT Jr, Chow LT. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. *J Virol* 2004; 78(20): 11172-86. (VUmc)

- 807.** Van Tuyl M, Blommaert PJE, de Boer PAJ, Wert SE, Ruijter JM, Islam S, Schnitzer J, Ellison AR, Tibboel D, Moorman AFM, Lamers WH. Prenatal exposure to thyroid hormone is necessary for normal postnatal development of murine heart and lungs. *Dev Biol* 2004; 272(1): 104-117. (AMC)
- 808.** Van Twillert G, Van Eeden S, Nellen FJB, Cornelissen M, Wszolek Z, Westermann AM. Spinal cord compression due to Kaposi's sarcoma [letter]. *Ann Oncol* 2004; 15(7): 1143-1148. (AMC)
- 809.** Van Valkengoed IG, Morre SA, van den Brule AJ, Meijer CJ, Bouter LM, Boeke AJ. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. *Int J Epidemiol* 2004; 33(2): 416-425. (VUmc)
- 810.** Van Vugt MATM, Bras A, Medema RH. Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells. *Mol Cell* 2004; 15: 799-811. (NKI)
- 811.** Van Vugt MATM, Medema RH. Checkpoint Adaptation and Recovery: Back with Polo after the Break. *Cell Cycle* 2004; 3: 1383-6. (NKI)
- 812.** Van Vugt MATM, Van de Weerd BC, Vader G, Janssen H, Calafat J, Klompmaker R et al. Polo-like Kinase-1 Is Required for Bipolar Spindle Formation but Is Dispensable for Anaphase Promoting Complex/Cdc20 Activation and Initiation of Cytokinesis. *J Biol Chem* 2004; 279: 36841-54. (NKI)
- 813.** Van Waardenburg RCAM, De Jong LA, Van Delft F, Van Eijndhoven MAJ, Bohlander M, Bjornsti MA et al. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. *Mol Cancer Ther* 2004; 3: 393-402. (NKI)
- 814.** Van Waardenburg RCAM, De Jong LA, Van Eijndhoven MAJ, Verseyden C, Pluim D, Jansen LE et al. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. *J Biol Chem* 2004; 279: 54502-9. (NKI)
- 815.** Van Wely M, Bayram N, van der Veen F, Bossuyt PMM. An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome. *Hum Reprod* 2004; 19(8): 1741-1745. (AMC)
- 816.** Van Wely M, Bayram N, van der Veen F, Bossuyt PMM. Are laparoscopic ovarian diathermy and gonadotropin administration the only therapeutic second-steps in clomiphene-citrate resistant women with polycystic ovary syndrome? [Reply]. *Hum Reprod* 2004; 19(11): 2683. (AMC)
- 817.** Van Westreenen HL, Westerterp M, Bossuyt PMM, Pruijm J, Sloof GW, van Lanschot JJB, Groen H, Plukker JTM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. *J Clin Oncol* 2004; 22(18): 3805-3812. (AMC)
- 818.** Van Westrhenen R, de Waart DR, Akman S, Krediet RT. Assessment of peritoneal fibrosis by conventional light microscopy and hydroxyproline measurements. *Periton Dialysis Int* 2004; 24(3): 290-297. (AMC)
- 819.** Van Zeeburg HJ, Snijders PJ, Joenje H, Brakenhoff RH. Re: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. *J Natl Cancer Inst* 2004; 96(12): 968-969. (VUmc)
- 820.** Van Zon A, Mossink MH, Schoester M, Scheper RJ, Sonneveld P, Wiemer EA. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression. *Cancer Res* 2004; 64(14): 4887-4892. (VUmc)
- 821.** Veldkamp R, Gholghesaei M, Bonjer HM, Meijer DW, Buunen M, Jeekel J, Anderberg B, Cuesta MA et al. Laparoscopic resection of colon cancer: Consensus of the European Association Endoscopic Surgery (EAES). *Surg Endosc* 2004; 18: 1163-85. (VUmc)
- 822.** Veldman RJ, Zerp S, Van Blitterswijk WJ, Verheij M. N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. *Br J Cancer* 2004; 90: 917-25. (NKI)
- 823.** Velthoven R, Peltier A, Laguna MP, Piechaud T. Laparoscopic extraperitoneal adenomectomy (Millin): pilot study on feasibility. *Eur Urol* 2004; 45(1): 103-109. (AMC)
- 824.** Verovnik F, Benko D, Vujkovic B, Linthorst GE. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. *Eur J Hum Genet* 2004; 12(8): 678-681. (AMC)
- 825.** Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P, Hooijberg E, Schumacher TN, Haanen JB, Spits H, Luiten RM. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. *Cancer Res* 2004; 64(6): 2153-2161. (NKI/VUmc)
- 826.** Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJ. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. *Brit J Cancer* 2004; 90(8): 1654-1659. (VUmc)
- 827.** Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJ. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects. *Biochem Pharmacol* 2004; 68(3): 493-502. (VUmc)
- 828.** Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G. Temozolomide in paediatric high-grade glioma: a key for

combination therapy? *Brit J Cancer* 2004; 91(3): 425-429. (AMC)

829. Verschuur AC, van Gennip AH, Leen R, van Kuilenburg ABP. Increased cytotoxicity of 2',2'-difluoro-2'-deoxycytidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine. *Nucleos Nucleot Nucl* 2004; 23(8&9): 1517-1521. (AMC)

830. Verstappen CC, Postma TJ, Geldof AA, Heimans JJ. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. *Anticancer Res* 2004; 24(4): 2337-2341. (VUmc)

831. Versteeg HH, Richel DJ, Peppelenbosch MP, Spek CA. Concerted action of coagulation factors on cell survival [letter]. *J Thromb Haemost* 2004; 2(4): 673-674. (AMC)

832. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. *Mol Med* 2004; 10(1-6): 6-11. (AMC)

833. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. *Oncogene* 2004; 23(2): 410-417. (AMC)

834. Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP. FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. *Circ Res* 2004; 94(8): 1032-1040. (AMC)

835. Versteeg HH. Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction. *Semin Hematol* 2004; 41(Suppl. 1): 168-172. (AMC)

836. Verwaal VJ, Boot H, Aleman BMP, Van Tinteren H, Zoetmulder FAN. Recurrences after Peritoneal Carcinomatosis of Colorectal Origin Treated by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and Outcome. *Ann Surg Oncol* 2004; 11: 375-9. (NKI)

837. Verwaal VJ, Van Tinteren H, Van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. *Br J Surg* 2004; 91: 739-46. (NKI)

838. Verwaal VJ, Van Tinteren H, Van Ruth S, Zoetmulder FAN. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. *J Surg Oncol* 2004; 85: 61-7. (NKI)

839. Verwaal VJ, Zoetmulder FAN. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. *Eur J Surg Oncol* 2004; 30: 280-5. (NKI)

840. Vischioni B, Giaccone G, Span SW, Kruyt FA, Rodriguez JA. Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the

subcellular localization of cIAP1 and cIAP2. *Exp Cell Res* 2004; 298(2): 535-548. (VUmc)

841. Vischioni B, van de Valk P, Span S, Kruyt FAE, Rodriguez JA, Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. *Ann Oncol* 2004; 15(11): 1654-1660. (VUmc)

842. Visser O, Van der Kooy K, Van Peppen AM, Ory FG, Van Leeuwen FE. Breast cancer risk among first-generation migrants in the Netherlands. *Br J Cancer* 2004; 90: 2135-7. (NKI/VUmc)

843. Visser O, van Wijnen JH, van Leeuwen FE. Residential traffic density and cancer incidence in Amsterdam, 1989-1997. *Cancer Causes Control* 2004; 15(4): 331-339. (NKI/VUmc)

844. Vleugel MM, Bos R, Van der Groep P, Greijer AE, Shvarts A, Stel HV, Van der Wall E, Van Diest PJ. Lack of lymphangiogenesis during breast carcinogenesis. *J Clin Pathol* 2004; 7: 746-751. (VUmc)

845. Voogd AC, van Tienhoven G. Breast conservation in patients of 35 years or younger [letter]. *J Nucl Med* 2004; 1(45): 1-7. (AMC)

846. Voorhoeve PM, Agami R. Unraveling human tumor suppressor pathways: a tale of the INK4A locus. *Cell Cycle* 2004; 3: 616-20. (NKI)

847. Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, Slotman BJ, Heimans JJ. Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. *Anticancer Res* 2004; 24(4): 2511-2514. (VUmc)

848. Voskuil DW, Bosma A, Vrieling A, Rookus MA, Van 't Veer LJ. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. *Breast Cancer Res Treat* 2004; 84: 225-33. (NKI)

849. Vrieling H, Reesink HW. HTLV-I/II prevalence in different geographic locations. *Transfus Med Rev* 2004; 18(1): 48-57. (AMC)

850. Vriesendorp TM, de Vries JH, Hulscher JBF, Holleman F, van Lanschot JJB, Hoekstra JBL. Early postoperative hyperglycaemia is not a risk factor for infectious complications and prolonged in-hospital stay in patients undergoing oesophagectomy: a retrospective analysis of a prospective trial [open access]. *Crit Care* 2004; 8: R437-R442. (AMC)

851. Vrouwenraets BC, Been HD, Brouwer-Mladin R, Bruno M, van Lanschot JJB. Esophageal perforation associated with cervical spine surgery: report of two cases and review of the literature. *Digest Surg* 2004; 21(3): 246-249. (AMC)

852. Vrouwenraets BC, Duijvendijk P van, Bemelman WA, Offerhaus GJA, Slors JFM. Adenocarcinoma in the anal canal after ileal pouch-anal anastomosis for familial adenomatous polyposis using a double-

- stapled technique: report of two cases. *Dis Colon Rectum* 2004; 47(4): 530-534. (AMC)
- 853.** Vuylsteke RJ, Molenkamp BG, Gietema HA, Van Leeuwen PA, Wijnands PG, Vos W, Van Diest PJ, Scheper RJ, Meijer S, De Gruijl TD. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. *Cancer Res* 2004; 64(22): 8456-8460. (VUmc)
- 854.** Wallner P, Arthur D, Bartelink H, Connolly J, Edmundson G, Giuliano A et al. Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. *J Natl Cancer Inst* 2004; 96: 175-84. (NKI)
- 855.** Wanders RJA. Metabolic and molecular basis of peroxisomal disorders: a review. *Am J Med Genet* 2004; 126A(4): 355-375. (AMC)
- 856.** Watkins S, Van Pouderooyen G, Sixma TK. Structural analysis of the bipartite DNA-binding domain of Tc3 transposase bound to transposon DNA. *Nucleic Acids Res* 2004; 32: 4306-12. (NKI)
- 857.** Weichenrieder O, Repanas K, Perrakis A. Crystal structure of the targeting endonuclease of the human LINE-1 retrotransposon. *Structure (Camb)* 2004; 12: 975-86. (NKI)
- 858.** Weigelt B, Van 't Veer LJ. Hard-wired genotype in metastatic breast cancer. *Cell Cycle* 2004; 3: 756-7. (NKI)
- 859.** Weigelt B, Verduijn P, Bosma AJ, Rutgers EJT, Peterse HL, Van 't Veer LJ. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. *Br J Cancer* 2004; 90: 1531-7. (NKI)
- 860.** Weijers M, Snow GB, Bezemer DP, Van der Wal JE, Van der Waal I. The status of the deep surgical margins in tongue and floor of mouth squamous cell carcinoma and risk of local recurrence: an analysis of 68 patients. *Int J Oral Maxil Surg* 2004; 33: 146-149. (VUmc)
- 861.** Weiss MM, Kuipers EJ, Postma C, Snijders AM, Pinkel D, Meuwissen SG, Albertson D, Meijer GA. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. *Cell Oncol* 2004; 26(5-6): 307-317. (VUmc)
- 862.** Werner AB, Tait SWG, De Vries E, Eldering E, Borst J. Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens. *J Biol Chem* 2004; 279: 28771-80. (NKI)
- 863.** Westermann AM. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [letter]. *Ann Oncol* 2004; 15(3): 537-538. (AMC)
- 864.** Westerterp M, van den Berg JG, Fockens P, van Lanschot JJB. Intramural bronchogenic cysts mimicking solid tumors. *Endoscopy* 2004; 36(12): 1119-1122. (AMC)
- 865.** Westerveld GH, Gianotten J, Leschot NJ, van der Veen F, Repping S, Lombardi MP. Heterogeneous nuclear ribonucleoprotein G-T (HNRNP G-T) mutations in men with impaired spermatogenesis. *Mol Hum Reprod* 2004; 10(4): 265-269. (AMC)
- 866.** Wijkstra H, Wink MH, de la Rosette JJMCH. Contrast specific imaging in the detection and localization of prostate cancer. *World J Urol* 2004; 22(5): 346-350. (AMC)
- 867.** Wijnberger LDE, Bilardo CM, Hecher K, Stigter RH, Visser GHA. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. *Ultrasound Obst Gyn* 2004; 23(6): 584-589. (AMC)
- 868.** Witlox AM, van Beusechem VW, Molenaar B, Bras H, Schaap GR, Alemany R, Curiel DT, Pinedo HM, Wuisman PI, Gerritsen WR. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. *Clin Cancer Res* 2004; 10(1 Pt 1): 61-67. (VUmc)
- 869.** Witmer AN, van Blijswijk BC, van Noorden CJF, Vrensen GFJM, Schlingemann RO. In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. *J Histochem Cytochem* 2004; 52 (1): 39-52. (AMC)
- 870.** Witte MG, Van der Geer J, Schneider C, Lebesque JV, Van Herk M. The effects of target size and tissue density on the minimum margin required for random errors. *Med Phys* 2004; 31: 3068-79. (NKI)
- 871.** Woelfe U, Sauter G, Santjer S, Brakenhoff RH, Pantel K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. *Clin Cancer Res* 2004; 10: 2670-2674. (VUmc)
- 872.** Woerdeman LAE, Hage JJ, Thio EA, Zoetmulder FAN, Rutgers EJT. Breast-conserving therapy in patients with a relatively large (T2 or T3) breast cancer: long-term local control and cosmetic outcome of a feasibility study. *Plast Reconstr Surg* 2004; 113: 1607-16. (NKI)
- 873.** Woerdeman LAE, Van Schijndel AW, Hage JJ, Smeulders MJC. Verifying surgical results and risk factors of the lateral thoracodorsal flap. *Plast Reconstr Surg* 2004; 113: 196-203. (NKI)
- 874.** Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TNM. Antigen bias in T cell cross-priming. *Science* 2004; 304: 1314-7. (NKI)
- 875.** Wu FP, Hoekman K, Meijer S, Bonjer HM, Cuesta MA. The effects of surgery on angiogenic response in patients treated for colorectal carcinoma. A randomized study. *Dis Colon Rectum* 2004; 47(10): 1670-1674. (VUmc)
- 876.** Wu FP, Westphal JR, Hoekman K, Mels AK, Muller MG, de Waal RW, Beelen RH, van Leeuwen PA, Meijer S, Cuesta MA. The effects of surgery,

with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma. *Cytokine* 2004; 25(2): 68-72. (VUmc)

877. Xiao Y, De Feyter E, van Oven CH, Stap J, Hoebe RA, Havenith S, van Noorden CJF, Aten JA. Induction and detection of bystander effects after combined treatment of cells with 5-bromo-2'-deoxyurine, Hoechst 33 258 and ultraviolet A light. *Int J Radiat Biol* 2004; 80(2): 105-114. (AMC)

878. Xiao Y, Hendriks J, Langerak P, Jacobs H, Borst J. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. *J Immunol* 2004; 172: 7432-41. (NKI)

879. Zamboni WC, Gervais AC, Egorin MJ, Schellens JHM, Zuhowski EG, Pluim D et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. *Cancer Chemother Pharmacol* 2004; 53: 329-36. (NKI)

880. Zeamari S, Roos E, Stewart FA. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue. *Eur J Cancer* 2004; 40: 1431-40. (NKI)

881. Zeamari S, Rumping G, Floot B, Lyons S, Stewart FA. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. *Br J Cancer* 2004; 90: 1259-64. (NKI)

882. Zhang P, Bos E, Heymann J, Gnaegi H, Kessel M, Peters PJ et al. Direct visualization of receptor arrays in frozen-hydrated sections and plunge-frozen specimens of *E. coli* engineered to overproduce the chemotaxis receptor Tsr. *J Microsc* 2004; 216: 76-83. (NKI)

883. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. *Obstet Gynecol Surv* 2004; 59(7): 543-55. (VUmc)

884. Zimmerman AW, Nelissen JMDT, Van Ernst-de Vries SE, Willems PHGM, De Lange F, Collard JG et al. Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKC α independently of Rho-like GTPases. *J Cell Sci* 2004; 117: 2841-52. (NKI)

885. Zuetenhorst JM, Korse CM, Bonfrer JMG, Bakker RH, Taal BG. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. *Br J Cancer* 2004; 90: 2073-9. (NKI)

886. Zuetenhorst JM, Korse CM, Bonfrer JMG, Peter E, Lamers CBHW, Taal BG. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic Acid in patients with carcinoid tumors. *Clin Chem* 2004; 50: 1634-9. (NKI)

887. Zuetenhorst JM, Valdés Olmos RA, Muller M, Hoefnagel CA, Taal BG. Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. *Endocr Relat Cancer* 2004; 11: 553-61. (NKI)

888. Zur Hausen A, van Rees BP, van Beek J, Craanen ME, Bloemena E, Offerhaus GJ, Meijer CJ, van den Brule AJ. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. *J Clin Pathol* 2004; 57(5): 487-491. (AMC/VUmc)

889. Zwaan ChM, Kaspers GJL. Possibilities for tailored and targeted therapy in paediatric AML. *Brit J Haematol* 2004; 127(3): 264-279. (VUmc)

890. Zweegman S, van den Born J, Mus AM, Kessler FL, Janssen JJ, Netelenbos T, Huijgens PC, Drager AM. Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells. *Exp Cell Res* 2004; 299(2): 383-392. (VUmc)

6.2. International papers 2005

1. Adachi Y, Suzuki H, Schinkel AH, Sugiyama Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. *Mol Pharmacol* 2005; 67: 923-8 (NKI)
2. Adam MP, Hennekam RCM, Keppen LD, Bull MJ, Clericuzio CL, Burke LW, Ormond KE, Hoyme HE. Marshall-Smith syndrome: natural history and evidence of an osteochondrodysplasia with connective tissue abnormalities. *Am J Med Genet* 2005; 137(2): 117-124 (AMC)
3. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna MP, Pizzocaro G. Guidelines on testicular cancer. *Eur Urol* 2005; 48(6): 885-894 (AMC)
4. Alblas J, Honing H, de Lavalette CR, Brown MH, Dijkstra CD, van den Berg TK. Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK. *Mol Cell Biol* 2005; 25(16): 7181-7192 (VUmc)
5. Ali SR, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassmann H, Lowenstein PR, Castro MG. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. *Cancer Res* 2005; 65(16): 7194-7204 (VUmc)
6. Alter BP, Joenje H, Oostra AB, Pals G. Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. *Arch Otolaryngol Head Neck Surg* 2005; 131(7): 635-639 (VUmc)
7. Alves NL, Arosa FAA, Lier RAW van. IL-21 sustains CD28 expression on IL-15-activated human naive CD8(+) T cells. *J Immunol* 2005; 175(2): 755-762 (AMC)
8. Andry G, Hamoir M, Leemans CR. The evolving role of surgery in the management of head and neck tumors. *Curr Opin Oncol* 2005; 17(3): 241-248 (VUmc)
9. Angenieux C, Fraissier V, Maitre B, Racine V, van der Wel N, Fricker D, Proamer F, Sachse M, Cazenave JP, Peters P, Goud B, Hanau D, Sibarita JB, Salamero J, de la Salle H. The cellular pathway of CD1e in immature and maturing dendritic cells. *Traffic* 2005; 6: 286-302 (NKI)
10. Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. *Genet Epidemiol* 2005; 29: 1-11 (NKI)
11. Appelman M, Wintzen M. Pruritus and leucocytoclastic vasculitis due to azathioprine. *Dermatology* 2005; 210(4): 366 (VUmc)
12. Appels NM, Van Maanen MJ, Rosing H, Schellens JHM, Beijnen JH. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2005; 19: 2187-92 (NKI)
13. Arens R, Baars JW, Jak M, Tesselaar NA, Van der Valk M, Van Oers MHJ, Van Lier RAW. Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation. *J Immunol* 2005; 174(10): 5915-5920 (AMC)
14. Aronica E, Gorter JA, Redeker S, Ramkema M, Spliet WGM, Van Rijen PC, Leenstra S, Troost D. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. *Neuropath Appl Neuro* 2005; 31(3): 280-291 (AMC)
15. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der Valk P, Leenstra S, Baayen JC, Spliet WG, Troost D. Localization of Breast Cancer Resistance Protein (BCRP) in microvessel endothelium of human control and epileptic brain. *Epilepsia* 2005; 46(6): 849-857 (AMC/VUmc)
16. Aronica E, Gorter JA, Rozemuller AJM, Yanyaka B, Troost D. Activation of metabotropic glutamate receptor 3 enhances interleukin (IL)-1beta-stimulated release of IL-6 in cultured human astrocytes. *Neuroscience* 2005; 130(4): 927-933 (AMC)
17. Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, Brown J, Philips A, Otte JB, Czauderna P, Mackinlay G, Vos A. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. *J Clin Oncol* 2005; 23(6): 1245-1252.
18. Aukema AAC, Mulder PGH, Fokkens WJ. Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. *J Allergy Clin Immunol* 2005; 115(5): 1017-1023 (AMC)
19. Baars PA, Sierro S, Arens R, Tesselaar NA, Hooibrink B, Klenerman P, Van Lier RAW. Properties of murine CD8(+)CD27(-) T cells. *Eur J Immunol* 2005; 35(11): 3131-3141 (AMC/NKI)
20. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, Van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. *Lung Cancer* 2005; 48: 291-6 (NKI)
21. Baas P. Chemotherapy for malignant mesothelioma. *Lung Cancer* 2005; 49 Suppl 1: S61-S64 (NKI)

22. Bacchiocchi R, Baldanzi G, Carbonari D, Capomagi C, Colombo E, Van Blitterswijk WJ, Graziani A, Fazioli F. Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. *Blood* 2005; 106: 2175-82 (NKI)
23. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. *J Clin Pathol* 2005; 58(10): 1096-1100 (VUmc)
24. Bais AG, Rebolj M, Snijders PJ, de Schipper FA, van der Meulen DA, Verheijen RH, Voorhorst FJ, van Ballegooijen M, Meijer CJ, Helmerhorst TJ. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. *Int J Cancer* 2005; 116(1): 122-129 (VUmc)
25. Bakker AH, Schumacher TNM. MHC multimer technology: current status and future prospects. *Curr Opin Immunol* 2005; 17: 428-33 (NKI)
26. Bakker-Woudenberg IA, van Vianen W, van Soolingen D, Verbrugh HA, van Agtmael MA. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. *Antimicrob Agents Chemother* 2005; 49(6): 2387-2398 (VUmc)
27. Bakx R, Sprangers MAG, Oort FJ, Van Tets WF, Bemelman WA, Slors JFM, Van Lanschot JJB. Development and validation of a colorectal functional outcome questionnaire. *Int J Colorectal Dis* 2005; 20(2): 126-136 (AMC)
28. Balciunaite E, Spektor A, Lents NH, Cam H, Te Riele H, Scime A, Rudnicki MA, Young R, Dynlacht BD. Pocket protein complexes are recruited to distinct targets in quiescent and proliferating cells. *Mol Cell Biol* 2005; 25: 8166-78 (NKI)
29. Balm AJM, Lohuis PJFM, Copper MP Surgical technique--unwrapping the neck node levels around a sternocleidomastoid muscle bar: a systematic way of performing (modified) radical neck dissection. *Eur J Surg Oncol* 2005; 31(10): 1216-1221 (AMC/NKI)
30. Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JHM, Tellingens OV. Metabolism of docetaxel in mice. *Cancer Chemother Pharmacol* 2005; 56: 299-306 (NKI)
31. Barendrecht MM, Koopmans RP, De la Rosette JJMCH, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. *Brit J Urol* 2005; 95(S 4): 19-28 (AMC)
32. Barr EL, Ouburg S, Igietseme JU, Morre SA, Okwandu E, Eko FO, Ifere G, Belay T, He Q, Lyn D, Nwankwo G, Lillard J, Black CM, Ananaba GA. Host inflammatory response and development of complications of *Chlamydia trachomatis* genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. *J Microbiol Immunol Infect* 2005; 38(4): 244-254 (VUmc)
33. Barreiro M, Nunez C, Dominguez-Munoz JE, Lorenzo A, Barreiro F, Potel J, Pena AS. Association of NOD2/CARD15 mutations with previous surgical procedures in Crohn's disease. *Rev Esp Enferm Dig* 2005; 97(8): 547-553 (VUmc)
34. Barry S, Brzezinski M, Yanay O, Seppen J, Osborne WRA. Sustained elevation of neutrophils in rats induced by lentivirus-mediated G-CSF delivery. *J Gene Med* 2005; 7(12): 1510-1516 (AMC)
35. Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, Hoekstra HJ. Impact of [(18)F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. *Br J Surg* 2005; 93: 243-249 (VUmc)
36. Batisse J, Manet E, Middeldorp JM, Sergeant A, Gruffat H. Epstein-Barr virus mRNA export factor EB2 is essential for intranuclear capsid assembly and production of gp350. *J Virol* 2005; 79(22): 14102-14111 (VUmc)
37. Batlle E, Bacani J, Begthel H, Jonkeer S, Gregorieff A, Van de Born M, Malats N, Sancho E, Boon EMJ, Pawson T, Gallinger S, Pals ST, Clevers H. EphB receptor activity suppresses colorectal cancer progression. *Nature* 2005; 435(7045): 1126-1130 (AMC)
38. Beelen RH, Oosterling SJ, van Egmond M, van den Born J, Zareie M. Omental milky spots in peritoneal pathophysiology (spots before your eyes). *Perit Dial Int* 2005; 25(1): 30-32 (VUmc)
39. Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. *Radiother Oncol* 2005; 75: 157-64 (NKI)
40. Bellini C, Boccardo F, Taddei G, Mazzella M, Arioni C, Villa G, Hennekam RCM, Serra G, Campisi C. Diagnostic protocol for lymphoscintigraphy in newborns. *Lymphology* 2005; 38(1): 9-15 (AMC)
41. Bemelman WA, D'Hoore A. Laparoscopic restorative proctocolectomy (*Br J Surg* 2005; 92: 88-93) [letter]. *Brit J Surg* 2005; 92(4): 493 (AMC)
42. Bemelman WA. Minimally invasive surgery for early lower GI cancer. *Best Pract Res CL GA* 2005; 19(6): 993-1005 (AMC)
43. Bende RJ, Aarts WM, Riedl RG, De Jong D, Pals ST, Van Noesel CJM. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. *J Exp Med* 2005; 201(8): 1229-1241 (AMC/NKI)
44. Bennink RJ, Hamann J, De Bruin K, Ten Kate FJW, Van Deventer SJH, Te Velde AA. Dedicated pinhole SPECT of intestinal neutrophil recruitment in a mouse model of dextran sulfate sodium-

- induced colitis. *J Nucl Med* 2005; 46(3): 526-531 (AMC)
45. Bennink RJ, Vetelainen RL, De Bruin K, Van Vliet AK, Van Gulik TM. Imaging of liver function with dedicated animal dynamic pinhole scintigraphy in rats. *Nucl Med Commun* 2005; 26(11): 1005-1012 (AMC)
46. Bentzen SM, Heeren G, Cottier B, Slotman BJ, Glimelius B, Lievens Y, van den Bogaert W. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. *Radiother Oncol* 2005; 75(3): 355-365 (VUmc)
47. Bergman AM, Eijk PP, Ruiz vH, V, Smid K, Veerman G, Hubeek I, van den IJssel P, Ylstra B, Peters GJ. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. *Cancer Res* 2005; 65(20): 9510-9516 (VUmc)
48. Bergman JJGHM, Tytgat GNJ. New developments in the endoscopic surveillance of Barrett's oesophagus. *Gut* 2005; 54(Suppl.I): 138-142 (AMC)
49. Bergman JJGHM. Best Practice & Research Clinical Gastroenterology - Preface. *Best Pract Res Clin GA* 2005; 19(6): 831-832 (AMC)
50. Bergman JJGHM. Diagnosis and therapy of early neoplasia in Barrett's esophagus. *Curr Opin Gastroen* 2005; 21(4): 466-471 (AMC)
51. Bergman JJGHM. Endoscopic treatment of high-grade intraepithelial neoplasia and early cancer in Barrett oesophagus. *Best Pract Res Cl GA* 2005; 19(6): 889-907 (AMC)
52. Bergman JJGHM. Gastroesophageal reflux disease and Barrett's Esophagus. *Endoscopy* 2005; 37(1): 8-18 (AMC)
53. Bergman MP, Klinkenberg-Knol EC, Faller G, Aar A, Lakhai W, Vandenbroucke-Grauls CM, Kuipers EJ, Appelmek BJ. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production. *Aliment Pharmacol Therap* 2005; 21(8): 977-983 (VUmc)
54. Berkers CR, Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. *Trends Pharmacol Sci* 2005; 26: 252-7 (NKI)
55. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. *Nat Methods* 2005; 2: 357-62 (NKI)
56. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. *Int J Cancer* 2005; 115(2): 268-275 (VUmc)
57. Bernards R. A functional approach to questions about life, death, and phosphorylation. *Cancer Cell* 2005; 7: 503-4 (NKI)
58. Berns A. Cancer: two in one. *Nature* 2005; 436: 787-9 (NKI)
59. Berns A. Stem cells for lung cancer? *Cell* 2005; 121: 811-3 (NKI)
60. Bertolino P, Deckers M, Lebrin F, Ten Dijke P. TGF- β signal transduction in angiogenesis and vascular disorders. *Chest* 2005; 128: 585S-90S (NKI)
61. Beumer JH, Hillebrand MJX, Pluim D, Rosing H, Foley K, Yule SM, Schellens JHM, Beijnen JH. Human metabolism of [(14C)]indisulam following i.v. infusion in cancer patients. *Invest New Drugs* 2005; 23: 317-30 (NKI)
62. Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JHM. Trabectedin (Yondelis(TM), formerly ET-743), a mass balance study in patients with advanced cancer. *Invest New Drugs* 2005; 23: 429-36 (NKI)
63. Beumer JH, Schellens JHM, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. *Pharmacol Res* 2005; 51: 391-8 (NKI)
64. Bex A, Kerst J, Mallo H, Van Tinteren H, Horenblas S, de Gast GC. Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b. *J Chemother* 2005; 17: 674-8 (NKI)
65. Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. *Cancer Immunol Immunother* 2005; 54: 713-9 (NKI)
66. Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, Van Boven H, Meinhardt W, Horenblas S. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. *Urology* 2005; 65: 295-9 (NKI)
67. Bierau J, Van Gennip AH van, Leen R, Meinsma R, Caron HN, Van Kuilenburg ABP. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. *Cancer Chemoth Pharm* 2005; 57(1): 105-113 (AMC)
68. Biezeveld MH, Van Mierlo G, Lutter R, Kuipers IM, Dekker T, Hack CE, Newburger JW, Kuipers TW. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. *Clin Exp Immunol* 2005; 141(1): 183-188 (AMC)
69. Bindels EMJ, van den Brekel MWM. Development of a conditional mouse model for head and neck squamous cell carcinoma. *Adv Otorhinolaryngol* 2005; 62: 1-11 (NKI)

70. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TNM, Haanen JBAG. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. *Nat Med* 2005; 11: 899-904 (NKI)
71. Bipat S, Phoa SSKS, Van Delden OM, Bossuyt PMM, Gouma DJ, Laméris JS, Stoker J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. *J Comput Assist Tomo* 2005; 29(4): 438-445 (AMC)
72. Bipat S, Van Leeuwen MS, Comans EFI, Pijl MEJ, Bossuyt PMM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. *Radiology* 2005; 237(1): 123-131 (AMC)
73. Blancafort P, Chen EI, Gonzalez B, Bergquist S, Zijlstra A, Guthy D, Brachat A, Brakenhoff RH, Quigley JP, Erdmann D, Barbas CF, III. Genetic reprogramming of tumor cells by zinc finger transcription factors. *Proc Natl Acad Sci USA* 2005; 102(33): 11716-11721 (VUmc)
74. Bleeker MC, Berkhof J, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Starink TM, Snijders PJ, Meijer CJ. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. *Br J Cancer* 2005; 92(8): 1388-1392 (VUmc)
75. Bleeker MC, Hogewoning CJ, Berkhof J, Voorhorst FJ, Hesselink AT, van Diemen PM, van den Brule AJ, Snijders PJ, Meijer CJ. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. *Clin Infect Dis* 2005; 41(5): 612-620 (VUmc)
76. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Berkhof J, Hesselink AT, Lettink M, Starink TM, Stoof TJ, Snijders PJ, Meijer CJ. HPV-associated flat penile lesions in men of a non-STD hospital population: less frequent and smaller in size than in male sexual partners of women with CIN. *Int J Cancer* 2005; 113(1): 36-41 (VUmc)
77. Bleiker E, Wigbout G, van Rens A, Verhoef S, van't Veer L, Aaronson N. Withdrawal from genetic counselling for cancer. *Hereditary Cancer Clin Pract* 2005; 3: 19-27 (NKI)
78. Bleiker EM, Menko FH, Taal BG, Kluijdt I, Wever LD, Gerritsma MA, Vasen HF, Aaronson NK. Screening behavior of individuals at high risk for colorectal cancer. *Gastroenterology* 2005; 128(2): 280-287 (NKI/VUmc)
79. Bloemendaal ALA, Verwaal VJ, Van Ruth S, Boot H, Zoetmulder FAN. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective study. *Eur J Surg Oncol* 2005; 31: 1145-51 (NKI)
80. Boeckxstaens GEE, De Jonge WJ, Van den Wijngaard RM, Benninga MA. Achalasia: from new insights in pathophysiology to treatment. *J Pediatr Gastr Nutr* 2005; 41(Suppl 1): S36-S37 (AMC)
81. Boeckxstaens GEE, Hirsch DP, Verkleij CB, Lei A, Holman R, Lehmann A, Rydholm H. Reproducibility of meal-induced transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. *Neurogastroent Motil* 2005; 17(1): 23-28 (AMC)
82. Boeckxstaens GEE. The lower oesophageal sphincter. *Neurogastroent Motil* 2005; 17(Suppl 1): 13-21 (AMC)
83. Boers M, Brooks PM, Simon LS, Strand V, Tugwell PS. OMERACT: an international initiative to improve outcome measurement in rheumatology. *Clin Exp Rheumatol* 2005; 23(5 Suppl 39): S10-S13 (VUmc)
84. Boers M. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in opposition. *Arthritis Rheum* 2005; 52(6): 1642-1645 (VUmc)
85. Boes M, van der Wel N, Peperzak V, Kim YM, Peters PJ, Ploegh H. In vivo control of endosomal architecture by class II-associated invariant chain and cathepsin S. *Eur J Immunol* 2005; 35: 2552-62 (NKI)
86. Bohsung J, Gillis S, Arrans R, Bakai A, De Wager C, Knoos T, Mijnheer BJ, Paiusco M, Perrin BA, Welleweerd H, Williams P. IMRT treatment planning: a comparative inter-system and inter-centre planning exercise of the ESTRO QUASIMODO group. *Radiother Oncol* 2005; 76: 354-61 (NKI)
87. Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Da Pozzo L, ThM de Reijke, Verbaeys A, Bosset JF, Van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). *Lancet* 2005; 366(9485): 572-578 (AMC)
88. Bontkes HJ, Ruizendaal JJ, Kramer D, Meijer CJ, Hooijberg E. Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. *Gynecol Oncol* 2005; 96(3): 897-901 (VUmc)
89. Bontkes HJ, Ruizendaal JJ, Schreurs MW, Kramer D, Meijer CJ, Hooijberg E. Antigen gene transfer to human plasmacytoid dendritic cells using recombinant adenovirus and vaccinia virus vectors. *Cell Oncol* 2005; 27(3): 175-182 (VUmc)
90. Boon EMJ, Kovarikova M, Derksen PWB, Van der Neut R. MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling. *Brit J Cancer* 2005; 92(6): 1078-1083 (AMC)
91. Boot RG, Bussink AP, Aerts JMFG. Human acidic mammalian chitinase erroneously known as eosinophil chemotactic cytokine is not the ortholog

of mouse YM1 [letter]. *J Immunol* 2005; 175(4): 2041-2042 (AMC)

92. Borggreven PA, Kuik DJ, Langendijk JA, Doornaert P, de Bree R, Leemans CR. Severe comorbidity negatively influences prognosis in patients with oral and oropharyngeal cancer after surgical treatment with microvascular reconstruction. *Oral Oncol* 2005; 41(4): 358-364 (VUmc)

93. Borggreven PA, Verdonck-de Leeuw IM, Langendijk JA, Doornaert P, Koster MN, de Bree R, Leemans CR. Speech outcome after surgical treatment for oral and oropharyngeal cancer: a longitudinal assessment of patients reconstructed by a microvascular flap. *Head Neck* 2005; 27(9): 785-793 (VUmc)

94. Borm ME, He J, Kelsall B, Pena AS, Strober W, Bouma G. A major quantitative trait locus on mouse chromosome 3 is involved in disease susceptibility in different colitis models. *Gastroenterology* 2005; 128(1): 74-85 (VUmc)

95. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NFkB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. *Int J Immunogenet* 2005; 32(6): 401-405 (VUmc)

96. Borodovsky A, Ovaa H, Meester WJ, Venanzi ES, Bogyo MS, Hekking BG, Ploegh HL, Kessler BM, Overkleeft HS. Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-specific proteases. *Chembiochem* 2005; 6: 287-91 (NKI)

97. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA, Lebesque JV. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. *Eur J Cancer* 2005; 41: 1533-41 (NKI)

98. Borst GR, De Jaeger K, Belderbos JSA, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with a long-term disease free survival. *Int J Radiat Oncol Biol Phys* 2005; 62: 639-44 (NKI)

99. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. *Curr Opin Immunol* 2005; 17: 275-81 (NKI)

100. Borst P. Ethidium DNA agarose gel electrophoresis: How it started. *IUBMB Life* 2005; 57: 745-7 (NKI)

101. Bos AM, De Vos FY, de Vries EGE, Beijnen JH, Rosing H, Mourits MJ, van der Zee AG, Gietema JA, Willemsse PH. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. *Eur J Cancer* 2005; 41: 539-48 (NKI)

102. Bos LJ, van der Geer J, Van Herk M, Mijnheer BJ, Lebesque JV, Damen EM. The sensitivity of dose distributions for organ motion and set-up uncertainties in prostate IMRT. *Radiother Oncol* 2005; 76: 18-26 (NKI)

103. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. *Histopathology* 2005; 46(1): 31-36 (VUmc)

104. Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JHM, Beijnen JH, Smits PH, Meijerman I. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. *Am J Pharmacogenomics* 2005; 5: 123-31 (NKI)

105. Bot I, Van Eck M, Van Santbrink PJ, Groot PHE, Hildebrand RB, Seppen J, Van Berkel TJC, Biessen EAL. Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo. *Blood* 2005; 106(4): 1147-1153 (AMC)

106. Boutaga K, van Winkelhoff AJ, Vandenbroucke-Grauls CM, Savelkoul PH. Periodontal pathogens: a quantitative comparison of anaerobic culture and real-time PCR. *FEMS Immunol Med Microbiol* 2005; 45(2): 191-199 (VUmc)

107. Bouts AHM, Davin JCMA, Krediet RT, Schröder CH, Monnens LAH, Nauta J, Van de Winkel GJG, Out TA. IgG and complement receptor expression in children treated by peritoneal dialysis. *Pediatr Nephrol* 2005; 20(8): 1162-1167 (AMC)

108. Boyce JM, Cookson B, Christiansen K, Hori S, Vuopio-Varkila J, Kocagoz S, Oztop AY, Vandenbroucke-Grauls CM, Harbarth S, Pittet D. Meticillin-resistant *Staphylococcus aureus*. *Lancet Infect Dis* 2005; 5(10): 653-663 (VUmc)

109. Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kasler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Potschke-Langer M, Poudal HN, Rajan B, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. *Lancet* 2005; 365: 1990-2 (NKI)

110. Braakhuis BJ, Brakenhoff RH, Leemans CR. Head and neck cancer: molecular carcinogenesis. *Ann Oncol* 2005; 16 Suppl 2: ii249-ii250 (VUmc)

111. Braakhuis BJ, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention?. *Oncologist* 2005; 10(7): 493-500 (VUmc)

112. Braakhuis BJ, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. *Semin Cancer Biol* 2005; 15(2): 113-120 (VUmc)

113. Braat H, Stokkers PCF, Hommes T, Cohn D, Vogels E, Pronk I, Spek A, Van Kampen A, Van

- Deventer SJH, Peppelenbosch MP, Hommes DW. Consequence of functional Nod2 and T1r4 mutations on gene transcription in Crohn's disease patients. *J Mol Med JMM* 2005; 83(8): 601-609 (AMC)
- 114.** Brakenhoff GJ, Worpel GW, Jalink K, Oomen L, Brocks L, Zwier JM. Characterization of sectioning fluorescence microscopy with thin uniform fluorescent layers: Sectioned Imaging Property or SIPcharts. *J Microsc* 2005; 219: 122-32 (NKI)
- 115.** Brandon EF, Meijerman I, Klijn JS, den Arend D, Sparidans RW, Lazaro LL, Beijnen JH, Schellens JHM. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. *Anticancer Drugs* 2005; 16: 935-43 (NKI)
- 116.** Brandon EF, van Ooijen RD, Sparidans RW, Lazaro LL, Heck AJ, Beijnen JH, Schellens JHM. Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. *J Mass Spectrom* 2005; 40: 821-31 (NKI)
- 117.** Brecht M, Steenvoorden ACM, Collard JG, Luf S, Erz D, Bartram CR, Janssen JWG. Activation of GEF-h1, a guanine nucleotide exchange factor for RhoA, by DNA transfection. *Int J Cancer* 2005; 113: 533-40 (NKI)
- 118.** Bredart A, Bottomley A, Blazeby JM, Conroy T, Coens C, D'Haese S, Chie WC, Hammerlid E, Arraras JJ, Efficace F, Rodary C, Schraub S, Costantini M, Costantini A, Joly F, Sezer O, Razavi D, Mehlitz M, Bielska-Lasota M, Aaronson NK. An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32). *Eur J Cancer* 2005; 41: 2120-31 (NKI)
- 119.** Breedveld P, Pluim D, Cipriani G, Wielinga P, Van Tellingen O, Schinkel AH, Schellens JHM. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. *Cancer Res* 2005; 65: 2577-82 (NKI)
- 120.** Bremmer JF, Braakhuis BJ, Ruijter-Schippers HJ, Brink AA, Duarte HM, Kuik DJ, Bloemena E, Leemans CR, Van der Waal I, Brakenhoff RH. A noninvasive genetic screening test to detect oral preneoplastic lesions. *Lab Invest* 2005; 85(12): 1481-1488 (VUmc)
- 121.** Breuer RH, Pasic A, Smit EF, van Vliet EA, Vonk Noordegraaf A, Risse EJ, Postmus PE, Sutedja GT. The natural course of preneoplastic lesions in bronchial epithelium. *Clin Cancer Res* 2005; 11(2 Pt 1): 537-543 (VUmc)
- 122.** Breuer RH, Postmus PE, Smit EF. Molecular pathology of non-small-cell lung cancer. *Respiration* 2005; 72(3): 313-330 (VUmc)
- 123.** Breuer RH, Snijders PJ, Sutedja GT, Sewalt RG, Otte AP, Postmus PE, Meijer CJ, Raaphorst FM, Smit EF. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. *Lung Cancer* 2005; 48(3): 299-306 (VUmc)
- 124.** Brink AA, Lloveras B, Nindl I, Heideman DA, Kramer D, Pol RP, Fuente MJ, Meijer CJ, Snijders PJ. Development of a general-primer-PCR-reverse-line-blotting system for detection of beta and gamma cutaneous human papillomaviruses. *J Clin Microbiol* 2005; 43(11): 5581-5587 (VUmc)
- 125.** Brink AA, Zielinski GD, Steenberg RD, Snijders PJ, Meijer CJ. Clinical relevance of human papillomavirus testing in cytopathology. *Cytopathol* 2005; 16(1): 7-12 (VUmc)
- 126.** Brinkman J, De Nef JJEM, Barth PG, Verschuur AC. Burkitt lymphoma in a child with Joubert syndrome. *Pediatr Blood Cancer* 2005; 44(4): 397-399 (AMC)
- 127.** Brinkman J, Wijburg FA, Hollak CEM, Groener JEM, Verhoek M, Scheij S, Aten J, Boot RG, Aerts JMFG. Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease. *J Inherit Metab Dis* 2005; 28(1): 13-20 (AMC)
- 128.** Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. *Clin Cancer Res* 2005; 11(9): 3155-3162 (VUmc)
- 129.** Bronke C, Palmer NM, Westerlaken GHA, Toebes M, van Schijndel GMW, Purwaha V, Van Meijgaarden KE, Schumacher TNM, Van Baarle D, Tesselaar K, Geluk A. Direct *Ex Vivo* detection of HLA-DR3-restricted cytomegalovirus- and *mycobacterium tuberculosis*-specific CD4⁺ T cells. *Hum Immunol* 2005; 66: 950-61 (NKI)
- 130.** Brosens LAA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FHM, Hyland LM, Offerhaus GJA, Giardiello FM, Goggins M. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. *Clin Cancer Res* 2005; 11(11): 4090-4096 (AMC)
- 131.** Brosens LAA, Keller JJ, Offerhaus GJA, Giardiello FM, Goggins M. Prevention and management of duodenal polyps in familial adenomatous polyposis. *Gut* 2005; 54(7): 1034-1043 (AMC)
- 132.** Brouwer C, De Abreu RA, Keizer-Garritsen JJ, Lambooy LH, Ament K, ter Riet PG, van Wering ER, Trijbels FJ, Veerman AJ, Hoogerbrugge PM, Bokkerink JP. Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects. *Eur J Cancer* 2005; 41(4): 613-623 (VUmc)

- 133.** Brouwer C, Vogels-Mentink TM, Keizer-Garritsen JJ, Trijbels FJ, Bokkerink JP, Hoogerbrugge PM, van Wering ER, Veerman AJ, De Abreu RA. Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. *Clin Chim Acta* 2005; 361(1-2): 95-103 (VUmc)
- 134.** Brouwer J, de Bree R, Hoekstra OS, Langendijk JA, Castelijns JA, Leemans CR. Screening for distant metastases in patients with head and neck cancer: what is the current clinical practice?. *Clin Otolaryngol* 2005; 30(5): 438-443 (VUmc)
- 135.** Brouwer J, de Bree R, Hoekstra OS, Golding RP, Langendijk JA, Castelijns JA, Leemans CR. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient?. *Laryngoscope* 2005; 115(10): 1813-1817 (VUmc)
- 136.** Brouwers EE, Tibben MM, Joerger M, Van Tellingem O, Rosing H, Schellens JHM, Beijnen JH. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. *Anal Bioanal Chem* 2005; 382: 1484-90 (NKI)
- 137.** Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. *Drug Resist Update* 2005; 8(4): 183-197 (VUmc)
- 138.** Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP, Jacobs JJ, Kieboom K, Tanger E, Hulsman D, Leung C, Arsenijevic Y, Marino S, Van Lohuizen M. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. *Genes Dev* 2005; 19: 1438-43 (NKI)
- 139.** Brummelkamp TR, Berns K, Hijmans EM, Mullenders J, Fabius A, Heimerikx M, Velds A, Kerkhoven RM, Madiredjo M, Bernards R, Beijersbergen RL. Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells. *Cold Spring Harb Symp Quant Biol* 2004; 69: 439-45 (NKI)
- 140.** Bruynsteyn K, Boers M, Kostense PJ, van der Linden S, Van der Heijde DM. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. *Ann Rheum Dis* 2005; 64(2): 179-182 (VUmc)
- 141.** Bruynzeel DP, Diepgen TL, Andersen KE, Brandao FM, Bruze M, Frosch PJ, Goossens A, Lahti A, Mahler V, Maibach HI, Menne T, Wilkinson JD. Monitoring the European standard series in 10 centres 1996-2000. *Contact Dermatitis* 2005; 53(3): 146-149 (VUmc)
- 142.** Buermans HP, Redout EM, Schiel AE, Musters RJ, Zuidwijk M, Eijk PP, van Hardeveld C, Kasanmoentalib S, Visser FC, Ylstra B, Simonides WS. Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure. *Physiol Genomics* 2005; 21(3): 314-323 (VUmc)
- 143.** Buffart TE, Coffa J, Hermsen MA, Carvalho B, van der Sijp JR, Ylstra B, Pals G, Schouten JP, Meijer GA. DNA copy number changes at 8q11-24 in metastasized colorectal cancer. *Cell Oncol* 2005; 27(1): 57-65 (VUmc)
- 144.** Buis DR, Lagerwaard FJ, Barkhof F, Dirven CM, Lycklama GJ, Meijer OW, van den Berg R, Langendijk HA, Slotman BJ, Vandertop WP. Stereotactic radiosurgery for brain AVMs: role of interobserver variation in target definition on digital subtraction angiography. *Int J Radiat Oncol Biol Phys* 2005; 62(1): 246-252 (VUmc)
- 145.** Buizer AI, De Sonnevile LM, van den Heuvel-Eibrink MM, Njikiktjen C, Veerman AJ. Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. *J Int Neuropsychol Soc* 2005; 11(5): 554-565 (VUmc)
- 146.** Buizer AI, De Sonnevile LM, van den Heuvel-Eibrink MM, Veerman AJ. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. *Pediatr Blood Cancer* 2005; 45(3): 281-290 (VUmc)
- 147.** Bulk S, Visser OJ, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998. Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. *Int J Cancer* 2005; 113(6): 1005-1009 (VUmc)
- 148.** Bulkman NW, Bleeker MC, Berkhof J, Voorhorst FJ, Snijders PJ, Meijer CJ. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. *Int J Cancer* 2005; 117(2): 177-181 (VUmc)
- 149.** Bulkman NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. *Br J Cancer* 2005; 92(9): 1800-1802 (VUmc)
- 150.** Bultink IE, Lems WF, Kostense PJ, Dijkman BA, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. *Arthritis Rheum* 2005; 52(7): 2044-2050 (VUmc)
- 151.** Bultink IE, Teerlink T, Heijst JA, Dijkman BA, Voskuyl AE. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. *Ann Rheum Dis* 2005; 64(9): 1362-1365 (VUmc)
- 152.** Burg G, Kempf W, Cozzio A, Feit J, Willemze R, Jaffe S, Dummer R, Berti E, Cerroni L, Chimenti S,

- Diaz-Perez JL, Grange F, Harris NL, Kazakov DV, Kerl H, Kurrer M, Knobler R, Meijer CJ, Pimpinelli N, Ralfkiaer E, Russell-Jones R, Sander C, Santucci M, Ste. WHO/EORTC classification of cutaneous lymphomas. 2005: histological and molecular aspects. *J Cutan Pathol* 2005; 32(10): 647-674 (VUmc)
- 153.** Buskens CJ, Marsman WA, Bosma PJ, Van Lanschot JJB. The current state of cancer gene therapy and its application in esophageal carcinoma. *Digest Surg* 2005; 22(4): 222-233 (AMC)
- 154.** Bustuoabad OD, Ruggiero RA, Di Gianni P, Lombardi MG, Belli C, Camerano GV, Dran G, Schere-Levy C, Costa H, Isturiz MA, Narvaiz M, van Rooijen N, Bustuoabad V de L, Meiss RP. Tumor transition zone: a putative new morphological and functional hallmark of tumor aggressiveness. *Oncol Res* 2005; 15: 169-182 (VUmc)
- 155.** Buwalda J, Freling NJM, Blank LECM, Balm AJM, Bras J. AMORE protocol in pediatric head and neck rhabdomyosarcoma: descriptive analysis of failure patterns. *Head Neck- J Sci Spec* 2005; 27(5): 390-396 (AMC/NKI)
- 156.** Cahen DL, Rauws EAJ, Fockens P, Weverling GJ, Huijbregtse K, Bruno MJ. Endoscopic drainage of pancreatic pseudocysts: Long-term outcome and procedural factors associated with safe and successful treatment. *Endoscopy* 2005; 37(10): 977-983 (AMC)
- 157.** Cahen DL, Van Berkel AM, Oskam D, Rauws EAJ, Weverling GJ, Huijbregtse K, Bruno MJ. Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis. *Eur J Gastroen Hepat* 2005; 17(1): 103-108 (AMC)
- 158.** Callen E, Casado JA, Tischkowitz MD, Bueren JA, Creus A, Marcos R, Dasi A, Estella JM, Munoz A, Ortega JJ, de Winter JP, Joenje H, Schindler D, Hanenberg H, Hodgson SV, Mathew CG, Surralles J. A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. *Blood* 2005; 105(5): 1946-1949 (VUmc)
- 159.** Carette JE, Graat HC, Schagen FH, Abou El Hassan MA, Gerritsen WR, van Beusechem VW. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. *J Gene Med* 2005; 7(8): 1053-1062 (VUmc)
- 160.** Carvalho R, Milne ANA, Polak M, Corver WE, Offerhaus GJA, Weterman MAJ. Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas. *Oncogene* 2005; 24(56): 8252-8258 (AMC)
- 161.** Caspary F, Elliott G, Navé BT, Verzaal P, Rohrbach M, Das PK, Nagelkerken L, Nieland JD. A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir. *Brit J Dermatol* 2005; 153(5): 937-944 (AMC)
- 162.** Casson AG, Van Lanschot JJB. Improving outcomes after esophagectomy: the impact of operative volume. *J Surg Oncol* 2005; 92(3): 262-266 (AMC)
- 163.** Casson AG, Van Lanschot JJB. Recent advances in the management of esophageal adenocarcinoma. *J Surg Oncol* 2005; 92(3): 149-150 (AMC)
- 164.** Celie JW, Beelen RH, van den Born J. Effect of fixation protocols on in situ detection of L-selectin ligands. *J Immunol Methods* 2005; 298(1-2): 155-159 (VUmc)
- 165.** Celie JW, Keuning ED, Beelen RH, Drager AM, Zweegman S, Kessler FL, Soininen R, van den Born J. Identification of L-selectin binding heparan sulfates attached to collagen type XVIII. *J Biol Chem* 2005; 280(29): 26965-26973 (VUmc)
- 166.** Celie PH, Kasheverov IE, Mordvintsev DY, Hogg RC, van Nierop P, van Elk R, Rossum-Fikkert SE, Zhmak MN, Bertrand D, Tsetlin V, Sixma TK, Smit AB. Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an alpha-conotoxin PnIA variant. *Nat Struct Mol Biol* 2005; 12: 582-8 (NKI)
- 167.** Celie PH, Klaassen RV, Rossum-Fikkert SE, van Elk R, van Nierop P, Smit AB, Sixma TK. Crystal structure of acetylcholine-binding protein from *Bulinus truncatus* reveals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors. *J Biol Chem* 2005; 280: 26457-66 (NKI)
- 168.** Chalandon Y, Degermann S, Villard J, Arlettaz L, Kaiser L, Vischer S, Walter S, Heemskerk MHM, Van Lier RAW, Helg C, Chapuis B, Roosnek E. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. *Blood* 2005; 107(1): 389-396 (AMC)
- 169.** Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, 't Veer LJ, Bartelink H, van de Rijn M, Brown PO, Van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *Proc Natl Acad Sci U S A* 2005; 102: 3738-43 (NKI)
- 170.** Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ova H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. *Cancer Cell* 2005; 8: 407-19 (NKI)
- 171.** Chen C, Slitt AL, Dieter MZ, Tanaka Y, Scheffer GL, Klaassen CD. Up-regulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats. *Biochem Pharmacol* 2005; 70: 1088-1095 (VUmc)
- 172.** Chen Y, Pikkarainen T, Elomaa O, Soininen R, Kodama T, Kraal G, Tryggvason K. Defective microarchitecture of the spleen marginal zone and

impaired response to a thymus-independent type 2 antigen in mice lacking scavenger receptors MARCO and SR-A. *J Immunol* 2005; 175(12): 8173-8180 (VUmc)

173. Ciavarra RP, Taylor L, Greene AR, Yousefieh N, Horeth D, van Rooijen N, Steel C, Gregory B, Birkenbach M, Sekellick M. Impact of macrophage and dendritic cell subset elimination on antiviral immunity, viral clearance and production of type 1 interferon. *Virology* 2005; 342(2): 177-189 (VUmc)

174. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. *Lancet* 2005; 366(9490): 991-998 (VUmc)

175. Coccoris M, de Witte MA, Schumacher TNM. Prospects and limitations of T cell receptor gene therapy. *Curr Gene Ther* 2005; 5: 583-93 (NKI)

176. Codacci-Pisanelli G, Pinedo HM, Lankelma J, Van Groeningen CJ, Van Kuilenburg ABP, Van Gennip AH, Peters GJ. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity. *J Chemother* 2005; 17(3): 315-320 (AMC/VUmc)

177. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. *Cell Death Differ* 2005; 12(Sppl 2): 1509-1518 (AMC)

178. Collette L, Van Poppel H, Bolla M, Van Cangh P, Vekemans K, Da Pozzo L. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). *Eur J Cancer* 2005; 41(17): 2662-2672 (AMC)

179. Cooper SM, Dean D, Allen JD, Kirtschig G, Wojnarowska F. Erosive lichen planus of the vulva: weak circulating basement membrane zone antibodies are present. *Clin Exp Dermatol* 2005; 30(5): 551-556 (VUmc)

180. Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, Bowdin SC, Riccio A, Sebastio G, Blik HJ, Schofield PN, Reik W, Macdonald F, Maher ER. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. *Eur J Hum Genet* 2005; 13(9): 1025-1032 (AMC)

181. Cox DG, Crusius JB, Peeters PH, Bueno-de-Mesquita HB, Pena AS, Canzian F. Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. *World J Gastroenterol* 2005; 11(38): 6003-6008 (VUmc)

182. Crawford J, Lower KM, Hennekam RCM, Van Esch H, Mégarbané A, Lynch SA, Turner G, Gecz J. Mutation screening in Borjeson-Forssman-Lehmann

syndrome: identification of a novel de novo PHF6 mutation in a female patient. *J Med Genet* 2005; 43(3): 238-243 (AMC)

183. Creighton MP, Roël G, Eichhorn PJA, Hijmans EM, Maurere I, Destrée O, Bernardis R. PR72, a novel regulator of Wnt signaling required for naked cuticle function. *Genes Dev* 2005; 19: 376-86 (NKI)

184. Cupedo T, Mebius RE. Cellular interactions in lymph node development. *J Immunol* 2005; 174(1): 21-25 (AMC/VUmc)

185. Cupedo T, Nagasawa M, Weijer K, Blom B, Spits H. Development and activation of regulatory T cells in the human fetus. *Eur J Immunol* 2005; 35(2): 383-390 (AMC)

186. Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, Plaschkes J, Perilongo G. Guidelines for surgical treatment of hepatoblastoma in the modern era- recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPeL). *Eur J Cancer* 2005; 41(7), 1031-1036 (AMC)

187. Dai H, 't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernardis R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. *Cancer Res* 2005; 65: 4059-66 (NKI)

188. Danen EH, Van Rheenen J, Franken W, Huvneers S, Sonneveld P, Jalink K, Sonnenberg A. Integrins control motile strategy through a Rho-cofilin pathway. *J Cell Biol* 2005; 169: 515-26 (NKI)

189. Danen EHJ. Integrins: regulators of tissue function and cancer progression. *Curr Pharm Des* 2005; 11: 881-91 (NKI)

190. De Almeida SF, Carvalho IF, Cardoso CS, Cordeiro JV, Azevedo JE, Neeffjes J, de Sousa M. HFE cross-talks with the MHC class I antigen presentation pathway. *Blood* 2005; 106: 971-7 (NKI)

191. De Boer EC, Rooyackers SJ, Schamhart DHJ, De Reijke ThM, Kurth KH. BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. *Eur Urol* 2005; 48(2): 333-338 (AMC)

192. De Boer EJ, Den Tonkelaar I, Burger CW, Van Leeuwen FE, on behalf of the OMEGA Project Group. Validity of self-reported causes of subfertility. *Am J Epidemiol* 2005; 161: 978-86 (NKI)

193. De Boer EJ, Den Tonkelaar I, Burger CW, Van Leeuwen FE. Are cause of subfertility and in vitro fertilization treatment risk factors for an earlier start of menopause? *Menopause* 2005; 12: 578-88 (NKI)

194. De Bree GJ, Van Leeuwen EMM, Out TA, Jansen HM, Jonkers RE, Van Lier RAW. Selective accumulation of differentiated CD8(+) T cells

- specific for respiratory viruses in the human lung. *J Exp Med* 2005; 202(10): 1433-1442 (AMC)
- 195.** De Bree GJ, Heidema J, Van Leeuwen EMM, Van Bleek GM, Jonkers RE, Jansen HM, Van Lier RAW, Out TA. Respiratory syncytial virus-specific CD8(+) memory T cell responses in elderly persons. *J Infect Dis* 2005; 191(10): 1710-1718 (AMC)
- 196.** De Castro SMM, Kuhlmann KFD, Busch ORC, Van Delden OM, Laméris JS, Van Gulik TM, Obertop H, Gouma DJ. Delayed massive hemorrhage after pancreatic and biliary surgery: embolization or surgery? *Ann Surg* 2005; 241(1): 85-91 (AMC)
- 197.** De Castro SMM, Kuhlmann KFD, Busch ORC, Van Delden OM, Laméris JS, Van Gulik TM, Obertop H, Gouma DJ. Incidence and management of biliary leakage after hepaticojejunostomy. *J Gastrointest Surg* 2005; 9(8): 1163-1173 (AMC)
- 198.** De Croon EM, Sluiter JK, Nijssen TF, Kammeijer M, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH. Work ability of Dutch employees with rheumatoid arthritis. *Scand J Rheumatol* 2005; 34(4): 277-283 (VUmc)
- 199.** De Graaf P, Barkhof F, Moll AC, Imhof SM, Knol DL, van der Valk P, Castelijns JA. Retinoblastoma. MR imaging parameters in detection of tumor extent. *Radiology* 2005; 235(1): 197-207 (VUmc)
- 200.** De Jaeger K, Seppenwoolde Y, Lebesque JV, Kampinga HH. In response to drs. Anscher and Kong. *Int J Radiat Oncol Biol Phys* 2005; 63: 308 (NKI)
- 201.** De Jaeger KE. Radiation-induced pulmonary toxicity in non-small cell lung cancer. Amsterdam: University of Amsterdam, 2005 (NKI).
- 202.** De Jong AE, Morreau H, Nagengast FM, Mathus-Vliegen EMH, Kleibeuker JH, Griffioen G, Cats A, Vasen HFA. Prevalence of adenomas among young individuals at average risk for colorectal cancer. *AM J Gastroenterol* 2005; 100(1): 139-143 (AMC/NKI)
- 203.** De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. *J Clin Oncol* 2005; 23: 6358-63 (NKI)
- 204.** De Jonge ME, Huitema AD, Holtkamp MJ, Van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. *Cancer Chemother Pharmacol* 2005; 56: 370-8 (NKI)
- 205.** De Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. *Clin Pharmacokinet* 2005; 44: 1135-64 (NKI)
- 206.** De Jonge ME, Huitema AD, Schellens JHM, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. *Clin Pharmacokinet* 2005; 44: 147-73 (NKI)
- 207.** De Jonge ME, Huitema AD, Schellens JHM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. *Br J Clin Pharmacol* 2005; 59: 325-34 (NKI)
- 208.** De Jonge ME, Huitema AD, Tukker AC, Van Dam SM, Rodenhuis S, Beijnen JH. Accuracy, feasibility, and clinical impact of prospective bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. *Clin Cancer Res* 2005; 11: 273-83 (NKI)
- 209.** De Jonge ME, Huitema AD, Van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. *Cancer Chemother Pharmacol* 2005; 55: 507-10 (NKI)
- 210.** De Jonge ME, Huitema AD, Van Dam SM, Rodenhuis S, Beijnen JH. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. *Anticancer Drugs* 2005; 16: 331-6 (NKI)
- 211.** De Jonge ME, Huitema AD, Van Dam SM, Rodenhuis S, Beijnen JH. Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramidate Mustard in a High-Dose Combination With Thiotepa and Carboplatin. *Ther Drug Monit* 2005; 27: 756-65 (NKI)
- 212.** De Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC). *Ther Drug Monit* 2005; 27: 393-402 (NKI)
- 213.** De Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJ, Peters GJ, Ravindranath Y, Pieters R, Lindemans J. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. *Blood* 2005; 106(2): 717-720 (VUmc)
- 214.** De Jonge WJ, Van der Zanden EP, The FO, Bijlsma MF, Van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, Van den Wijngaard RMJGJ, Boeckxstaens GEE. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. *Nat Immunol* 2005; 6(8): 844-851 (AMC)
- 215.** De Kraker J, Jones KP. Treatment of Wilms tumor: an international perspective [letter]. *J Clin Oncol* 2005; 23(13): 3156-3157 (AMC)
- 216.** De Lange SM, van der Born K, Kroep JR, Jensen HA, Pfeiffer P, Cleverly A, Van Groeningen CJ, Peters GJ. No evidence of gemcitabine accumulation during weekly administration. *Eur J Clin Pharmacol* 2005; 61(11): 843-849 (VUmc)

217. De Leng WWJ, Keller JJ, Luiten S, Musler AR, Jansen M, Baas AF, De Rooij FWM, Gille JJP, Menko FH, Offerhaus GJA, Weterman MAJ. STRAD in Peutz-Jeghers syndrome and sporadic cancers. *J Clin Pathol* 2005; 58(10): 1091-1095 (AMC/VUmc)
218. De Reijke ThM, Kurth K-H, Sylvester RJ, Hall RR, Brausi M, Van de Beek K, Landsoght KEJ, Carpentier P. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). *J Urology* 2005; 173(2): 405-409 (AMC)
219. De Rooij J, Kerstens A, Danuser G, Schwartz MA, Waterman-Storer CM. Integrin-dependent actomyosin contraction regulates epithelial cell scattering. *J Cell Biol* 2005; 171: 153-64 (NKI)
220. De Ruijter AJM, Meinsma RJ, Bosma P, Kemp S, Caron HN, van Kuilenburg ABP. Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. *Exp Cell Res* 2005; 309(2): 451-467 (AMC)
221. De Turenne-Tessier M, Jolicoeur P, Middeldorp JM, Ooka T. Expression and analysis of the Epstein-Barr virus BARP1-encoded protein from a tetracycline-regulatable adenovirus system. *Virus Res* 2005; 109(1): 9-18 (VUmc)
222. De Visser M, Van Ballegooijen M, Bloemers SM, Van Deventer SJH, Jansen JBMJ, Jespersen J, Kluit, C, Meijer GA, Stoker J, De Valk GA, Verweij MF, Vleems FA. Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT. *Cell Oncol* 2005; 27(1): 17-29 (AMC/VUmc)
223. De Vos JP, Burm AGD, Focker BP, Boschloo H, Karsijns M, Van der Waal I. Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma. *Veterinary Comparat Oncol* 2005; 16-24: 16-24 (VUmc)
224. De Vries-Bouwstra JK, Dijkmans BA, Breedveld FC. Biologics in early rheumatoid arthritis. *Rheum Dis Clin North Am* 2005; 31(4): 745-762 (VUmc)
225. De Weerd L, Woerdeman LA, Hage JJ. The lateral thoracodorsal flap as a salvage procedure for partial transverse rectus abdominis myocutaneous or deep inferior epigastric perforator flap loss in breast reconstruction. *Ann Plast Surg* 2005; 54: 590-4 (NKI)
226. De Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in atherogenesis. *Arterioscler Thromb Vasc Biol* 2005; 25(5): 904-914 (VUmc)
227. De Wit E, Greil F, van Steensel B. Genome-wide HP1 binding in *Drosophila*: developmental plasticity and genomic targeting signals. *Genome Res* 2005; 15: 1265-73 (NKI)
228. De Witt Hamer PhC, Jonker A, Leenstra S, Ruijter JM, Van Noorden CJF. Quantification of viability in organotypic multicellular spheroids of human malignant glioma using lactate dehydrogenase activity: A rapid and reliable automated assay. *J Histochem Cytochem* 2005; 53(1): 23-34 (AMC)
229. De Witte L, van Kooyk Y, Geijtenbeek TB. Pathogen interactions with DC-SIGN modulate immune responses: A Toll tale?. *Current Immunology reviews* 2005; 2: 157-164 (VUmc)
230. Deganello A, de Bree R, Dolivet G, Leemans CR. Infrahyoid myocutaneous flap reconstruction after wide local excision of a Merkel cell carcinoma. *Acta Otorhinolaryngol Ital* 2005; 25(1): 50-53 (VUmc)
231. Dekker E, Fockens P. Advances in colonic imaging: new endoscopic imaging methods. *Eur J Gastroen Hepat* 2005; 17(8), 803-808 (AMC)
232. Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Smitt PA. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. *Mol Cell Proteomics* 2005; 4: 1341-9 (NKI)
233. Deloose STP, Smit LA, Pals FT, Van Noesel CJM, Pals ST. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. *Leukemia* 2005; 19(5), 851-855 (AMC)
234. Den Brok MW, Nuijen B, Challa EE, Lutz C, Opitz HG, Beijnen JH. Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility. *Anticancer Drugs* 2005; 16: 727-32 (NKI)
235. Den Brok MW, Nuijen B, Hillebrand MJX, Grieshaber CK, Harvey MD, Beijnen JH. Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form 169. *J Pharm Biomed Anal* 2005; 39: 46-53 (NKI)
236. Den Brok MW, Nuijen B, Hillebrand MJX, Lutz C, Opitz HG, Beijnen JH. LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. *J Pharm Biomed Anal* 2005; 38: 686-94 (NKI)
237. Den Brok MW, Nuijen B, Kettenes-Van Den Bosch JJ, Van Steenberghe MJ, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH. Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311 19. *PDA J Pharm Sci Technol* 2005; 59: 285-97 (NKI)

238. Den Brok MW, Nuijen B, Lutz C, Opitz HG, Beijnen JH. Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent. *J Pharm Sci* 2005; 94: 1101-14 (NKI)
239. Den Brok MW, Nuijen B, Meijer DM, Millan E, Manada C, Beijnen JH. Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl 76. *PDA J Pharm Sci Technol* 2005; 59: 246-57 (NKI)
240. Den Herder C, Van Tinteren H, de Vries N. Hyoidthyroidpexia: a surgical treatment for sleep apnea syndrome. *Laryngoscope* 2005; 115: 740-5
241. Den Herder C, Van Tinteren H, de Vries N. Sleep endoscopy Versus Modified Mallampati Score in Sleep Apnea and Snoring. *Laryngoscope* 2005; 115: 735-9 (NKI)
242. Den Hoed IDM, Granzen B, Aronson DC, Pauwels P, De Kraker J, Van Heurn LWE. Metastasized angiosarcoma of the spleen in a 2-year-old girl. *Pediatr Hemat Oncol* 2005; 22(5): 387-390 (AMC)
243. Descargues P, Deraison C, Bonnard C, Kreft M, Kishibe M, Ishida-Yamamoto A, Elias P, Barrandon Y, Zambruno G, Sonnenberg A, Hovnanian A. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. *Nat Genet* 2005; 37: 56-65 (NKI)
244. Deurloo EE, Muller SH, Peterse JL, Besnard AP, Gilhuijs KGA. Clinically and mammographically occult breast lesions on MR images: potential effect of computerized assessment on clinical reading. *Radiology* 2005; 234: 693-701 (NKI)
245. Deurloo EE, Peterse JL, Rutgers EJT, Besnard APE, Muller SH, Gilhuijs KGA. Additional breast lesions in patients eligible for breast-conserving therapy by MRI: impact on preoperative management and potential benefit of computerised analysis 176. *Eur J Cancer* 2005; 41: 1393-401 (NKI)
246. Deurloo JA, Ekkelkamp S, Taminiu JAJM, Kneepkens CMF, ten Kate FJW, Bartelsman JFWM, Legemate DA, Aronson DC. Esophagitis and Barrett esophagus after correction of esophageal atresia. *J Pediatr Surg* 2005; 40(8), 1227-1231 (AMC)
247. Deurloo KEI, Steenbakkens RJHM, Zijp LJ, De Bois JA, Nowak PJCM, Rasch CRN, Van Herk M. Quantification of shape variation of prostate and seminal vesicles during external beam radiotherapy. *Int J Radiat Oncol Biol Phys* 2005; 61: 228-38 (NKI)
248. Di Nisio M, Niers TMH, Reitsma PH, Buller HR. Plasma cytokine and P-selectin levels in advanced malignancy. *Cancer* 2005; 104(10): 2275-2281 (AMC)
249. Dicker F, Kater AP, Fukuda T, Kipps TJ. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. *Blood* 2005; 105(8), 3193-3198 (AMC)
250. Diks J, van Hoorn DE, Nijveldt RJ, Boelens PG, Hofman Z, Bouritius H, van Norren K, van Leeuwen PA. Preoperative fasting: an outdated concept?. *J Parenter Enteral Nutr* 2005; 29(4): 298-304 (VUmc)
251. Dinant S, Gerhards MF, Busch ORC, Obertop H, Gouma DJ, Van Gulik TM. The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma. *HPB* 2005; 7(4), 263-267 (AMC)
252. DiPaolo C, Kieft R, Cross M, Sabatini R. Regulation of trypanosome DNA glycosylation by a SWI2/SNF2-like protein. *Mol Cell* 2005; 17: 441-51 (NKI)
253. Dirac AM, Nijman SM, Brummelkamp TR, Bernards R. Functional annotation of deubiquitinating enzymes using RNA interference. *Methods Enzymol* 2005; 398: 554-67 (NKI)
254. Djouadi F, Aubey F, Schlemmer D, Ruiter JPN, Wanders RJA, Strauss AW, Bastin J. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. *Hum Mol Genet* 2005; 14(18), 2695-2703 (AMC)
255. Dorresteijn LDA, Kappelle AC, Scholz NM, Munneke M, Scholma JT, Balm AJM, Bartelink H, Boogerd W. Increased carotid wall thickening after radiotherapy on the neck 181. *Eur J Cancer* 2005; 41: 1026-30 (NKI)
256. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. *Int J Gynecol Cancer* 2005; 15: 679-91 (NKI)
257. Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K, Van Meeteren LA, Moolenaar WH, Wilke N, Siess W, Tigyi G, Miller DD. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin 404. *J Med Chem* 2005; 48: 4919-30 (NKI)
258. Duursma A, Agami R. p53-Dependent regulation of Cdc6 protein stability controls cellular proliferation. *Mol Cell Biol* 2005; 25: 6937-47 (NKI)
259. Duursma AM, Agami R. CDK-dependent stabilization of Cdc6: linking growth and stress signals to activation of DNA replication 50. *Cell Cycle* 2005; 4: 1725-8 (NKI)
260. Eich HP, de la Calle G, Diaz C, Boyer S, Pena AS, Loos BG, Ghazal P, Bernstein I. Practical Approaches to the Development of Biomedical Informatics: the INFOBIOMED Network of

Excellence. *Stud Health Technol Inform* 2005; 116: 39-44 (VUmc)

261. Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, Baars PA, Van Lier RAW, Barkhof F, Uitdehaag BMJ, Polman CH. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. *J Neuroimmunol* 2005; 158(1-2): 222-230 (AMC)

262. Einav Y, Agami R, Canaani D. shRNA-mediated RNA interference as a tool for genetic synthetic lethality screening in mouse embryo fibroblasts 184. *FEBS Lett* 2005; 579: 199-202 (NKI)

263. El Zimaity HM, Wotherspoon A, De Jong D. Interobserver variation in the histopathological assessment of malt/malt lymphoma: towards a consensus 185. *Blood Cells Mol Dis* 2005; 34: 6-16 (NKI)

264. Eldering EF, Van Lier RAW. B-cell antigen receptor-induced apoptosis: looking for clues. *Immunol Lett* 2005; 96(2):187-194 (AMC)

265. Engbers LH, Vollenbroek-Hutten MM, van Harten WH. A comparison of patient characteristics and rehabilitation treatment content of chronic low back pain (CLBP) and stroke patients across six European countries. *Health Policy* 2005; 71: 359-73 (NKI)

266. Epping MT, Wang L, Edell MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. *Cell* 2005; 122: 835-47 (NKI)

267. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti CJ, Thomas NS, Medema RH, Lam EW. Direct transcriptional regulation of Bim by FoxO3a mediates ST1571-induced apoptosis in Bcr-Abl-expressing cells. *Oncogene* 2005; 24: 2317-29 (NKI)

268. Everts B, Van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. *Cancer Gene Ther* 2005; 12: 141-61 (NKI)

269. Ezendam J, Kosterman K, Spijkerboer H, Bleumink R, Hassing I, van Rooijen N, Vos JG, Pieters R. Macrophages are involved in hexachlorobenzene-induced adverse immune effects. *Toxicol Appl Pharmacol* 2005; 209(1): 19-27 (VUmc)

270. Faber C, Hoogendoorn RJW, Lyaruu DM, Stallmann HP, Van Marle J, Van Nieuw Amerongen A, Smit TH, Wuisman PIJM. The effect of the antimicrobial peptide, Dhvar-5, on gentamicin release from a polymethyl methacrylate bone cement. *Biomaterials* 2005; 26(28), 5717-5726 (AMC)

271. Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. *Immunobiology* 2005; 210(2-4): 153-160 (VUmc)

272. Fabry HF, Zonderhuis BM, Meijer S, Berkhof J, van Leeuwen PA, van der Sijp JR. Cosmetic outcome

of breast conserving therapy after sentinel node biopsy versus axillary lymph node dissection. *Breast Cancer Res Treat* 2005; 92(2): 157-162 (VUmc)

273. Faivre L, Portnoi MF, Pals G, Stoppa-Lyonnet D, Le Merrer M, Thauvin-Robinet C, Huet F, Mathew CG, Joenje H, Verloes A, Baumann C. Should chromosome breakage studies be performed in patients with VACTERL association?. *Am J Med Genet A* 2005; 137(1): 120-130 (VUmc)

274. Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. *Ann Rheum Dis* 2005; 64(7): 1003-1008 (VUmc)

275. Fehlaue F, Muench M, Rades D, Stalpers LJ, Leenstra S, van der Valk P, Slotman BJ, Smid EJ, Sminia P. Effects of irradiation and cisplatin on human glioma spheroids: inhibition of cell proliferation and cell migration. *J Cancer Res Clin Oncol* 2005; 131(11): 723-732 (AMC/VUmc)

276. Feller N, Jansen-van der Weide MC, van der Pol MA, Westra GA, Ossenkoppele GJ, Schuurhuis GJ. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. *Exp Hematol* 2005; 33(1): 120-130 (VUmc)

277. Feller N, van der Pol MA, Waaijman T, Weijers GW, Westra GA, Ossenkoppele GJ, Schuurhuis GJ. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. *Clin Cancer Res* 2005; 11(13): 4793-4801 (VUmc)

278. Fernandez-Borja M, Janssen L, Verwoerd D, Hordijk P, Neefjes J. RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1. *J Cell Sci* 2005; 118: 2661-70 (NKI)

279. Ferrer L, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, Broccoli V, Callyzot N, Mooyer P, Selhorst J, Vreken P, Wanders RJA, Mandel JL, Pujol A. Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. *Hum Mol Genet* 2005; 14(23): 3565-3577 (AMC)

280. Ferrer M, Rodriguez JA, Spierings EA, de Winter JP, Giaccone G, Kruyt FA. Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. *Hum Mol Genet* 2005; 14(10): 1271-1281 (VUmc)

281. Ferrer M, Span SW, Vischioni B, Oudejans JJ, van Diest PJ, de Winter JP, Giaccone G, Kruyt FA. FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. *Clin Lung Cancer* 2005; 6(4): 250-254 (VUmc)

282. Fidler H, Chowers Y, Ackerman Z, Pollak RD, Crusius JB, Livneh A, Bar-Meir S, Avidan B, Shinhar Y. The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease. *Am J Gastroenterol* 2005; 100(2): 338-343 (VUmc)
283. Fiets WE, Bellot FE, Struikmans H, Blankenstein MA, Nortier JW. Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours. *Eur J Surg Oncol* 2005; 31(2): 128-133 (VUmc)
284. Fijneman RJ. Genetic predisposition to sporadic cancer: how to handle major effects of minor genes?. *Cell Oncol* 2005; 27(5-6): 281-292 (VUmc)
285. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. *Cancer Res* 2005; 65(1): 291-299 (VUmc)
286. Florie J, Van Gelder RE, Stoker J. Colonography by computed tomography. *Eur J Gastroen Hepat* 2005; 17(8), 809-813 (AMC)
287. Fluiter K, Frieden M, Vreijling J, Koch T, Baas F. Evaluation of LNA-modified DNazymes targeting a single nucleotide polymorphism in the large subunit of RNA polymerase II. *Oligonucleotides* 2005; 15(4), 246-254 (AMC)
288. Fluiter K, Frieden M, Vreijling J, Rosenbohm C, De Wissel MB, Christensen SM, Koch T, Orum H, Baas F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. *ChemBioChem* 2005; 6(6): 1104-1109 (AMC)
289. Foijer F, Wolthuis RM, Doodeman V, Medema RH, Te Riele H. Mitogen requirement for cell cycle progression in the absence of pocket protein activity. *Cancer Cell* 2005; 8: 455-66 (NKI)
290. Fokkens WJ, Lund V, Bachert C, Clement P, Hellings P, Holmstrom M, Jones N, Kalogjera L, Kennedy D, Kowalski M, Malmberg K, Mullol J, Passali D, Stammberger H, Stierna P. EAACI position paper on rhinosinusitis and nasal polyps executive summary. *Allergy* 2005; 60(5): 583-601 (AMC)
291. Franceschi S, Rajkumar R, Snijders PJ, Arslan A, Mahe C, Plummer M, Sankaranarayanan R, Cherian J, Meijer CJ, Weiderpass E. Papillomavirus infection in rural women in southern India. *Br J Cancer* 2005; 92(3): 601-606 (VUmc)
292. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Braziel RM, Muller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. *Blood* 2005; 106: 4315-21 (NKI)
293. Fukushima A, Ozaki A, Ishida W, van Rooijen N, Fukata K, Ueno H. Suppression of macrophage infiltration into the conjunctiva by clodronate liposomes in experimental immune-mediated blepharoconjunctivitis. *Cell Biol Int* 2005; 29(4): 277-286 (VUmc)
294. Furukawa T, Klöppel G, Adsay NV, Albores-Saavedra J, Fukushima N, Horii A, Hruban RH, Kato Y, Klimstra DS, Longnecker DS, Lüttges J, Offerhaus GJA, Shimizu M, Sunamura M, Suriawinata A, Takaori K, Yonezawa S. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. *Virchows Arch* 2005; 447(5): 794-799 (AMC)
295. Galardy PJ, Ploegh HL, Ovaa H. Mechanism-based proteomics tools based on ubiquitin and ubiquitin-like proteins: crystallography, activity profiling, and protease identification. *Methods Enzymol* 2005; 399: 120-31 (NKI)
296. Garcia Vallejo JJ, van Dijk W, van Die I, Gringhuis SI. Tumor necrosis factor-alpha up-regulates the expression of beta1,4-galactosyltransferase I in primary human endothelial cells by mRNA stabilization. *J Biol Chem* 2005; 280(13): 12676-12682 (VUmc)
297. Garcia-Gonzalez MA, Lanas A, Wu J, Benito R, Santolaria S, Cuijpers JP, Pena AS. Lack of association of IL-12 p40 gene polymorphism with peptic ulcer disease. *Hum Immunol* 2005; 66(1): 72-76 (VUmc)
298. Garcia-Gonzalez MA, Savelkoul PH, Benito R, Santolaria S, Crusius JB, Pena AS, Lanas A. No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. *Int J Immunogenet* 2005; 32(5): 299-306 (VUmc)
299. Garzon MR, Berraondo P, Cretzaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, van Rooijen N, Ruiz J, Prieto J, Zulueta J, Gonzalez-Aseguinolaza G. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. *Vaccine* 2005; 23(11): 1384-1392 (VUmc)
300. Geerts D, Revet IM, Jorritsma G, Schilderink N, Versteeg R. MEIS homeobox genes in neuroblastoma. *Cancer Lett* 2005; 228(1-2): 43-50 (AMC)
301. Geier A, Zollner G, Dietrich CG, Wagner M, Fickert P, Denk H, van Rooijen N, Matern S, Gartung C, Trauner M. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. *Hepatology* 2005; 41(3): 470-477 (VUmc)
302. Geiger TR, Peeper DS. The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. *Cancer Res* 2005; 65: 7033-6 (NKI)
303. Genest PA, ter Riet B, Dumas C, Papadopoulou B, Van Luenen HG, Borst P. Formation of linear inverted repeat amplicons following targeting of an essential gene in Leishmania. *Nucleic Acids Res* 2005; 33: 1699-709 (NKI)

- 304.** Geogerger B, van Beusechem VW, Opolon P, Morizet J, Laudani L, Lecluse Y, Barrois M, Idema S, Grill J, Gerritsen WR, Vassal G. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. *J Gene Med* 2005; 7(5): 584-594 (VUmc)
- 305.** Geubbels EL, Wille JC, Nagelkerke NJ, Vandembroucke-Grauls CM, Grobbee DE, de Boer AS. Hospital-related determinants for surgical-site infection following hip arthroplasty. *Infect Cont Hosp Ep* 2005; 26(5): 435-441 (VUmc)
- 306.** Geurts TW, Nederlof PM, Van den Brekel MWM, Van 't Veer LJ, De Jong D, Hart AAM, Van Zandwijk N, Klomp H, Balm AJM, Velthuysen MLF. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: Metastasis or second primary? *Clin Cancer Res* 2005; 11(18): 6608-6614 (AMC/NKI)
- 307.** Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, Zafar Jafri S, Vicini FA, Matter RC, Brabbins DS, Martinez AA. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). *Int J Radiat Oncol Biol Phys* 2005; 62: 406-17 (NKI)
- 308.** Giardiello FM, Hyland LM, Trimbath JD, Hamilton SR, Romans KE, Cruz-Correa M, Corretti MC, Offerhaus GJA, Yang VW. Oral contraceptives and polyp regression in familial adenomatous polyposis. *Gastroenterology* 2005; 128(4): 1077-1080 (AMC)
- 309.** Gillis S, De Wagter C, Bohsung J, Perrin B, Williams P, Mijneer BJ. An inter-centre quality assurance network for IMRT verification: preliminary results of the European QUASIMODO project. *Radiother Oncol* 2005; 76: 340-53 (NKI)
- 310.** Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16. *J Clin Invest* 2005; 115: 3228-38 (NKI)
- 311.** Glas AM, Kersten MJ, Delahaye LJM, Witteveen AT, Kibbelaar RE, Velds A, Wessels LFA, Joosten P, Kerkhoven RM, Bernards R, Van Krieken JHJM, Kluin PM, Van 't Veer LJ, De Jong D. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. *Blood* 2005; 105(1): 301-307 (AMC/NKI)
- 312.** Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Runday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum* 2005; 52(11): 3381-3390 (VUmc)
- 313.** Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hahlen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. *Blood* 2005; 106(10): 3532-3537 (VUmc)
- 314.** Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. *Leukemia* 2005; 19(9): 1536-1542 (VUmc)
- 315.** Gontier Y, Taivainen A, Fontao L, Sonnenberg A, van der Flier A, Carpen O, Faulkner G, Borradori L. The Z-disc proteins myotilin and FATZ-1 interact with each other and are connected to the sarcolemma via muscle-specific filamins. *J Cell Sci* 2005; 118: 3739-49 (NKI)
- 316.** Gorgels TG, Hu X, Scheffer GL, van der Wal AC, Toonstra J, de Jong PT, van Kuppevelt TH, Levelt CN, de Wolf A, Loves WJ, Scheper RJ, Peek R, Bergen AA. Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. *Hum Mol Genet* 2005; 14(13): 1763-1773 (VUmc)
- 317.** Gravas S, Laguna MP, Ehrnebo M, Wagrell L, Mattiasson A, De la Rosette JJMCH. Seeking evidence that cell kill guided thermotherapy gives results not inferior to those of transurethral prostate resection: results of a pooled analysis of 3 studies of feedback transurethral microwave thermotherapy. *J Urology* 2005; 174(3): 1002-1006 (AMC)
- 318.** Greber UF, Fornerod M. Nuclear trafficking in viral infections. *Curr Top Microbiol Immunol* 2005; 285: 109-38 (NKI)
- 319.** Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, van der Wall E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. *Cell Oncol* 2005; 27(1): 43-49 (VUmc)
- 320.** Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). *J Pathol* 2005; 206(3): 291-304 (VUmc)
- 321.** Griekspoor A, Zwart W, Neefjes J. Presenting antigen presentation in living cells using biophysical techniques. *Curr Opin Microbiol* 2005; 8: 338-43 (NKI)
- 322.** Grill J, Lamfers ML, van Beusechem VW, van der Valk P, Huisman A, Sminia P, Alemany R, Curiel DT, Vandertop WP, Gerritsen WR, Dirven CM. Oncolytic virotherapy of meningiomas in vitro with replication-competent adenovirus. *Neurosurgery* 2005; 56(1): 146-153 (VUmc)

323. Gringhuis SI, Garcia Vallejo JJ, van het Hof B, van Dijk W. Convergent actions of I kappa B kinase beta and protein kinase C delta modulate mRNA stability through phosphorylation of 14-3-3 beta complexed with tristetraprolin. *Mol Cell Biol* 2005; 25(15): 6454-6463 (VUmc)
324. Groninger E, Meeuwssen-de Boer T, Koopmans P, Uges D, Sluiter W, Veerman AJ, Kamps WA, de Graaf S. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). *Eur J Cancer* 2005; 41(1): 98-103 (VUmc)
325. Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, van Kooyk Y, de Jong EC, Berkhout B. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. *J Virol* 2005; 79(5): 3009-3015 (VUmc)
326. Groothuis TAM, Griekspoor AC, Neijssen JJ, Herberts CA, Neeffjes JJ. MHC class I alleles and their exploration of the antigen-processing machinery. *Immunol Rev* 2005; 207: 60-76 (NKI)
327. Groothuis TAM, Neeffjes J. The many roads to cross-presentation. *J Exp Med* 2005; 202: 1313-8 (NKI)
328. Groothuis TAM, Reits EAJ. Monitoring the distribution and dynamics of proteasomes in living cells. *Method Enzymol* 2005; 399: 549-563 (AMC/NKI)
329. Gruvberger B, Andersen KE, Brandao FM, Bruynzeel DP, Bruze M, Frosch PJ, Goossens A, Lahti A, Maibach HI, Menne T, Orton D, Seidenari S. Repeated open application test with methylidibromo glutaronitrile, a multicentre study within the EECDRG. *Contact Dermatitis* 2005; 52(1): 19-23 (VUmc)
330. Gruvberger B, Andersen KE, Brandao FM, Bruynzeel DP, Bruze M, Frosch PJ, Goossens A, Lahti A, Lindberg M, Menne T, Orton D, Seidenari S. Patch testing with methylidibromo glutaronitrile, a multicentre study within the EECDRG. *Contact Dermatitis* 2005; 52(1): 14-18 (VUmc)
331. Guikema JEJ, Rosati S Akkermans K, Bende RJ, Van Noesel CJM, Van Krieken JHJM, Hansmann ML, Schuurin E, Kluin PM. Quantitative RT-PCR analysis of activation-induced cytidine deaminase expression in tissue samples from mantle cell lymphoma and B-cell chronic lymphocytic leukemia patients [research letter]. *Blood* 2005; 105(7): 2997-2998 (AMC)
332. Guo QS, Xia B, Jiang Y, Morre SA, Cheng L, Li J, Crusius JB, Pena AS. Polymorphisms of CD14 gene and TLR4 gene are not associated with ulcerative colitis in Chinese patients. *Postgrad Med J* 2005; 81(958): 526-529 (VUmc)
333. Haas RL, Poortmans P, De Jong D, Verheij M, van der Hulst M, de Boer JP, Bartelink H. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. *Eur J Cancer* 2005; 41: 1724-30 (NKI)
334. Hage JJ, Woerdeman LAE, Smeulders MJ. The Truly Distal Lateral Arm Flap: Rationale and Risk Factors of a Microsurgical Workhorse in 30 Patients. *Ann Plast Surg* 2005; 54: 153-9 (NKI)
335. Halstead JR, Jalink K, Divecha N. An emerging role for PtdIns(4,5)P(2)-mediated signalling in human disease. *Trends Pharmacol Sci* 2005; 26: 654-60 (NKI)
336. Hamelinck D, Zhou H, Li L, Verweij CL, Dillon D, Feng Z, Costa JL, Haab BB. Optimized normalization for antibody microarrays and application to serum-protein profiling. *Mol Cell Proteomics* 2005; 4(6): 773-784 (VUmc)
337. Hammouda D, Munoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedat B, Fontaniere B, Snijders PJ, Meijer CJ, Franceschi S. Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors. *Int J Cancer* 2005; 113(3): 483-489 (VUmc)
338. Hamprecht K, Pfau M, Schaller HE, Jahn G, Middeldorp JM, Rennekampff HO. Human cytomegalovirus infection of a severe-burn patient: evidence for productive self-limited viral replication in blood and lung. *J Clin Microbiol* 2005; 43(5): 2534-2536 (VUmc)
339. Hansma AH, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G, Pinedo HM, Hoekman K. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. *Ann Oncol* 2005; 16(10): 1695-1701 (VUmc)
340. Harding CV, Neeffjes J. Antigen processing and recognition. *Curr Opin Immunol* 2005; 17: 55-7 (NKI)
341. Hashimoto K, Kato Z, Nagase T, Shimosawa N, Kuwata K, Omoya K, Li A, Matsukuma E, Yamamoto Y, Ohnishi H, Tochio H, Shirakawa M, Suzuki Y, Wanders RJA, Kondo N. Molecular mechanism of a temperature-sensitive phenotype in peroxisomal biogenesis disorder. *Pediatr Res* 2005; 58(2): 263-269 (AMC)
342. Heemsbergen WD, Hoogeman MS, Hart GA, Lebesque JV, Koper PC. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2005; 61: 1011-8 (NKI)
343. Heideman DA, Steenbergen RD, van der Torre J, Scheffner M, Alemany R, Gerritsen WR, Meijer CJ, Snijders PJ, van Beusechem VW. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and

selective replication in cervical cancer. *Mol Ther* 2005; 12(6): 1083-1090 (VUmc)

344. Heideman DAM, Overmeer RM, Van Beusechem VW, Lamers WH, Hakvoort TBM, Snijders PJ, Craanen ME, Offerhaus GJA, Meijer CJ, Gerritsen WR. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. *Cancer Gene Ther* 2005; 12(12): 954-962 (AMC/VUmc)

345. Hekking LH, Zweers MM, Keuning ED, Driesprong BA, de Waart DR, Beelen RH, van den Born J. Apparent successful mesothelial cell transplantation hampered by peritoneal activation. *Kidney Int* 2005; 68(5): 2362-2367 (VUmc)

346. Hendriks J, Planelles L, De Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. *Cell Death Differ* 2005; 12(6): 637-648 (AMC)

347. Hendriks J, Xiao Y, Rossen JWA, Van der Sluijs KF, Sugamura K, Ishii N, Borst J. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8(+) memory T cells and their capacity for secondary expansion. *J Immunol* 2005; 175(3): 1665-1676 (AMC/NKI)

348. Hennekam RCM. Severe infantile Marfan syndrome versus neonatal Marfan syndrome [editorial comment]. *Am J Med Genet* 2005; 139(1): 1 (AMC)

349. Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. *J Immunother* 2005; 28(4): 343-351 (VUmc)

350. Herder GJ, Van Tinteren H, Golding RP, Kostense PJ, Comans EF, Smit EF, Hoekstra OS. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. *Chest* 2005; 128: 2490-6 (NKI/VUmc)

351. Hermsen MA, Alonso GM, Meijer GA, van Diest PJ, Suarez NC, Marcos CA, Sampedro A. Chromosomal changes in relation to clinical outcome in larynx and pharynx squamous cell carcinoma. *Cell Oncol* 2005; 27(3): 191-198 (VUmc)

352. Hermsen MA, Snijders A, Guervos MA, Taenzer S, Koerner U, Baak J, Pinkel D, Albertson D, van Diest PJ, Meijer GA, Schrock E. Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas. *Oncogene* 2005; 24(9): 1571-1579 (VUmc)

353. Hermsen MA, Tijssen M, Acero IH, Meijer GA, Ylstra B, Toral JF. High resolution microarray CGH and MLPA analysis for improved genotype/phenotype evaluation of two childhood

genetic disorder cases: ring chromosome 19 and partial duplication 2q. *Eur J Med Genet* 2005; 48(3): 310-318 (VUmc)

354. Hesselink AT, van den Brule AJ, Groothuismink ZM, Molano M, Berkhof J, Meijer CJ, Snijders PJ. Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. *J Clin Microbiol* 2005; 43(9): 4868-4871 (VUmc)

355. Hienonen T, Sammalkorpi H, Isohanni P, Versteeg R, Karikoski R, Aaltonen LA. A 17p11.2 germline deletion in a patient with Smith-Magenis syndrome and neuroblastoma. *J Med Genet* 2005; 42(1): e3 (AMC)

356. Hill DA, Gilbert E, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, 't Veer M, Storm H, Pukkala E, Stovall M, Curtis RE, Allan JM, Boice JD, Travis LB. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. *Blood* 2005; 106: 3358-65 (NKI)

357. Hoefnagel JJ, Vermeer MH, Jansen PM, Heule F, Voorst Vader PC, Sanders CJ, Gerritsen MJ, Geerts ML, Meijer CJ, Noordijk EM, Willemze R. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. *Arch Dermatol* 2005; 141(9): 1139-1145 (VUmc)

358. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. *J Clin Oncol* 2005; 23(33): 8362-8370 (NKI/VUmc)

359. Hoekstra R, Deurholt T, Poyck PPC, Ten Bloemendaal L, Chhatta AA. Increased reproducibility of quantitative reverse transcriptase-PCR. *Anal Biochem* 2005; 340(2): 376-379 (AMC)

360. Hogemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basellion JP. The transferring receptor: a potential molecular imaging marker for human cancer. *Neoplasia* 2003; 5: 495-506 (NKI)

361. Holtje M, Hoffmann A, Hofmann F, Mucke C, Grosse G, van Rooijen N, Kettenmann H, Just I, Ahnert-Hilger G. Role of Rho GTPase in astrocyte morphology and migratory response during in vitro wound healing. *J Neurochem* 2005; 95(5): 1237-1248 (VUmc)

362. Hong Y, Garcia M, Levisohn S, Lysnyansky I, Leitig V, Savelkoul PH, Kleven SH. Evaluation of amplified fragment length polymorphism for differentiation of avian mycoplasma species. *J Clin Microbiol* 2005; 43(2): 909-912 (VUmc)

- 363.** Hong Y, Garcia M, Levisohn S, Savelkoul PH, Leiting V, Lysnyansky I, Ley DH, Kleven SH. Differentiation of *Mycoplasma gallisepticum* strains using amplified fragment length polymorphism and other DNA-based typing methods. *Avian Dis* 2005; 49(1): 43-49 (VUmc)
- 364.** Honing H, Van den Berg TK, Dijkstra CD, Van der Kammen RA, Collard JG, De Vries HE. RhoA activation promotes transendothelial migration of monocytes via ROCK. *J Leukoc Biol* 2005; 75: 523-8 (NKI)
- 365.** Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, Molthoff CF. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. *J Clin Endocr Metab* 2005; 90(1): 328-334 (VUmc)
- 366.** Hoogeman MS, Peeters ST, De Bois J, Lebesque JV. Absolute and relative dose-surface and dose-volume histograms of the bladder: which one is the most representative for the actual treatment? *Phys Med Biol* 2005; 50: 3589-97 (NKI)
- 367.** Hoogeman MS, Van Herk M, De Bois J, Lebesque JV. Strategies to reduce the systematic error due to tumor and rectum motion in radiotherapy of prostate cancer. *Radiother Oncol* 2005; 74: 177-85 (NKI)
- 368.** Horlings H, Demant P. Lung tumor location and lymphocyte infiltration in mice are genetically determined. *Exp Lung Res* 2005; 31: 513-25 (NKI)
- 369.** Hornberg JJ, Bruggeman FJ, Binder B, Geest CR, de Vaate AJ, Lankelma J, Heinrich R, Westerhoff HV. Principles behind the multifarious control of signal transduction: ERK phosphorylation and kinase/phosphatase control. *FEBS J* 2005; 272(1): 244-258 (VUmc)
- 370.** Hubeek I, Peters GJ, Broekhuizen AJ, Sargent J, Gibson BE, Creutzig U, Kaspers GJ. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. *Br J Haematol* 2005; 131(2): 219-222 (VUmc)
- 371.** Hubeek I, Peters GJ, Broekhuizen AJ, Talianidis I, Sigmond J, Gibson BE, Creutzig U, Giaccone G, Kaspers GJ. Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. *J Clin Pathol* 2005; 58(7): 695-699 (VUmc)
- 372.** Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. *Br J Cancer* 2005; 93(12): 1388-1394 (VUmc)
- 373.** Huber C, Dias-Santtagata D, Glaser A, O'Sullivan J, Brauner R, Wu K, Xu X, Pearce K, Wang R, Uzielli MLG, Dagoneau N, Chemaitilly W, Superti-Furga A, Dos Santos H, Mégarbané A, Morin G, Gillissen-Kaesbach G, Hennekam RCM, Van der Burgt I, Black GCM, Clayton PE, Read A, Le Merrer M, Scambler PJ, Munnich A, Pan ZQ. Identification of mutations in *CUL7* in 3-M syndrome. *Nat Genet* 2005; 37(10): 1119-1124 (AMC)
- 374.** Huisman MT, Chhatta AA, Van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. *Int J Cancer* 2005; 16(5): 824-829 (AMC/NKI)
- 375.** Hulscher JBF, Van Lanschot JJB. Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction. *Digest Surg* 2005; 22(3): 130-134 (AMC)
- 376.** Hunting CB, Noort WA, Zwaginga JJ. Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization. *Vox Sang* 2005; 88(1): 1-9 (AMC)
- 377.** Hustinx SR, Fukushima N, Zahurak ML, Riall TS, Maitra A, Brosens LAA, Cameron JL, Yeo CHJ, Offerhaus GJA, Hruban RH, Goggins M. Expression and Prognostic Significance of 14-3-3sigma and ERM Family Protein Expression in Periampullary Neoplasms. *Cancer Biol Ther* 2005; 4(5): 596-601 (AMC)
- 378.** Hustinx SR, Hruban RH, Leoni LM, Iacobuzio-Donahue C, Cameron JL, Yeo CHJ, Brown PN, Argani P, Ashfaq R, Fukushima N, Goggins M, Kern SE, Maitra A. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. *Cancer Biol Ther* 2005; 4(1): 83-86 (AMC)
- 379.** Hustinx SR, Leoni LM, Yeo CHJ, Brown PN, Goggins M, Kern SE, Hruban RH, Maitra A. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. *Modern Pathol* 2005; 18(7): 959-963 (AMC)
- 380.** Idema S, Lamfers ML, Heukelom S, van Beusechem VW, Gerritsen WR, Vandertop WP, Dirven CM. Increased oncolytic potency of the conditionally replicative adenovirus Add24-p53 when combined with radiotherapy in vivo. *Neuro-Oncology* 2005; 7(3): 380 (VUmc)
- 381.** Ifergan I, Jansen G, Assaraf YG. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. *Mol Pharmacol* 2005; 67(4): 1349-1359 (VUmc)
- 382.** Ifergan I, Scheffer GL, Assaraf YG. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. *Cancer Res* 2005; 65(23): 10952-10958 (VUmc)

- 383.** In der Maur CD, Klokman WJ, Van Leeuwen FE, Tan IB, Rutgers EJT, Balm AJM. Increased risk of breast cancer development after diagnosis of salivary gland tumour. *Eur J Cancer* 2005; 41: 1311-5 (NKI)
- 384.** Ivanova K, Van den Wijngaard R, Gerzer R, Lamers WH, Das PK. Non-lesional vitiliginous melanocytes are not characterized by an increased proneness to nitric oxide-induced apoptosis. *Exp Dermatol* 2005; 14(6): 445-453 (AMC)
- 385.** Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. *Mol Pharmacol* 2005; 68(2): 502-510 (VUmc)
- 386.** Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. *J Clin Oncol* 2005; 23: 4509-17 (NKI)
- 387.** Jansen JG, Tsaalbi-Shtylik A, Langerak P, Calleja F, Meijers CM, Jacobs H, De Wind N. The BRCT domain of mammalian Rev1 is involved in regulating DNA translesion synthesis. *Nucleic Acids Res* 2005; 33: 356-65 (NKI)
- 388.** Jansen MC, Van Duijnhoven FH, Van Hillegersberg R, Rijken AM, Van Coevorden F, Van der Sijp J, Prevoo W, Van Gulik TM. Adverse effects of radiofrequency ablation of liver tumours in the Netherlands. *Brit J Surg* 2005; 92(10): 1248-1254 (AMC/NKI)
- 389.** Jansen MC, Van Hillegersberg R, Chamuleau RAFM, Van Delden OM, Gouma DJ, Van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. *Eur J Surg Oncol* 2005; 31(4): 331-347 (AMC)
- 390.** Jansen NC, Kingma A, Tellegen P, van Dommelen RI, Bouma A, Veerman AJ, Kamps WA. Feasibility of neuropsychological assessment in leukaemia patients shortly after diagnosis: directions for future prospective research. *Arch Dis Child* 2005; 90(3): 301-304 (VUmc)
- 391.** Janssen HL, Balm AJM, Haustermans KM, Begg AC. Hypoxia in head and neck tumors: how much, how important? *Head Neck* 2005; 27: 622-38 (NKI)
- 392.** Janssen HL, Ljungkvist AS, Rijken PF, Sprong D, Bussink J, van der Kogel AJ, Haustermans KM, Begg AC. Thymidine analogues to assess microperfusion in human tumors. *Int J Radiat Oncol Biol Phys* 2005; 62: 1169-75 (NKI)
- 393.** Janssen JJ, Klaver SM, Waisfisz Q, Pasterkamp G, de Kleijn DP, Schuurhuis GJ, Ossenkuppele GJ. Identification of genes potentially involved in disease transformation of CML. *Leukemia* 2005; 19(6): 998-1004 (VUmc)
- 394.** Jeeninga RE, Jan B, Van der Linden B, Van den Berg H, Berkhout B. Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: Towards a new virotherapy approach. *Cancer Res* 2005; 65(8): 3347-3355 (AMC)
- 395.** Jellema AP, Doornaert P, Slotman BJ, Leemans CR, Langendijk JA. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?. *Radiother Oncol* 2005; 77(2): 164-171 (VUmc)
- 396.** Joerger M, Huitema AD, Meenhorst PL, Schellens JHM, Beijnen JH. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. *Cancer Chemother Pharmacol* 2005; 55: 488-96 (NKI)
- 397.** Joerger M, Koeberle D, Neumann HPH, Gillesen S. Von Hippel-Lindau disease--a rare disease important to recognize. *Onkologie* 2005; 28: 159-63 (NKI)
- 398.** Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF, Abbott MH, Aughton DJ, Aylsworth AS, Bamshad MJ, Booth C, Curry CJ, David A, Dinulos MB, Flannery DB, Fox MA, Graham JM, Grange DK, Guttmacher AE, Hannibal MC, Henn W, Hennekam RCM, Holmes LB, Hoyme HE, Leppig KA, Lin AE, MacLeod P, Manchester DK, Marcelis C, Mazzanti L, McCann, E, McDonald MT, Mendelsohn NJ, Moeschler JB, Moghaddam B, Neri G, Newbury-Ecob R, Pagon RA, Philips III JA, Sadler LS, Stoler JM, Tilstra D, Walsh Vockley CM, Zackai EH, Zadeh TM, Brueton L, Black GCM, Biesecker LG. Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations. *Am J Hum Genet* 2005; 76(4): 609-622 (AMC)
- 399.** Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC. Contribution of the ABC Transporters Bcrp1 and Mdr1a/1b to the Side Population Phenotype in Mammary Gland and Bone Marrow of Mice. *Stem Cells* 2005; 23: 1059-65 (NKI)
- 400.** Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. *Nat Med* 2005; 11: 127-9 (NKI)
- 401.** Jordens I, Marsman M, Kuijl C, Neefjes J. Rab proteins, connecting transport and vesicle fusion. *Traffic* 2005; 6: 1070-7 (NKI)
- 402.** Joshi U, Raijmakers PG, van Lingen A, Comans EF, Pijpers R, Teule GJ, Hoekstra OS. Evaluation of pulmonary nodules: comparison of a prototype dual crystal (LSO/NAI) dual head coincidence camera and full ring positron emission tomography (PET). *Eur J Radiol* 2005; 55(2): 250-254 (VUmc)
- 403.** Kaas R, Hart AAM, Rutgers EJT. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer. *Breast* 2005; 14: 310-6 (NKI)

- 404.** Kapma MR, Vrouwenraets BC, Nieweg OE, van Geel AN, Noorda EM, Eggermont AMM, Kroon BBR. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. *Eur J Surg Oncol* 2005; 31: 95-9 (NKI)
- 405.** Kapma S, Leschot NJ, Aalfs CM. DNA-diagnostiek bij erfelijke kanker: het belang van betrouwbare familiegegevens. *Ned Tijdschr Geneesk* 2005; 149(2): 57-60 (AMC)
- 406.** Kappelhoff BS, Huitema AD, Mairuhu AT, Schellens JHM, Beijnen JH. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. *Anticancer Drugs* 2005; 16: 627-30 (NKI)
- 407.** Kara MA, Peters FP, Rosmolen WD, Krishnadath KK, Ten Kate FJW, Fockens P, Bergman JJGHM. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study. *Endoscopy* 2005; 37(10): 929-936 (AMC)
- 408.** Kara MA, Peters FP, Ten Kate FJW, Van Deventer SJH, Fockens P, Bergman JJGHM. Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. *Gastrointest Endosc* 2005; 61(6): 679-685 (AMC)
- 409.** Kara MA, Smits ME, Rosmolen WD, Bultje AC, Ten Kate FJW, Fockens P, Tytgat GNJ, Bergman JJGHM. A randomized crossover study comparing light-induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett's esophagus. *Gastrointest Endosc* 2005; 61(6): 671-678 (AMC)
- 410.** Kardos G, Zwaan CM, Kaspers GJ, de Graaf SS, de Bont ES, Postma A, Bokkerink JP, Weening RS, van der Does-van den Berg, van Wering ER, Korbijn C, Hahlen K. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. *Leukemia* 2005; 19(12): 2063-2071 (VUmc)
- 411.** Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. *Drugs Today (Barc)* 2005; 41(7): 453-459 (VUmc)
- 412.** Karimi O, Pena AS. Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. *Rev Esp Enferm Dig* 2005; 97(8): 570-574 (VUmc)
- 413.** Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. *J Med Virol* 2005; 75(4): 593-602 (VUmc)
- 414.** Kashiwayama Y, Asahina K, Shibata H, Morita M, Muntau AC, Roscher AA, Wanders RJA, Shimozawa N, Sakaguchi M, Kato H, Imanaka T. Role of Pex19p in the targeting of PMP70 to peroxisome. *Biochim Biophys Acta* 2005; 1746(2): 116-128 (AMC)
- 415.** Kasperkovitz PV, Timmer TC, Smeets TJ, Verbeet NL, Tak PP, van Baarsen LG, Baltus B, Huizinga TW, Pieterman E, Fero M, Firestein GS, van der Pouw Kraan CT, Verweij CL. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. *Arthritis Rheum* 2005; 52(2): 430-441 (VUmc)
- 416.** Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. *Leukemia* 2005; 19(12): 2025-2029 (VUmc)
- 417.** Kaspers GJ, Wijnands JJ, Hartmann R, Huismans L, Loonen AH, Stackelberg A, Henze G, Pieters R, Hahlen K, van Wering ER, Veerman AJ. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. *Eur J Cancer* 2005; 41(9): 1300-1303 (VUmc)
- 418.** Kaspers GJ. 6th International Symposium and expert workshops on Leukemia and Lymphoma. 17-19 March, 2005, Amsterdam, The Netherlands. *Expert Rev Anticancer Ther* 2005; 5(3): 415-417 (VUmc)
- 419.** Kaspers GJ. Use of the differential staining cytotoxicity assay to predict chemosensitivity. *Methods Mol Med* 2005; 110: 49-57 (VUmc)
- 420.** Kasperts N, Slotman BJ, Leemans CR, Langendijk JA. A review on re-irradiation for recurrent and second primary head and neck cancer. *Oral Oncol* 2005; 41(3): 225-243 (VUmc)
- 421.** Kater AP, Dicker F, Mangiola M, Welsh K, Houghton R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. *Blood* 2005; 106(5): 1742-1748 (AMC)
- 422.** Kemp S, Valianpour F, Denis S, Ofman R, Sanders RJ, Mooyer P, Barth PG, Wanders RJA. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. *Mol Genet Metab* 2005; 84(2): 144-151 (AMC)
- 423.** Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. *Cancer Immunol Immunother* 2005; 54: 926-31 (NKI)
- 424.** Kessels HW, Wolkers MC, Schumacher TNM. Gene transfer of MHC-restricted receptors. *Methods Mol Med* 2005; 109: 201-14 (NKI)
- 425.** Khabir A, Karray H, Rodriguez S, Rose M, Daoud J, Frikha M, Boudawara T, Middeldorp JM,

- Jlidi R, Busson P. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. *Virology* 2005; 2: 39 (VUmc)
426. Khamri W, Moran AP, Worku ML, Karim QN, Walker MM, Annuk H, Ferris JA, Appelmelk BJ, Eggleton P, Reid KB, Thursz MR. Variations in *Helicobacter pylori* lipopolysaccharide to evade the innate immune component surfactant protein D. *Infect Immun* 2005; 73(11): 7677-7686 (VUmc)
427. Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D. Interventions for bullous pemphigoid. *Cochrane Database Syst Rev* 2005; (3): CD002292 (VUmc)
428. Kirtschig G, Brink AA, Scheper RJ, Jaspars EH. No oncogenic mucosal human papillomaviruses in erosive vulval lichen planus. *Br J Dermatol* 2005; 152(6): 1367-1368 (VUmc)
429. Kirtschig G, Wakelin SH, Wojnarowska F. Mucosal vulval lichen planus: outcome, clinical and laboratory features. *J Eur Acad Dermatol Venereol* 2005; 19(3): 301-307 (VUmc)
430. Kirtschig G. Erratum. *J Eur Acad Dermatol Venereol* 2005; 19(4): 530 (VUmc)
431. Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. *Cancer Epidemiol Biomarkers Prev* 2005; 14(6): 1528-1533 (VUmc)
432. Klein S, Hage JJ, Woerdeman LA. Donor-site necrosis following fibula free-flap transplantation: a report of three cases. *Microsurgery* 2005; 25: 538-42 (NKI)
433. Klerk CPW, Smorenburg SM, Otten JMMB, Lensing AWA, Prins MH, Piovella F, Prandoni P, Bos MMEM, Richel DJ, Van Tienhoven G, Büller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. *J Clin Oncol* 2005; 23(10): 2130-2135 (AMC)
434. Kluiver J, Poppema S, De Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. *J Pathol* 2005; 207: 243-9 (NKI)
435. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. *J Clin Oncol* 2005; 23: 3830-42 (NKI)
436. Kok HP, Van Haaren PMA, Van de Kamer JB, Wiersma J, Van Dijk JDP, Crezee J. High-resolution temperature-based optimization for hyperthermia treatment planning. *Phys Med Biol* 2005; 50(13): 3127-3141 (AMC)
437. Kok HP, Van Haaren PMA, Van Dijk JDP, Crezee J. On estimation of the temperature maximum in intraluminal or intracavitary hyperthermia. *Int J Hyperther* 2005; 21(4): 287-304 (AMC)
438. Kolfshoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernardis R, Voorhoeve PM, Agami R. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. *Cell* 2005; 121: 849-58 (NKI)
439. Komen JC, Duran M, Wanders RJA. Characterization of phytanic acid omega-hydroxylation in human liver microsomes. *Mol Genet Metab* 2005; 85(3): 190-195 (AMC)
440. Kondo C, Onuki R, Kusuhara H, Suzuki H, Suzuki M, Okudaira N, Kojima M, Ishiwata K, Jonker JW, Sugiyama Y. Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). *Pharm Res* 2005; 22: 613-8 (NKI)
441. Koomen I, Raat H, Jennekens-Schinkel A, Grobbee DE, Roord JJ, van Furth AM. Academic and behavioral limitations and health-related quality of life in school-age survivors of bacterial meningitis. *Qual Life Res* 2005; 14(6): 1563-1572 (VUmc)
442. Koornstra JJ, Rijcken FEM, Oldenhuis CNAM, Zwart N, Van der Sluis T, Hollema H, De Vries EGE, Keller JJ, Offerhaus GJA, Giardiello FM, Kleibeuker JH. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. *Cancer Epidemiol Biomarkers Prev* 2005; 14(7): 1608-1612 (AMC)
443. Kop EN, Kwakkenbos MJ, Teske GJD, Kraan MC, Smeets TJM, Stacey M, Lin HH, Tak PP, Hamann J. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. *Arthritis Rheum* 2005; 52(2): 442-450 (AMC)
444. Koppel EA, Ludwig IS, Appelmelk BJ, van Kooyk Y, Geijtenbeek TB. Carbohydrate specificities of the murine DC-SIGN homologue mSIGNR1. *Immunobiology* 2005; 210(2-4): 195-201 (VUmc)
445. Koppel EA, Saeland E, de Cooker DJ, van Kooyk Y, Geijtenbeek TB. DC-SIGN specifically recognizes *Streptococcus pneumoniae* serotypes 3 and 14. *Immunobiology* 2005; 210(2-4): 203-210 (VUmc)
446. Koppel EA, van Gisbergen KP, Geijtenbeek TB, van Kooyk Y. Distinct functions of DC-SIGN and its homologues L-SIGN (DC-SIGNR) and mSIGNR1 in pathogen recognition and immune regulation. *Cell Microbiol* 2005; 7(2): 157-165 (VUmc)
447. Koppel EA, Wieland CW, van den Berg V, Litjens M, Florquin S, van Kooyk Y, van der Poll T, Geijtenbeek TB. Specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for defense against pulmonary *Streptococcus*

pneumoniae infection. *Eur J Immunol* 2005; 35(10): 2962-2969 (VUmc)

448. Koppers-Lalic D, Reits EAJ, Rensing ME, Lipinska AD, Abele R, Koch J, Rezende MM, Admiraal P, Van Leeuwen D, Bienkowska-Szewczyk K, Mettenleiter TC, Rijsewijk FAM, Tampe R, Neefjes J, Wiertz EJJ. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. *Proc Natl Acad Sci U S A* 2005; 102: 5144-9 (NKI)

449. Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. *Cancer Biol Ther* 2005; 4(3): 289-294 (VUmc)

450. Korokhov N, Nouredini SC, Curiel DT, Santegoets SJ, Scheper RJ, de Gruijl TD. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. *Mol Pharmacol* 2005; 2(3): 218-223 (VUmc)

451. Kovács G, Pötter R, Loch T, Hammer J, Kalkman-Deurloo I-K, De la Rosette JJMCH, Bertermann H. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. *Radiother Oncol* 2005; 74(2): 137-148 (AMC)

452. Kragt A, Voorn-Brouwer T, Van den Berg M, Distel B. Endoplasmic reticulum-directed Pex3p routes to peroxisomes and restores peroxisome formation in a *Saccharomyces cerevisiae* pex3Delta strain. *J Biol Chem* 2005; 280(40): 34350-34357 (AMC)

453. Kragt A, Voorn-Brouwer T, Van den Berg M, Distel B. The *Saccharomyces cerevisiae* peroxisomal import receptor Pex5p is monoubiquitinated in wild type cells. *J Biol Chem* 2005; 280(9): 7867-7874 (AMC)

454. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstrasser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. *Blood* 2005; 106(6): 2183-2185 (VUmc)

455. Kreimer AR, Clifford GM, Snijders PJ, Castellsague X, Meijer CJ, Pawlita M, Viscidi R, Herrero R, Franceschi S. HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. *Int J Cancer* 2005; 115(2): 329-332 (VUmc)

456. Kresse M, Latta M, Kunstle G, Riehle HM, van Rooijen N, Hentze H, Tiegs G, Biburger M, Lucas R, Wendel A. Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. *J Immunol* 2005; 175(6): 4076-4083 (VUmc)

457. Kreukels BPC, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, Van Dam FSAM. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. *Breast Cancer Res Treat* 2005; 94: 53-61 (NKI)

458. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linhorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, De Koning HJ, Rutgers T, Klijn JG. Efficacy of Magnetic Resonance Imaging and Mammography for Breast Cancer Screening in Women With a Familial or Genetic Predisposition. *Obstet Gynecol Surv* 2005; 60: 107-9 (NKI)

459. Kroon BK, Horenblas S, Deurloo EE, Nieweg OE, Teertstra HJ. Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. *BJU Int* 2005; 95: 517-21 (NKI)

460. Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MPW, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. *J Urol* 2005; 173: 816-9 (NKI)

461. Kroon BK, Horenblas S, Meinhardt W, Van der Poel HG, Bex A, Van Tinteren H, Valdes Olmos RA, Nieweg OE. Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience. *Eur Urol* 2005; 47: 601-6 (NKI)

462. Kroon BK, Horenblas S, Nieweg OE. Contemporary management of penile squamous cell carcinoma. *J Surg Oncol* 2005; 89: 43-50 (NKI)

463. Kroon BK, Lont AP, Valdés Olmos RA, Nieweg OE, Horenblas S. Morbidity of dynamic sentinel node biopsy in penile carcinoma. *J Urol* 2005; 173: 813-5 (NKI)

464. Kroon BK, Valdés Olmos RA, Nieweg OE, Horenblas S. Non-visualization of sentinel lymph nodes in penile carcinoma. *Eur J Nucl Med Mol Imaging* 2005; 32: 1096-9 (NKI)

465. Kroon BK, Valdes Olmos RA, Van der Poel HG, Nieweg OE, Horenblas S. Prepubic sentinel node location in penile carcinoma. *Clin Nucl Med* 2005; 30: 649-50 (NKI)

466. Kroon BK, Valdés Olmos RA, Van Tinteren H, Nieweg OE, Horenblas S. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with penile carcinoma. *J Urol* 2005; 174: 2214-7 (NKI)

467. Kuijpers TW, Alders M, Tool ATJ, Mellink CHM, Roos D, Hennekam RCM. Hematologic abnormalities in Shwachman Diamond syndrome: lack of genotype-phenotype relationship. *Blood* 2005; 106(1): 356-361 (AMC)

468. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. Review article: drugs interfering with visceral sensitivity for the treatment of functional

gastrointestinal disorders--the clinical evidence. *Aliment Pharm Therap*; 21(6): 633-651 (AMC)

469. Kuiperij HB, van der Horst A, Raaijmakers J, Weijzen S, Medema RH, Bos JL, Burgering BM, Zwartkruis FJ. Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP. *Oncogene* 2005; 24: 2087-95 (NKI)

470. Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mommaas AM, van den Elsen PJ. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. *Hum Immunol* 2005; 66(6): 653-665 (VUmc)

471. Kuipers HF, Biesta PJ, Groothuis TAM, Neefjes JJ, Mommaas AM, van den Elsen PJ. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. *Hum Immunol* 2005; 66: 653-65 (NKI)

472. Kuppens IE, Breedveld P, Beijnen JH, Schellens JHM. Modulation of oral drug bioavailability. *Cancer Invest* 2005; 23: 443-64 (NKI)

473. Kuppens IE, Van Maanen MJ, Rosing H, Schellens JHM, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. *Biomed Chromatogr* 2005; 19: 355-61 (NKI)

474. Kuppens IELM, Bosch TM, Van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JHM. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). *Cancer Chemother Pharmacol* 2005; 55: 72-8 (NKI)

475. Kwakkenbos MJ, Pouwels W, Matmati M, Stacey M, Lin HH, Gordon S, Van Lier RAW, Hamann J. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. *J Leukocyte Biol* 2005; 77(1): 112-119 (AMC)

476. Lagarde SM, Cense HA, Hulscher JBF, Tilanus HW, Ten Kate FJW, Obertop H, Van Lanschot JJB. Prospective analysis of patients with adenocarcinoma of the gastric cardia and lymph node metastasis in the proximal field of the chest. *Brit J Surg* 2005; 92(11): 1404-1408 (AMC)

477. Lagarde SM, Omlou JMT, De Jong K, Busch ORC, Obertop H, Van Lanschot JJB. Incidence and management of chyle leakage after esophagectomy. *Ann Thorac Surg* 2005; 80(2): 449-454 (AMC)

478. Lagerveld BW, Laguna MP, De Bruyne FMJ, De la Rosette JJMCH. Holmium:YAG laser for treatment of strictures of vesicourethral anastomosis after radical prostatectomy. *J Endourol* 2005; 19(4): 497-501 (AMC)

479. Laine ML, Morre SA, Murillo LS, van Winkelhoff AJ, Pena AS. CD14 and TLR4 gene polymorphisms

in adult periodontitis. *J Dent Res* 2005; 84(11): 1042-1046 (VUmc)

480. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. *Clin Cancer Res* 2005; 11: 5175-80 (NKI)

481. Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA, Gerritsen WR. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. *Cancer Res* 2005; 65(20): 9398-9405 (VUmc)

482. Lammers KM, Ouburg S, Morre SA, Crusius JB, Gionchetti P, Rizzello F, Morselli C, Caramelli E, Conte R, Morselli C, Campieri M, Pena AS. Combined carriage of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. *World J Gastroenterol* 2005; 11(46): 7323-7329 (VUmc)

483. Langendijk JA, Slotman BJ, Van der Waal I, Doornaert P, Berkof J, Leemans CR. Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. *Cancer* 2005; 104(7): 1408-1417 (VUmc)

484. Langerak P, Nygren AOH, Schouten JP, Jacobs H. Rapid and quantitative detection of homologous and non-homologous recombination events using three oligonucleotide MLPA. *Nucleic Acids Res* 2005; 33: e188 (NKI)

485. Laouar A, Haridas V, Vargad D, Zhinan X, Chaplin D, Van Lier RAW, Manjunath N. CD70(+) antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. *Nat Immunol* 2005; 6(7): 698-706 (AMC)

486. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. *Nat Cell Biol* 2005; 7: 126-36 (NKI)

487. Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, de Wit M, Edwards IR, Fries JF, Furst DE, Kirwan JR, Tugwell PS, Woodworth TG, Brooks PM. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. *J Rheumatol* 2005; 32(10): 2037-2041 (VUmc)

488. Lawlor KE, Wong PK, Campbell IK, van Rooijen N, Wicks IP. Acute CD4+ T lymphocyte-dependent

- interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor. *Arthritis Rheum* 2005; 52(12): 3749-3754 (VUmc)
- 489.** Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. *J Clin Oncol* 2005; 23: 576-84 (NKI)
- 490.** Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, Van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. *Lung Cancer* 2005; 47: 69-80 (NKI)
- 491.** Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. *Cardiovasc Res* 2005; 65: 599-608 (NKI)
- 492.** Lee YJ, Kusahara H, Jonker JW, Schinkel AH, Sugiyama Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. *J Pharmacol Exp Ther* 2005; 312: 44-52 (NKI)
- 493.** Leemans JC, Thepen T, Weijer S, Florquin S, Van Rooijen N, Van de Winkel JG, Van der Poll T. Macrophages play a dual role during pulmonary tuberculosis in mice. *J Infect Dis* 2005; 191(1): 65-74 (AMC/VUmc)
- 494.** Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, Arwert F, Mathew CG, Zdzienicka MZ, Hiom K, de Winter JP, Joenje H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. *Nat Genet* 2005; 37(9): 934-935 (VUmc)
- 495.** Lie-A-Ling M, Bakker CTM, Deurholt T, Hoekstra R, Wesseling JG, Afford SC, Bosma PJ, Roos A. Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma. *J Hepatol*; 44(1): 126-133 (AMC)
- 496.** Lie-A-Ling M, Bakker CT, Wesseling JG, Bosma PJ. AdEasy-based cloning system to generate tropism expanded replicating adenoviruses expressing transgenes late in the viral life cycle. *Gene Ther* 2005; 12(17): 1347-1352 (AMC)
- 497.** Lingg RM, Hempel G, Rots MG, van Zantwijk CH, Boos J, Kaspers GJ. Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. *Cancer Chemother Pharmacol* 2005; 56(3): 322-327 (VUmc)
- 498.** Linnoila RI, Naizhen X, Meuwissen R, Berns A, Demayo FJ. Mouse Lung Neuroendocrine Carcinomas: Distinct Morphologies, Same Transcription Factors. *Exp Lung Res* 2005; 31: 37-55 (NKI)
- 499.** Lintsen AM, Pasker-de Jong PC, De Boer EJ, Burger CW, Jansen CA, Braat DD, Van Leeuwen FE. Effects of subfertility cause, smoking and body weight on the success rate of IVF. *Hum Reprod* 2005; 20: 1867-75 (NKI)
- 500.** Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, Press MF, Rae J, Sledge GW, van't Veer L, Wicha M. Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. *Breast Cancer Res Treat* 2005; 90: 1-3 (NKI)
- 501.** Litjens SH, Wilhelmsen K, de Pereda JM, Perrakis A, Sonnenberg A. Modeling and experimental validation of the binary complex of the plectin actin-binding domain and the first pair of fibronectin type III (FNIII) domains of the beta4 integrin. *J Biol Chem* 2005; 280: 22270-7 (NKI)
- 502.** LJ, Benit-Deekman J, Van Kampen AHC, Baas F, Kool M. Full transcriptome analysis of rhabdomyosarcoma, normal and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. *Faseb J* 2005; 19(1): 404 (AMC)
- 503.** Lok CAR, Reekers JA, Westermann AM, Van der Velden J. Embolization for hemorrhage of liver metastases from choriocarcinoma. *Gynecol Oncol* 2005; 98(3): 506-509 (AMC)
- 504.** Loonen MP, Hage JJ, Kon M. Who benefits from peer review? An analysis of the outcome of 100 requests for review by Plastic and Reconstructive Surgery. *Plast Reconstr Surg* 2005; 116: 1461-72 (NKI)
- 505.** Lotz HT, Van Herk M, Betgen A, Pos F, Lebesque JV, Remeijer P. Reproducibility of the bladder shape and bladder shape changes during filling. *Med Phys* 2005; 32: 2590-7 (NKI)
- 506.** Lou DQ, Lesbordes JC, Nicolas G, Viatte L, Bennoun M, van Rooijen N, Kahn A, Renia L, Vaulont S. Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. *Hepatology* 2005; 41(5): 1056-1064 (VUmc)
- 507.** Löwenberg M, Tuynman JB, Bilderbeek J, Gaber T, Buttgerit F, Van Deventer SJH, Peppelenbosch MP, Hommes DW. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. *Blood* 2005; 106(5): 1703-1710 (AMC)
- 508.** Löwenberg M, Verhaar A, Van den Blink B, Ten Kate FJW, Van Deventer SJH, Peppelenbosch MP, Hommes DW. Specific inhibition of c-Raf activity by

semapimod induces clinical remission in severe Crohn's disease. *J Immunol* 2005; 175(4): 2293-2300 (AMC)

509. Luedeking A, Van Noorden CJF, Koehler A. Identification and characterisation of a multidrug resistance-related protein mRNA in the blue mussel *Mytilus edulis*. *Mar Ecol-Prog Ser* 2005; 286: 167-175 (AMC)

510. Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kastele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients. *J Clin Oncol* 2005; 23: 8978-91 (NKI)

511. Luppino FS, Pameijer FA, Balm AJM. Radiology quiz case 2. Laryngeal plasmacytoma in a patient with known multiple myeloma (MM). *Arch Otolaryngol Head Neck Surg* 2005; 131: 74 (NKI)

512. Lyons JM, Ito JI, Morre SA. The influence of vaginally applied imiquimod on the course of *Chlamydia trachomatis* serovar D infection in a murine model. *Infect Dis Obstet Gynecol* 2005; 13(1): 1-3 (VUmc)

513. Lyons JM, Ito JI, Pena AS, Morre SA. Differences in growth characteristics and elementary body associated cytotoxicity between *Chlamydia trachomatis* oculogenital serovars D and H and *Chlamydia muridarum*. *J Clin Pathol* 2005; 58(4): 397-401 (VUmc)

514. Lyons JM, Morre SA, Airo-Brown LP, Pena AS, Ito JI. Acquired homotypic and heterotypic immunity against oculogenital *Chlamydia trachomatis* serovars following female genital tract infection in mice. *BMC Infect Dis* 2005; 5: 105 (VUmc)

515. Lyons JM, Morre SA, Airo-Brown LP, Pena AS, Ito JI. Comparison of multiple genital tract infections with *Chlamydia trachomatis* in different strains of female mice. *J Microbiol Immunol Infect* 2005; 38(6): 383-393 (VUmc)

516. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. *Cancer Res* 2005; 65: 5730-9 (NKI)

517. Mackus WJM, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MHH, De Castro S de, Kipps TJ, Van Lier RAW, Van Oers MHJ, Eldering EF. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. *Leukemia* 2005; 19(3): 427-434 (AMC)

518. Madalinska JB, Hollenstein J, Bleiker E, Van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van

Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. *J Clin Oncol* 2005; 23: 6890-8 (NKI)

519. Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. *Hepatology* 2005; 42: 1091-8 (NKI)

520. Maris NA, De Vos AF, Bresser P, Van der Zee JS, Meijers JCM, Lijnen R, Levi M, Jansen HM, Van der Poll T. Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers. *Thromb Haemostasis* 2005; 93(6): 1036-1040 (AMC)

521. Maris NA, De Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, Van der Zee JS, Bresser P, Van der Poll T. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. *Am J Resp Crit Care* 2005; 172(9): 878-884 (AMC)

522. Markusic DM, Oude Elferink RJP, Das AT, Berkhout B, Seppen J. Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. *Nucleic Acids Res* 2005; 33(6): e63-e (AMC)

523. Marshall JC, Vincent JL, Guyatt G, Angus DC, Abraham E, Bernard G, Bombardier C, Calandra T, Jorgensen HS, Sylvester R, Boers M. Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. *Crit Care Med* 2005; 33(8): 1708-1716 (VUmc)

524. Marsman M, Jordens I, Griekspoor A, Neeffjes J. Chaperoning Antigen Presentation by MHC Class II Molecules and their Role in Oncogenesis. *Adv Cancer Res* 2005; 93: 129-58 (NKI)

525. Marsman WA, Buskens CJ, Wesseling JG, Van Lanschot JJB, Bosma PJ. Gene therapy for Barrett's esophagus: adenoviral gene transfer in different intestinal models. *Cancer Gene Ther* 2005; 12(9): 778-786 (AMC)

526. Marsman WA, Tytgat GNJ, Ten Kate FJW, Van Lanschot JJB. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. *J Surg Oncol* 2005; 92(3): 160-168 (AMC)

527. Marsman WA, Westerterp M, Heek NJ, Ten Kate FJW, Izbiccki JR, Van Lanschot JJB. Epithelial cells in bone marrow: do they matter? [letter]. *Gut* 2005; 54(12): 1821-1822 (AMC)

528. Marti R, Verschuuren JJGM, Buchman A, Hirano I, Tadesse S, Van Kuilenburg ABP, Van Gennip AH, Poorthuis BJHM, Hirano M. Late-onset MNGIE due to partial loss of thymidine phosphorylase activity. *Ann Neurol* 2005; 58(4): 649-652 (AMC)

529. Martin ST, Sato N, Dhara S, Chang R, Hustinx SR, Maitra A, Goggins M. Aberrant Methylation of the Human Hedgehog Interacting Protein (HHIP) Gene in Pancreatic Neoplasms. *Cancer Biol Ther* 2005; 4(7): 728-733 (AMC)
530. Maruyama K, Li M, Cursiefen C, Jackson DG, Keino H, Tomita M, van Rooijen N, Takenaka H, D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. *J Clin Invest* 2005; 115(9): 2363-2372 (VUmc)
531. Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. *Lung Cancer* 2005; 50: 83-6 (NKI)
532. Matter M, Mumprecht S, Pinschewer DD, Pavelic V, Yagita H, Krautwald S, Borst J, Ochsenbein AF. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. *Eur J Immunol* 2005; 35: 3229-39 (NKI)
533. Mauch P, Ng A, Aleman B, Carde P, Constine L, Diehl V, Dinshaw K, Gospodarowicz M, Hancock S, Hodgson D, Hoppe R, Liang R, Loeffler M, Specht L, Travis LB, Wirth A, Yahalom J. Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. *Eur J Haematol Suppl* 2005; 68-76 (NKI)
534. Mayer R, Hamilton-Farrell MR, van der Kleij AJ, Schmutz J, Granstrom G, Sicko Z, Melamed Y, Carl UM, Hartmann KA, Jansen EC, Ditri L, Sminia P. Hyperbaric oxygen and radiotherapy. *Strahlenther Onkol* 2005; 181(2): 113-123 (VUmc)
535. Mayer R, Sminia P, McBride WH, Stranzl H, Prettenhofer U, Fruhwirth J, Poschauko J. Lymphatic fistulas: obliteration by low-dose radiotherapy. *Strahlenther Onkol* 2005; 181(10): 660-664 (VUmc)
536. McSheehy PM, Port RE, Rodrigues LM, Robinson SP, Stubbs M, van der Born K, Peters GJ, Judson IR, Leach MO, Griffiths JR. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. *Cancer Chemother Pharmacol* 2005; 55(2): 117-128 (VUmc)
537. Mebius RE, Kraal G. Structure and function of the spleen. *Nat Rev Immunol* 2005; 5(8): 606-616 (VUmc)
538. Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, Steltenpool J, Stone S, Dokal I, Mathew CG, Hoatlin M, Joenje H, de Winter JP, Wang W. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. *Nat Genet* 2005; 37(9): 958-963 (VUmc)
539. Meij V, Zuetenhorst JM, Van Hillegersberg R, Kroger R, Prevoo W, Van Coevorden F, Taal BG. Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. *World J Surg Oncol* 2005; 3: 75 (NKI)
540. Meijer AH, Verbeek FJ, Salas-Vidal E, Corredor-Adamez M, Bussman J, van der Sar AM, Otto GW, Geisler R, Spaink HP. Transcriptome profiling of adult zebrafish at the late stage of chronic tuberculosis due to *Mycobacterium marinum* infection. *Mol Immunol* 2005; 42(10): 1185-1203 (VUmc)
541. Meijer GA, Oudejans JJ. Targeted therapies: who detects the target?. *Cell Oncol* 2005; 27(3): 165-167 (VUmc)
542. Meijer GA. Chromosomes and cancer, Boveri revisited. *Cell Oncol* 2005; 27(5-6): 273-275 (VUmc)
543. Meijer S, Fergusson WD, Oostra AB, Medhurst AL, Waisfisz Q, de Winter JP, Chen F, Carr TF, Clayton-Smith J, Clancy T, Green M, Barber L, Eden OB, Will AM, Joenje H, Taylor GM. A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations. *Genes Chromosomes Cancer* 2005; 42(4): 404-415 (VUmc)
544. Meijer S, van Liempt E, Imberty A, van Kooyk Y, Geyer H, Geyer R, van Die I. DC-SIGN mediates binding of dendritic cells to authentic pseudo-LewisY glycolipids of *Schistosoma mansoni* cercariae, the first parasite-specific ligand of DC-SIGN. *J Biol Chem* 2005; 280(45): 37349-37359 (VUmc)
545. Meijnen P, Peterse JL, Oldenburg HS, Woerdeman LA, Rutgers EJ. Changing patterns in diagnosis and treatment of ductal carcinoma in situ of the breast. *Eur J Surg Oncol* 2005; 31: 833-9 (NKI)
546. Mendez F, Munoz N, Posso H, Molano M, Moreno V, van den Brule AJ, Ronderos M, Meijer CJ, Munoz A. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. *J Infect Dis* 2005; 192(7): 1158-1165 (VUmc)
547. Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, Schinkel AH. Transport of anthelmintic benzimidazole drugs by Breast Cancer Resistance Protein (BCRP/ABCG2). *Drug Metab Dispos* 2005; 33: 614-8 (NKI)
548. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The Breast Cancer Resistance Protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion and milk secretion of the antibiotic nitrofurantoin. *Mol Pharmacol* 2005; 67: 1758-64 (NKI)
549. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Gender-dependent expression and activity of the ABC transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in liver. *Mol Pharmacol* 2005; 67: 1765-71 (NKI)

550. Merkel PA, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, Cuthbertson D, Felson DT, Hellmich B, Hoffman GS, Jayne DR, Kallenberg CG, Krischer J, Mahr A, Matteson EL, Specks U, Luqmani R, Stone J. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. *J Rheumatol* 2005; 32(12): 2488-2495 (VUmc)
551. Merks JHM, Caron HN, Hennekam RCM. High incidence of malformation syndromes in a series of 1,073 children with cancer. *Am J Med Genet* 2005; 134(2): 132-143 (AMC)
552. Mertens AE, Rygiel TP, Olivo C, van der Kammen R, Collard JG. The Rac activator Tiam1 controls tight junction biogenesis in keratinocytes through binding to and activation of the Par polarity complex. *J Cell Biol* 2005; 170: 1029-37 (NKI)
553. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, Dirks RW, Jochemsen AG. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. *Mol Cell* 2005; 18: 565-76 (NKI)
554. Meuwissen R, Berns A. Mouse models for human lung cancer. *Genes Dev* 2005; 19: 643-64 (NKI)
555. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. *Nature* 2005; 436: 720-4 (NKI)
556. Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, Mohar A, Pinedo HM, Lankelma J. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. *Clin Cancer Res* 2005; 11: 1863-9 (NKI/VUmc)
557. Middeldorp JM. Comment letter on "Virus-specific T-cells as therapy for nasopharyngeal carcinoma". *Enhancer Biotherapy of Cancer* 2005; 3(3): 18-21 (VUmc)
558. Minard ME, Herynk MH, Collard JG, Gallick GE. The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. *Oncogene* 2005; 24: 2568-73 (NKI)
559. Misaghi S, Galardy PJ, Meester WJ, Ovaa H, Ploegh HL, Gaudet R. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. *J Biol Chem* 2005; 280: 1512-20 (NKI)
560. Mochtar CA, Kiemeny LALM, Laguna MP, Van Riemsdijk MM, Barnett GS, Debruyne FMJ, De la Rosette JJMCH. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. *Urology* 2005; 65(2): 300-305 (AMC)
561. Moed H, von Blomberg BM, Bruynzeel DP, Scheper RJ, Gibbs S, Rustemeyer T. Regulation of nickel-induced T-cell responsiveness by CD4+CD25+ cells in contact allergic patients and healthy individuals. *Contact Dermatitis* 2005; 53(2): 71-74 (VUmc)
562. Moed H, von Blomberg BM, Bruynzeel DP, Scheper RJ, Gibbs S, Rustemeyer T. Improved detection of allergen-specific T-cell responses in allergic contact dermatitis through the addition of 'cytokine cocktails'. *Exp Dermatol* 2005; 14(8): 634-640 (VUmc)
563. Mohammadi T, Pietersz RN, Scholtalbers LA, Vandebroucke-Grauls CM, Savelkoul PH, Reesink HW. Optimal sampling time after preparation of platelet concentrates for detection of bacterial contamination by quantitative real-time polymerase chain reaction. *Vox Sang* 2005; 89(4): 208-214 (VUmc)
564. Mohammadi T, Pietersz RN, Vandebroucke-Grauls CM, Savelkoul PH, Reesink HW. Detection of bacteria in platelet concentrates: comparison of broad-range real-time 16S rDNA polymerase chain reaction and automated culturing. *Transfusion* 2005; 45(5): 731-736 (VUmc)
565. Mohammadi T, Reesink HW, Pietersz RN, Vandebroucke-Grauls CM, Savelkoul PH. Amplified-fragment length polymorphism analysis of *Propionibacterium* isolates implicated in contamination of blood products. *Br J Haematol* 2005; 131(3): 403-409 (VUmc)
566. Mohammadi T, Reesink HW, Vandebroucke-Grauls CM, Savelkoul PH. Removal of contaminating DNA from commercial nucleic acid extraction kit reagents. *J Microbiol Methods* 2005; 61(2): 285-288 (VUmc)
567. Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JH. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). *Cancer Chemother Pharmacol* 2005; 56: 344-50 (NKI)
568. Molano M, Meijer CJ, Weiderpass E, Arslan A, Posso H, Franceschi S, Ronderos M, Munoz N, van den Brule AJ. The natural course of *Chlamydia trachomatis* infection in asymptomatic Colombian women: a 5-year follow-up study. *J Infect Dis* 2005; 191(6): 907-916 (VUmc)
569. Molenkamp BG, Stadius Muller MG, Vuylsteke RJ, van der Sijp JR, Meijer S, van Leeuwen PA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. *Eur J Surg Oncol* 2005; 31(2): 211-212 (VUmc)
570. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos W, Wijnands PG, Scheper RJ, de Gruijl TD. Matched skin and sentinel lymph node samples

of melanoma patients reveal exclusive migration of mature dendritic cells. *Am J Pathol* 2005; 167(5): 1301-1307 (VUmc)

571. Molling JW, Kolgen W, van der Vliet HJ, Boomsma MF, Kruijzena H, Smorenburg CH, Molenkamp BG, Langendijk JA, Leemans CR, von Blomberg BM, Scheper RJ, van den Eertwegh AJ. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. *Int J Cancer* 2005; 116(1): 87-93 (VUmc)

572. Monfregola J, Cevenini A, Terracciano A, Van Vlies N, Arbucci S, Wanders RJA, Vaz FM, Ursini MV. Functional analysis of TMLH variants and definition of domains required for catalytic activity and mitochondrial targeting. *J Cell Physiol* 2005; 204(4): 839-847 (AMC)

573. Monsuur AJ, de Bakker PI, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E, Franke L, van't Slot R, van Belzen MJ, Lavrijsen IC, Diosdado B, Daly MJ, Mulder CJ, Mearin ML, Meijer JW, Meijer GA, van Oort E, Wapenaar MC, Koeleman BP, Wijmenga C. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. *Nat Genet* 2005; 37(12): 1341-1344 (VUmc)

574. Mooij MJ, Schouten I, Vos G, Van Belkum A, Vandenbroucke-Grauls CM, Savelkoul PH, Schultz C. Class 1 integrins in ciprofloxacin-resistant *Escherichia coli* strains from two Dutch hospitals. *Clin Microbiol Inf* 2005; 11(11): 898-902 (VUmc)

575. Moreno ML, Crusius JB, Chernavsky A, Sugai E, Sambuelli A, Vazquez H, Maurino E, Pena AS, Bai JC. The IL-1 gene family and bone involvement in celiac disease. *Immunogenetics* 2005; 57(8): 618-620 (VUmc)

576. Moreno SA, Moreno ML, Moreno FJ, Eguiluz C, van Rooijen N, Benito A. Experimental infection of immunomodulated NOD/LtSz-SCID mice as a new model for *Plasmodium falciparum* erythrocytic stages. *Parasitol Res* 2005; 95(2): 97-105 (VUmc)

577. Morgan NV, Essop F, Demuth I, de Ravel T, Jansen S, Tischkowitz MD, Lewis CM, Wainwright L, Poole J, Joenje H, Digweed M, Krause A, Mathew CG. A common Fanconi anemia mutation in black populations of sub-Saharan Africa. *Blood* 2005; 105(9): 3542-3544 (VUmc)

578. Morre SA, Spaargaren J, Fennema JS, de Vries HJ, Coutinho RA, Pena AS. Real-time polymerase chain reaction to diagnose lymphogranuloma venereum. *Emerg Infect Dis* 2005; 11(8): 1311-1312 (VUmc)

579. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. *Ann Surg* 2005; 242: 302-11 (NKI)

580. Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, Bron D, Meerwaldt JH, Van Glabbeke M, Raemaekers JM, Kluin-Nelemans HC. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. *Clin Lymphoma Myeloma* 2005; 6: 122-30 (NKI)

581. Mulder J, Ariaens A, van Horck FP, Moolenaar WH. Inhibition of RhoA-mediated SRF activation by p116(Rip). *FEBS Lett* 2005; 579: 6121-7 (NKI)

582. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, Luckner C, Doschko G, Soler G, Eichmann K, Muller FM, Ho AD, Goerner M, Modolell M. Arginase 1 is constitutively expressed in human granulocytes and participates in fungicidal activity. *Blood* 2005; 105: 2549-56 (NKI)

583. Munneke M, de Jong Z, Zwinderman AH, Runday HK, van Schaardenburg D, Dijkmans BA, Kroon HM, Vliet Vlieland TP, Hazes JM. Effect of a high-intensity weight-bearing exercise program on radiologic damage progression of the large joints in subgroups of patients with rheumatoid arthritis. *Arthritis Rheum* 2005; 53(3): 410-417 (VUmc)

584. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken JH, Jiwa NM, Jansen PM, Kluin-Nelemans HC, Ossenkuppele GJ, Gundy CM, Meijer CJ, Oudejans JJ. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. *Blood* 2005; 105(7): 2916-2923 (VUmc)

585. Mutsaerts EL, Van Ruth S, Zoetmulder FA, Rutgers EJT, Hart AA, Van Coevorden F. Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. *J Gastrointest Surg* 2005; 9: 178-86 (NKI)

586. Muylers-Chen I, Hernández-Muñoz I, Lund AH, Valk-Lingbeek ME, Van der Stoop P, Boutsma E, Tolhuis B, Bruggeman SWM, Taghavi P, Verhoeven E, Hulsman D, Noback S, Tanger E, Theunissen H, Van Lohuizen M. Emerging roles of Polycomb silencing in X-inactivation and stem cell maintenance. *Cold Spring Harb Symp Quant Biol* 2004; 69: 319-26 (NKI)

587. Naarding MA, Ludwig IS, Groot F, Berkhout B, Geijtenbeek TB, Pollakis G, Paxton WA. Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. *J Clin Invest* 2005; 115(11): 3256-3264 (VUmc)

588. Naiemi NA, Duim B, Savelkoul PH, Spanjaard L, de Jonge E, Bart A, Vandenbroucke-Grauls CM, de Jong MD. Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. *J Clin Microbiol* 2005; 43(9): 4862-4864 (VUmc)

589. Nannenber EA, Bijlmer RFGM, Van Geel BM, Hennekam RCM. Neonatal paroxysmal trismus and

camptodactyly: the Crisponi syndrome. *Am J Med Genet* 2005; 133(1): 90-92 (AMC)

590. Nauta AJ, De Haij S, Bottazzi B, Mantovani A, Borrias MC, Aten J, Rastaldi P, Daha MR, Van Kooten C, Roos A. Human renal epithelial cells produce the long pentraxin PTX3. *Kidney Int* 2005; 67(2): 543-553 (AMC)

591. Neijenhuis S, Begg AC, Vens C. Radiosensitization by a dominant negative to DNA polymerase beta is DNA polymerase beta-independent and XRCC1-dependent. *Radiother Oncol* 2005; 76: 123-8 (NKI)

592. Neijssen J, Herberts C, Drijfhout JW, Reits E, Janssen L, Neeffjes J. Cross-presentation by intercellular peptide transfer through gap junctions. *Nature* 2005; 434: 83-8 (NKI)

593. Nemmar A, Nemery B, Hoet PH, van Rooijen N, Hoylaerts MF. Silica particles enhance peripheral thrombosis: key role of lung macrophage-neutrophil cross-talk. *Am J Respir Crit Care Med* 2005; 171(8): 872-879 (VUmc)

594. Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M, Tolmachev V. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. *Eur J Nucl Med Mol I* 2005; 32(11): 1296-1304 (VUmc)

595. Neven N, Vis M, Voskuyl AE, Wolbink GJ, Nurmohamed MT, Dijkmans BA, Lems WF. Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice. *Ann Rheum Dis* 2005; 64(4): 645-646 (VUmc)

596. Newman J, Egan D, Walter TS, Meged R, Berry I, Ben Jelloul M, Sussman JL, Stuart DI, Perrakis A. Towards rationalization of crystallization screening for small- to medium-sized academic laboratories: the PACT/JCSG+ strategy. *Acta Crystallogr D Biol Crystallogr* 2005; 61: 1426-31 (NKI)

597. Neymark N, Lianes P, Smit EF, van Meerbeeck JP. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. *Pharmacoeconomics* 2005; 23(11): 1155-1166 (VUmc)

598. Nicke B, Bastien J, Khanna SJ, Warne PH, Cowling V, Cook SJ, Peters G, Delpuech O, Schulze A, Berns K, Mullenders J, Beijersbergen RL, Bernardis R, Ganesan TS, Downward J, Hancock DC. Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells 10. *Mol Cell* 2005; 20: 673-85 (NKI)

599. Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LVAM, Van der Wall EE, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, Van der Graaf WTA, TenVergert EM, Van Tinteren H, De Vries EGE. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. *J Clin Oncol* 2005; 23(33): 8296-8304 (AMC/NKI)

600. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden LA, Dijkmans BA, Hamann D. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. *Ann Rheum Dis* 2005; 64(8): 1199-1204 (VUmc)

601. Nielsen M, Franken PF, Reinards THCM, Weiss MM, Wagner A, Van der Klift H, Kloosterman S, Houwing-Duistermaat JJ, Aalfs CM, Ausems MGEM, Bröcker-Vriends AHJT, Gomez Garcia EB, Hoogerbrugge N, Menko FH, Sijmons RH, Verhoef S, Kuipers EJ, Morreau H, Breuning MH, Tops CM, Wijnen JT, Vasen HFA, Fodde R, Hes FJ. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP) [electronic letter]. *J Med Genet* 2005; 42(9), e54 (AMC/VUmc)

602. Nierkens S, Bleumink R, Bol M, Hassing I, van Rooijen N, Pieters R. The reactive D-glucopyranose moiety of streptozotocin is responsible for activation of macrophages and subsequent stimulation of CD8+ T cells. *Chem Res Toxicol* 2005; 18(5): 872-879 (VUmc)

603. Nieuwenhuijzen JA, Horenblas S, Bex A, Kerst JM, Schornagel JH, Van Tinteren H, Meinhardt W. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. *J Urol* 2005; 174: 80-5 (NKI)

604. Nieuwenhuijzen JA, Meinhardt W, Horenblas S. Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. *J Urol* 2005; 173: 1314-7 (NKI)

605. Nieuwenhuijzen JA, Pos F, Moonen LM, Hart AA, Horenblas S. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. *Eur Urol* 2005; 48: 239-45 (NKI)

606. Nieuwenhuis EE, Gillessen S, Scheper RJ, Exley MA, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Blumberg RS, Wilson SB. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. *Exp Dermatol* 2005; 14(4): 250-258 (VUmc)

607. Nieuwenhuis EJ, Van der Waal I, Leemans CR, Kummer JA, Pijpers R, Castelijns JA, Brakenhoff RH, Snow GB. Histopathologic validation of the sentinel node concept in oral and oropharyngeal squamous cell carcinoma. *Head Neck* 2005; 27(2): 150-158 (VUmc)

608. Nieveen van Dijkum EJM, Kuhlmann KFD, Terwee CB, Obertop H, De Haes JCJM, Gouma DJ. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. *Brit J Surg* 2005; 92(4): 471-477 (AMC)

609. Nieweg OE, Van Rijk MC, Valdes Olmos RA, Hoefnagel CA. Sentinel node biopsy and selective lymph node clearance--impact on regional control

- and survival in breast cancer and melanoma 281. *Eur J Nucl Med Mol Imaging* 2005; 32: 631-4 (NKI)
- 610.** Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R. The Deubiquitinating Enzyme USP1 Regulates the Fanconi Anemia Pathway. *Mol Cell* 2005; 17: 331-9 (NKI)
- 611.** Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A genomic and functional inventory of deubiquitinating enzymes 18. *Cell* 2005; 123: 773-86 (NKI)
- 612.** Nikolic T, Geutskens SB, van Rooijen N, Drexhage HA, Leenen PJ. Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulinitis of the nonobese diabetic mouse: a phagocyte depletion study. *Lab Invest* 2005; 85(4): 487-501 (VUmc)
- 613.** Nolte MA, Arens R, Van Os R, Van Oosterwijk M, Hooibrink B, Van Lier RAW, Van Oers MHJ. Immune activation modulates hematopoiesis through interactions between CD27 and CD70. *Nat Immun* 2005; 6(4): 412-418 (AMC)
- 614.** Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, Marshall GM, Allen JD, Haber M. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. *Mol Cancer Ther* 2005; 4: 547-53 (NKI/VUmc)
- 615.** Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. *Drugs* 2005; 65(5): 661-694 (VUmc)
- 616.** Obertop H. How surgeons make decisions: authority and evidence. *Ann Surg* 2005; 242(6): 753-756 (AMC)
- 617.** Oestreicher N, Ramsey SD, Linden HM, McCune JS, Van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? *Genet Med* 2005; 7: 380-9 (NKI)
- 618.** Oey NA, Den Boer MEJ, Wijburg FA, Vekemans M, Augé J, Steiner C, Wanders RJA, Waterham HR, Ruiters JPN, Attié-Bitach T. Long-chain fatty acid oxidation during early human development. *Pediatr Res* 2005; 57(6): 755-759 (AMC)
- 619.** Oey NA, Ijlst L, Van Roermund CWT, Wijburg FA, Wanders RJA. dif-1 and colt, both implicated in early embryonic development, encode carnitine acylcarnitine translocase. *Mol Genet Metab* 2005; 85(2): 121-124 (AMC)
- 620.** Oezen I, Rossmanith W, Forss-Petter S, Kemp S, Voigtländer T, Moser-Thier K, Wanders RJA, Bittner RE, Berger J. Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency. *Hum Mol Genet* 2005; 14(9): 1127-1137 (AMC)
- 621.** Olie KH, Goodship THJ, Verlaak R, Florquin S, Groothoff JW, Strain L, Weening JJ, Davin JCMA. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. *Am J Kidney Dis* 2005; 45(1), e12-e15 (AMC)
- 622.** Olivier RI, Lubsen-Brandtsma LA, Van Boven H, Van Beurden M. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? *Gynecol Oncol* 2005; 96: 439-43 (NKI)
- 623.** Oostenbrug LE, Drenth JPH, De Jong DJ, Nolte IM, Oosterom E, Van Dullemen HM, Van der Linde K, Te Meerman GJ, Van der Steege G, Kleibeuker JH, Jansen PLM. Association between Toll-like receptor 4 and inflammatory bowel disease. *Inflamm Bowel Dis* 2005; 11(6): 567-575 (AMC)
- 624.** Oosterhoff D, Overmeer RM, de Graaf M, van der Meulen I, Giaccone G, van Beusechem VW, Haisma HJ, Pinedo HM, Gerritsen WR. Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. *Br J Cancer* 2005; 92(5): 882-887 (VUmc)
- 625.** Oosterhoff D, Pinedo HM, Witlox MA, Carette JE, Gerritsen WR, van Beusechem VW. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. *Gene Ther* 2005; 12(12): 1011-1018 (VUmc)
- 626.** Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, Meijer S, van der Sijp JR, Beelen RH, van Egmond M. Macrophages direct tumour histology and clinical outcome in a colon cancer model. *J Pathol* 2005; 207(2): 147-155 (VUmc)
- 627.** Oosterling SJ, van der Bij GJ, van Egmond M, van der Sijp JR. Surgical trauma and peritoneal recurrence of colorectal carcinoma. *Eur J Surg Oncol* 2005; 31(1): 29-37 (VUmc)
- 628.** Oostra RJ, Hennekam RCM, De Rooij L, Moorman AFM. Malformations of the axial skeleton in Museum Vrolik I: homeotic transformations and numerical anomalies. *Am J Med Genet* 2005; 134A(3): 268-281 (AMC)
- 629.** Oostra RJ, Van der Wolk JP, Maas M, Hennekam RCM. Malformations of the axial skeleton in the Museum Vrolik: II: Craniosynostoses and suture-related conditions. *Am J Med Genet* 2005; 136A(4): 327-342 (AMC)
- 630.** Op de Coul BM, Ackerstaff AH, As-Brooks CJ, van den Hoogen FJ, Meeuwis CA, Manni JJ, Hilgers FJM. Compliance, quality of life and quantitative voice quality aspects of hands-free speech. *Acta Otolaryngol* 2005; 125: 629-37 (NKI)

- 631.** Op de Coul BM, Ackerstaff AH, van As CJ, van den Hoogen FJ, Meeuwis CA, Manni JJ, Hilgers FJ. Quality of life assessment in laryngectomized individuals: do we need additions to standard questionnaires in specific clinical research projects? *Clin Otolaryngol* 2005; 30: 169-75 (NKI)
- 632.** Ossendorp F, Fu N, Camps M, Granucci F, Gobin SJ, van den Elsen PJ, Schuurhuis D, Adema GJ, Lipford GB, Chiba T, Sijts A, Kloetzel PM, Ricciardi-Castagnoli P, Melief CJ. Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. *J Immunol* 2005; 174(12): 7815-7822 (VUmc)
- 633.** Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, van de Winkel JG, van Egmond M. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. *J Immunol* 2005; 174(9): 5472-5480 (VUmc)
- 634.** Ouburg S, Bart AC, Klinkenberg-Knol EC, Mulder CJ, Salvador PA, Morre SA. A candidate gene approach of immune mediators effecting the susceptibility to and severity of upper gastrointestinal tract diseases in relation to *Helicobacter pylori* and Epstein-Barr virus infections. *Eur J Gastroen Hepat* 2005; 17(11): 1213-1224 (VUmc)
- 635.** Ouburg S, Mallant-Hent R, Crusius JB, van Bodegraven AA, Mulder CJ, Linskens R, Pena AS, Morre SA. The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the *Saccharomyces cerevisiae* mannan-LBP-CD14-TLR4 pathway. *Gut* 2005; 54(3): 439-440 (VUmc)
- 636.** Ouburg S, Spaargaren J, den Hartog JE, Land JA, Fennema JS, Pleijster J, Pena AS, Morre SA. The CD14 functional gene polymorphism -260 C>T is not involved in either the susceptibility to *Chlamydia trachomatis* infection or the development of tubal pathology. *BMC Infect Dis* 2005; 5: 114 (VUmc)
- 637.** Oude Elferink RPJ. Manipulation of biliary lipids by gene therapy: potential consequences for patients with progressive familial intrahepatic cholestasis. *Curr Drug Targets* 2005; 5(2): 199-202 (AMC)
- 638.** Oudejans JJ, Harijadi A, Cillessen SA, Busson P, Tan IB, Dukers DF, Vos W, Hariwiyanto B, Middeldorp J, Meijer CJ. Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome. *Mod Pathol* 2005; 18: 877-85 (NKI/VUmc)
- 639.** Oudejans JJ, Muris JJ, Meijer CJ. Inhibition of caspase 9 and not caspase 8 mediated apoptosis may determine clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. *Cell Cycle* 2005; 4(4): 526-528 (VUmc)
- 640.** Oudesluijs GG, Hordijk R, Boon M, Sijens PE, Hennekam RCM. Plantar lipomatosis, unusual facies, and developmental delay: confirmation of Pierpont syndrome. *Am J Med Genet* 2005; 137(1): 77-80 (AMC)
- 641.** Oumlker G, Rodenhuis S. Early onset of oral aphthous ulcers with weekly docetaxel. *Neth J Med* 2005; 63: 364-6 (NKI)
- 642.** Ouwehand K, De Ruijter AJM, Van Bree C, Caron HN, Van Kuilenburg ABP. Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. *Febs Lett* 2005; 579(6): 1523-1528 (AMC)
- 643.** Ovaa H, Galardy PJ, Ploegh HL. Mechanism-based proteomics tools based on ubiquitin and ubiquitin-like proteins: synthesis of active site-directed probes. *Methods Enzymol* 2005; 399: 468-78 (NKI)
- 644.** Ozgen H, Overweg-Plandsoen WCG, Bleeck-Pelk J, Besselaar PP, Hennekam RCM. Cerebellar hypoplasia-endosteal sclerosis: a long term follow-up. *Am J Med Genet* 2005; 134(2), 215-219 (AMC)
- 645.** Pannekoek Y, Spaargaren J, Langerak AA, Merks J, Morre SA, van der Ende A. Interrelationship between polymorphisms of *inca*, fusogenic properties of *Chlamydia trachomatis* strains, and clinical manifestations in patients in The Netherlands. *J Clin Microbiol* 2005; 43(5): 2441-2443 (VUmc)
- 646.** Pasic A, Brokx HA, Comans EF, Herder CJ, Risse EK, Hoekstra OS, Postmus PE, Sutedja GT. Detection and staging of preinvasive lesions and occult lung cancer in the central airways with 18F-fluorodeoxyglucose positron emission tomography: a pilot study. *Clin Cancer Res* 2005; 11(17): 6186-6189 (VUmc)
- 647.** Pasic A, Grunberg K, Mooi WJ, Paul MA, Postmus PE, Sutedja GT. The natural history of carcinoma in situ involving bronchial resection margins. *Chest* 2005; 128(3): 1736-1741 (VUmc)
- 648.** Patiwaal JA, Wintzen M, Rustemeyer T, Bruynzeel DP. Airborne irritant contact dermatitis due to synthetic fibres from an air-conditioning filter. *Contact Dermatitis* 2005; 52(3): 126-129 (VUmc)
- 649.** Pavsek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, Schinkel AH. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. *J Pharmacol Exp Ther* 2005; 312: 144-52 (NKI)
- 650.** Peeters ST, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PC, Lebesque JV. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2005; 63: 1142-52 (NKI)

- 651.** Peeters STH, Heemsbergen WD, Van Putten WLJ, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PCM. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. *Int J Radiat Oncol Biol Phys* 2005; 61: 1019-34 (NKI)
- 652.** Pellis-van Berkel W, Verheijen MHG, Cuppen E, Asahina M, de Rooij J, Jansen G, Plasterk RHA, Bos JL, Zwartkruis FJT. Requirement of the *Caenorhabditis elegans* RapGEF pxf-1 and rap-1 for epithelial integrity. *Mol Biol Cell* 2005; 16: 106-16 (NKI)
- 653.** Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. *J Nucl Med* 2005; 46(11): 1898-1906 (VUmc)
- 654.** Peters FP, Kara MA, Rosmolen WD, Aalders MCG, Ten Kate FJW, Bultje AC, Krishnadath KK, Fockens P, Van Lanschot JJB, Van Deventer SJH, Bergman JJGHM. Endoscopic resection combined with photodynamic therapy for high grade dysplasia and early cancer in Barrett's esophagus. *Gastrointest Endosc* 2005; 61(4): 506-514 (AMC)
- 655.** Peters FP, Kara MA, Rosmolen WD, Aalders MCG, Ten Kate FJW, Krishnadath KK, Van Lanschot JJB, Fockens P, Bergman JJGHM. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. *Endoscopy* 2005; 37(5): 418-424 (AMC)
- 656.** Peters GJ, Hooijberg JH, Kaspers GJ, Jansen G. Folates and antifolates in the treatment of cancer: role of folic acid supplementation on efficacy of folate and non-folate drugs. *Trends in Food Science & Technology* 2005; 16: 289-297 (VUmc)
- 657.** Petersen MA, Groenvold M, Aaronson N, Brenne E, Fayers P, Nielsen JD, Sprangers M, Bjorner JB. Scoring based on item response theory did not alter the measurement ability of EORTC QLQ-C30 scales. *J Clin Epidemiol* 2005; 58: 902-8 (NKI)
- 658.** Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, Meijer CJ, Courville P, Joly P, Grange F, De Muret A, Machet L, Dompnmartin A, Bosq J, Durlach A, Bernard P, Dalac S, Dechelotte P, D'Incan M, Wechsler J, Teitell MA. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. *Am J Clin Pathol* 2005; 123(5): 662-675 (VUmc)
- 659.** Phoa SSKS, Tilleman EHB, Van Delden OM, Bossuyt PMM, Gouma DJ, Laméris JS. Value of CT criteria in predicting survival in patients with potentially resectable pancreatic head carcinoma. *J Surg Oncol* 2005; 91(1): 33-40 (AMC)
- 660.** Pichler A, Knipscheer P, Oberhofer E, van Dijk WJ, Korner R, Olsen JV, Jentsch S, Melchior F, Sixma TK. SUMO modification of the ubiquitin-conjugating enzyme E2-25K. *Nat Struct Mol Biol* 2005; 12: 264-9 (NKI)
- 661.** Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnicka-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. *Clin Cancer Res* 2005; 11: 4487-94 (NKI)
- 662.** Pioche-Durieu C, Keryer C, Souquere S, Bosq J, Faigle W, Loew D, Hirashima M, Nishi N, Middeldorp JM, Busson P. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. *J Virol* 2005; 79(21): 13326-13337 (VUmc)
- 663.** Piriou E, Jansen CA, Van Dort K, De Cuyper I, Nanlohy NM, Lange JMA, Van Oers MHJ van, Miedema F, Van Baarle D. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. *J Immunol* 2005; 175(3): 2010-2017 (AMC)
- 664.** Piriou E, Van Dort K, Nanlohy NM, Van Oers MHJ, Miedema F, Van Baarle D. Loss of EBNA1-specific memory CD4(+) and CD8(+) T cells in HIV-infected patients progressing to AIDS-related non-hodgkin lymphoma. *Blood* 2005; 106(9): 3166-3174 (AMC)
- 665.** Plaat RE, de Bree R, Kuik DJ, van den Brekel MW, van Hattum AH, Snow GB, Leemans CR. Prognostic importance of paratracheal lymph node metastases. *Laryngoscope* 2005; 115(5): 894-898 (NKI/VUmc)
- 666.** Ploeger LS, Huisman A, van der Gugten J, van der Giezen DM, Belien JA, Abbaker AY, Dullens HF, Grizzle W, Poulin NM, Meijer GA, van Diest PJ. Implementation of accurate and fast DNA cytometry by confocal microscopy in 3D. *Cell Oncol* 2005; 27(4): 225-230 (VUmc)
- 667.** Poland DC, Vallejo JJ, Niessen HW, Nijmeyer R, Calafat J, Hack CE, Het Hof B, Van Dijk W. Activated human PMN synthesize and release a strongly fucosylated glycoform of α 1-acid glycoprotein, which is transiently deposited in human myocardial infarction. *J Leukoc Biol* 2005; 78: 453-61 (NKI)
- 668.** Polderman MC, Wintzen M, le Cessie S, Pavel S. UVA-1 cold light therapy in the treatment of atopic dermatitis: 61 patients treated in the Leiden University Medical Center. *Photodermatol Photoimmunol Photomed* 2005; 21(2): 93-96 (VUmc)
- 669.** Poortmans PM, Ataman F, Davis JB, Bartelink H, Horiot JC, Pierart M, Collette L, van Tienhoven G. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. *Radiother Oncol* 2005; 76: 278-84 (NKI)

- 670.** Pos F, Horenblas S, Dom P, Moonen L, Bartelink H. Organ preservation in invasive bladder cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment? *Int J Radiat Oncol Biol Phys* 2005; 61: 678-86 (NKI)
- 671.** Pos F, Moonen L. Brachytherapy in the treatment of invasive bladder cancer. *Semin Radiat Oncol* 2005; 15: 49-54 (NKI)
- 672.** Postma C, Hermsen MA, Coffa J, Baak JP, Mueller JD, Mueller E, Bethke B, Schouten JP, Stolte M, Meijer GA. Chromosomal instability in flat adenomas and carcinomas of the colon. *J Pathol* 2005; 205(4): 514-521 (VUmc)
- 673.** Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. *Eur J Cancer* 2005; 41(8): 1135-1139 (NKI/VUmc)
- 674.** Postmus PE. Bronchoscopy for lung cancer. *Chest* 2005; 128(1): 16-18 (VUmc)
- 675.** Postmus PE. Second-line for small cell lung cancer: how-to-do-it?. *Lung Cancer* 2005; 48(2): 263-265 (VUmc)
- 676.** Postmus PE. The future of lung cancer and mesothelioma. *Hospital Pharmacy Europe* 2005; 20: 61-62 (VUmc)
- 677.** Press RR, Buckle T, Beijnen JH, Van Tellingen O. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. *Cancer Chemother Pharmacol* 2005; 1-7 (NKI)
- 678.** Preti M, van Seters M, Sideri M, Van Beurden M. Squamous Vulvar Intraepithelial Neoplasia. *Clin Obstet Gynecol* 2005; 48: 845-61 (NKI)
- 679.** Prieur X, Schaap FG, Coste H, Rodriguez JC. Hepatocyte nuclear factor-4alpha regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-gamma coactivator-1alpha, AMP-activated protein kinase, and mitogen-activated protein kinase pathway. *Mol Endocrinol* 2005; 19(12): 3107-3125 (AMC)
- 680.** Prins HA, Meijer CJ, Boelens PG, Nijveldt RJ, Siroen MP, Masson S, Daveau M, Scotte M, Diks J, van Leeuwen PA. The role of Kupffer cells after major liver surgery. *J Parenter Enteral Nutr* 2005; 29(1): 48-55 (VUmc)
- 681.** Pritchard J, Cotterill SJ, Germond SM, Imeson J, De Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European neuroblastoma study group. *Pediatr Blood Cancer* 2005; 44(4): 348-357 (AMC)
- 682.** Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ. A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. *J Clin Pathol* 2005; 58(5): 493-499 (VUmc)
- 683.** Quante M, Heeg S, von Werder A, Goessel G, Fulda C, Doebele M, Nakagawa H, Beijersbergen R, Blum HE, Opitz OG. Differential transcriptional regulation of human telomerase in a cellular model representing important genetic alterations in esophageal squamous carcinogenesis. *Carcinogenesis* 2005; 26: 1879-89 (NKI)
- 684.** Raa ST, Oosterling SJ, van der Kaaij NP, van den Tol MP, Beelen RH, Meijer S, van Eijck CH, van der Sijp JR, van Egmond M, Jeekel J. Surgery promotes implantation of disseminated tumor cells, but does not increase growth of tumor cell clusters. *J Surg Oncol* 2005; 92(2): 124-129 (VUmc)
- 685.** Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheper RJ, Scheffer GL, de Witte TJ, Raymakers RA. Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia. *Clin Cancer Res* 2005; 11(6): 2436-2444 (VUmc)
- 686.** Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheffer GL, Scheper RJ, de Witte TJ, Raymakers RA. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. *Leuk Res* 2005; 29(12): 1455-1458 (VUmc)
- 687.** Rademaker-Lakhai JM, Cruil M, Pluim D, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. *Anticancer Drugs* 2005; 16: 1029-36 (NKI)
- 688.** Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JHM. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. *Clin Cancer Res* 2005; 11: 1854-62 (AMC/NKI)
- 689.** Rades D, Stalpers LJA, Hulshof MCCM, Borgmann K, Karstens JH, Koning CCE, Alberti W. Comparison of 1 x 8 Gy and 10 x 3 Gy for functional outcome in patients with metastatic spinal cord compression. *Int J Radiat Oncol* 2005; 62(2): 514-518 (AMC)
- 690.** Rades D, Stalpers LJA, Hulshof MCCM, Zschenker O, Alberti W, Koning CCE. Effectiveness and toxicity of single-fraction radiotherapy with 1 x 8 Gy for metastatic spinal cord compression. *Radiother Oncol* 2005; 75(1): 70-73 (AMC)
- 691.** Rades D, Stalpers LJA, Veninga T, Schulte R, Hoskin PJ, Obralic N, Bajrovic A, Rudat V, Schwarz R, Hulshof MCCM, Poortmans P, Schild SE. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord

- compression. *J Clin Oncol* 2005; 23(12): 3366-3375 (AMC)
- 692.** Rasch C, Steenbakkers R, Van Herk M. Target definition in prostate, head, and neck. *Semin Radiat Oncol* 2005; 15: 136-45 (NKI)
- 693.** Raymond K, Kreft M, Janssen H, Calafat J, Sonnenberg A. Keratinocytes display normal proliferation, survival and differentiation in conditional β 4-integrin knockout mice. *J Cell Sci* 2005; 118: 1045-60 (NKI)
- 694.** Rea DW, Nortier JWR, Ten Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, De Bakker J, Semiond D, Kerr DJ, Punt CJA. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. *Ann Oncol* 2005; 16(7): 1123-1132 (AMC)
- 695.** Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 2005; 23: 7804-10 (NKI)
- 696.** Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, Geurts-Moespot A, Visser MC, Taphoorn MJ. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. *Neurology* 2005; 65: 1120-2 (NKI)
- 697.** Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease [editorial]. *Lancet* 2005; 365(9459) (AMC)
- 698.** Renckens R, Roelofs DJTH, De Waard V, Florquin S, Lijnen R, Carmeliet P, Van der Poll T. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. *J Thromb Haemost* 2005; 3(5): 1018-1025 (AMC)
- 699.** Renckens R, Roelofs DJTH., Ter Horst SAJ, Van 't Veer C, Havik SR, Florquin S, Wagenaar GTM, Meijers JCM, Van der Poll T. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. *J Immunol* 2005; 175(10): 6764-6771 (AMC)
- 700.** Rensing ME, Van Leeuwen D, Verreck FAW, Keating S, Gomez R, Franken K, Ottenhof THM, Spriggs M, Schumacher TNM, Hutt-Fletcher LM, Rowe M, Wiertz EJHJ. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble s-gp42 that mediates HLA class II immune evasion. *J Virol* 2005; 79: 841-52 (NKI)
- 701.** Reuchlin-Vroklage LM, Bierma-Zeinstra SMA, Benninga MA, Berger MY. Diagnostic value of abdominal radiography in constipated children: a systematic review. *Arch Pediat Adom Med* 2005; 159(7): 671-678 (AMC)
- 702.** Richters CD, Hoekstra MJ, du Pont JS, Kreis RW, Kamperdijk EW. Immunology of skin transplantation. *Clin Dermatol* 2005; 23(4): 338-342 (VUmc)
- 703.** Riemersma SA, Oudejans JJ, Vonk MJ, Dreef EJ, Prins FA, Jansen PM, Vermeer MH, Blok P, Kibbelaar RE, Muris JJ, Schuurin EM, Kluijn PM. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. *J Pathol* 2005; 206(3): 328-336 (VUmc)
- 704.** Rittersma SZH, Kremer Hovinga JA, Koch KT, Boekholdt SM, Van Aken BE, Scheepmaker A, Bax M, Schotborgh CE, Piek JJ, Tijssen JGP, Reitsma PH, De Winter RJ. Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and Toll-like receptor 4 gene polymorphisms. *Clin Chem* 2005; 51(3): 516-521 (AMC)
- 705.** Rodenhuis S. Is high-dose chemotherapy dead? [Editorial comment]. *Eur J Cancer* 2005; 41: 9-11 (NKI)
- 706.** Roelfsema JH, White SJ, Ariyürek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, Den Dunnen JT, Van Ommen GJB, Breuning MH, Hennekam RCM, Peters DJM. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. *Am J Hum Genet* 2005; 76(4): 572-580 (AMC)
- 707.** Roepman P, Wessels LFA, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, Reinders MJ, Slootweg PJ, Holstege FCP. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. *Nat Genet* 2005; 37: 182-6 (NKI)
- 708.** Ronco G, Ghisetti V, Segnan N, Snijders PJ, Gillio-Tos A, Meijer CJ, Merletti F, Franceschi S. Prevalence of human papillomavirus infection in women in Turin, Italy. *Eur J Cancer* 2005; 41(2): 297-305 (VUmc)
- 709.** Rook EJ, Hillebrand MJX, Rosing H, van Ree JM, Beijnen JH. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2005; 824: 213-21 (NKI)
- 710.** Rothem L, Berman B, Stark M, Jansen G, Assaraf YG. The reduced folate carrier gene is a novel selectable marker for recombinant protein overexpression. *Mol Pharmacol* 2005; 68(3): 616-624 (VUmc)
- 711.** Rouschop KMA, Roelofs DJTH, Claessen N, Da Costa Martins P, Zwaginga JJ, Pals ST, Weening JJ, Florquin S. Protection against renal ischemia reperfusion injury by CD44 disruption. *J Am Soc Nephrol* 2005; 16(7): 2034-2043 (AMC)

712. Rowland BD, Bernardis R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. *Nat Cell Biol* 2005; 7: 1074-82 (NKI)
713. Rozendaal L, Le Cessie S, Hennekam RCM. Growth-reductive therapy in children with marfan syndrome. *J Pediatr* 2005; 147(5): 674-679 (AMC)
714. Rutgers EJT. Guidelines to assure quality in breast cancer surgery. *Eur J Surg Oncol* 2005; 31: 568-76 (NKI)
715. Samsom JN, van Berkel LA, van Helvoort JM, Unger WW, Jansen W, Thepen T, Mebius RE, Verbeek SS, Kraal G. Fc gamma RIIB regulates nasal and oral tolerance, a role for dendritic cells. *J Immunol* 2005; 174(9): 5279-5287 (VUmc)
716. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. *Eur J Hum Genet* 2005; 13: 731-41 (NKI)
717. Sanders RJ, Ofman R, Valianpour F, Kemp S, Wanders RJA. Evidence for two enzymatic pathways for omega-oxidation of docosanoic acid in rat liver microsomes. *J Lipid Res* 2005; 46(5): 1001-1008 (AMC)
718. Scagliotti GV, Smit EF, Bosquee L, O'Brien M, Ardizzone A, Zatlouk P, Eberhardt-Geirnaerd M, de Bruin HG, Dussenne S, Legrand C, Giaccone G. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). *Lung Cancer* 2005; 50(1): 91-96 (VUmc)
719. Schaaf GJ, Ruijter JM, Van Ruissen F, Zwijnenburg PJG, Waaijer RJA, Valentijn
720. Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands E, Gimeno R, Vyth-Dreese FA, Blom B, Spits H. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. *Nat Immunol* 2005; 6(3): 303-313 (AMC/NKI)
721. Schellens JH. Challenges of oral chemotherapy. *Clin Adv Hematol Oncol* 2005; 3: 99-100 (NKI)
722. Schepers K, Arens R, Schumacher TN. Dissection of cytotoxic and helper T cell responses. *Cell Mol Life Sci* 2005; 62: 2695-710 (NKI)
723. Schimmel K, Bennink RJ, De Bruin K, Leen R, Sand K, Van den Hoff MJB, Van Kuilenburg ABP, Vanderheyden J-L, Steinmetz N, Pfaffendorf M, Verschuur AC, Guchelaar HJ. Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats. *Arch Toxicol* 2005; 79(5): 268-276 (AMC)
724. Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. *EMBO Rep* 2005; 6: 866-72 (NKI)
725. Schmieg J, Yang G, Franck RW, van Rooijen N, Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. *Proc Natl Acad Sci USA* 2005; 102(4): 1127-1132 (VUmc)
726. Schnater JM, Kuijper CF, Zsiros J, Heij HA, Aronson DC. Pre-operative diagnostic biopsy and surgery in paediatric liver tumours--the Amsterdam experience. *Eur J Surg Oncol* 2005; 31(10): 1160-1165 (AMC)
727. Schnater JM, Schouten-van Meeteren AY, Heins YM, Aronson DC. Hepatoblastoma in a patient with a partial trisomy 9p syndrome: a case report. *Cancer Genet Cytogenet* 2005; 156(1): 77-79 (AMC/VUmc)
728. Schnater JM, Zalen-Sprock RM, Schaap AHP, Festen S, Aronson DC. Ileal atresia and thromboembolic liver calcifications diagnosed after treatment with intrauterine laser coagulation therapy for twin-to-twin transfusion syndrome: report of 2 cases. *J Pediatr Surg* 2005; 40(5): 875-876 (AMC)
729. Schneider E, Machavoine F, Pleau JM, Bertron AF, Thurmond RL, Ohtsu H, Watanabe T, Schinkel AH, Dy M. Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. *J Exp Med* 2005; 202: 387-93 (NKI)
730. Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. *Cancer Chemother Pharmacol* 2005; 55: 263-70 (NKI)
731. Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, Veenbergen S, Meijer CJ, Hooijberg E. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. *Clin Immunol* 2005; 114(2): 119-129 (VUmc)
732. Schooten E, Klous P, van den Elsen PJ, Holling TM. Lack of MHC-II expression in activated mouse T cells correlates with DNA methylation at the CIITA-PIII region. *Immunogenetics* 2005; 57(10): 795-799 (VUmc)
733. Schraders M, De Jong D, Kluin P, Groenen P, van Krieken H. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. *J Pathol* 2005; 205: 329-35 (NKI)
734. Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Van Limpt V, Sievert H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. *Cancer Lett* 2005; 228(1-2): 143-153 (AMC)

735. Schreuder MI, Hoeve MA, Groothuis L, Boot H, Boerrigter LH, De Jong D, Veenendaal RA, Jansen JH, Van Krieken JHJM. Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. *Br J Haematol* 2005; 131: 619-23 (NKI)
736. Schreurs MW, Hermsen MA, Geltink RI, Scholten KB, Brink AA, Kueter EW, Tijssen M, Meijer CJ, Ylstra B, Meijer GA, Hooijberg E. Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes. *Blood* 2005; 106(8): 2663-2670 (VUmc)
737. Schreurs MW, Kueter EW, Scholten KB, Kramer D, Meijer CJ, Hooijberg E. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. *Cancer Immunol Immun* 2005; 54(7): 703-712 (VUmc)
738. Schreurs MW, Kueter EW, Scholten KB, Lemonnier FA, Meijer CJ, Hooijberg E. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. *Vaccine* 2005; 23(31): 4005-4010 (VUmc)
739. Schrier BPh, Laguna MP, Van der Pal F, Isorna S, Witjes JA. Comparison of orthotopic sigmoid and ileal neobladders: continence and urodynamic parameters. *Eur Urol* 2005; 47(5): 679-685 (AMC)
740. Schuurman T, van Breda A, de Boer R, Kooistra-Smid M, Beld M, Savelkoul PH, Boom R. Reduced PCR sensitivity due to impaired DNA recovery with the MagNA Pure LC total nucleic acid isolation kit. *J Clin Microbiol* 2005; 43(9): 4616-4622 (VUmc)
741. Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, le Sage C, Chen BP, Chen DJ, Agami R, Kerem B. Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. *Genes Dev* 2005; 19: 2715-26 (NKI)
742. Schwarz M, Alber M, Lebesque JV, Mijnheer BJ, Damen EM. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2005; 62: 561-70 (NKI)
743. Senan S, De Ruyscher D. Critical review of PET-CT for radiotherapy planning in lung cancer. *Crit Rev Oncol Hematol* 2005; 56(3): 345-351 (VUmc)
744. Senan S, Lagerwaard FJ. The role of radiotherapy in non-small-cell lung cancer. *Ann Oncol* 2005; 16 Suppl 2: ii223-ii228 (VUmc)
745. Senan S, Slotman BJ. Clinical use of four-dimensional computed tomography scans. *Eur Oncol Review* 2005; 1: 68-71 (VUmc)
746. Sesink AL, Arts IC, de Boer VC, Breedveld P, Schellens JH, Hollman PC, Russel FG. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. *Mol Pharmacol* 2005; 67: 1999-2006 (NKI)
747. Seto E, Yang L, Middeldorp JM, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T, Takada K. Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. *J Med Virol* 2005; 76(1): 82-88 (VUmc)
748. Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. *Cancer Res* 2005; 65(18): 8414-8422 (VUmc)
749. Shang J, Pena AS. Multidisciplinary approach to understand the pathogenesis of gastric cancer. *World J Gastroenterol* 2005; 11(27): 4131-4139 (VUmc)
750. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. *J Immunol* 2005; 175(5): 3244-3251 (VUmc)
751. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). *Oncologist* 2005; 10: 579-89 (NKI)
752. Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A, Solanki B, Beijnen JH, Schellens JH. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra(R)), R115777 in combination with gemcitabine and cisplatin in patients with advanced solid tumours. *Br J Cancer* 2005; 93: 1222-9 (NKI)
753. Sigmond J, Peters GJ. Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity. *Nucleos Nucleot Nucl* 2005; 24(10-12): 1997-2022 (VUmc)
754. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus Jr EV, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease. Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; 19 Suppl A: 5-36 (VUmc)
755. Silvertand LH, Vazvaei F, Weigl P, Rosing H, Hillebrand MJX, Van Maanen MJ, Beijnen JH. Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-

performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2005; 19: 3673-80 (NKI)

756. Simons PJ, Van den Pangaart PS, Van Roomen CPAA, Aerts JMFG, Boon L. Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: evidence that tumor necrosis factor-alpha- and interleukin-1 beta-treated human preadipocytes are potent leptin producers. *Cytokine* 2005; 32(2): 94-103 (AMC)

757. Singhal D, Van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. *Surg Oncol* 2005; 14(2): 59-74 (AMC)

758. Siroen MP, van Leeuwen PA, Nijveldt RJ, Teerlink T, Wouters PJ, van den Berghe G. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality?. *Crit Care Med* 2005; 33(3): 504-510 (VUmc)

759. Sivula A, Buskens CJ, Van Rees BP, Haglund C, Offerhaus GJA, van Lanschot JJB, Ristimäki A. Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. *Int J Cancer* 2005; 116(6): 903-908 (AMC)

760. Skokowa J, Ali SR, Felda O, Kumar V, Konrad S, Shushakova N, Schmidt RE, Piekorz RP, Nurnberg B, Spicher K, Birnbaumer L, Zwirner J, Claassens JW, Verbeek JS, van Rooijen N, Kohl J, Gessner JE. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. *J Immunol* 2005; 174(5): 3041-3050 (VUmc)

761. Skrekas T, Laguna MP, De la Rosette JJMCH. Laparoscopic radical prostatectomy: a European virus. *Minim Invasiv Ther* 2005; 14(2): 98-103 (AMC)

762. Slats AM, Egeler RM, van der Does-van den Berg, Korbijn C, Hahlen K, Kamps WA, Veerman AJ, Zwaan CM. Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. *Leukemia* 2005; 19(4): 537-544 (VUmc)

763. Slofstra SH, Van 't Veer C, Buurman WA, Reitsma PH, Ten Cate H, Spek CA. Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. *Crit Care Med* 2005; 33(6): 1365-1370 (AMC)

764. Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. *Radiother Oncol* 2005; 75(3): 349-354 (VUmc)

765. Slottje P, Bijlsma JA, Smidt N, Twisk JW, Huizink AC, Lems WF, van Hoogstraten I, Witteveen AB, van Mechelen W, Smid T. Epidemiologic study of the autoimmune health effects of a cargo aircraft disaster. *Arch Intern Med* 2005; 165(19): 2278-2285 (VUmc)

766. Smeenk HG, De Castro S, Jeekel JJ, Kazemier G, Busch ORC, Incrocci L, Erdmann J, Hop WC, Gouma DJ, Van Eijck CHJ. Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil: a first step to neoadjuvant treatment? *Digest Surg* 2005; 22(3): 191-197 (AMC)

767. Smeets LC, van Agtmael MA, van der Vorm ER. Successful treatment of a disseminated *Nocardia brasiliensis* infection. *Eur J Clin Microbiol Infect Dis* 2005; 24(5): 350-351 (VUmc)

768. Sminia P, Kuipers GK, Geldof AA, Lafleur MV, Slotman BJ. COX-2 inhibitors act as radiosensitizer in tumor treatment. *Biomed and Pharmacother* 2005; 59: S272-S275 (VUmc)

769. Sminia P, Stoter TR, van der Valk P, Elkhuizen PH, Tadema TM, Kuipers GK, Vandertop WP, Lafleur MV, Slotman BJ. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. *J Cancer Res Clin Oncol* 2005; 131(10): 653-661 (VUmc)

770. Smit LH, Korse CM, Bonfrer JM. Comparison of four different assays for determination of serum S-100B. *Int J Biol Markers* 2005; 20: 34-42 (NKI)

771. Smit LH, Nieweg OE, Korse CM, Bonfrer JM, Kroon BB. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. *J Surg Oncol* 2005; 90: 66-9 (NKI)

772. Smit LHM, Korse CM, Hart AAM, Bonfrer JMG, Haanen JBAG, Kerst JM, Nieweg OE, de Gast GC. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. *Eur J Cancer* 2005; 41: 386-92 (NKI)

773. Smith FJ, Liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P, Joval I, van Steensel MA, Bjorck E, Callif-Daley F, Pals G, Collins P, Leachman SA, Munro CS, McLean WH. The genetic basis of pachyonychia congenita. *J Invest Dermatol Symp Proc* 2005; 10(1): 21-30 (VUmc)

774. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, Zaat BA, Yazdanbakhsh M, Wierenga EA, van Kooyk Y, Kapsenberg ML. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. *J Allergy Clin Immunol* 2005; 115(6): 1260-1267 (VUmc)

775. Smitsmans MH, De Bois J, Sonke JJ, Betgen A, Zijp LJ, Jaffray DA, Lebesque JV, Van Herk M. Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy. *Int J Radiat Oncol Biol Phys* 2005; 63: 975-84 (NKI)

- 776.** Smulders SA, Smeenk FW, Janssen-Heijnen ML, Wielders PL, de Munck DR, Postmus PE. Surgical mediastinal staging in daily practice. *Lung Cancer* 2005; 47(2): 243-251 (VUmc)
- 777.** Snijders PJ, van den Brule AJ, Jacobs MV, Pol RP, Meijer CJ. HPV DNA detection and typing in cervical scrapes. *Methods Mol Med* 2005; 119: 101-114 (VUmc)
- 778.** Songun I, Litvinov SV, Van de Velde CJH, Pals ST, Hermans J, Van Krieken JHJM. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. *Brit J Cancer* 2005; 92(9): 1767-1772 (AMC)
- 779.** Souverein PC, Van Riemsdijk MM, De la Rosette JJMCH, Opdam PCE, Leufkens HGM. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. *Eur Urol* 2005; 47(4): 505-510 (AMC)
- 780.** Spaan AN, Ijlst L, Van Roermund CWT, Wijburg FA, Wanders RJA, Waterham HR. Identification of the human mitochondrial FAD transporter and its potential role in multiple acyl-CoA dehydrogenase deficiency. *Mol Genet Metab* 2005; 86(4): 441-447 (AMC)
- 781.** Spaargaren J, Fennema HS, Morre SA, de Vries HJ, Coutinho RA. New lymphogranuloma venereum *Chlamydia trachomatis* variant, Amsterdam. *Emerg Infect Dis* 2005; 11(7): 1090-1092 (VUmc)
- 782.** Spaargaren J, Schachter J, Moncada J, de Vries HJ, Fennema HS, Pena AS, Coutinho RA, Morre SA. Slow epidemic of lymphogranuloma venereum L2b strain. *Emerg Infect Dis* 2005; 11(11): 1787-1788 (VUmc)
- 783.** Spermon JR, Hoffmann AL, Horenblas S, Verbeek AL, Witjes JA, Kiemeny LA. The efficacy of different follow-up strategies in clinical stage I Non-seminomatous Germ Cell Cancer: a Markov simulation study. *Eur Urol* 2005; 48: 258-67 (NKI)
- 784.** Spiekerkoetter U, Tokunaga C, Wendel U, Mayatepek E, Ijlst L, Vaz FM, Van Vlies N, Overmars H, Duran M, Wijburg FA, Wanders RJA, Strauss AW. Tissue carnitine homeostasis in very-long-chain acyl-CoA dehydrogenase-deficient mice. *Pediatr Res* 2005; 57(6): 760-764 (AMC)
- 785.** Spiekstra SW, Toebak MJ, Sampat-Sardjoepersad S, van Beek PJ, Boorsma DM, Stoof TJ, von Blomberg BM, Scheper RJ, Bruynzeel DP, Rustemeyer T, Gibbs S. Induction of cytokine (interleukin-1 α and tumor necrosis factor- α) and chemokine (CCL20, CCL27, and CXCL8) alarm signals after allergen and irritant exposure. *Exp Dermatol* 2005; 14(2): 109-116 (VUmc)
- 786.** Spijkers PPEM, Da Costa Martins P, Westein E, Gahmberg CG, Zwaginga JJ, Lenting PJ. LDL-receptor-related protein regulates beta 2-integrin-mediated leukocyte adhesion. *Blood* 2005; 105(1): 170-177 (AMC)
- 787.** Stalmeier PFM, De Boer AGEM, Sprangers MAG, De Haes JCJM, Van Lanschot JJB. Validity of utilities of patients with esophageal cancer. *Int J Technol Assess* 2005; 21(1): 113-118 (AMC)
- 788.** Stalpers LJA, Da Costa HC, Merbis MAE, Fortuin AA, Muller MJ, Van Dam FSAM. Hypnotherapy in radiotherapy patients: a randomized trial. *Int J Radiat Oncol* 2005; 61(2): 499-506 (AMC/NKI)
- 789.** Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, van Rooijen N, Andjelkovic AV. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. *J Cereb Blood Flow Metab* 2005; 25(5): 593-606 (VUmc)
- 790.** Stearne LE, Vonk AG, Kullberg BJ, Gyssens IC. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice. *Antimicrob Agents Chemother* 2005; 49(9): 3668-3675 (VUmc)
- 791.** Steenbakkens RJ, Duppen JC, Fitton I, Deurloo KE, Zijp L, Uitterhoeve AL, Rodrigus PT, Kramer GW, Bussink J, Jaeger KD, Belderbos JS, Hart AA, Nowak PJ, Herk MV, Rasch CR. Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: A 'Big Brother' evaluation. *Radiother Oncol* 2005; 77: 182-90 (NKI)
- 792.** Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ. HPV-mediated transformation of the anogenital tract. *J Clin Virol* 2005; 32 Suppl 1: S25-S33 (VUmc)
- 793.** Steggerda M, Schneider C, Van Herk M, Zijp L, Moonen L, van der Poel H. The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants. *Med Phys* 2005; 32: 2262-70 (NKI)
- 794.** Stein U, Bergmann S, Scheffer GL, Scheper RJ, Royer HD, Schlag PM, Walther W. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. *Oncogene* 2005; 24(22): 3606-3618 (VUmc)
- 795.** Stevens SJ, Brink AA, Middeldorp JM. Profiling of Epstein-Barr virus latent RNA expression in clinical specimens by gene-specific multiprimed cDNA synthesis and PCR. *Methods Mol Biol* 2005; 292: 27-38 (VUmc)
- 796.** Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi A, Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. *J Clin Microbiol* 2005; 43(7): 3066-3073 (NKI/VUmc)
- 797.** Stevens SJ, Verkuijlen SA, Middeldorp JM. Quantitative detection of Epstein-Barr virus DNA in clinical specimens by rapid real-time PCR targeting

a highly conserved region of EBNA-1. *Methods Mol Biol* 2005; 292: 15-26 (VUmc)

798. Stokman G, Leemans JC, Claessen N, Weening JJ, Florquin S. Hematopoietic stem cell mobilization therapy accelerates recovery of renal function independent of stem cell contribution. *J Am Soc Nephrol* 2005; 16(6): 1684-1692 (AMC)

799. Stokvis E, Rosing H, Beijnen JH. Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs. *Mass Spectrom Rev* 2005; 24: 887-917 (NKI)

800. Stokvis E, Rosing H, Beijnen JH. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? *Rapid Commun Mass Spectrom* 2005; 19: 401-7 (NKI)

801. Strand CV, Simon LS, Tugwell PS, Brooks PM, Boers M. Omeract 7 -- 7th international consensus conference on outcome measures in rheumatology clinical trials. *J Rheumatol* 2005; 32(10): 2014-2015 (VUmc)

802. Stromme P, Van der Hagen CB, Haakonsen M, Risberg K, Hennekam RCM. Follow-up of a girl with cleft lip and palate and multiple malformations: trisomy 20 mosaicism. *Scand J Plast Recons* 2005; 39(3): 178-179 (AMC)

803. Swanson JA, Peters PJ. Techniques: Subcellular imaging technologies - microscopic visual thinking. *Curr Opin Microbiol* 2005; 8: 313-5 (NKI)

804. Swerdlow AJ, Van Leeuwen FE. Late effects after treatment for Hodgkin lymphoma. In: Degos L, Linch DC, Löwenberg B, editors. *Textbook of malignant hematology*; second edition. London: Taylor & Francis, 2005: p. 753-768 (NKI)

805. Taal BG, Smits M. Developments in diagnosis and treatment of metastatic midgut carcinoid tumors. A review. *Minerva Gastroenterol Dietol* 2005; 51: 335-44 (NKI)

806. Taal BG. Diagnosis and treatment in intestinal carcinoid tumors. *Curr Gastroenterol Rep* 2005; 7: 1-3 (NKI)

807. Takkenberg RB, Vrouwenraets BC, van Geel AN, Nieweg OE, Noorda EM, Eggermont AM, Kroon BB. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. *J Surg Oncol* 2005; 91: 107-11 (NKI)

808. Tanis PJ, Van Rijk MC, Nieweg OE. The posterior lymphatic network of the breast rediscovered. *J Surg Oncol* 2005; 91: 195-8 (NKI)

809. Tefsen B, Bos MP, Beckers F, Tommassen J, de Cock H. MsbA is not required for phospholipid transport in *Neisseria meningitidis*. *J Biol Chem* 2005; 280(43): 35961-35966 (VUmc)

810. Tefsen B, Geurtsen J, Beckers F, Tommassen J, de Cock H. Lipopolysaccharide transport to the

bacterial outer membrane in spheroplasts. *J Biol Chem* 2005; 280(6): 4504-4509 (VUmc)

811. Temmink OH, de Bruin M, Comijn EM, Fukushima M, Peters GJ. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. *Anticancer Drugs* 2005; 16(3): 285-292 (VUmc)

812. Ter Bals E, Kaspers GJ. Treatment of childhood acute myeloid leukemia. *Expert Rev Anticancer Ther* 2005; 5(5): 917-929 (VUmc)

813. Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, Den Ende PL, Burlage F. The role of radiotherapy in the treatment of malignant salivary gland tumors. *Int J Radiat Oncol Biol Phys* 2005; 61: 103-11 (NKI)

814. Theodore C, Geoffrois L, Vermorken JB, Caponigro F, Fiedler W, Chollet P, Ravaud A, Peters GJ, de Balincourt C, Lacombe D, Fumoleau P. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. *Eur J Cancer* 2005; 41(8): 1150-1157 (VUmc)

815. Tilanus-Linthorst MM, Kriege M, Boetes C, Hop WC, Obdeijn IM, Oosterwijk JC, Peterse HL, Zonderland HM, Meijer S, Eggermont AM, de Koning HJ, Klijn JG, Brekelmans CT. Hereditary breast cancer growth rates and its impact on screening policy. *Eur J Cancer* 2005; 41(11): 1610-1617 (VUmc)

816. Timmers GJ, van Vuurden DG, Swart EL, Simoons-Smit AM, Huijgens PC. Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies. *Haematologica* 2005; 90(7): 1005-1006 (VUmc)

817. Tjernberg P, Van der Heijden JF, Eikenboom JCJ, Reitsma PH. Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists. *J Throm Haemost* 2005; 3(4): 797-798 (AMC)

818. Tjin EPM, Bende RJ, Derksen PWB, Van Huijstee A-P, Kataoka H, Spaargaren M, Pals ST. Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator. *J Immunol* 2005; 175(5): 2807-2813 (AMC)

819. Tong M, Jacobi CE, van de Rijke FM, Kuijper S, van de Werken S, Lowary TL, Hokke CH, Appelmelk BJ, Nagelkerke NJ, Tanke HJ, van Gijlswijk RP, Veuskens J, Kolk AH, Raap AK. A multiplexed and miniaturized serological tuberculosis assay identifies antigens that discriminate maximally between TB and non-TB sera. *J Immunol Methods* 2005; 301(1-2): 154-163 (VUmc)

820. Tony B, Vos MJ, Berkhof J, Postma TJ, van Lingen A, Heimans JJ, Hoekstra OS. Interobserver variability in the semi-quantitative assessment of

201TI SPECT in cerebral gliomas. *Nucl Med Commun* 2005; 26(1): 45-48 (VUmc)

821. Travis LB, Hill D, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, 't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD, Jr., Gilbert E, Gail MH. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. *J Natl Cancer Inst* 2005; 97: 1428-37 (NKI)

822. Tribulatti MV, Mucci J, van Rooijen N, Leguizamón MS, Campetella O. The trans-sialidase from *Trypanosoma cruzi* induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents. *Infect Immun* 2005; 73(1): 201-207 (VUmc)

823. Triesscheijn M, Ruevekamp M, Aalders M, Baas P, Stewart FA. Outcome of mTHPC Mediated Photodynamic Therapy is Primarily Determined by the Vascular Response. *Photochem Photobiol* 2005; 81: 1161-7 (NKI)

824. Tseng HC, Ovaas H, Wei NJ, Ploegh H, Tsai LH. Phosphoproteomic analysis with a solid-phase capture-release-tag approach. *Chem Biol* 2005; 12: 769-77 (NKI)

825. Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, Pantin-Jackwood MJ, Schultz-Cherry S, Solorzano A, van Rooijen N, Katz JM, Basler CF. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. *J Virol* 2005; 79(23): 14933-14944 (VUmc)

826. Tuynman JB, Buskens CJ, Kemper K, Ten Kate FJW, Offerhaus GJA, Richel DJ, Van Lanschot JJB. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. *Ann Surg* 2005; 242(6): 840-850 (AMC)

827. Ulfman LH, Alblas J, Van Aalst CW, Zwaginga JJ, Koenderman L. Differences in potency of CXC chemokine ligand 8-, CC chemokine ligand 11-, and C5a-induced modulation of integrin function on human eosinophils. *J Immunol* 2005; 175(9): 6092-6099 (AMC)

828. Underberg RW, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. *Int J Radiat Oncol Biol Phys* 2005; 62(2): 554-560 (VUmc)

829. Underberg RW, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S. Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. *Int J Radiat Oncol Biol Phys* 2005; 63(1): 253-260 (VUmc)

830. Uren AG, Kool J, Berns A, Van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. *Oncogene* 2005; 24: 7656-72 (NKI)

831. Uyl-de Groot CA, Vermorken JB, Hanna MG, Jr., Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. *Vaccine* 2005; 23(17-18): 2379-2387 (VUmc)

832. Valentijn LJ, Koppen A, Van Asperen R, Root HA, Haneveld F, Versteeg R. Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. *Cancer Res* 2005; 65(8): 3136-3145 (AMC)

833. Valentini V, Glimelius B, Minsky BD, Van Cutsem E, Bartelink H, Beets-Tan RG, Gerard JP, Kosmidis P, Pahlman L, Picciocchi A, Quirke P, Tepper J, Tonato M, van de Velde CJ, Cellini N, Latini P. The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus. *Radiother Oncol* 2005; 76: 241-50 (NKI)

834. Valianpour F, Mitsakos V, Schlemmer D, Towbin JA, Taylor JM, Ekert PG, Thorburn DR, Munnich A, Wanders RJA, Barth PG, Vaz FM. Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis. *J Lipid Res* 2005; 46(6): 1182-1195 (AMC)

835. Van Agthoven M, Heule-Dieleman HA, de Boer MF, Kaanders JH, Baatenburg de Jong RJ, Kremer B, Leemans CR, Marres HA, Manni JJ, Langendijk JA, Levendag PC, Tjho-Heslinga RE, de Jong JM, Uyl-de Groot CA, Knegt PP. Evaluating adherence to the Dutch guideline for diagnosis, treatment and follow-up of laryngeal carcinomas. *Radiother Oncol* 2005; 74(3): 337-344 (VUmc)

836. Van Amerongen R, Berns A. Re-Evaluating the Role of Frat in Wnt-Signal Transduction. *Cell Cycle* 2005; 4: 1065-72 (NKI)

837. Van Amerongen R, Nawijn M, Franca-Koh J, Zevenhoven J, Van der Gulden H, Jonkers J, Berns A. Frat is dispensable for canonical Wnt signaling in mammals. *Genes Dev* 2005; 19: 425-30 (NKI)

838. Van As-Brooks CJ, Hilgers FJM, Koopmans-van Beinum FJ, Pols LCW. Anatomical and functional correlates of voice quality in tracheoesophageal speech. *J Voice* 2005; 19: 360-72 (NKI)

839. Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. *J Med Genet* 2005; 42(9): 711-719 (NKI/VUmc)

840. Van Baal J, De Widt J, Divecha N, Van Blitterswijk WJ. Translocation of diacylglycerolkinase *zeta* from cytosol to plasma membrane in response to activation of G-protein-coupled receptors and protein kinase C. *J Biol Chem* 2005; 280: 9870-8 (NKI)

- 841.** Van Baal JWPM, Milano F, Rygiel A, Bergman JJGHM, Rosmolen WD, Van Deventer SJH, Wang KK, Peppelenbosch MP, Krishnadath KK. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. *Gastroenterology* 2005; 129(4): 1274-1281 (AMC)
- 842.** Van Baarle D, Tsegaye A, Miedema F, Akbar A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. *Immunol Lett* 2005; 97(1): 19-29 (AMC)
- 843.** Van Beek EM, Cochrane F, Barclay AN, van den Berg TK. Signal regulatory proteins in the immune system. *J Immunol* 2005; 175(12): 7781-7787 (VUmc)
- 844.** Van Beek J, zur Hausen A, Snel SN, Berkhof J, Klein Kranenbarg E, van de Velde CJH, van den Brule AJC, Middeldorp JM, Meijer CJLM, Bloemena E. Morphological evidence of an activated cytotoxic T cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. *Am J Surg Pathol* 2005; 30: 59-65 (VUmc)
- 845.** Van Beers EH, Van Welsem T, Wessels LFA, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FBL, 't Veer LJ, Nederlof PM. CGH profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. *Cancer Res* 2005; 65: 822-7 (NKI)
- 846.** Van Bergen J, Stewart CA, van den Elsen PJ, Trowsdale J. Structural and functional differences between the promoters of independently expressed killer cell Ig-like receptors. *Eur J Immunol* 2005; 35(7): 2191-2199 (VUmc)
- 847.** Van Berkel AM, Fockens P, Bruno MJ. Palliation of malignant pancreaticobiliary obstruction. *Malignant pancreaticobiliary tract disorders* 2005: 821-837 (AMC)
- 848.** Van Beusechem VW, van den Doel PB, Gerritsen WR. Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. *Mol Cancer Ther* 2005; 4(6): 1013-1018 (VUmc)
- 849.** Van Bree C, Rodermond HM, De Vos J, Haveman J, Franken NAP. Mismatch repair proficiency is not required for radioenhancement by gemcitabine. *Int J Radiat Oncol* 2005; 62(5): 1504-1509 (AMC)
- 850.** Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines [COCHRANE REVIEW]. *Cochrane Database Syst Rev* 2005; 4?(CD003917)(AMC)
- 851.** Van Dalen EC, van der Pal HJH, Reitsma JB, de Winter RJ, Helbing WA, Ottenkamp J, Caron HN, Kremer LCM. Management of asymptomatic anthracycline-induced cardiac damage after treatment for childhood cancer - A postal survey among dutch adult and pediatric cardiologists. *J Pediatr Hematol Oncol* 2005; 27(6): 319-322 (AMC)
- 852.** Van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. *Oncologist* 2005; 10 Suppl 2: 30-4 (NKI)
- 853.** Van de Vijver MJ. Biological variables and prognosis of DCIS. *Breast* 2005; 14: 509-19 (NKI)
- 854.** Van de Weerd BC, van Vugt MA, Lindon C, Kauh JJ, Rozendaal MJ, Klompemaker R, Wolthuis RM, Medema RH. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. *Mol Cell Biol* 2005; 25: 2031-44 (NKI)
- 855.** Van de Wetering MD, De Witte MA, Kremer LCM, Offringa M, Scholten RJPM, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. *Eur J Cancer* 2005; 41(10): 1372-1382 (AMC)
- 856.** Van de Wetering MD, Van Woensel JBM, Kremer LCM, Caron HN. Prophylactic antibiotics for preventing early Gram-positive central venous catheter infections in oncology patients, a Cochrane systematic review. *Cancer Treat Rev* 2005; 31(3): 186-196 (AMC)
- 857.** Van de Wiel MA, Costa JL, Smid K, Oudejans CB, Bergman AM, Meijer GA, Peters GJ, Ylstra B. Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations. *Cancer Res* 2005; 65(22): 10208-10213 (VUmc)
- 858.** Van de Wiel MA, Smeets SJ, Brakenhoff RH, Ylstra B. CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data. *Bioinformatics* 2005; 21(14): 3193-3194 (VUmc)
- 859.** Van den Berg A, Kuiper M, Snoek M, Timens W, Postma DS, Jansen HM, Lutter R. Interleukin-17 induces hyperresponsive interleukin-8 and interleukin-6 production to tumor necrosis factor-alpha in structural lung cells. *Am J Resp Cell Mol* 2005; 33(1): 97-104 (AMC)
- 860.** Van den Berg A, Snoek M, Jansen HM, Lutter R. EIA expression dysregulates IL-8 production and suppresses IL-6 production by lung epithelial cells. *Resp Res* 2005; 6(art.111) (AMC)
- 861.** Van den Berg R. Imaging and management of head and neck paragangliomas. *Eur Radiol* 2005; 15(7): 1310-1318 (VUmc)
- 862.** Van den Berg TK, Kraal G. A function for the macrophage F4/80 molecule in tolerance induction. *Trends Immunol* 2005; 26(10): 506-509 (VUmc)
- 863.** Van den Berg TK, van Beek EM, Buhning HJ, Colonna M, Hamaguchi M, Howard CJ, Kasuga M, Liu Y, Matozaki T, Neel BG, Parkos CA, Sano S, Vignery A, Vivier E, Wright M, Zawatzky R, Barclay AN. A nomenclature for signal regulatory protein

- family members. *J Immunol* 2005; 175(12): 7788-7789 (VUmc)
- 864.** Van den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, Salmivirta M. Novel heparan sulfate structures revealed by monoclonal antibodies. *J Biol Chem* 2005; 280(21): 20516-20523 (VUmc)
- 865.** Van den Brande JMH, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn's disease. *J Rheumatol* 2005; 32(S74): 26-30 (AMC)
- 866.** Van den Brekel MW, Castelijns JA. What the clinician wants to know: surgical perspective and ultrasound for lymph node imaging of the neck. *Cancer Imaging* 2005; 5 Suppl: S41-S49 (NKI/VUmc)
- 867.** Van den Brink DM, Van Miert JM, Wanders RJA. Assay for Sjogren-Larsson syndrome based on a deficiency of phytol degradation. *Clin Chem* 2005; 51(1): 240-242 (AMC)
- 868.** Van den Brink DM, Van Miert JN, Dacremont G, Rontani J-F, Wanders RJA. Characterization of the final step in the conversion of phytol into phytanic acid. *J Biol Chem* 2005; 280(29): 26838-26844 (AMC)
- 869.** Van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, Tamminga R, de Kraker J, Schouten-van Meeteren AY, Bruin M, Korthof ET. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. *Br J Haematol* 2005; 128(4): 571-577 (VUmc)
- 870.** Van den Ijssel P, Tijssen M, Chin SF, Eijk PP, Carvalho B, Hopmans E, Holstege H, Bangarusamy DK, Jonkers J, Meijer GA, Caldas C, Ylstra B. Human and mouse oligonucleotide-based array CGH. *Nucleic Acids Res* 2005; 33(22): e192 (NKI/VUmc)
- 871.** Van den Wijngaard R, Welting O, De Jonge WJ, Boeckxstaens G. Parental care, mast cells and visceral hypersensitivity. *J Pediatr Gastr Nutr* 2005; 41(Spl 1): S12-S13 (AMC)
- 872.** Van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. *Ann Rheum Dis* 2005; 64(12): 1761-1764 (VUmc)
- 873.** Van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH, van Egmond M. The role of macrophages in tumor development. *Cell Oncol* 2005; 27(4): 203-213 (VUmc)
- 874.** Van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH, van Egmond M. Therapeutic potential of Kupffer cells in prevention of liver metastases outgrowth. *Immunobiology* 2005; 210(2-4): 259-265 (VUmc)
- 875.** Van der Deen M, de Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS. ATP-binding cassette (ABC) transporters in normal and pathological lung. *Respir Res* 2005; 6(1): 59 (VUmc)
- 876.** Van der Heijde DM, Klareskog L, Boers M, Landewe RB, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. *Ann Rheum Dis* 2005; 64(11): 1582-1587 (VUmc)
- 877.** Van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJA, Isacoff WH, Hruban RH, Kern SE. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. *Clin Cancer Res* 2005; 11(20): 7508-7515 (AMC)
- 878.** Van der Linde K, Boor PP, van Bodegraven AA, de Jong DJ, Crusius JB, Naber TH, Kuipers EJ, Wilson JH, de Rooij FW. A functional interleukin-10 mutation in Dutch patients with Crohn's disease. *Dig Liver Dis* 2005; 37(5): 330-335 (VUmc)
- 879.** Van der Paardt M, Crusius JB, de Koning MH, Morre SA, van de Stadt RJ, Dijkmans BA, Pena AS, van der Horst-Bruinsma IE. No evidence for involvement of the Toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. *Ann Rheum Dis* 2005; 64(2): 235-238 (VUmc)
- 880.** Van der Paardt M, Crusius JB, Garcia-Gonzalez MA, Dijkmans BA, Pena AS, van der Horst-Bruinsma IE. Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor beta 1 (TGFβ1) gene polymorphisms. *Ann Rheum Dis* 2005; 64(4): 616-619 (VUmc)
- 881.** Van der Pal HJH, Van Dalen EC, Kremer LCM, Bakker PJM, Van Leeuwen FE. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. *Cancer Treat Rev* 2005; 31(3): 173-185 (AMC/NKI)
- 882.** Van der Poel HG, Antonini N, Van Tinteren H, Horenblas S. Upper urinary tract cancer: location is correlated with prognosis. *Eur Urol* 2005; 48: 438-44 (NKI)
- 883.** Van der Poel HG. Androgen receptor and TGFβ1/Smad signaling are mutually inhibitory in prostate cancer. *Eur Urol* 2005; 48: 1051-8 (NKI)
- 884.** Van der Sluijs K, Van Elden LJR, Arens R, Nijhuis MJG, Schuurman R, Florquin S, Kwakkel J, Akira S, Jansen HM, Lutter R, Van der Poll T. Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. *Immunology* 2005; 114(1): 112-120 (AMC)
- 885.** Van der Sluijs-Gelling AJ, van der Velden V, Roeffen ET, Veerman AJ, van Wering ER. Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death. *Leukemia* 2005; 19(10): 1845-1847 (VUmc)

- 886.** Van der Veen JN, Kruit JK, Havinga R, Baller JFW, Chimini G, Lestavel S, Staels B, Groot PHE, Groen AK, Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. *J Lipid Res* 2005; 46(3): 526-534 (AMC)
- 887.** Van der Vliet HJ, Molling JW, von Blomberg BM, Kolgen W, Stam AG, de Grijl TD, Mulder CJ, Janssen HL, Nishi N, van den Eertwegh AJ, Scheper RJ, van Nieuwkerk CJ. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. *Clin Immunol* 2005; 114(2): 183-189 (VUmc)
- 888.** Van der Waal RI, Huijgens PC, van der Valk P, Van der Waal I. Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index. *Int J Oral Max Surg* 2005; 34(4): 391-395 (VUmc)
- 889.** Van der Wel NN, Fluitsma DM, Dascher CC, Brenner MB, Peters PJ. Subcellular localization of mycobacteria in tissues and detection of lipid antigens in organelles using cryo-techniques for light and electron microscopy. *Curr Opin Microbiol* 2005; 8: 323-30 (NKI)
- 890.** Van der Woude CJ, Moshage H, Homan M, Kleibeuker JH, Jansen PLM. Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis. *J Clin Pathol* 2005; 58(8): 811-814 (AMC)
- 891.** Van der Zwet WC, Kaiser AM, van Elburg RM, Berkhof J, Fetter WP, Parlevliet GA, Vandenbroucke-Grauls CM. Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. *J Hosp Infect* 2005; 61(4): 300-311 (VUmc)
- 892.** Van Dijk MA, Mulders J, Poutsma A, Konst AA, Lachmeijer AM, Dekker GA, Blankenstein MA, Oudejans CB. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. *Nat Genet* 2005; 37(5): 514-519 (VUmc)
- 893.** Van Dinten LC, Pul N, van Nieuwpoort AF, Out CJ, Jager MJ, van den Elsen PJ. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. *Invest Ophthalmol Vis Sci* 2005; 46(1): 24-30 (VUmc)
- 894.** Van Duijnhoven FH, Rovers JP, Engelmann K, Krajina Z, Purkiss SF, Zoetmulder FAN, Vogl TJ, Terpstra OT. Photodynamic Therapy With 5,10,15,20-Tetrakis(m-Hydroxyphenyl) Bacteriochlorin for Colorectal Liver Metastases Is Safe and Feasible: Results From a Phase I Study. *Ann Surg Oncol* 2005; 12: 808-16 (NKI)
- 895.** Van Eeden S, de Leng WWJ, GJA Offerhaus., FHM Morsink, MAJ Weterman. Pancreatic endocrine tumors with ductules [author's reply]. *Am J Surg Pathol* 2005 (AMC)
- 896.** Van Elmpt WJ, Nijsten SM, Mijnheer BJ, Minken AW. Experimental verification of a portal dose prediction model. *Med Phys* 2005; 32: 2805-18 (NKI)
- 897.** Van Gelder RE, Florie J, Stoker J. Colorectal cancer screening and surveillance with CT colonography: current controversies and obstacles. *Abdom Imaging* 2005; 30(1): 5-12 (AMC)
- 898.** Van Gisbergen KP, Aarnoudse CA, Meijer GA, Geijtenbeek TB, van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. *Cancer Res* 2005; 65(13): 5935-5944 (VUmc)
- 899.** Van Gisbergen KP, Geijtenbeek TB, van Kooyk Y. Close encounters of neutrophils and DCs. *Trends Immunol* 2005; 26(12): 626-631 (VUmc)
- 900.** Van Gisbergen KP, Ludwig IS, Geijtenbeek TB, van Kooyk Y. Interactions of DC-SIGN with Mac-1 and CEACAM1 regulate contact between dendritic cells and neutrophils. *FEBS Lett* 2005; 579(27): 6159-6168 (VUmc)
- 901.** Van Gisbergen KP, Paessens LC, Geijtenbeek TB, van Kooyk Y. Molecular mechanisms that set the stage for DC-T cell engagement. *Immunol Lett* 2005; 97(2): 199-208 (VUmc)
- 902.** Van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. *J Exp Med* 2005; 201(8): 1281-1292 (VUmc)
- 903.** Van Gogh CD, Festen JM, Verdonck-de Leeuw IM, Parker AJ, Traissac FR, Cheesman AD, Mahieu HF. Acoustical analysis of tracheoesophageal voice. *Speech Communication* 2005; 47: 160-168 (VUmc)
- 904.** Van Gogh CD, Verdonck-de Leeuw IM, Boon-Kamma BA, Langendijk JA, Kuik DJ, Mahieu HF. A screening questionnaire for voice problems after treatment of early glottic cancer. *Int J Radiat Oncol Biol Phys* 2005; 62(3): 700-705 (VUmc)
- 905.** Van Griethuysen A, van Loo I, Van Belkum A, Vandenbroucke-Grauls CM, Wannet W, van Keulen P, Kluytmans JA. Loss of the mecA gene during storage of methicillin-resistant *Staphylococcus aureus* strains. *J Clin Microbiol* 2005; 43(3): 1361-1365 (VUmc)
- 906.** Van Gulik TM, Lang H. Isolated resection of segment 1 of the liver. *Digest Surg* 2005; 22(3): 143-148 (AMC)
- 907.** Van Gulik TM, Schoots IG. Anastomosis of Riolan revisited: the meandering mesenteric artery. *Arch Surg-Chicago* 2005; 140(12): 1225-1229 (AMC)
- 908.** Van Gulik TM. Symposium on hilar cholangiocarcinoma [editorial]. *HPB* 2005; 7(4): 243 (AMC)

- 909.** Van Heek NT, Clayton SJ, Sturm PDJ, Walker J, Gouma DJ, Noorduyn LA, Offerhaus GJA, Fox JC. Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. *J Clin Pathol* 2005; 58(12): 1315-1320 (AMC)
- 910.** Van Heek NT, Kuhlmann KFD, Scholten RJPM, De Castro SMM, Busch ORC, Van Gulik TM, Obertop H, Gouma DJ. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. *Ann Surg* 2005; 242(6): 781-788 (AMC)
- 911.** Van Heijst JW, Niessen HW, Hoekman K, Schalkwijk CG. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. *Ann NY Acad Sci* 2005; 1043: 725-733 (VUmc)
- 912.** Van Herwaarden AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CMM, Schellens JHM, Beijnen JH, Schinkel AH. Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. *Drug Metab Dispos* 2005; 33: 892-5 (NKI)
- 913.** Van Hoorn EC, Middelaar-Voskuilen MC, van Limpt CJ, Lamb KJ, Bouritius H, Vriesema AJ, van Leeuwen PA, van Norren K. Preoperative supplementation with a carbohydrate mixture decreases organ dysfunction-associated risk factors. *Clin Nutr* 2005; 24(1): 114-123 (VUmc)
- 914.** Van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, Rimoldi D, Muris JJ, Hooijberg E, Gundy CM, Meijer CJ, Kummer JA. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. *Clin Cancer Res* 2005; 11(17): 6400-6407 (VUmc)
- 915.** Van Imhoff GW, Van der Holt B, MacKenzie MA, Ossenkuppele GJ, Wijermans PW, Kramer MHH, Van 't Veer MB, Schouten HC, Van Marwijk Kooy M, Van Oers MHJ, Raemaekers JMM, Sonneveld P, Meulendijks LAMH, Kluin PM, Kluin-Nelemans HC, Verdonck LF. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. *Leukemia* 2005; 19(6): 945-952 (AMC)
- 916.** Van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam 355. *Invest New Drugs* 2005; 23: 225-34 (NKI)
- 917.** Van Kuilenburg ABP, Meinsma R, Beke E, Bobba B, Boffi P, Enns GM, Witt DR, Dobritzsch D. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function. *Biol Chem* 2005; 386(4): 319-324 (AMC)
- 918.** Van Kuilenburg ABP, Zoetekouw L. Determination of thymidine phosphorylase activity by a non-radiochemical assay using reversed-phase high-performance liquid chromatography. *J Chromatogr B* 2005; 820(2): 271-275 (AMC)
- 919.** Van Lanschot JJB, Bergman JJGHM. Tailored therapy for early Barrett's lesions. *Brit J Surg* 2005; 92(7): 791-792 (AMC)
- 920.** Van Lanschot JJB, Gouma DJ. Preface [guest editors]. *Digest Surg* 2005; 22(4): 221 (AMC)
- 921.** Van Leeuwen EMM, De Bree CJ, Remmerswaal EBM, Yong YH, Tesselaar NA, Ten Berge IJM, Van Lier RAW. IL-7 receptor at chain expression distinguishes functional subsets of virus-specific human CD8(+) T cells. *Blood* 2005; 106(6): 2091-2098 (AMC)
- 922.** Van Leeuwen EMM, Van Buul JD, Remmerswaal EBM, Hordijk PL, Ten Berge IJM, Van Lier RAW. Functional re-expression of CCR7 on CMV-specific CD8(+) T cells upon antigenic stimulation. *Int Immunol* 2005; 17(6): 713-719 (AMC)
- 923.** Van Leeuwen F, van Steensel B. Histone modifications: from genome-wide maps to functional insights. *Genome Biol* 2005; 6: 113 (NKI)
- 924.** Van Limpt V, Chan A, Schramm A, Eggert A, Versteeg R. Phox2B mutations and the Delta-Notch pathway in neuroblastoma. *Cancer Lett* 2005; 228(1-2): 59-63 (AMC)
- 925.** Van Luenen HG, Kieft R, Musmann R, Engstler M, ter Riet B, Borst P. Trypanosomes change their transferrin receptor expression to allow effective uptake of host transferrin. *Mol Microbiol* 2005; 58: 151-65 (NKI)
- 926.** Van Maldergem L, Moser AB, Vincent MF, Roland D, Reding R, Otte JB, Wanders RJA, Sokal E. Orthotopic liver transplantation from a living-related donor in an infant with a peroxisome biogenesis defect of the infantile Refsum disease type. *J Inher Metab Dis* 2005; 28(4): 593-600 (AMC)
- 927.** Van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar WH. Inhibition of autotaxin by lysophosphatidic acid and sphingosine-1-phosphate. *J Biol Chem* 2005; 280: 21155-61 (NKI)
- 928.** Van Poelgeest MI, van Seters M, Van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. *Clin Cancer Res* 2005; 11: 5273-80 (NKI)

- 929.** Van Rheeën J, Achame EM, Janssen H, Calafat J, Jalink K. PIP2 signaling in lipid domains: a critical re-evaluation 361. *EMBO J* 2005; 24: 1664-73 (NKI)
- 930.** Van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ, Schuurhuis GJ. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. *Clin Cancer Res* 2005; 11(18): 6520-6527 (VUmc)
- 931.** Van Rhijn BW, Van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review 362. *Eur Urol* 2005; 47: 736-48 (NKI)
- 932.** Van Rijk MC, Nieweg OE, Valdés Olmos RA, Rutgers EJT, Hoefnagel CA, Kroon BBR. Non-axillary breast cancer recurrences after sentinel node biopsy. *J Surg Oncol* 2005; 92: 292-8 (NKI)
- 933.** Van Rossum MA, Boers M, Zwinderman AH, van Soesbergen RM, Wieringa H, Fiselier TJ, Franssen MJ, ten Cate R, Suijlekom-Smit LW, Wulffraat NM, van Luijk WH, Oostveen JC, Kuis W, Dijkmans BA. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. *Arthritis Rheum* 2005; 52(9): 2865-2872 (VUmc)
- 934.** Van Royen N, Schirmer SH, Atasever B, Behrens CYH, Ubbink DT, Buschmann EE, Voskuil M, Bot PTG, Hofer IE, Schlingemann RO, Biemond BJ, Tijssen JGP, Bode C, Schaper W, Oskam J, Legemate DA, Piek JJ, Buschmann I. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. *Circulation* 2005; 112(7): 1040-1046 (AMC)
- 935.** Van Royen-Kerkhof A, Sanders EA, Walraven V, Voorhorst-Ogink M, Saeland E, Teeling JL, Gerritsen A, van Dijk MA, Kuis W, Rijkers GT, Vitale L, Keler T, McKenzie SE, Leusen JH, van de Winkel JG. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcγRIIA transgenic mice. *Br J Haematol* 2005; 130(1): 130-137 (VUmc)
- 936.** Van Ruissen F, Ruijter JM, Schaaf GJ, Asgharnegad L, Zwijnenburg DA, Kool M, Baas F. Evaluation of the similarity of gene expression data estimated with SAGE and Affymetrix GeneChips. *BMC Genomics* 2005; 6(91)(AMC)
- 937.** Van Santen HM, Aronson DC, Van Trotsenburg ASP, Ten Kate FJW, Van de Wetering MD, Wiersinga WM, De Vijlder JJM, Vulsma T. Disseminated medullary thyroid carcinoma despite early thyroid surgery in the multiple endocrine neoplasia-2A syndrome. *Thyroid* 2005; 15(5): 485-488 (AMC)
- 938.** Van Santen HM, De Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. *Eur J Cancer* 2005; 41(12): 1767-1774 (AMC)
- 939.** Van Santen HM, Thonissen NM, De Kraker J, Vulsma T. Changes in thyroid hormone state in children receiving chemotherapy. *Clin Endocrinol* 2005; 62(2): 250-257 (AMC)
- 940.** Van Santen HM, Van Dijk JE, Rodermond H, Vansenne F, Meertens N, Haveman J, Endert E, De Vijlder JJM, Vulsma T. The effect of cervical X-irradiation on activity index of thyrocytes and plasma TSH: a pre-clinical model for radiation-induced thyroid damage. *J Endocrinol Invest* 2005; 28(3): 261-269 (AMC)
- 941.** Van Schil P, Van Meerbeek J, Kramer G, Splinter T, Legrand C, Giaccone G, Manegold C, Van Zandwijk N. Morbidity and mortality in the surgery arm of EORTC 08941 trial. *Eur Respir J* 2005; 26: 192-7 (NKI)
- 942.** Van Seters M, Van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients 364. *Gynecol Oncol* 2005; 97: 645-51 (NKI)
- 943.** Van Sornsen de Koste JR, Senan S, Underberg RW, Oei SS, Elshove D, Slotman BJ, Lagerwaard FJ. Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC. *Int J Radiat Oncol Biol Phys* 2005; 63(2): 334-339 (VUmc)
- 944.** Van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, Van Asperen CJ, Rutgers EJT, 't Veer LJ, Tollenaar RA. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. *Br J Cancer* 2005; 93: 287-92 (NKI)
- 945.** Van Stijn A, Feller N, Kok A, van der Pol MA, Ossenkoppele GJ, Schuurhuis GJ. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. *Clin Cancer Res* 2005; 11(7): 2540-2546 (VUmc)
- 946.** Van Til NP, Markusic DM, Van der Rijt R, Kunne C, Hiralall JK, Vreeling H, Frederiks WM, Oude Elferink RPJ, Seppen J. Kupffer cells and not liver sinusoidal endothelial cells prevent lentiviral transduction of hepatocytes. *Mol Ther* 2005; 11(1): 26-34 (AMC)
- 947.** Van Velthuysen MLF, Taal BG, van der Hoeven JJ, Peterse JL. Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. *Histopathology* 2005; 46: 153-7 (NKI)
- 948.** Van Vlies N, Tian L, Overmars H, Bootsma AH, Kulik W, Wanders RJA, Wood PA, Vaz FM. Characterization of carnitine and fatty acid metabolism in the long-chain acyl-CoA dehydrogenase-deficient mouse. *Biochem J* 2005; 387(Pt 1): 185-193 (AMC)
- 949.** Van Vliet SJ, van Liempt E, Saeland E, Aarnoudse CA, Appelmelk BJ, Irimura T, Geijtenbeek TB, Blixt O, Alvarez R, van Die I, van Kooyk Y. Carbohydrate profiling reveals a

distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. *Int Immunol* 2005; 17(5): 661-669 (VUmc)

950. Van Vugt MATM, Medema RH. Polo-like kinase-1: activity measurements and RNAi-mediated knockdown. In: Brooks G, Humphrey TC, editors. *Cell cycle protocols: methods and techniques*. Totowa: Humana Press, 2005: p. 296-369 (NKI)

951. Van Vuurden DG, Plotz FB, de Jong M, Bokenkamp A, van Wijk JA. Therapeutic total plasma exchange in a child with neuroblastoma-related anti-Hu syndrome. *Pediatr Nephrol* 2005; 20(11): 1655-1656 (VUmc)

952. Van Westerloo DJ, Florquin S, De Boer AM, Daalhuisen JB, De Vos AF, Bruno MJ, Van der Poll T. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. *AM J PATHOL*, 166(3), 721-728 (AMC)

953. Van Westerloo DJ, Giebelen IAJ, Florquin S, Daalhuisen JB, Bruno MJ, De Vos AF, Tracey KJ, Van der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. *J Infect Dis* 2005; 191(12), 2138-2148 (AMC)

954. Van Westerloo DJ, Knapp S, Van 't Veer C, Buurman WA, De Vos AF, Florquin S, Van der Poll. Aspiration pneumonitis primes the host for an exaggerated inflammatory response during pneumonia. *Crit Care Med* 2005; 33(8): 1770-1778 (AMC)

955. Van Westerloo DJ, Van der Poll T. Acute vagotomy activates the cholinergic anti-inflammatory pathway: reply. *Am J Physiol-Heart C*; 288(2): H977-H978 (AMC)

956. Van Westerloo DJ, Weijer S, Bruno MJ, De Vos AF, Van 't Veer C, Van der Poll T. Toll-like receptor 4 deficiency and acute pancreatitis act similarly in reducing host defense during murine *Escherichia coli* peritonitis. *Crit Care Med* 2005; 33(5): 1036-1043 (AMC)

957. Van Westreenen HL, Westerterp M, Jager PL, Van Dullemen HM, Sloof GW, Comans EFI, Van Lanschot JJB, Wiggers T, Plukker JTM. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. *J Nucl Med* 2005; 46(8): 1321-1325 (AMC/VUmc)

958. Van Zandwijk N. Chemoprevention in lung carcinogenesis - An overview. *Eur J Cancer* 2005; 41: 1990-2002 (NKI)

959. Van Zeeburg HJ, Snijders PJ, Pals G, Hermsen MA, Roommans MA, Bagby G, Soulier J, Gluckman E, Wennerberg J, Leemans CR, Joenje H, Brakenhoff RH. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. *Cancer Res* 2005; 65(4): 1271-1276 (VUmc)

960. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. *J Infect Dis* 2005; 192(12): 2099-2107 (VUmc)

961. Vanrompay D, Hoang TQ, De Vos L, Verminnen K, Harkinezhad T, Chiers K, Morre SA, Cox E. Specific-pathogen-free pigs as an animal model for studying *Chlamydia trachomatis* genital infection. *Infect Immun* 2005; 73(12): 8317-8321 (VUmc)

962. Van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. *J Clin Oncol* 2005; 23: 1631-5 (NKI)

963. Vasen HF, Tesfay E, Boonstra H, Mourits MJ, Rutgers E, Verheyen R, Oosterwijk J, Beex L. Early detection of breast and ovarian cancer in families with BRCA mutations. *Eur J Cancer* 2005; 41: 549-54 (NKI)

964. Vecchio MD, Foschini MP, Peterse JL, Eusebi V. Lobular Carcinoma of the Breast With Hybrid Myoepithelial and Secretory ("Myosecretory") Cell Differentiation. *Am J Surg Pathol* 2005; 29: 1530-6 (NKI)

965. Veerman AJ, Sutaryo, Sumadiono. Twinning: a rewarding scenario for development of oncology services in transitional countries. *Pediatr Blood Cancer* 2005; 45(2): 103-106 (VUmc)

966. Vega H, Waisfisz Q, Gordillo M, Sakai N, Yanagihara I, Yamada M, van Gosliga D, Kayserili H, Xu C, Ozono K, Jabs EW, Inui K, Joenje H. Roberts syndrome is caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion. *Nat Genet* 2005; 37(5): 468-470 (VUmc)

967. Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, Van Blitterswijk WJ. Co-formulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. *J Pharmacol Exp Ther* 2005; 315: 704-10 (NKI)

968. Ventura FV, Ruiter J, Ijlst L, De Almeida IT, Wanders RJA. Differential inhibitory effect of long-chain acyl-CoA esters on succinate and glutamate transport into rat liver mitochondria and its possible implications for long-chain fatty acid oxidation defects. *Mol Genet Metab* 2005; 86(3): 344-352 (AMC).

969. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. *J Nucl Med* 2005; 46 Suppl 1: 164S-171S (VUmc)

970. Verlinden L, Eelen G, Beullens I, Van Camp M, Van Hummelen P, Engelen K, Van Hellefont R, Marchal K, De Moor B, Foijer F, Te Riele H, Beullens M, Bollen M, Mathieu C, Bouillon R, Verstuyf A. Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target

genes down-regulated by 1,25-dihydroxyvitamin D3. *J Biol Chem* 2005; 280: 37319-30 (NKI)

971. Verra N, De Jong D, Bex A, Batchelor D, DelleMijn T, Sein J, Nooijen W, Meinhardt W, Horenblas S, De Gast G, Vyth-Dreese F. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. *Eur Urol* 2005; 48: 527-33 (NKI)

972. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. *Neurology* 2005; 64(6): 1076-1077 (VUmc)

973. Verstegen MJT, Van den Munckhof P, Troost D, Bouma GJ. Multiple meningiomas in a patient with Rubinstein-Taybi syndrome. Case report. *J Neurosurg* 2005; 102(1): 167-168 (AMC)

974. Verwaal VJ, Van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol* 2005; 12: 65-71 (NKI)

975. Vink SR, Schellens JHM, Van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. *Invest New Drugs* 2005; 23: 279-86 (NKI)

976. Vis M, Bultink IE, Dijkmans BA, Lems WF. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. *Osteoporos Int* 2005; 16(11): 1432-1435 (VUmc)

977. Vis M, Nurmohamed MT, Wolbink GJ, Voskuyl AE, de Koning MH, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. *J Rheumatol* 2005; 32(2): 252-255 (VUmc)

978. Vis M, Voskuyl AE, Wolbink GJ, Dijkmans BA, Lems WF. Bone mineral density in patients with rheumatoid arthritis treated with infliximab. *Ann Rheum Dis* 2005; 64(2): 336-337 (VUmc)

979. Visser O, Nieuwenhuijzen JA, Horenblas S. Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater amsterdam. *J Urol* 2005; 174: 97-102 (NKI)

980. Visser O, Van Leeuwen FE. Stage-specific survival of epithelial cancers in North-Holland/Flevoland, The Netherlands. *Eur J Cancer* 2005; 41: 2321-30 (NKI)

981. Visser O, van Peppen AM, Ory FG, Van Leeuwen FE. Results of breast cancer screening in first generation migrants in Northwest Netherlands. *Eur J Cancer Prev* 2005; 14: 251-5 (NKI)

982. Visser O, van Wijnen JH, Van Leeuwen FE. Incidence of cancer in the area around Amsterdam Airport Schiphol in 1988-2003: a population-based

ecological study. *BMC Public Health* 2005; 5: 127 (NKI)

983. Visser WF, Van Roermund CWT, Ijlst L, Hellingwerf KJ, Wanders RJA, Waterham HR. Demonstration and characterization of phosphate transport in mammalian peroxisomes. *Biochem J* 2005; 389(Pt 3): 717-722 (AMC)

984. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. *J Clin Pathol* 2005; 58(2): 172-177 (NKI/VUmc)

985. Vleugel MM, Greijer AE, van der Wall E, van Diest PJ. Mutation analysis of the HIF-1alpha oxygen-dependent degradation domain in invasive breast cancer. *Cancer Genet Cytogenet* 2005; 163(2): 168-172 (VUmc)

986. Vondrusková E, Van den Burg J, Zíková A, Ernst MF, Stuart K, Benne R, Lukes J. RNA interference analyses suggest a transcript-specific regulatory role for mitochondrial RNA-binding proteins MRP1 and MRP2 in RNA editing and other RNA processing in *Trypanosoma brucei*. *J Biol Chem* 2005; 280(4): 2429-2438 (AMC)

987. Voogd AC, van Oost FJ, Rutgers EJ, Elkhuizen PH, van Geel AN, Scheijmans LJ, van der Sangen MJ, Botke G, Hoekstra CJ, Jobsen JJ, van de Velde CJ, von Meyenfeldt MF, Tabak JM, Peterse JL, van de Vijver MJ, Coebergh JW, van Tienhoven G. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. *Eur J Cancer* 2005; 41(17): 2637-2644 (NKI/VUmc)

988. Voogd AC, Van Oost FJ, Rutgers EJT, Elkhuizen PHM, Van Geel AN, Scheijmans LJEE, Van Sangen MJC, Botke G, Hoekstra CJ, Jobsen JJ, Van de Velde CJH, Von Meyenfeldt MF, Tabak JM, Peterse JL, Van de Vijver MJ, Coebergh JWW, Van Tienhoven G. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. *Eur J Cancer* 2005; 41(17): 2637-2644 (AMC)

989. Vos MJ, Turowski B, Zanella FE, Paquis P, Siefert A, Hideghety K, Haselsberger K, Grochulla F, Postma TJ, Wittig A, Heimans JJ, Slotman BJ, Vandertop WP, Sauerwein W. Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. *Int J Radiat Oncol Biol Phys* 2005; 61(2): 392-399 (VUmc)

990. Voskuil DW, Vrieling A, 't Veer LJ, Kampman E, Rookus MA. The insulin-like growth factor (IGF) system in cancer prevention: potential of dietary intervention strategies. *Cancer Epidemiol Biomarkers Prev* 2005; 13: 195-203 (NKI)

991. Vossen MTM, Biezeveld MH, De Jong MD, Gent MR, Baars PA, Von Rosenstiel IA, Van Lier RAW, Kuijpers TW. Absence of circulating natural killer

and primed CD8(+) cells in life-threatening varicella. *J Infect Dis* 2005; 191(2): 198-206 (AMC)

992. Vossen MTM, Gent MR, Peters KMC, Wertheim-van Dillen PME, Dolman KM, Van Breda A, Van Lier RAW, Kuijpers TW. Persistent detection of varicella-zoster virus DNA in a previously healthy child after severe chickenpox. *J Clin Microbiol* 2005; 43(11): 5614-5621 (AMC)

993. Vranken JH, Troost D, Wegener JT, Kruis MR, Van der Vegt MH. Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. *Pain* 2005; 117(1-2): 231-235 (AMC)

994. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, Gietema HA, Molenkamp BG, Stadius Muller MG, van Diest PJ, van der Sijp JR, Meijer S. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. *Ann Surg Oncol* 2005; 12(6): 440-448 (VUmc)

995. Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA, Smit EF. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. *Br J Cancer* 2005; 92(1): 15-20 (VUmc)

996. Wanders RJA, Waterham HR. Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders. *Clin Genet* 2005; 67(2): 107-133 (AMC)

997. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van't Veer LJ. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. *Cancer Res* 2005; 65: 9155-8 (NKI)

998. Weigelt B, Peterse JL, Van't Veer LJ. Breast cancer metastasis: markers and models. *Nat Rev Cancer* 2005; 5: 591-602 (NKI)

999. Weigelt B, Wessels LFA, Bosma AJ, Glas AM, Nuyten DS, He YD, Dai H, Peterse JL, van't Veer LJ. No common denominator for breast cancer lymph node metastasis. *Br J Cancer* 2005; 93: 924-32 (NKI)

1000. Weijer S, Florquin S, Van der Poll T. Endogenous interleukin-12 improves the early antimicrobial host response to murine *Escherichia coli* peritonitis. *Shock* 2005; 23(1): 54-58 (AMC)

1001. Weijer S, Wieland C, Florquin S, Van der Poll T. A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis. *Blood*; 106(8): 2761-2768 (AMC)

1002. Welling L, van Harten SM, Patka P, Bierens JJ, Boers M, Luitse JS, Mackie DP, Trouwborst A, Gouma DJ, Kreis RW. Medical management after indoor fires: a review. *Burns* 2005; 31(6): 673-678 (VUmc)

1003. Welling L, van Harten SM, Patka P, Bierens JJ, Boers M, Luitse JS, Mackie DP, Trouwborst A, Gouma DJ, Kreis RW. The cafe fire on New Year's Eve in Volendam, the Netherlands: description of events. *Burns* 2005; 31(5): 548-554 (VUmc)

1004. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, Johnson KR, Kirwan JR, Landewe RB, Lassere MN, Michaud K, Suarez-Almazor M, Silman AJ, Smolen J. Minimal disease activity for rheumatoid arthritis: a preliminary definition. *J Rheumatol* 2005; 32(10): 2016-2024 (VUmc)

1005. Wertheim HF, van Leeuwen WB, Snijders S, Vos MC, Voss A, Vandenbroucke-Grauls CM, Kluytmans JA, Verbrugh HA, Van Belkum A. Associations between *Staphylococcus aureus* Genotype, Infection, and In-Hospital Mortality. A Nested Case-Control Study. *J Infect Dis* 2005; 192(7): 1196-1200 (VUmc)

1006. Wessels LFA, Reinders MJT, Hart AAM, Veenman CJ, Dai H, He YD, Van't Veer LJ. A protocol for building and evaluating predictors of disease state based on microarray data. *Bioinformatics* 2005; 21: 3755-62 (NKI)

1007. West CM, McKay MJ, Holscher T, Baumann M, Stratford IJ, Bristow RG, Iwakawa M, Imai T, Zingde SM, Anscher MS, Bourhis J, Begg AC, Haustermans K, Bentzen SM, Hendry JH. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. *Int J Radiat Oncol Biol Phys* 2005; 62: 1264-73 (NKI)

1008. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M. Determination of stromal signatures in breast carcinoma. *PLoS Biol* 2005; 3: e187 (NKI)

1009. Westermann AM, Jones EL, Schem BC, Van der Steen-Banasik E, Koper P, Mella O, Uitterhoeve ALJ, De Wit LT, Van der Velden J, Burger C, Van der Wilt CL, Prosnitz LR, Van der Zee J. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. *Cancer* 2005; 104(4): 763-770 (AMC)

1010. Westerterp M, Busch ORC, Bergman JJGHM, Ten Kate FJW, Van Lanschot JJB. A "crackleware" oesophagus. *J Clin Pathol* 2005; 58(12): 1325-1327 (AMC)

1011. Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, Ten Kate FJW, Bergman JJGHM, Siersma PD, Van Dekken H, Van Lanschot JJB. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. *Virchows Arch* 2005; 446(5): 497-504 (AMC)

1012. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Eck-

- Smit BL, Plukker JT, van Lanschot JJ, Sloof GW. Esophageal cancer CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. *Radiology* 2005; 236(3): 841-851 (AMC/VUmc)
- 1013.** Westra JL, Hollema H, Schaapveld M, Platteel I, Oien KA, Keith WN, Mauritz R, Peters GJ, Buys CH, Hofstra RM, Plukker JT. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. *Ann Oncol* 2005; 16(10): 1646-1653 (VUmc)
- 1014.** Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, De Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. *J Clin Oncol* 2005; 23: 5635-43 (NKI)
- 1015.** Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers GJ, Wijnholds J, Jansen G, Peters GJ, Borst P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. *Cancer Res* 2005; 65(10): 4425-4430 (NKI/VUmc)
- 1016.** Wiggeraad R, Koning CCE, Westermann C, Jansen C, Van der Zee J. Two cases of fatal necrosis of the lesser pelvis in patients treated with combined radiotherapy and hyperthermia for cervical carcinoma. *Int J Hyperther* 2005; 21(3): 185-192 (AMC)
- 1017.** Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S. WHO-EORTC classification for cutaneous lymphomas. *Blood* 2005; 105(10): 3768-3785 (VUmc)
- 1018.** Williams CP, Van den Berg M, Distel B. *Saccharomyces cerevisiae* Pex14p contains two independent Pex5p binding sites, which are both essential for. *FEBS Lett* 2005; 576(16): 3416-3420 (AMC)
- 1019.** Woerdeman LAE, Hage JJ, van Turnhout AAWM. Extended deepithelialization to secure double-breasted closure of the skin. *Ann Plast Surg* 2005; 55: 338-40 (NKI)
- 1020.** Wolthaus JWH, Van Herk M, Muller SH, Belderbos JS, Lebesque JV, De Bois JA, Rossi MMG, Damen EMF. Fusion of respiration-correlated PET and CT scans: correlated lung tumour motion in anatomical and functional scans. *Phys Med Biol* 2005; 50: 1569-83 (NKI)
- 1021.** Woodman CB, Collins SI, Vavrusova N, Rao A, Middeldorp JM, Kolar Z, Kumari A, Nelson P, Young LS, Murray PG. Role of sexual behavior in the acquisition of asymptomatic Epstein-Barr virus infection: a longitudinal study. *Pediatr Infect Dis J* 2005; 24(6): 498-502 (VUmc)
- 1022.** Wouters D, Wiessenberg HD, Hart M, Bruins P, Voskuyl AE, Daha MR, Hack CE. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation. *J Immunol Methods* 2005; 298(1-2): 35-45 (VUmc)
- 1023.** Wurdinger T, Verheije MH, Broen K, Bosch BJ, Haijema BJ, de Haan CA, van Beusechem VW, Gerritsen WR, Rottier PJ. Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor. *J Virol* 2005; 79(24): 15314-15322 (VUmc)
- 1024.** Wurdinger T, Verheije MH, Raaben M, Bosch BJ, de Haan CA, van Beusechem VW, Rottier PJ, Gerritsen WR. Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. *Gene Ther* 2005; 12(18): 1394-1404 (VUmc)
- 1025.** Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. *Qual Life Res* 2005; 14: 285-95 (NKI)
- 1026.** Zareie M, De Vriese AS, Hekking LH, ter Wee PM, Schalkwijk CG, Driesprong BA, Schadee-Eestermans IL, Beelen RH, Lameire N, van den Born J. Immunopathological changes in a uraemic rat model for peritoneal dialysis. *Nephrol Dial Transplant* 2005; 20(7): 1350-1361 (VUmc)
- 1027.** Zareie M, Keuning ED, ter Wee PM, Beelen RH, van den Born J. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats. *Nephrol Dial Transplant* 2005; 20(1): 189-193 (VUmc)
- 1028.** Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, Schadee-Eestermans IL, Schalkwijk CG, Beelen RH, van den Born J. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. *Nephrol Dial Transplant* 2005; 20(12): 2783-2792 (VUmc)
- 1029.** Zareie M, van Lambalgen AA, ter Wee PM, Hekking LH, Keuning ED, Schadee-Eestermans IL, Faict D, Degreve B, Tangelder GJ, Beelen RH, van den Born J. Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. *Perit Dial Int* 2005; 25(1): 58-67 (VUmc)
- 1030.** Zeelenberg IS, Roos E. The role of chemokine receptors, in particular CXCR4, in lymphoma and carcinoma metastasis. In: Meadows GG, editor. *Integration/interaction of oncologic growth*. Dordrecht: Springer, 2005: p. 233-244 (NKI)
- 1031.** Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJA, Luo J, De Marzo AM, Isaacs WB. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. *Prostate* 2005; 63(4): 316-323 (AMC)

1032. Zoet YM, Eijssink C, Kardol MJ, Franke-van Dijk ME, Wilson GL, de Paus R, Mickelson E, Heemskerk M, van den Elsen PJ, Claas FH, Mulder A, Doxiadis II. The single antigen expressing lines (SALS) concept: an excellent tool for screening for HLA-specific antibodies. *Hum Immunol* 2005; 66(5): 519-525 (VUmc)

1033. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. *Oncologist* 2005; 10: 123-31 (NKI)

1034. Zuetenhorst JM. Diagnostic and treatment modalities in carcinoid tumours. University of Amsterdam, 2005 (NKI)

1035. Zwaan CM, Veerman AJ. Do minor differences in primary therapy influence rescue-ability after relapse in childhood ALL?. *Pediatr Blood Cancer* 2005; 45(1): 2-4 (VUmc)

1036. Zwaan M, Joenje H, Pals G, Madan K. Fanconi anemia: an overview. *Eur Cytogen Ass Newsl* 2005; 15: 16-19 (VUmc)

1037. Zwart W, Griekspoor A, Kuijl C, Marsman M, Van Rheenen J, Janssen H, Calafat J, van Ham M, Janssen L, van Lith M, Jalink K, Neeffjes J. Spatial Separation of HLA-DM/HLA-DR Interactions within MIIC and Phagosome-Induced Immune Escape. *Immunity* 2005; 22: 221-33 (NKI)

7. Theses

7.1. Theses 2004

In 2004 62 graduate students acquired a PhD degree. They are listed below. The institute in which the research was carried out is given between brackets.

name	:	Bennink RJ (AMC)
title	:	Nuclear gastroenterology: novel techniques in clinical and experimental gastrointestinal mobility, IBD and hepatology
university	:	Universiteit van Amsterdam
(co)promotores	:	Van Eck-Smit B, Van Deventer SJH, Boeckxstaens GEE, van Gulik TM
date	:	29-04-2004
name	:	Beumer JH (NKI)
title	:	Mass balance and pharmacokinetic investigations of novel anticancer drugs
university	:	Universiteit van Utrecht
(co)promotores	:	Prof.dr. J.H. Beijnen, Prof.dr. J.H.M. Schellens, Dr. O. van Tellingen
date	:	8-12-2004
name	:	Bevers RFM (AMC)
title	:	Interactions of BCG with urothelial tumor cells in immunotherapy for superficial bladder cancer
university	:	Universiteit van Amsterdam
(co)promotores	:	Kurth KH, Schamhart DHJ
date	:	14-04-2004
name:	:	Bol MGW (VUmc)
title	:	Proliferation biomarkers, computerized morphometric and whole genome DNA analysis of TaT1 urinary bladder cancers
university	:	Vrije Universiteit Amsterdam
(co)promotores	:	Prof.dr. J.P.A. Baak
date	:	23-04-2004
name	:	Bosch AM (AMC)
title	:	Classical galactosemia revisited
university	:	Universiteit van Amsterdam
(co)promotores	:	Heymans HSA, Wanders RJA, Bakker HD, Wijburg FA
date	:	08-12-2004
name	:	Buskens CJ (AMC)
title	:	The development of new treatment strategies for oesophageal cancer
university	:	Universiteit van Amsterdam
(co)promotores	:	Van Lanschot JJB, ten Kate FJW, Bosma PJ
date	:	15-10-2004
name	:	Buwalda J (AMC)
title	:	AMORE (Ablative surgery, MOulage technique brachytherapy and REconstruction) for childhood head and neck rhabdomyosarcoma
university	:	Universiteit van Amsterdam
(co)promotores	:	Caron HN, Schouwenburg PF
date	:	07-09-2004
name	:	Castro Kreder N (AMC)
title	:	In vitro studies on radiation effects and radiosensitization: HDR vs LDR and cytotoxic agents.
university	:	Universiteit van Amsterdam
(co)promotores	:	González González D, Haveman J
date	:	16-06-2004

name : **Colnot DR** (VUmc)
 title : Radioimmunotherapy in head and neck cancer patients
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. G.A.M.S. Van Dongen, Prof.dr. G.B. Snow, Dr. J.C. Roos
 date : 30-06-2004

name : **De Boer EJ** (NKI)
 title : Subfertility and menopause in an IVF-treated population
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. F.E. van Leeuwen, Prof.dr. C.W. Burger, Dr. I. Den
 Tonkelaar
 date : 13-10-2004

name : **De Bruin M** (VUmc)
 title : Role of thymidine phosphorylase/platelet derived endothelial cell growth factor in
 drug sensitivity and angiogenesis
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. H.M. Pinedo, Prof.dr. G.J. Peters
 date : 10-11-2004

name : **De Graaf M** (VUmc)
 title : Selective chemotherapy with glycoside prodrugs of anthracyclines
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. H.M. Pinedo
 date : 02-07-2004

name : **De Jonge ME** (NKI)
 title : Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents
 university : Universiteit Utrecht
 (co)promotores : Prof.dr. J.H. Beijnen, Prof.dr. J.H.M. Schellens, Dr. A.D.R. Huitema
 date : 17-12-2004

name : **De Julio M** (AMC)
 title : Signal-transduction pathways inducing a pericentral phenotype in hepatocytes
 university : Universiteit van Amsterdam
 (co)promotores : Lamers WH, Hakvoort TBM, Perret C
 date : 29-09-2004

name : **De Kreuk AM** (VUmc)
 title : Transplantation potential of G-SCF mobilized white blood
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. P.C. Huijgens
 date : 16-04-2004

name : **De Reijke ThM** (AMC)
 title : Measurable effects of immunotherapy for superficial bladder cancer
 university : Universiteit van Amsterdam
 (co)promotores : Kurth KH, Boer EC de, Schamhart DHJ
 date : 28-01-2004

name : **Dols A** (VUmc)
 title : Immunotherapy strategies in breast cancer and melanoma
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. R.J. Scheper
 date : 27-02-2004

name : **Dubbelhuis PF** (AMC)
 title : Regulation of metabolism by amino acid dependant signal transduction
 university : Universiteit van Amsterdam
 (co)promotores : Aerts JMFG, Meijer AJ
 date : 28-06-2004

name : **Gianotten J** (AMC)
 title : Spermatogenic failure. A genetic Odyssey
 university : Universiteit van Amsterdam

(co)promotores : Van der Veen F, Leschot NJ, Lombardi MPRL, Hoffer MJV
date : 08-10-2004

name : **Gootjes J** (AMC)
title : Molecular, biochemical and clinical aspects of peroxisomes biogenesis disorders
university : Universiteit van Amsterdam
(co)promotores : Wanders, R.J.A., & Waterham, H.R.
date : 19-02-2004

name : **Haarman EG** (VUmc)
title : Glucocorticoid resistance in childhood leukemia; mechanisms and modulation
university : Vrije Universiteit Amsterdam
(co)promotores : Prof.dr. A.J.P. Veerman, Prof.dr. R. Pieters, Dr. G.J.L. Kaspers
date : 05-11-2004

name : **Hendriks JA** (NKI)
title : Contributions of CD27 and relatives to the specific immune response
university : Universiteit van Amsterdam
(co)promotores : Prof.dr. J. Borst
date : 21-9-2004

name : **Hogenboom S** (AMC)
title : Subcellular localization of the hum isoprenoid biosynthesis pathway
university : Universiteit van Amsterdam
(co)promotores : Wanders RJA, Waterham HR
date : 13-01-2004

name : **Houtzager BA** (AMC)
title : Siblings of pediatric cancer patients. Coping, risk factors and psychological health
university : Universiteit van Amsterdam
(co)promotores : Caron HN, Last BF, Grootenhuis MA
date : 28-05-2004

name : **Kemper EM** (NKI)
title : Inhibition of P-glycoprotein at the blood-brain barrier; Implications for treatment of brain tumors with taxanes
university : Universiteit Utrecht
(co)promotores : Prof.dr. J.H. Beijnen
date : 27-02-2004

name : **Kuiken SD** (AMC)
title : Gut feelings: visceral hypersensitivity and functional gastrointestinal disorders
university : Universiteit van Amsterdam
(co)promotores : Tytgat GNJ, Boeckxstaens GEE
date : 11-03-2004

name : **Kuppens IELM** (NKI)
title : Clinical and pharmacological studies with oral anti-cancer drugs
university : Universiteit Utrecht
(co)promotores : Prof.dr. J.H.M. Schellens, Prof.dr. J.H. Beijnen
date : 16-12-2004

name : **Lagerwaard FJ** (VUmc)
title : Towards 4-dimensional conformal radiotherapy for early stage non-small cell lung cancer
university : Vrije Universiteit Amsterdam
(co)promotores : Prof.dr. S. Senan
date : 26-05-2004

name : **Lakhai JM** (NKI)
title : Clinical pharmacology of metal-based and marine-derived anticancer agents
university : Universiteit Utrecht
(co)promotores : Prof.dr. J.H.M. Schellens, Prof.dr. J.H. Beijnen

date : 19-11-2004
 name : **Lisman CQ** (AMC)
 title : The Golgi: a transposition point in membrane lipid composition and topology.
 university : Universiteit van Amsterdam
 (co)promotores : Meer GFBP van, Holthuis JCM
 date : 17-12-2004

name : **Lüdeking A** (AMC)
 title : Multi-xenobiotic resistance (MXR) transporters and biotransformation enzymes in the blue mussel *Mytilus edulis*
 university : Universiteit van Amsterdam
 (co)promotores : Van Noorden CJF, Köhler A
 date : 07-05-2004

name : **Meijer SL** (VUmc)
 title : Tumor-reactive T cells in clinical immunotherapy for the treatment of cancer
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. R.J. Scheper
 date : 27-02-2004

name : **Merks JHM** (AMC)
 title : Phenotypic abnormalities in childhood cancer patients; clues for molecular defects?
 university : Universiteit van Amsterdam
 (co)promotores : Caron HN, Hennekam RCM
 date : 16-11-2004

name : **Mook ORF** (AMC)
 title : Tumor development of colon cancer in rat liver
 university : Universiteit van Amsterdam
 (co)promotores : Van Noorden CJF, Frederiks WM
 date : 05-03-2004

name : **Piek JMJ** (VUmc)
 title : Hereditary serous ovarian carcinogenesis, a hypothesis
 university : Vrije Universiteit Amsterdam
 (co)promotores : prof. dr. R.H.M. Verheijen, prof. dr. P. Kenemans, prof. dr. P.J. van Diest
 date : 29-10-2004

name : **Schoenmakers SHHF** (AMC)
 title : Studies on coagulation-induced inflammation in mice
 university : Universiteit van Amsterdam
 (co)promotores : Reitsma PH, Spek CA
 date : 29-04-2004

name : **Schoneveld JLM** (AMC)
 title : The hormonal regulation of carbamoylphosphate synthetase I expression
 university : Universiteit van Amsterdam
 (co)promotores : Lamers WH, Gaemers IC
 date : 14-05-2004

name : **Schoots IG** (AMC)
 title : Clinical and experimental studies on treatment of acute mesenteric ischemia
 university : Universiteit van Amsterdam
 (co)promotores : Van Gulik TM, Levi MM
 date : 10-12-2004

name : **Sommeijer DW** (AMC)
 title : Coagulation and inflammation in diabetes mellitus
 university : Universiteit van Amsterdam
 (co)promotores : Ten Cate H, Reitsma PH
 date : 16-12-2004

name : **Tabor MP** (VUmc)
 title : Second field tumors

university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. C.R. Leemans, Dr. B.J.M. Braakhuis, Dr. R.H. Brakenhoff
 date : 28-04-2004

name : **Valdimarsdottir G** (NKI)
 title : TGF-beta signal Transduction in Endothelial Cells
 university : Uppsala Universiteit
 (co)promotores : Prof.dr. Carl-Henrik Heldin, Dr. P. ten Dijke
 date : 25 mei 2004

name : **Valianpour F** (AMC)
 title : A mass spectrometric approach to investigate cardiolipin metabolism in Barth syndrome
 university : Universiteit van Amsterdam
 (co)promotores : Wanders RJA, Barth PG, Van Gennip AH
 date : 17-09-2004

name : **Van Breda Vriesman AC** (AMC)
 title : Infaction and idiopathic inflammation of intraperitoneal fat. Implications of diagnostic imaging of the acute abdomen
 university : Universiteit van Amsterdam
 (co)promotores : Laméris JS, Puylaert JBCM
 date : 11-05-2004

name : **Van Dartel M** (AMC)
 title : Amplification and overexpression of genes in chromosome region 17p1.2-p12 in human osteocarcinoma
 university : Universiteit van Amsterdam
 (co)promotores : Westerveld A, Hulsebos TJM
 date : 18-11-2004

name : **Van de Kerkhove MP** (AMC)
 title : Optimization and clinical application of the AMC-bioartificial liver
 university : Universiteit van Amsterdam
 (co)promotores : Gulik TM van, Chamuleau RAFM, Hoekstra R
 date : 26-03-2004

name : **Van der Heijden JF** (AMC)
 title : Risk factors for bleeding during treatment with anti-thrombotics
 university : Universiteit van Amsterdam
 (co)promotores : Reitsma PH, Vermeulen M, Büller HR
 date : 30-01-2004

name : **Van der Hoeven JJM** (VUmc)
 title : Prospects for positron emission tomography in the staging and treatment of breast cancer patients
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. G.J.J. Teule, Prof.dr. S. Meijer, Dr. O.S. Hoekstra
 date : 08-10-2004
 : 5-11-2004

name : **Van de Wetering MD** (AMC)
 title : Prediction and prevention of infectious complications in children with cancer
 university : Universiteit van Amsterdam
 (co)promotores : Caron HN, Kuijpers TW
 date : 23-04-2004

name : **Van Duin M** (VUmc)
 title : Insight into HPV-mediated carcinogenesis: viral and host aspects
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. C.J.L.M. Meijer, Dr. P.J.F. Snijders
 date : 2-4-2004

name : **Van Gelder RE** (AMC)
 title : CT colonography for screening of patients at increased risk for colorectal cancer -

accuracy patient acceptance and radiation issues
 university : Universiteit van Amsterdam
 (co)promotores : Laméris JS, Stoker J
 date : 19-11-2004

name : **Van Heek NT** (AMC)
 title : Genes and surgery in pancreatic cancer
 university : Universiteit van Amsterdam
 (co)promotores : Gouma DJ, Offerhaus GJA, Goggins MG
 date : 16-12-2004

name : **Van Hensbergen Y** (VUmc)
 title : The role of CD13/Aminopeptidase N in vascular and ovarian cancer biology
 university : Vrije Universiteit Amsterdam
 (co)promotores: : Prof.dr. H.M. Pinedo, Prof.dr. V.W.M. van Hinsbergh
 date : 12-05-2004

name : **Van Horck FPG** (NKI)
 title : p190RhoGEF and Type I PIPkinase: Modulators of Rho-mediated Neurite Remodeling
 university : Universiteit van Leiden
 (co)promotores : Prof.dr. W.H. Moolenaar
 date : 16-11-2004

name : **Van Sörnsen de Koste JR** (VUmc)
 title : Optimizing three-dimensional conformal radiotherapy in lung cancer
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. S. Senan
 date : 23-05-2004

name : **Van Stijn A** (VUmc)
 title : Apoptosis parameters in acute myeloid leukemia and the relation with minimal residual disease
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. P.C. Huijgens, Prof.dr. G.J. Ossenkoppele, Dr. G.J. Schuurhuis
 date : 15-12-2004

name : **Verschraagen M** (VUmc)
 title : Preclinical and clinical pharmacological aspects of BNP7787 in combination with cisplatin
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. W.J.F. van der Vijgh
 date : 23-01-2004.

name : **Werner AB** (NKI)
 title : Apoptosis signaling to mitochondria by death receptors and DNA damaging anti-cancer regimens
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. J. Borst
 date : 10-6-2004

name : **Willemsen LEM** (AMC)
 title : Intestinal barrier function: regulation of epithelial permeability and mucin expression
 university : Universiteit van Amsterdam
 (co)promotores : Van Deventer SJH, Van Tol EA
 date : 16-01-2004

name : **Zeelenberg I** (NKI)
 title : Chemokine receptor signals: Role in migration, invasion and cancer metastasis
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. A.J.M. Berns
 date : 25-05-2004

name : **Zhong L (AMC)**
title : Studies on autofluorescence of gastric cancer and imaging of pancreaticobiliary diseases
university : Universiteit van Amsterdam
(co)promotores : Tytgat GNJ, Xiao SD
date : 03-11-2004

name : **Zielinski GD (VUmc)**
title : Human papillomavirus and development of cervical cancer: implications for management of CIN lesions
university : Vrije Universiteit Amsterdam
(co)promotores : Prof.dr. C.J.L.M. Meijer, Dr. P.J.F. Snijders, Dr. L. Rozendaal
date : 1-7-04

name : **Zur Hausen A (VUmc)**
title : Epstein Barr virus-carrying gastric carcinomas: pathogenesis and clinical aspects
university : Vrije Universiteit Amsterdam
(co)promotores : Prof.dr. C.J.L.M. Meijer
date : 07-01-2004

7.2. Theses 2005

In 2005 46 graduate students acquired a PhD degree. They are listed below. The institute in which the research was carried out is given between brackets.

name	: Appels N (NKI)
title	: Translational and clinical research on prenyl transferase inhibitors
university	: Universiteit Utrecht
(co)promotores	: Prof.dr. J. Schellens/Prof.dr. J. Beijnen
date	: 3-11-2006
name	: Bleeker MCG (VUMC)
title	: Human papillomavirus infection in sexual partners
university	: Vrije Universiteit Amsterdam
(co)promotores	: Prof.dr. C.J.L.M. Meijer, Dr. P.J.F. Snijders, Dr. F.J. Voorhorst
date	: 8-7-2005
name	: Borggreven PA (VUmc)
title	: Surgical treatment with microvascular reconstruction of oral and oropharyngeal cancer. Prognostic factors and outcome
university	: Vrije Universiteit Amsterdam
(co)promotores	: Prof.dr. C.R. Leemans, Dr. I.M. Verdonck-de Leeuw
date	: 22-12-2005
name	: Breedveld P (NKI)
title	: The role of BCRP (ABCG2) in the preclinical pharmacology of anticancer drugs
university	: Universiteit Utrecht
(co)promotores	: Prof.dr. J.H.M. Schellens/Prof.dr. J.H. Beijnen
date	: 14-9-2005
name	: Breuer R (VUmc)
title	: Studies on molecular pathology of lung cancer
university	: Vrije Universiteit Amsterdam
(co)promotores	: Prof.dr. P.E. Postmus, Prof.dr. C.J.L.M. Meijer, Prof.dr. E.F. Smit, Dr. P.J.F. Snijders
date	: 6-4-2005
name	: De Haar SF (AMC)
title	: Cathepsin C in the defence against Actinobacillus actinomycetemcomitans. Studies on Papillon-Lefèvre syndrome
university	: Universiteit van Amsterdam
(co)promotores	: Prof.dr. W. Beertsen, Prof.dr. V. Everts
date	: 04-10-2005
name	: De Ruijter AJM (AMC)
title	: Characterization of the effects of a novel histone deacetylase inhibitor, BL1521, on neuroblastoma cells
university	: Universiteit van Amsterdam
(co)promotores	: Prof.dr. H.N. Caron, Dr. A.B.P. van Kuilenburg
date	: 14-06-2005
name	: Faneyte I (NKI)
title	: Markers for effectiveness of chemotherapy and drug resistance in breast cancer
university	: Universiteit van Amsterdam
(co)promotores	: Prof.dr. S. Rodenhuis, Dr. M.J. van de Vijver
date	: 23-6-2005
name	: Ferrer M (VUmc)
title	: Fanconi Anaemia and cisplatin sensitivity: implications for cancer therapy
university	: Vrije Universiteit Amsterdam
(co)promotores	: Dr. F.A.E. Kruyt, Prof.dr. G. Giaccone
date	: 14-9-2005
name	: Georger B (VUmc)

title : Conditionally replicative adenoviruses for the treatment of malignant glioma and neuroblastoma
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. W.P. Vandertop, Dr. G. Vassal, Dr. V.W. van Beusechem, Dr. C.M.F. Dirven
 date : 20-12-2005

name : **Grill J** (VUmc)
 title : Gene therapy and virotherapy of brain tumors with recombinant adenoviruses
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. H.M. Pinedo, Prof.dr. W.P. Vandertop, Dr. W.R. Gerritsen, Dr. C.M.F. Dirven
 date : 20-12-2005

name : **Hoof L** (VUmc)
 title : Molecular imaging in rare diseases: the case of thyroid cancer and positron emission tomography
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. M Boers, Prof.dr. G.J.J. Teule, Dr. O.S. Hoekstra, Dr. M.W. van Tulder
 date : 24-6-2005

name : **Hubeek I** (VUmc)
 title : Cytarabine resistance in childhood acute myeloid leukemia
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. A.J.P. Veerman, Prof.dr. G.J. Peters, Dr. G.J.L. Kaspers
 date : 10-11-2005

name : **Jordens I** (NKI)
 title : Transport of Lysosome-related Organelles
 university : Universiteit van Leiden
 (co)promotores : Prof.dr. J. Neefjes
 date : 23-11-2005

name : **Kappelhoff B** (NKI)
 title : Clinical Pharmacological Investigations of antiretroviral drugs
 university : Universiteit Utrecht
 (co)promotores : Prof.dr. J.H. Beijnen, Dr. A.D.R. Huitema
 date : 18-2-2005

name : **Klerk CPW** (AMC)
 title : Cancer, coagulation and thrombotics
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. C.J.F. van Noorden, Prof.dr. H.R. Büller, Prof.dr. D.J. Richel, Dr. S.M. Smorenburg
 date : 18-01-2005

name : **Kragt A** (AMC)
 title : Studies on the role of the Er and ubuquitin in peroxisomes biogenesis
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. J.M.F.G. Aerts, Dr. B. Distel.
 date : 04-10-2005

name : **Lakhai W** (NKI)
 title : Clinical pharmacology of molecular targeted anticancer therapy
 university : Universiteit Utrecht
 (co)promotores : Prof.dr. J. Schellens/Prof.dr. J. Beijnen
 date : 23-6-2005

name : **Levitus M** (VUmc)
 title : Genetic predisposition to cancer: the Fanconi anemia connection
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. H. Joenje, Dr. F. Arwert, Dr. J.P. de Winter
 date : 21-9-2005

name : **Lie-A-Ling M** (AMC)
 title : Gene therapy for cholangiocarcinoma
 university : Universiteit van Amsterdam

(co)promotores : Prof.dr. R.P.J. Oude Elferink, Dr. P.J. Bosma
date : 18-11-2005

name : **Lingbeek M** (NKI)
title : Role of the Ink4a/Arf tumor suppressors in cerebellar development, stem cells and cancer
university : Universiteit Utrecht
(co)promotores : Prof.dr. M. van Lohuijzen
date : 25-7-2005

name : **Marsman M** (NKI)
title : Control of Lysosomal and phago-lysosomal fusion and degradation
university : Universiteit van Leiden
(co)promotores : Prof.dr. J. Neefjes
date : 21-11-2005

name : **Mulder J** (NKI)
title : p116Rip: a new player in RhoA signaling
university : Universiteit Leiden
(co)promotores : Prof.dr. W.H. Moolenaar
date : 21-9-2005

name : **Oosterhoff D** (VUmc)
title : Adenoviral gene therapy combined with (selective) chemotherapy for the treatment of cancer
university : Vrije Universiteit Amsterdam
(co)promotores : Prof.dr. H.M. Pinedo, Dr. W.R. Gerritsen, Dr. V.W. van Beusechem
date : 17-6-2005

name : **Pasic A** (VUmc)
title : Preneoplastic lesions and early lung cancer: detection, intervention and follow-up
university : Vrije Universiteit Amsterdam
(co)promotores : Prof.dr. P.E. Postmus, Dr. T.G. Sutedja
date : 29-4-2005

name : **Perez Amodio SG** (AMC)
title : Novel roles of bone lining cells in bone remodeling
university : Universiteit van Amsterdam
(co)promotores : Prof.dr. V. Everts, Prof.dr. W. Beertsen
date : 16-06-2005

name : **Rowland B** (NKI)
title : Cellular mechanisms of proteins against oncogenic transformation
university : Universiteit Utrecht
(co)promotores : Prof.dr. R. Bernards, Dr. D. Peeper
date : 29-11-2005

name : **Tjin EPM** (AMC)
title : The HFG/MET and WNT signaling pathways in B cell differentiation and neoplasia
university : Universiteit van Amsterdam
(co)promotores : Prof.dr. S.T. Pals, Dr. M. Spaargaren
date : 25-10-2005

name : **Torrenga H** (VUmc)
title : Sentinel node biopsy in breast cancer. A routine procedure in daily clinical practice
university : Vrije Universiteit Amsterdam
(co)promotores : Prof.dr. S. Meijer, Dr/ J.R.M. van der Sijp
date : 15-4-2005

name : **Van Amerongen R** (NKI)
title : The mouse trap: resolving the role of Frat in Wnt-signal transduction
university : Universiteit van Amsterdam
(co)promotores : Prof.dr. A.J.M. Berns
date : 15-11-2005

name : **Van Beek J** (VUmc)
 title : Epstein-Barr virus bearing gastric carcinomas:Expression patterns, pathogenesis and clinical features
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. J.M. Middeldorp, Prof.dr. C.J.L.M. Meijer
 date : 11-10-2005

name : **Van den Brink DM** (AMC)
 title : Molecular aspects of refsum disease and th enzymatic degradation of phytol to phytanic acid
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. R.J.A.. Wanders
 date : 25-05-2005

name : **Van der Heijden MS** (AMC)
 title : The Fanconi anemia/BRCA2 pathway in pancreatic cancer
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. G.J.A. Offerhaus, Dr. S.E. Kern.
 date : 15-09-2005

name : **Van der Torn M** (VUmc)
 title : A sound producing prosthesis
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. H.F. Mahieu, Dr. J.M. Festen, Dr. I.M. Verdonck-de Leeuw
 date : 19-12-2005

name : **Van Eeden S** (AMC)
 title : Endocrine tumors of the pancreas and gastrointestinal tract
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. G.J.A. Offerhaus, Prof.dr. F.J.W. ten Kate, Dr. M-L.F.Velthuysen
 date : 08-06-2005

name : **Van Kleffens T** (VUmc)
 title : Decision making in clinical oncology. An ethical exploration of cancer treatment refusal
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. E. van Leeuwen
 date : 7-1-2005

name : **Van Leeuwen EMM** (AMC)
 title : Induction and maintenance of human virus-specific T cells.
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. R.J.M. ten Berge, Prof.dr. R.A.W. van Lier
 date : 15-12-2005

name : **Van Limpt VAME** (AMC)
 title : Neuroblastoma, developmental control genes and cell fates decisions in the sympathetic nervous system
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. R. Versteeg
 date : 19-01-2005

name : **Van Noesel MM** (AMC)
 title : Aberrant DNA hypermethylation and apoptotic defects in pediatric neuroblastomas
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. R. Versteeg, Prof.dr. P.A. Voute
 date : 20-01-2005

name : **Van Santen HM** (AMC)
 title : Thyroid problems in pediatric oncology; damage, prevention and consequences
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. J.J.M. de Vijlder, Dr. T. Vulsma, Dr.J de Kraker
 date : 26-01-2005

name : **Van Vugt M** (NKI)

title : Cell cycle regulation by Polo-like kinase-1
 university : Universiteit Utrecht
 (co)promotores : Prof.dr. R. Medema
 date : 17-3-2005

name : **Verstappen CCP** (VUmc)
 title : Cancer therapy related neurotoxicity
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. J.J. Heimans, Dr. T.J. Postma, Dr A.A. Geldof
 date : 10-6-2005

name : **Visser WF** (AMC)
 title : Metabolite transport across the peroxisomal membrane
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. R.J.A. Wanders, Dr. H.R. Waterham, Dr. C.W.T. van Roermund
 date : 18-10-2005

name : **Weigelt B** (NKI)
 title : Molecular markers of breast cancer metastasis
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. S. Rodenhuis
 date : 9-9-2005

name : **Westers TM** (VUmc)
 title : Principles of dendritic-cell based immunotherapy in myeloid leukemia
 university : Vrije Universiteit Amsterdam
 (co)promotores : Prof.dr. G.J. Ossenkoppele
 date : 30-9-2005

name : **Wiersma J** (AMC)
 title : Hyperthermia treatment planning for the AMC-4 system using the WF-CGFFT method
 university : Universiteit van Amsterdam
 (co)promotores : Prof.dr. C.C.E. Koning, Dr. J.D.P. van Dijk
 date : 13-04-2005

Faculty of the OOA

Prof.dr. N.K. Aaronson (Theme 2B)
Division of Psychosocial Research and
Epidemiology
Netherlands Cancer Institute

Prof.dr. J.M.F.G. Aerts (Theme 1B)
Department of Medical Biochemistry
Academic Medical Center / Universiteit van
Amsterdam

Dr. R. Agami (Theme 1A, 1B)
Division of Tumor Biology
Netherlands Cancer Institute

Prof.dr. F. Baas (Theme 1A)
Neurogenetics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.M.M. Bartelink (Theme 2B)
Division of Radiotherapy
Netherlands Cancer Institute

Prof.dr. A. Begg (Theme 2B)
Division of Experimental Therapy
Netherlands Cancer Institute

Dr. R. Benne (Theme 1A)
Department of Medical Biochemistry
Academic Medical Center / Universiteit van
Amsterdam

Prof. Dr. B. Berkhout (Theme 1A)
Department of Retrovirology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. R. Bernards (Theme 1A;1B)
Division of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. A.J.M. Berns (Theme 1A;1B)
Division of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. J.H. Beijnen (Theme 2B)
Division of Pharmacology
Netherlands Cancer Institute

Prof.dr. J.G. Borst (Theme 1B)
Division of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. R.H. Brakenhoff (Theme 1A;2B)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Prof.dr. P. Borst (Theme 1A;1B)
Division of Molecular Biology
Netherlands Cancer Institute

Prof.dr. M.P.M. Burger (Theme 2A;2B)
Department of Gynaecology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. H. N. Caron (Theme 1A; 2A)
Pediatric Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. J.G.N.M. Collard (Theme 1A; 1B)
Division of Cell Biology
Netherlands Cancer Institute

Dr. B. Distel (Theme 1A; 1B)
Department of Medical Biochemistry
Academic Medical Centre / Universiteit van
Amsterdam

Dr. P. ten Dijke (Theme 1B)
Department of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. G.A.M.S. van Dongen (Theme 1A;2A)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Dr. W.R. Gerritsen (Theme 2B)
Department of Medical Oncology
VU University Medical Center

Prof.dr. G. Giaccone (Theme 2A;2B)
Department of Medical Oncology
VU University Medical Center

Prof.dr. D.J. Gouma (Theme 2A;2B)
Department of Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. T.M. van Gulik (Theme 2B)
Department of Experimental Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. O.S. Hoekstra (Theme 2A)
Department of Nuclear Medicine
VU University Medical Center

Prof.dr. P.C. Huijgens (Theme 1B; 2B)
Department of Haematology
VU University Medical Center

Prof.dr.P.L.M. Jansen (Theme 2B)
Department of Hepatology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. H. Joenje (Theme 1A)
Department of Human Genetics

Faculty of Medicine, Vrije Universiteit

Dr. G.J. Kaspers (Theme 2B)
Department of Paediatrics
VU University Medical Center

Prof.dr. C.C.E. Koning (Theme 2B)
Department of Radiotherapy
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. W.H. Lamers (Theme 1B)
Department of Anatomy & Embryology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. A.A. Lammertsma (Theme 2A; 2B)
Department of Nuclear Medicine
VU University Medical Center

Prof.dr. J.J.B. van Lanschot (Theme 2A, 2B)
Department of surgery
Academic Medical Centre / Universiteit van
Amsterdam

Dr. S. Leenstra (Theme 2B)
Department of Neurosurgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. Ch.R. Leemans (Theme 2A;2B)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Prof.dr. M. van Lohuizen (Theme 1A;1B)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. J.P. Medema (Theme 1B)
Laboratory of Experimental Oncology and
Radiotherapy
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. R. Medema (Theme 1A;1B)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. C.J.L.M. Meijer (Theme 1A;1B;2A)
Department of Pathology
VU University Medical Center

Prof.dr. G.A. Meijer (Theme 1A;1B;2A)
Department of Pathology
VU University Medical Center

Prof.dr. S. Meijer (Theme 2B)
Department of Surgical oncology
VU University Medical Center

Prof. dr. W.H. Moolenaar (Theme 1B)
Division of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. J.M. Middeldorp (Theme 1B;2A)
Department of Pathology
VU University Medical Center

Prof.dr. J.J.C. Neefjes (Theme 1B)
Division of Tumor Biology
Netherlands Cancer Institute

Prof.dr. C.J.F. van Noorden (Theme 1B; 2A)
Department of Cell Biology & Histology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.J.A. Offerhaus (Theme 1B;2A)
Department of Pathology
Academic Medical Centre / Universiteit van
Amsterdam

Prof. dr. G.J. Ossenkoppele (Theme 1B;2B)
Department of Haematology
VU University Medical Center

Prof.dr. R.P.J. Oude Elferink (Theme 1A; 2B)
Department of Gastro-enterology & Hepatology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. S.T. Pals (Theme 1B; 2A)
Department of Pathology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. A. Parrakis (Theme 1B)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Dr. D. Peeper (Theme 1A, 1B)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. G.J. Peters (Theme 2B)
Department of Clinical Oncology
VU University Medical Center

Prof.dr. P.J. Peters (Theme 1B)
Department of Tumor Biology
Netherlands Cancer Institute

Prof.dr. H.M. Pinedo (Theme 2A;2B)
Department of Clinical Oncology
VU University Medical Center

Prof.dr. P. Postmus (Theme 2A;2B)
Department of Pulmonology
VU University Medical Center

Prof.dr. P.H. Reitsma (Theme 1A;2A)
Department of experimental internal medicine
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. D.J. Richel (Theme 1A; 2B)
Medical Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. H.P.J. te Riele (Theme 1A)
Division of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. S. Rodenhuis (Theme 2A;2B)
Division of Internal Medicine
Netherlands Cancer Institute

Dr. E. Roos (Theme 1B)
Division of Cell Biology
Netherlands Cancer Institute

Prof.dr. J.J.M.C.H. de la Rosette (Theme 2A, 2B)
Department of Urology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. J.H.M. Schellens (Theme 2B)
Division of Internal Medicine
Netherlands Cancer Institute

Prof.dr. R.J. Scheper (Theme 1B;2B)
Department of Pathology
VU University Medical Center

Dr. J.H. Schornagel (Theme 2B)
Division of Internal Medicine
Netherlands Cancer Institute

Prof.dr. S. Senan (Theme 2a;2B)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. T.K. Sixma (Theme 1B)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. B.J. Slotman (Theme 1B;2B)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. E.F. Smit (Theme 2a; 2B)
Department of Pulmonology
VU University Medical Center

Dr. A. Sonnenberg (Theme 1B)
Division of Cell Biology
Netherlands Cancer Institute

Prof.dr. H. Spits (Theme 1B)
Department of Cell Biology & Histology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. J. Stoker (Theme 2B)
Department of Radiology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. Y van Kooyk (Theme 1B; 2B)
Department of Molecular Biology and Immunology
VU University Medical Center

Prof.dr. W.P. Vandertop (Theme 2a; 2B)
Department of Neurosurgery

VU University Medical Center

Prof.dr. A.J.P. Veerman (Theme 2A;2B)
Department of Paediatrics
VU University Medical Center

Prof.dr. R.H.M. Verheijen (Theme 2A;2B)
Dept. of Obstetrics & Gynaecology
VU University Medical Center

Prof.dr. R. Versteeg (1A; 2A)
Department of Antropogenetics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. R.J.A. Wanders (Theme 1B)
Laboratory for Genetic Metabolic Disorders
Academic Medical Center / Universiteit van
Amsterdam

Staff member of the OOA

Netherlands Cancer Institute

Cell Biology

Dr. J.G. Collard
Dr. C. Jalink
Dr. E. Roos
Dr. A. Sonnenberg

Molecular Carcinogenesis

Prof.dr. R. Bernardis
Dr. R. Beijersbergen
Dr. A. Perrakis
Prof.dr. T.K. Sixma

Cellular Biochemistry

Dr. W.J. van Blitterswijk
Dr. N. Divecha
Dr. F. van Leeuwen
Prof.dr. W.H. Moolenaar
Dr. H. Ovaa
Dr. M. Verheij

Immunology

Prof.dr. J. Borst
Dr. J.B.A.G. Haanen
Dr. H. Jacobs
Prof.dr. T.N.M. Schumacher
Dr. F.A. Vyth-Dreese

Molecular Biology

Prof.dr. P. Borst (honorary staff member)
Dr. J. Jonkers
Dr. H. van Luenen
Prof.dr. R. Medema
Prof.dr. H. te Riele

Tumor Biology

Dr. R. Agami
Dr. M. Fornerod
Dr. J. Hilkens
Dr. R.J.A.M. Michalides
Prof.dr. J.J. Neeffjes
Prof.dr. P.J. Peters

Molecular Genetics

Prof.dr. A.J.M. Berns
Dr. P. Krimpenfort
Prof.dr. M. van Lohuizen
Dr. M. Snoek
Dr. B. van Steensel
Dr. M.A. van der Valk

Experimental therapy

Prof.dr. A.C. Begg
Dr. A. Schinkel
Dr. F.A. Stewart
Prof.dr. M.J. van de Vijver
Dr. L.J. van 't Veer

Radiotherapy

B.M.P. Aleman
Prof.dr. G.M.M.. Bartelink
Dr. J.S.A. Belderbos
Dr. R.W. de Boer
Dr. M. Boersma
Dr. I. Bruinvis
B.N.F.M. van Bunningen
Dr. E.M.F. Damen
Dr. L.G.H. Dewit
Dr. R.L.M. Haas
Dr. A.A.M. Hart
Dr. W. Heemsbergen
Dr. M. van Herk
Dr. F.J.M. Hoebers
Dr. E.P.M. Jansen
Dr. J.V. Lebesque
Dr. C.A.M. Marijnen
E.A.H. Masselink
Dr. B.J. Mijnheer
Dr. L.M.F. Moonen
Dr. F.J. Pos
Dr. C.R.N. Rasch
Dr. P. Remeijer
Dr. N.S. Russell
J.G. Salverda
Dr. C.Schneider
Dr. J. Stroom
Dr. J.C.M. Theuws
Dr. C. van Vliet
Dr. M. Verheij
Dr. F.W. Wittkämper

Medical Oncology

Dr. J.W. Baars
Dr. P. Baas
Drs. E.M. Bais
Prof.dr. J.H. Beijnen
Dr. J.P. de Boer
Dr. W.W. ten Bokkel Huinink
Dr. W. Boogerd
Dr. H. Boot
Dr. J.A.. Burgers
Dr. A. Cats
Prof.dr. G.C. de Gast
L. Gualthérie van Weezel
Dr. J.B.A.G. Haanen
Dr. A. Huitema
Dr. J.M. Kerst
Dr. S.C. Linn
Dr. A. Lukas
Dr. H. Neering
Prof.dr. S. Rodenhuis
Dr. J.J. van der Sande
Dr. J.H.M. Schellens
Dr. J.H. Schornagel
Dr. M. Smits
Dr. B.G. Taal

Dr. M. van der Weide
Dr. N. van Zandwijk
Surgical Oncology
Prof.dr. B.B.R. Kroon
Dr. A.J.M. Balm
Dr. M. van Beurden
Dr. A. Bex
Dr. M.W.M. van den Brekel
Dr. D.R. Buitelaar
Prof.dr. M.P.M. Burger
Dr. J. ten Cate
Dr. F. van Coevorden
Dr. M.P. Copper
Dr. W. van Driel
Dr. G. Fons
Dr. S. Gonggrijp
Dr. J.J. Hage
Prof.dr. F.J.M. Hilgers
Prof.dr. S. Horenblas
Dr. H. Huitink
Dr. C. Keijzer
H. Klomp
Dr. F.H.M. Kroon
Dr. P.J.F.M. Lohuis
Dr. M.A.C. Lubsen
Dr. W. Meinhardt
Dr. O.E. Nieweg
Dr. H.S.A. Oldenburg
Dr. H.G. van der Poel
J.M. Ronday
Dr. E.J.Th. Rutgers
Dr. P.F.E. Schutte
Dr. L.E. Smeele
Dr. T. Stoppa
Dr. I.B. Tan
Dr. A.P. Timmers
Dr. I.B. Tan
Dr. A.P. Timmers
Dr. N. van der Vange
Dr. V.J. Verwaal
Dr. M.J. Vrancken Peeters
L.A.E. Woerdeman
Dr. F.A.N. Zoetmulder

**Psychosocial Research and
Epidemiology**

Prof.dr. N.K. Aaronson
Prof.dr. F.S.A.M. van Dam
Prof.dr. W.J. van Harten
Prof.dr. F.E. van Leeuwen
Dr. M.A. Rookus

Pathology

Dr. M.J. van de Vijver
Dr. T. Alderliesten
Dr. J.M. G. Bonfrer
Dr. H. van Boven
Dr. M.P.W. Gallee
Dr. K. Gilhuijs
Dr. C.A. Hoefnagel
Dr. F.B.L. Hogervorst
Dr. D. de Jong
Dr. J. Kluijt
Dr. W. Koops
Dr. R. Kröger

Dr. C. Loo
Dr. W.J. Mooi
S.H. Muller
Dr. P.M. Nederlof
Dr. W.J. Nooijen
F.A. Pameijer
Dr. R. van Pel
Dr. J.L. Peters
Dr. W. Prevoo
Dr. M. Sinaasappel
Dr. F. Sivo
Dr. J. Teertstra
Dr. O. van Tellingen
Dr. R.A. Valdès Olmos
Dr. M.L.F. van Velthuisen
Dr. S. Verhoef

Radiology

A.P.E. Besnaard
W. Koops
Dr. R. Kröger

VU University Medical Center

Anaesthesiology

Prof.dr. W.W.A. Zuurmond

Clinical and Human Genetics

Dr. F. Arwert
Prof.dr. H. Joenje
Dr. F. Menko
Dr. G. Pals
Dr. J. de Winter

Molecular Cell Biology

Prof.dr. R.H.J. Beelen
Prof.dr. G. Kraal
Prof.dr. Y. van Kooyk

Clinical Chemistry

Dr. C.B.M. Oudejans
Prof.dr. M.A. Blankenstein

Gastro-enterology

Dr. M. Craanen
Prof.dr. C Mulder

Medical Oncology

Prof.dr. E. Boven
Dr. H.J. Broxterman
Dr. J. Buter
Dr. T.D. de Gruijl
Dr. R.J.A. Fijneman
Dr. W.R. Gerritsen
Prof.dr. G.G. Giaccone
Dr. K. Hoekman
Dr. F.A.E. Kruyt
Prof.dr. J. Lankelma
Prof.dr. G.J. Peters
Prof.dr. H.M. Pinedo
Dr. C.H. Smorenburg
Dr. C.J. van Groeningen
Dr. A.J.M. van den Eertwegh

Haematology

Dr. A. Dräger
Prof.dr. P.C. Huijgens
Prof. dr. G.J. Ossenkoppele
Dr. G.J. Schuurhuis
Dr. A.A. van de Loosdrecht
Dr. Q. Waisfisz
Dr. S. Zweegman

Surgical Oncology

Prof.dr. M.A. Cuesta
Dr. M. van Egmond
Prof.dr. P.A.M. van Leeuwen
Prof.dr. S. Meijer

Otolaryngology / Head and Neck Surgery

Dr. B.J.M. Braakhuis
Prof.dr. R.H. Brakenhoff
Dr. R. de Bree
Prof.dr. G.A.M.S. van Dongen
Prof.dr. Dr. Ch.R. Leemans
Prof.dr. H.F. Mahieu

Dr. I. Verdonck-de Leeuw

Paediatrics

Dr. J. Cloos
Dr. G.J. Kaspers
Drs. A.Y.N. Schouten - van Meeteren
Prof. Dr. A.J.P. Veerman

Pulmonology

Dr. P.W.A. Kunst
Prof.dr. P.E. Postmus
Prof.dr. E.F. Smit
Dr. T.G. Sutedja

Medical Psychology

Prof dr.P.T. Cohen-Kettenis
Dr. J. Huisman
Dr. M. Klein
Prof.dr. H.M. Ploeg

Neurosurgery

Dr. J.C. Baayen
Dr. C.M.F. Dirven
Dr. M.L.M. Lamfers
Dr. D.P. Noske
Prof.dr. W.P. Vandertop

Neurology

Prof.dr. J.J. Heimans
Dr. T. Postma

Nuclear Medicine

Dr. E.F.I. Comans
Dr. J.D.M. Herscheid
Prof.dr. O.S. Hoekstra
Prof.dr. A.A. Lammertsma
Dr. C.F.M. Molthoff

Ophthalmology

Dr. S. Imhoff
Dr. A. Moll
Prof.dr. P.J. Ringens

Oral and maxillofacial surgery and pathology

Prof.dr. I. van der Waal

Orthopaedics

Prof.dr. P.I.J.M. Wuisman

Pathology

Dr. J. Beliën
Dr. E. Bloemena
Dr. B. Carvalho
Dr. E. Hooijberg
Dr. F.J. van Kemenade
Prof.dr. C.J.L.M. Meijer
Prof.dr. G.A. Meijer
Prof.dr. J.M. Middeldorp
Prof.dr. W.J. Mooi
Dr. J.J. Oudejans
Prof.dr. R.J. Scheper
Dr. P.J.F. Snijders
Dr. R. Steenbergen
Prof.dr. P.J. van der Elsen
Prof.dr. P. van der Valk
Dr. B.M.E. von Blomberg-van der Flier
Dr. B. Ylstra

Radiology

Prof.dr. J.A. Castelijns

Radiation Oncology

Dr. F.J. Lagerwaard

Dr. J.A. Langendijk

Dr. M.V.M. Lafleur

Prof.dr. S. Senan

Prof.dr. B.J. Slotman

Dr. P. Sminia

Dr. B. van Triest

Urology

Prof.dr. B.L.H. Bemelmans

Dr. P.A.M.J. Frantzen

Dr. A.A. Geldof

Dr. R.J.A. Moorselaar

Obstetrics and Gynaecology

Prof.dr. P. Kenemans

Dr. S. von Mensdorff-Pouilly

Prof.dr. R.H.M. Verheijen

Dr. A.A. Verstraeten

University of Amsterdam

Anatomy & Embryology

Dr. I.C. Gaemers
Dr. T. Hakvoort
Prof.dr. W.H. Lamers
Dr. M. van Roon

Medical Biochemistry

Prof.dr. J.M.F.G. Aerts
Dr. R. Benne
Dr. B. Distel
Dr. F. Hochstenbach
Dr. A.J. Meijer
Dr. P. Sloof

Cell Biology & Histology

Dr. J.A. Aten
Prof.dr.V. Everts
Dr. W.M. Frederiks
Dr. J. van Marle
Dr. K. Weijer

Experimental Internal Medicine

Prof. dr. P.H. Reitsma
Dr. C.A. Spek
Dr. A.A. te Velde

Gastro-enterology & Hepatology

Dr. J.J.G.A.M. Bergman
Prof.dr. G.E.E. Boeckxstaens
Dr. W. Boers
Dr. P.J. Bosma
Dr. R.A.F.M. Chamuleau
Dr. A.K. Groen
Prof.dr. P.L.M. Jansen
Prof.dr. L. Mathus-Vliegen
Prof.dr. R.P.J. Oude Elferink
Dr. E.A.J. Rauws
Dr. H.W. Reesink

Gynaecology

Prof.dr. M.P.M. Burger
Dr. M.R. Buist

Human Genetics

Dr. H.A.M. Geerts
Prof.dr. R.C.M. Hennekam
Dr. M.M.A.M. Mannens
Dr. L.J. Valentijn
Prof.dr. R. Versteeg

Human Retrovirology and Virology

Prof.dr. B. Berkhout
Dr. A.T. Das

Lab. Genetic Metabolic Diseases

Dr. A.B.P. van Kuilenburg
Prof.dr. B.T. Poll-Thé
Prof.dr. R.J.A. Wanders
Dr. H. Waterham

Medical Oncology

Dr. P.J.M. Bakker

Dr. M.M. Geenen
Prof.dr. D.J. Richel

Neurogenetics

Prof. Dr. F. Baas
Dr. Th.J.M. Hulsebos
Dr. M.A.J. Weterman

Neuropathology

Prof.dr. D. Troost

Neurosurgery

Dr. S. Leenstra
Prof.dr. W.P. Vandertop

Pathology

Dr. A. Bosma
Dr. H. Bras
Dr. K.P. Dingemans
Prof.dr. F.J.W. ten Kate
Prof.dr. C.J.M. van Noesel
Prof.dr. G.J.A. Offerhaus
Prof.dr. S.T. Pals
Dr. M. Spaargaren

Pediatric Oncology

Dr. H. van den Berg
Prof.Dr. H.N. Caron
Dr. A.B.P. van Kuilenburg
Dr. M.D. van Wetering

Pediatrics and Pediatric Surgery

Dr. D.C. Aronson
Dr. M.A. Benninga
Dr. D.K. Bosman
Prof.dr. H.A. Heij
Dr. J.A.J.M. Taminiau

Radiology

Prof.dr. J. Stoker

Radiotherapy

Dr. A. Bel
Dr. L.E.C.M. Blank
Dr. C. van Bree
Dr. J. Crezee
Dr. J.D.P. van Dijk
Dr. N.A.P. Franken
Dr. J. Haveman
Prof.dr. C.C.E. Koning
Prof.dr. J.P. Medema
Dr. L.J.A. Stalpers
Dr. G. van Tienhoven

Surgery

Dr. W.A. Bemelman

Dr. M.A. Boermeester
Dr. O.R.C. Busch
Prof.dr. D.J. Gouma
Prof.dr. T.M. van Gulik
Prof.dr. J.J.B. van Lanschot
Prof.dr. H. Obertop
Dr. A.R van Vliet

Urology

Dr. M.P. Laguna Pes
Dr. T.M. de Reijke
Prof.dr. J.J.M.C.H. de la Rosette
Dr.Ir. H. Wijkstra